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1 Introduction 
 
“The most fruitful basis of the discovery of a new drug is to start with an old drug.” 
Sir James Black 
 
With these words the pharmacologist and Nobel laureate Sir James Black established a basis 
for drug repurposing. The fact that an already known drug is used for a new indication that 
differs from the original indication is called drug repurposing. Thereby new targets can be 
identified for the old drugs. Another approach, beside these new targets, is that the scaffolds 
of the old drugs or natural compounds can also serve as an inspiration for the synthesis of 
novel small-molecules[1].  
This thesis deals with two pore channel 2 (TPC2) as the target and tetrandrine (1, Figure 1) 
as the natural compound with the need to be developed. In 2015, Sakurai et al. linked the entry 
of Ebola virus into host cells to two pore channels (TPCs). The inhibition of TPCs with 
tetrandrine (1) halted virus trafficking and prevented infection[2], creating the fundament for this 
work. 
 
Figure 1: Chemical structure of the alkaloid tetrandrine (1), identified as a TPC2 inhibitor.  
 
1.1 Two pore channels  
Two pore channels are part of the family of voltage-gated ion channels and are localized in the 
endo-lysosomal system. They share parts of the sequential identity with voltage-gated calcium 
(Cav) and sodium (Nav) channels[3]. Two isoforms of two pore channels (TPC1 and TPC2) can 
be found in primates. TPC1 is preferentially found in early endosomal compartments and TPC2 
in late endosomal and lysosomal compartments[4-6]. In 2016, Kintzler and Stroud presented the 
crystal structure of the NAADP antagonist trans-Ned-19 (2) bound to TPC1 from Arabidopsis 
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thaliana[7]. The cryo-EM structure of human TPC2 has recently been resolved by She et al.[8] 
and verifies the dimeric nature and the duplicated domains of two pore channels. Two times 
six transmembrane helices form one domain and two domains form the ion channel. TPCs are 
non-selective cation channels, permeable to calcium and sodium and they are involved in 
endo-lysosomal trafficking, autophagy, mTOR and TFEB signaling[9]. Whether TPC2 is sodium 
or calcium permeable was subject of controversial debates in the last decade. While TPC2 
was first described as non-selective, calcium permeable cation channel activated by NAADP 
(3)[10-14], other research groups claimed that TPC2 was a sodium-selective channel activated 
by the endo-lysosomal phosphoinositide PI(3,5)P2 (4)[15, 16]. Both views independently received 
support in the past couple of years[5, 17-21] and the controversy has just recently been resolved[22] 
in the course of this project, as described in chapter 3.4.5.  
Two pore channels have been a hot topic in recent literature, not only because of their 
controversially discussed ion permeability but also because of their involvement in various 
diseases like viral and bacterial infections and cancer cell migration. This makes two pore 
channels a promising target for drug research.  
 
1.2 Two pore channels and disease 
As mentioned before, in recent years TPCs have emerged as highly exciting potential drug 
targets for a number of diseases associated with the endo-lysosomal system[23]. Dysfunction 
of TPCs has been found to interfere with cholesterol trafficking resulting in fatty liver disease[5], 
the β-adrenergic stimulation of glucagon secretion in diabetes[24] and β-adrenoceptor signaling 
in the heart in cardiovascular diseases[25]. Melanin production and pigmentation are also 
influenced by TPC activity[26-28]. Furthermore, Parkinson’s disease caused by LRRK2 
mutations has been linked to TPC functions[29]. In addition, several bacterial toxins such as 
diphtheria toxin, anthrax toxin, cholera toxin, or Pasteurella multocida toxin have been shown 
to require functional TPCs[4, 6]. Beside its role in bacterial infections, TPCs have been 
demonstrated to play a role in various infectious diseases such as Ebola filovirus, Middle East 
respiratory syndrome coronavirus (MERS-CoV), severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2), or HIV-1 retrovirus infections [2, 30-33]. Furthermore there is a 
growing amount of evidence that TPCs are necessary for sustaining cancer hallmarks like cell 
migration and neoangiogenesis[9, 34-36].  
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1.2.1 Two pore channels and cancer 
The role of TPCs in cancer research is complex, because TPCs are involved in different 
processes during carcinogenesis. The fact that prostate cancer patients with high levels of 
TPC2 gene expression showed poor survival probabilities was a strong evidence for the 
correlation between TPCs and cancer hallmarks[37]. Nguyen et al. confirmed these results and 
showed that silencing of TPC2 reduced migration and adhesion of invasive lung tumor cells[36]. 
The endo-lysosomal system promotes trafficking of integrins. During cell migration integrins 
pass the endocytic cycle. They are released from their substrate and taken back by 
endocytosis. If this recycling process is disturbed, cancer cell migration in vitro and metastasis 
in vivo are impaired[36]. Vascular endothelial growth factors (VEGF) play an important role 
during neoangiogenesis, including vascularization of solid tumors. Inhibition of VEGF reduces 
vessel formation, a fundamental step for the vascularization of solid tumors. Hence VEGF 
inhibitors are already used to treat cancer[38]. The role of TPC2-mediated calcium release in 
neoangiogenesis was demonstrated in TPC knockout mice. In TPC2, but not in TPC1, 
knockout mice the VEGF pathway was inhibited and vessel formation was reduced[35]. Whether 
TPCs and especially TPC2 are involved in other cancer hallmarks, such as proliferation and 
dysregulation of the cellular energy metabolism[38], remained largely unknown and was 
investigated in the studies presented in chapter 3.6.3.  
 
1.2.2 Two pore channels and viral infections 
Especially in the year 2020, viral infections are a hot topic. The corona pandemic has hospitals 
reaching their bed capacities, causing many deaths. The WHO is currently promoting a study 
for drug repurposing, including drugs that have already been in use for HIV and malaria 
therapy[39]. The connection between viral infections and two pore channel activity has already 
been shown for Ebola virus, MERS-CoV, HIV-1 and lately for the new SARS-CoV-2[2, 30-33]. Ou 
et al. described that SARS-CoV-2 enters the cell via endocytosis and that PIKfyve and TPC2 
were required for entering the cells[33]. The enzyme PIKfyve is responsible for phosphorylation 
of phosphatidylinositol 3-phosphate in C-5 position to PI(3,5)P2 (4), an endogenous compound 
that is activating TPCs and is regulating endo-lysosomal vesicle trafficking. Inhibition of the 
mucolipin TRPML1 (see chapter 1.3) using an unfortunately not further specified TRPML1 
inhibitor was ineffective, while inhibition of TPC2 with tetrandrine (1) halted the SARS-CoV-2 
entry[33]. Tetrandrine (1) has already been shown to successfully prevent Ebola virus infection 
by blocking TPC1 and TPC2 activity[2]. A link to the transporter protein Niemann-Pick C1 has 
been demonstrated for SARS-CoV[40], similar to Ebola virus[2]. For Ebola virus both isoforms of 
TPC, TPC1 and TPC2, are required for virus trafficking and infectivity while for SARS-CoV-2 
this correlation is not confirmed. Many facts are still unknown with respect to these correlations 
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and further investigation is of high interest. Having tailored tool compounds would surely boost 
studies to assess the correlation of TPCs and SARS-CoV-2 in more detail and would benefit 
the combat against viral infections.  
 
1.3 Modulators of two pore channels 
As part of the controversial debate about the ion permeability of TPCs, two different hydrophilic 
activators have been used in the past decade. The phosphoinositide phosphatidylinositol 3,5-
bisphosphate (PI(3,5)P2 (4)), a major constituent of endo-lysosomal membranes, has first been 
described by Dong et al.[41] as an activator of transient receptor potential mucolipin (TRPML) 
channels. TPCs and TRPMLs share PI(3,5)P2 (4) as activator but are only distantly related to 
each other in terms of sequence similarities[15, 16]. Both channel families share a number of 
functional features. They are non-selective cation channels located in endo-lysosomes and 
permeable to sodium and calcium. Both are involved in endo-lysosomal trafficking, autophagy, 
TFEB and mTOR signaling[9]. Thus, TPCs are, in addition to PI(3,5)P2 (4), activated by nicotinic 
acid adenine dinucleotide phosphate (NAADP (3))[10-14]. Both activators are highly hydrophilic 
and are not plasma membrane permeable. A plasma membrane permeable variant of NAADP 
(3), NAADP/AM (5) is commercially available[42, 43]. This lipophilic acetoxymethyl (AM) ester 
prodrug (5) is, however, due to its instability very limited in use (Figure 2).  
 
Figure 2: Phosphatidylinositol 3,5-bisphosphate (PI(3,5)P2 (4)) and NAADP (3) and its membrane 
permeable variant NAADP/AM (5). Inositol 4 carries phosphate glycerol esters and various fatty acids 
in C-1 position (e.g. n = 16 or 18). 
 
The same applies to the membrane permeable PI(3,5)P2 variant. Dinkel et al. published a 
synthesis for the PI(3,5)P2 variant with increased lipophilicity and membrane permeability. AM-
esters were introduced to protect phosphate residues, as it was already known from 
NAADP/AM (5), and the secondary alcohol groups were protected as butyrates[44]. 
Unfortunately, these derivatives are only available via an extensive, multi-step synthesis.  
As there is an urgent need for lipophilic, plasma membrane permeable small-molecule 
activators of TPCs, a high-throughput screening for the identification of novel, small-molecule 
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TPC2 activators was arranged. The screening of an 80.000 compound strong library obtained 
from Roche (Basel, CH) was performed within this project. 
For the identification of TPC inhibitors, different approaches were pursued. Penny et al. 
performed a virtual screening of Ebola virus entry inhibitors in order to identify possible TPC 
blockers[31]. The hits were confirmed as TPC2 inhibitors by blocking NAADP-evoked calcium 
release in a sea urchin egg homogenate model and via patch clamp experiments. This group 
identified different dopamine receptor-affine drugs and selective estrogen receptor modulators 
(SERMs) as additional TPC blockers: the anti-psychotics trifluoperazine, prochlorperazine, 
thioridazine and fluphenazine (6) as well as the SERMs clomiphene, tamoxifene, toremifene, 
bazedoxifene and raloxifene (7).  
 
Figure 3: Structures of TPC2 inhibitors. (A) Most promising TPC2 inhibitors identified by Penny et al.[31]: 
raloxifene (7) and fluphenazine (6). (B) The flavonoid naringenin (8) and trans-Ned-19 (2).  
 
The most promising TPC2 inhibitors identified by Penny et al., raloxifene (7) and fluphenazine 
(6), are approved drugs (Figure 3 A). Both exhibited low IC50 values in endo-lysosomal patch 
clamp experiments (0.63 µM and 8.2 µM) after stimulation with PI(3,5)P2 (4)[31]. The SERM 
raloxifene (7) is known to reduce breast cancer risk[45] and is used for treatment and prevention 
of osteoporosis. Moreover, it is limited in its approval to postmenopausal women regarding the 
influence upon hormone levels. It has also been reported that raloxifene (7) blocks L-type and 
T-type voltage-sensitive calcium channels[46, 47] as well as Kv4.3 channels[48]. Fluphenazine (6) 
is an anti-psychotic drug used to treat psychotic disorders such as schizophrenia with severe 
adverse effects, in particular extrapyramidal effects including acute dystonia, akathisia, tardive 
dyskinesia and Parkinsonism[49]. Fluphenazine (6) blocks postsynaptic mesolimbic 
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dopaminergic D1 and D2 receptors in the brain, neuronal voltage-gated sodium channels[50] 
and the ATP-sensitive potassium (KATP) channel[51].  
Besides its known broad spectrum of targets in mammalian organisms, the flavonoid 
naringenin (8, Figure 3 B) was also identified as a TPC2 blocker by Pafumi et al.[52]. 
Furthermore, it was investigated on its inhibitory effect in cell migration[53]. Naringenin (8) can 
also block several other ion channels: the melastatin channel TRPM3 (calcium channel)[54], 
voltage-gated sodium channels (Navs)[55] and cardiac HERG channels (potassium channel)[56]. 
Additionally it enhances the activity of large-conductance Ca2+-activated potassium (BK) 
channels[57]. However, naringenin (8) is most prominent for the inhibitory effect on cytochrome 
P450 enzymes like CYP1A2[58] or CYP3A4[59] – a property which bears the risk of undesired 
drug-drug interactions. 
The NAADP antagonist and therefore indirect TPC2 blocker trans-Ned-19 (2, Figure 3 B) has 
been known for many years[60] and the crystal structure solved by Kintzler and Stroud 
confirmed the interaction with TPCs[7], albeit discussed controversially.  
Examining these compounds, it is of interest that many of them are discussed in their 
relationship to cancer. Aforementioned, raloxifene (7) is known to reduce breast cancer risk[45]. 
Naringenin (8) was investigated on its inhibitory effect in cell migration[53] and to affect VEGF-
evoked tube formation[52] but requires very high concentrations (≥ 500 µM), as well as trans-
Ned-19 (2). The latter, trans-Ned-19 (2), was able to reduce NAADP-induced Ca2+ release and 
prevented the activation of the VEGF signaling pathway[35] as well as cancer cell migration[36] 
in high micromolar doses (≥ 100 µM). All these compounds are not applicable for in vivo 
experiments due to the side effects or required high doses. Though, there is an emerging need 
for the development of efficacious TPC2 inhibitors with drug-like properties and antitumor 
activity to study the involvement of TPC2 in cancer. 
Tetrandrine (1, Figure 3 A) is the most prominent TPC inhibitor in current literature and was 
first described as such by Sakurai et al. in 2015[2]. It is known to also block voltage-gated Ca2+ 
channels, large-conductance Ca2+-activated K+ (BK) channels and intracellular Ca2+ pumps[61]. 
Additionally, tetrandrine (1) was recently identified to effectively inhibit cancer cell migration[36] 
and infections with Ebola[2], MERS-CoV[30] and SARS-CoV-2[33] viruses. These effects were 
most likely induced via directly acting on TPCs. Tetrandrine (1) is used in different studies as 
exemplary TPC inhibitor and therefore represents a promising lead structure for the 
development of TPC2 blockers. 
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1.4 Tetrandrine (1) – opportunities and limitations 
The bisbenzylisoquinoline alkaloid tetrandrine (1) is isolated from the Asian plant Stephania 
tetrandra and is used in traditional Chinese medicine for treating asthma, tuberculosis, malaria 
or hyperglycemia[62]. Apart from its traditional applications, tetrandrine (1) is under 
pharmacological investigation. Its activity spectrum extends inflammations, antidiabetic 
effects, antimicrobial and anticancer activities, the use as antioxidant, P-gp and calcium 
channel inhibition[62], as depicted in Figure 4. Plenty of these pharmacological activities can 
also be related to TPCs, as tetrandrine (1) is a known TPC1 and 2 inhibitor[2]. Studies about 
viral infections (Ebola[2], MERS-CoV[30] and SARS-CoV-2[33]) and the influence of TPC2 were 
carried out using tetrandrine (1) but it is also under investigation for bacterial infections (e.g. 
Staphylococcus aureus)[63] or fungus (e.g. Candida albicans)[64]. Also for investigations in 
cancer research connected with TPCs, tetrandrine (1) is state-of-the-art[36]. Tetrandrine (1) was 
also highlighted in a study to prevent diabetes[65], which now can be related to its inhibitory 
effect on TPCs[24].  
 
Figure 4: Overview of the activity spectrum of tetrandrine (1).  
 
P-glycoprotein (P-gp) however, appears as novel target for tetrandrine (1), which was identified 
as a highly potent P-gp inhibitor[66, 67]. P-gp is an efflux pump with a broad substrate spectrum. 
These transporters pump foreign substances out of cells and are therefore responsible for 
multidrug resistance of tumors. Correlations to TPCs have not been investigated yet.  
Despite all these positive features tetrandrine (1) also has a few drawbacks. One example is 
the poor solubility. In some studies the sample preparation was not commented[68, 69] and 
others reported that they needed to acidify the injection solution for dissolution before in vivo 
application[2, 70]. These circumstances make tetrandrine (1) poorly applicable for in vivo studies. 
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Furthermore, a high toxicity is described in animal models. There are hints that the toxicity of 
tetrandrine (1) is based on oxidative metabolism by cytochromes P450s 3A4 and 3A5. The 
authors claimed that the methoxy group at C-12 (Figure 4) is metabolized to a free phenol and 
further oxidized to give a reactive para-quinone methide intermediate that can directly be 
trapped by bio-nucleophiles like glutathione[70, 71]. This toxicity is based on the reaction with 
other bio-nucleophiles like cysteine residues in proteins that would then be destroyed, while 
glutathione would detox the para-quinone methide intermediate. The broad activity spectrum 
of tetrandrine (1) is maybe related to its ability to inhibit TPC1 and 2, but other side effects are 
certain to occur and need to be reduced as well. 
The alkaloid is mainly obtained by extraction of the roots of Stephania tetrandra or by complex, 
multi-step chemical synthesis. The synthesis of enantiomerically pure tetrandrine (1) involves 
more than 20 steps[72]. A recently published synthesis from our research group shortened the 
sequence to 12 steps after which the racemic mixture of tetrandrine (1) is obtained[73].  
The opportunities and limitations of tetrandrine (1) generate a suitable basis for the 
development of this long known bioactive compound. The outlined drawbacks were aimed to 
be overcome in this project by simplification of the structure, substitutions and derivatizations.  
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2 Objectives 
TPCs are of rising importance. Involved in many diseases but mechanistically poorly 
understood, there is an emerging need for further investigations. Despite its drawbacks, 
tetrandrine (1) was the most promising candidate for developing new TPC inhibitors.  
New anti-cancer agents with the potential to block TPCs were e.g. easily accessible derivatives 
of tetrandrine (1) with modifications in C-5[74, 75] and C-14[76, 77] position, other related natural 
compounds like fangchinoline (9, also originated from Stephania tetrandra)[78], analogs of 
berbamine (10, from Berberis amurensis)[79], or seco-derivatives as dauricine (11, from 
Menispermum dauricum DC)[80] and neferine (12, from Nelumbo nucifera)[81], as depicted in 
Figure 5.  
 
Figure 5: Structures of the alkaloids fangchinoline (9), berbamine (10), dauricine (11) and neferine (12). 
Berbamine analogs are glycosides in C-12 position of berbamine (10). Differences to tetrandrine (1) are 
marked in red.  
 
All these molecules, however, lacked variability because they were obtained from natural 
extracts and their derivatization was restricted to certain functional groups. If isolation from 
plants was not possible or a diversified substitution pattern was encouraged, complex multi-
step syntheses need to be performed. Iturriaga-Vásquez et al. designed simplified and more 
accessible congeners of tetrandrine (1), only representing one benzylisoquinoline half of the 
molecule and carrying extensions like O-benzyl groups (Figure 6). These derivatives had 
similar potential to block L-type calcium channels (Cavs) like tetrandrine (1)[82]. The fact that 
TPCs were a family intermediate of channels related to voltage-gated calcium (Cav) and 
sodium channels (Nav)[83] suggested that these simplified structures could have high potential 
to block TPCs and further have high anticancer or antiviral activity. In addition, these truncated 
variants could overcome the lack of bioavailability, increase efficacy, be less toxic, more 
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specific, have a good solubility and are easily accessible and variable via a short, fast and 
efficient synthesis.  
 
Figure 6: Truncation of tetrandrine (1) should give monomers, resembling one half of tetrandrine (1)[82].  
 
To analyze TPC inhibitors in cellular systems the unique lysosomal patch clamp technique is 
required. Channel inhibition can be observed by this technique right after activation with the 
endogenous TPC2 activators PI(3,5)P2 (4) or NAADP (3). Though this is a complex technique 
and only a few people in the world are able to perform these complex experiments. In order to 
analyze large compound libraries of potential TPC2 blockers, an easily accessible 
experimental setup was crucial. Ca2+ imaging experiments, using different Ca2+ indicating dyes 
like Fura-2 (13) or Fluo-4 (14) are well known but require intact cells and cell-permeable 
activators.  
Therefore, novel small-molecule activators of TPC2 need to be identified first, synthesized and 
further analyzed to investigate their biological and pharmacological properties. These 
activators would then be used in a second step as chemical tools for the identification and 
analysis of TPC2 blockers, but in addition may play an independent role as lead structures for 
potential therapeutics in lysosomal storage diseases (LSDs).  
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3 Results and discussion 
The results of this thesis are presented in this section and are divided into two main parts, 
agonists and antagonists of TPC2.  
Starting with the performance of a high-throughput screening, the first part represents the 
identification of novel TPC2 activators. These hits were confirmed by synthesis, 
characterization and subsequent pharmacological experiments. Furthermore, analogs of these 
hits were synthesized to analyze structure-activity relationships (SAR). This was achieved by 
single cell Ca2+ imaging experiments. Concentration-effect relationships were analyzed and 
further results from cooperation partners are briefly described to present of the whole outcome 
of this interdisciplinary project.  
The second main part of this chapter describes the synthesis and characterization of truncated 
tetrandrine analogs as novel TPC2 inhibitors. A Ca2+ imaging protocol to analyze TPC2 
inhibitors, using our novel TPC2 activators, was developed. Biological activity of the inhibitors 
is of high interest and the effects on cancer were evaluated by cooperation partners. 
Furthermore, the enantiomers of the most promising substances were separated to distinguish 
between eutomer and distomer.  
Additionally, results of some side projects are presented and briefly described.  
 
3.1 Identification of novel TPC2 activators 
Lysosomal storage diseases (LSDs) are a very hot topic not only in academic research, but 
also in industrial research. A cooperative project with F. Hoffmann-La Roche (Basel, CH) 
provided the opportunity to use two of their compound libraries (Xplore X30 and X50) to 
perform a high-throughput screening (HTS). The aim of this screening was to identify novel 
activators of Battenin (CLN3) and TPC2. 
CLN3 is a putative lysosomal transporter or channel of unknown function but with a high 
relevance in inherited neurodegenerative disorder (Batten disease). Mutations in CLN3 lead to 
the loss of CLN3 function, causing Batten disease, also known as juvenile neuronal ceroid 
lipofuscinosis (JNCL) disease[84, 85]. Batten disease is the most common NCL with an onset of 
symptoms in childhood, characterized by progressive loss of vision, seizures, psychomotor 
disturbances and eventually premature death[86, 87]. As CLN3 and TPC2 are both lysosomal 
transmembrane proteins both proteins were screened in parallel serving as controls for each 
other.  
In cooperation with Dr. Phuong Nguyen from Prof. Dr. Angelika Vollmar’s group (LMU, Munich) 
and Prof. Dr. Michael Schaefer’s group (Rudolf Boehm Institute, Leipzig) the high-throughput 
RESULTS AND D ISCUSSION 
12 
screening was performed in Leipzig, using a custom-made fluorescence imaging plate reader 
(FLIPR) built into a robotic liquid handling station (for 96 tips), as previously described[88]. 
HEK293 cells stably expressing the plasma membrane variant of hTPC2, TPC2L11A/L12A-RFP 
and another cell line stably expressing the plasma membrane variant of hCLN3, 
CLN3L253A/I254A -RFP were used[22]. For the screening around 80.000 compounds on 221 384-
well plates from two different libraries (X50 and X30) were provided by Roche (Basel, CH). All 
compounds were tested on both cell lines and double positive hits were excluded to ensure 
the accuracy of the hits in a first instance.  
The membrane permeable, single-wavelength fluorescent dye Fluo-4/AM (15) was selected 
as Ca2+-indicator. With this indicator experiments in cell suspension were possible, which was 
ideal for high-throughput screenings (Figure 7 A). Fluo-4/AM (15) entered the cells as lipophilic 
ester and was hydrolyzed inside the cells by esterases. Resulting Fluo-4 (14) is barely 
fluorescent, but fluorescence increases at least 100 times on Ca2+ binding when excited at 
488 nm (Figure 7 B). An increase in fluorescence reflects rise in cytoplasmic Ca2+ levels 
caused by activation of the ion channels[89, 90]. 
 
Figure 7: The principle of Fluo-4 based Ca2+-imaging. (A) Short schematic overview of Fluo-4 based 
Ca2+-imaging. Fluo-4/AM (15) can enter the cell as a membrane permeable molecule. Esterases cleave 
the AM esters and the free dye 14 remains. Fluo-4 (14) can complex Ca2+ ions which results in increased 
fluorescence at 516 nm. (B) Structures of Fluo-4/AM (15) and the free Fluo-4 (14) anion. 
 
Compounds were screened on both cell lines. Hitlists of single hits were generated giving a 
total amount of 118 CLN3 primary hits and 133 TPC2 primary hits (Figure 8 A). Since 
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availability of the compounds as well as the quantity was limited, only the strongest hits 
(highest fluorescence increase) for each cell line were selected and further investigated by 
concentration-effect experiments. Thus, only 25 CLN3 primary hits and 12 TPC2 primary hits 
were further considered. Concentration-effect experiments in the range of 50 µM to 24 nM 
resulted in two secondary CLN3 hits (A09 and C15) and four secondary TPC2 hits (N19, N10, 
H07 and L13). These secondary hits were all evaluated in Fura-2 based Ca2+-imaging 
experiments (see chapter 3.4 for the method). None of the analyzed CLN3 hits showed a 
specific activation. One TPC2 hit had no effect and another one showed unspecific or toxic 
effects. Hence only two final hits for TPC2 (N19, named TPC2-A1-N (16) and H07, named 
TPC2-A1-P (17)) remained that were able to activate the TPC2 ion channel (Figure 8 B). The 
activity of these two compounds was further confirmed by the electrophysiological endo-
lysosomal patch clamp technique.  
 
Figure 8: Summary of the high-throughput screening. (A) Simplified overview for the stepwise 
identification of the two TPC2 screening hits. (B) Structure of the two screening hits N19 (new name: 
TPC2-A1-N (16)) and H07 (new name: TPC2-A1-P (17)), as presented to us by Roche (Basel, CH). 
 
To verify the postulated structure and assess SAR, generally applicable syntheses for both 
hits had to be developed and the resulting compounds had to be re-evaluated via Fura-2 
calcium imaging 
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3.2 Synthesis of TPC2-A1-N (16) and analogs 
Starting with TPC2-A1-N (16), first a synthesis to confirm the structure of the hit had to be 
developed. A fast, efficient and versatile synthesis was desired. Thus, a compound library can 
be generated to examine SAR. Variations of both aromatic rings, the necessity of a secondary 
amide, as well as the extension of the middle part were investigated. Sjogren et al. published 
a two-step synthesis for related α-cyano-β-hydroxypropenamides, which resulted in exactly the 
desired scaffold of TPC2-A1-N (I, Scheme 1)[91]. 
 
Scheme 1: Retrosynthetic overview showing the synthesis of α-cyano-β-hydroxypropenamides (I) in 
two steps. By using different aniline (IV) and benzoic acid (III) building blocks, a large variability of 
combinations is possible.  
 
Following these procedures an C-acylation using different activated benzoic acid building 
blocks (III, Scheme 1) and NaH as strong base should easily yield desired 
hydroxypropeneamides (I, Scheme 1). Therefore the required α-cyano amide (II, Scheme 1) 
could be synthesized using different aniline building blocks (IV, Scheme 1), 2-cyanoacetic 
acid (18) and a standard coupling reagent as DCC. This synthesis resulted in the desired 
α-cyano-β-hydroxypropenamides (I, Scheme 1) in only two steps and without need for 
purification by column chromatography, which gave the opportunity to establish a broad 
compound library.  
 
Scheme 2: Synthesis of 2-cyano-N-(4-(trifluoromethyl)phenyl)acetamide (SGA-34, 19), according to 
Sjogren et al.[91].  
 
Starting with the structure confirmation of the hit TPC2-A1-N (16) commercially available 
4-(trifluoromethyl)aniline (20), 2-cyanoacetic acid (18) and DCC were used in DMF. After one 
hour the reaction was completed. Purification by filtration and recrystallization yielded the pure 
2-cyano-N-(4-(trifluoromethyl)phenyl)acetamide (SGA-34, 19) in high yield (73%, Scheme 2). 
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Only a few modifications in equivalents were made compared to the original literature in order 
to achieve the best results. For the synthesis of variably substituted α-cyano amides this 
method was applied (II, Table 1). This resulted in mainly p-substituted α-cyano amides (entry 
1-14, Table 1), as well as unsymmetrically (entry 15-19, Table 1) and symmetrically substituted 
aryls (entry 20, 21, Table 1). Electron-withdrawing groups like halide, nitro, nitrile or carbonyl 
substituents represented the majority. The methyl group (entry 2, Table 1) was introduced as 
the electron-donating bioisostere to the screening hit’s trifluoromethyl group (entry 1, Table 1). 
A variant with a tertiary amide (entry 22, Table 1) and another one being derived from a 
benzylamine (entry 23, Table 1) completed the α-cyano amides. Yields were all moderate to 
high, very poor only for N-benzyl-acetamide (entry 23, Table 1).  
Table 1: Overview of the results for the synthesis of α-cyano amides (II). Different aniline building blocks 
(IV and a homologous benzylamine in entry 23) and 2-cyanoacetic acid (18) were used as starting 
materials.  
 
entry starting material (IV) product  (II) yield 
1 R = 4-CF3 (20) 2-cyano-N-(4-(trifluoromethyl)phenyl)acetamide (SGA-34, 19) 73% 
2 R = 4-CH3 2-cyano-N-(p-tolyl)acetamide (21) 71% 
3 R = H 2-cyano-N-phenylacetamide (22) 76% 
4 R = 4-OCH3 2-cyano-N-(4-methoxyphenyl)acetamide (23) 41% 
5 R = 4-Cl N-(4-chlorophenyl)-2-cyanoacetamide (24) 77% 
6 R = 4-Br N-(4-bromophenyl)-2-cyanoacetamide (25) 40% 
7 R = 4-F 2-cyano-N-(4-fluorophenyl)acetamide (26) 75% 
8 R = 4-I 2-cyano-N-(4-iodophenyl)acetamide (27) 77% 
9 R = 4-NO2 2-cyano-N-(4-nitrophenyl)acetamide (28) 62% 
10 R = 4-CN 2-cyano-N-(4-cyanophenyl)acetamide (29) 78% 
11 R = 4-Ac N-(4-acetylphenyl)-2-cyanoacetamide (30) 54% 
12 R = 4-OPr 2-cyano-N-(4-propoxyphenyl)acetamide (31) 62% 
13 R = 4-OCF3 2-cyano-N-(4-(trifluoromethoxy)phenyl)acetamide (32) 72% 
14 R = 4-COOCH3 methyl 4-(2-cyanoacetamido)benzoate (33) 65% 
15 R = 2-Br, 4-Cl N-(2-bromo-4-chlorophenyl)-2-cyanoacetamide (34) 69% 
16 R = 2-I 2-cyano-N-(2-iodophenyl)acetamide (35) 70% 
17 R = 2,4-F2, 3-Cl N-(3-chloro-2,4-difluorophenyl)-2-cyanoacetamide (36) 68% 
18 R = 3,4-(OCH3)2 2-cyano-N-(3,4-dimethoxyphenyl)acetamide (37) 76% 
19 R = 2,3-Cl2 2-cyano-N-(2,3-dichlorophenyl)acetamide (38) 29% 
20 R = 2,6-Br2 2-cyano-N-(2,6-dibromophenyl)acetamide (39) 40% 
21 R = 3,5-(CF3)2 N-(3,5-bis(trifluoromethyl)phenyl)-2-cyanoacetamide (40) 81% 
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22 N-methyl-4-(trifluoromethyl)aniline 
2-cyano-N-methyl-N-(4-
(trifluoromethyl)phenyl)acetamide (41) 74% 
23 4-(trifluoromethyl) benzylamine 2-cyano-N-(4-(trifluoromethyl)benzyl)acetamide (42) 7% 
 
For the synthesis of TPC2-A1-N (16) acylation of the appropriate α-cyano acetamide (SGA-
34, 19) was performed using 3,5-dichlorobenzoyl chloride (43) and NaH in THF[91]. After one 
hour the reaction was completed and purification by filtration and recrystallization yielded pure 
2-cyano-3-(3,5-dichlorophenyl)-3-hydroxy-N-(4-(trifluoromethyl)phenyl)acrylamide (TPC2-A1-
N, 16) in high yield (69%, Scheme 3). NMR analysis of TPC2-A1-N (16) showed that the enol-
form is favored compared with the keto-form, as described below. 
 
Scheme 3: Synthesis of 2-cyano-3-(3,5-dichlorophenyl)-3-hydroxy-N-(4-(trifluoromethyl)phenyl)-
acrylamide (TPC2-A1-N, 16), following a procedure published by Sjogren et al.[91].  
 
This procedure was beneficial in many ways. It was fast and the easy work up gave highly pure 
crystalline products. These products did not need purification by FCC, which saved time and 
material. Furthermore FCC would also cause problems, as it is reported that 1,3-diketones 
form chelate complexes with metal ions, e.g. Fe3+[91-93]. The commonly used silica in chemical 
laboratories contains slight impurities of Fe3+, which would result in colorful contaminated 
products. Different α-cyano amides (II, Table 2) were already prepared and plenty benzoic 
acid building blocks (III) were commercially available. Depending on biological results a 
variety of compounds could be synthesized by different combinations of these building blocks. 
Hence, a set of α-cyano-β-hydroxypropenamides (I, Table 2) was synthesized using this 
method. This resulted in a compound library of 44 TPC2-A1-N analogs. The newly synthesized 
α-cyano amides (blue, II, Table 2) were used for different moieties on the anilide side (blue, 
entry 1-7, 10, 11, 14, 15, 18-20, 27-32, 43, Table 2) of the molecule. Widely varying benzoic 
acid building blocks (green, III, Table 2) were commercially available, which gave the 
opportunity to introduce 17 different aryl groups (green, entry 1, 8, 9, 12, 13, 17, 21-23, 34, 36-
39, 41, 42, 44, Table 2). Combinations of different amide (II, Table 2) and benzoic acid (III, 
Table 2) building blocks resulted in 6 more compounds (entry 16, 24-26, 33, 35, Table 2). One 
variant with a tertiary amide (entry 40, Table 2) and another one replacing the anilide moiety 
with a benzyl amide (entry 45, Table 2), completed the compound list. Nearly all yields are 
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moderate to high, which indicates that this protocol is extendable to a wide variety of α-cyano 
amides (II, Table 2) and benzoic acid building blocks (III, Table 2).  
Table 2: Overview of the results for the synthesis of α-cyano-β-hydroxypropenamides (I). Different 
benzoic acid building blocks (III) are combined with the α-cyano amides (II). *If the appropriate acid 
chloride was not commercially available, the benzoic acid was converted into the acid chloride using 
thionyl chloride.  
 
entry amide (II) benzoic acid 
chloride* (III) product (I) yield 
1 R = 4-CF3  (SGA-34, 19) R = 3,5-Cl2 (43) 
 
69% 
2 R = H (22) R = 3,5-Cl2 (43) 
 
68% 
3 R = 4-Cl (24) R = 3,5-Cl2 (43) 
 
70% 
4 R = 4-Br (25) R = 3,5-Cl2 (43) 
 
70% 
5 R = 4-CH3 (21) R = 3,5-Cl2 (43) 
 
53% 
6 R = 4-F (26) R = 3,5-Cl2 (43) 
 
63% 
7 R = 4-I (27) R = 3,5-Cl2 (43) 
 
61% 
8 R = 4-CF3  (SGA-34, 19) R = H 
 
56% 
9 R = 4-CF3  (SGA-34, 19) R = 3,5-(NO2)2 
 
29% 
10 R = 4-OCH3 (23) R = 3,5-Cl2 (43) 
 
61% 
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11 R = 4-NO2 (28) R = 3,5-Cl2 (43) 
 
55% 
12 R = 4-CF3  (SGA-34, 19) R = 4-NO2 
 
69% 
13 R = 4-CF3  (SGA-34, 19) R = 4-Cl 
 
61% 
14 R = 2-Br, 4-Cl (34) R = 3,5-Cl2 (43) 
 
74% 
15 R = 3,4-(OCH3)2 (37) R = 3,5-Cl2 (43) 
 
51% 
16 R = H (22) 1-methylpyrrole-2-
carbonyl chloride 
 
75% 
17 R = 4-CF3  (SGA-34, 19) 
1-methylpyrrole-2-
carbonyl chloride 
 
66% 
18 R = 2,4-F2, 3-Cl (36) R = 3,5-Cl2 (43) 
 
72% 
19 R = 4-CN (29) R = 3,5-Cl2 (43) 
 
38% 
20 R = 2-I (35) R = 3,5-Cl2 (43) 
 
52% 
21 R = 4-CF3  (SGA-34, 19) R = 2,3,4,5,6-F5  
 
56% 
22 R = 4-CF3  (SGA-34, 19) R* = 3,5-Br2 
 
42% 
23 R = 4-CF3  (SGA-34, 19) R = 2,4,6-Cl3 
 
36% 
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24 R = 4-Br (25) R = 2,4,6-Cl3 
 
51% 
25 R = 2,4-F2, 3-Cl (36) R = 2,4,6-Cl3 
 
50% 
26 R = 4-Br (25) R* = 3,5-Br2 
 
44% 
27 R = 4-Ac (30) R = 3,5-Cl2 (43) 
 
79% 
28 R = 2,6-Br2 (39) R = 3,5-Cl2 (43) 
 
13% 
29 R = 2,3-Cl2 (38) R = 3,5-Cl2 (43) 
 
86% 
30 R = 4-OPr (31) R = 3,5-Cl2 (43) 
 
63% 
31 R = 3,5-(CF3)2 (40) R = 3,5-Cl2 (43) 
 
68% 
32 R = 4-OCF3 (32) R = 3,5-Cl2 (43) 
 
83% 
33 R = 2,4-F2, 3-Cl (36) R* = 3,5-Br2 
 
76% 
34 R = 4-CF3  (SGA-34, 19) acetyl chloride 
 
76% 
35 R = 4-CH3 (21) R = 3,5-(CF3)2 
 
50% 
36 R = 4-CF3  (SGA-34, 19) R = 3,5-(CF3)2 
 
76% 
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37 R = 4-CF3  (SGA-34, 19) R = 3,5-(CH3)2 
 
49% 
38 R = 4-CF3  (SGA-34, 19) R = 3,5-(OCH3)2 
 
79% 
39 R = 4-CF3  (SGA-34, 19) R = 4-OCF3 
 
48% 
40 N-methyl-acetamide (41) R = 3,5-Cl2 (43) 
 
48% 
41 R = 4-CF3  (SGA-34, 19) nicotinoyl chloride 
 
51% 
42 R = 4-CF3  (SGA-34, 19) R* = 3-Br, 5-I 
 
62% 
43 R = 4-COOCH3 (33) R = 3,5-Cl2 (43) 
 
85% 
44 R = 4-CF3  (SGA-34, 19) 
5-chloronicotinic 
acid* 
 
61% 
45 benzyl-acetamide (42) R = 3,5-Cl2 (43) 
 
55% 
 
The methyl ester group of SGA-133 (85, entry 43, Table 2) could easily be converted into the 
free carboxylic acid using alkaline hydrolysis. With an excess of LiOH, the ester was cleaved 
within 3 h at room temperature. Precipitation gave the free acid SGA-137 (88) in high yield 
(Scheme 4).  
 
Scheme 4: Deprotection of ester SGA-133 (85) using alkaline conditions gave the free acid SGA-137 
(88). 
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Sjogren et al. applied a second method to generate α-cyano-β-hydroxypropenamides (I, Table 
2). This procedure was using benzoic acid building blocks (III, Table 2) and acetonitrile to give 
3-oxopropanenitriles and condensed these with isocyanates or isothiocyanates[91]. More 
precisely the thioamide analog of TPC2-A1-N (16) was synthesized this way within an Erasmus 
project, as depicted in Scheme 5. Benzoyl chloride 43 together with the lithium salt of 
acetonitrile gave the 3-oxopropanenitrile 89. Subsequent condensation with arylisothiocyanate 
90 in the presence of NaH yielded SGA-167 (91) in moderate yields, which was in accordance 
with literature[91]. Due to a complex work-up of the intermediate 89, yields were not as high as 
on the first route.  
 
Scheme 5: Synthesis of SGA-167 (91) according to Sjogren et al.[91].  
 
Structural analysis of TPC2-A1-N (16) and analogs was a more difficult process as expected. 
1H-NMR analysis showed mainly aromatic signals and 13C NMR spectra of the numerous 
fluorinated products showed plenty carbon fluorine splits. The carbon fluorine coupling resulted 
in 1J coupling constants of around 270 Hz, 2J coupling constants of around 30 Hz, 3J coupling 
constants of around 3.5 Hz and a multiplicity of n + 1. The 1J coupling constant was observed 
in every 13C spectrum of a fluorine containing substance, the more distant ones were only 
observed in the absence of heteroatoms. As known from related 1,3-dicarbonyl compounds 
such as acetylacetone, two tautomeric structures are possible, the keto- and the enol-form, 
which could also be observed by 1H-NMR. It is reported, that the enol-form of acetylacetone is 
more stable than the keto-form, due to the formation of a hydrogen bond between one carbonyl 
and the enol-hydroxy group[94]. For β-ketoamides a hydrogen bond between the β-ketone 
group and the amide NH is also possible (“keto-amide” form; Scheme 6). Both forms were 
found by Laurella et al. in studies of tautomeric equilibria of β-ketoamides. Furthermore these 
authors discovered that electron-withdrawing groups at the benzoyl ring stabilize the enol-
amide tautomer, electron donors stabilize the keto-amide form and bulky groups in C-2 position 
favor the enol-form as well[95]. Transferred to the scaffold of TPC2-A1-N (16), the enol-tautomer 
was more likely to be the fitting style, as the nitrile residue is highly electronegative. This was 
further confirmed by NMR analysis. In most 1H-NMR spectra no standard or shifted hydroxyl 
group was observed, but nevertheless no proton in C-2 position was found. In addition, this 
carbon was always indicated as quaternary in 13C/HSQC analysis.  
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Scheme 6: Keto-enol tautomerism of the blank TPC2-A1-N scaffold. The two most likely tautomers to 
occur are displayed, the keto-amide (left) and the enol-amide (right). Both structures are able to form a 
hydrogen bond to stabilize the conformation.  
 
Collectively, 47 compounds were synthesized in moderate to high yields, including the hit 
TPC2-A1-N (16), the amide SGA-34 (19) as half of the molecule, two drugs (prinomide (58) 
and teriflunomide (76)) and a large variety of analogs. All of them were fully characterized by 
NMR, TLC, HRMS, IR and melting points and the purities were confirmed by analytical HPLC.  
 
3.3 Synthesis of TPC2-A1-P (17) and analogs 
The same procedure as for TPC2-A1-N (16) needed to be applied for TPC2-A1-P (17). In more 
detail, the hit TPC2-A1-P (17) needed to be confirmed, a synthesis to generate TPC2-A1-P 
(17) and analogs had to be developed and a variety of analogs had to be synthesized and 
characterized for structure-activity analysis.  
Examining the structure of TPC2-A1-P (17) the highly substituted pyrrole moiety stands out. 
Pyrrole syntheses have been known for decades and syntheses of highly substituted pyrroles 
were thoroughly examined by many groups. Nevertheless, construction of the appropriately 
substituted pyrrole ring was the key step. The free carboxylic acid (I, Scheme 7) could be 
generated by alkaline deprotection of an ester intermediate (II, Scheme 7), which is generated 
by suitable pyrrole synthesis. The easily available and variable α-halogenated acetophenone 
(IV, Scheme 7), β-ketoester (V, Scheme 7) and primary amine (III, Scheme 7) building blocks 
are the basis for pyrrole formation (Scheme 7).  
 
Scheme 7: Retrosynthetic overview for the synthesis of TPC2-A1-P (17) and analogs (I) derived from 
different α-halogenated acetophenone (IV), β-ketoester (V) and primary amine (III) building blocks.  
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The Hantzsch pyrrole synthesis is one famous reaction to generate pyrroles[96]. Condensation 
of primary amine (III, Scheme 8) and β-ketoester (V, Scheme 8) building blocks gives an 
enamino ester intermediate (VI, Scheme 8). C-Alkylation by the α-halogenated acetophenone 
(IV, Scheme 8) gives a 2-substituted enamino ester (VII, Scheme 8) which undergoes 
intramolecular cyclocondensation to give the desired 2,3,5-trisubstituted pyrrole (II, Scheme 
8)[96-98].  
 
Scheme 8: Commonly accepted mechanism for the Hantzsch pyrrole synthesis, yielding a multi-
substituted pyrrole (II). 
 
Zhao et al. published a microwave-assisted one-pot method for the synthesis of N-substituted 
2-methyl-1H-pyrrole-3-carboxylate derivatives[99]. This method is notable because of the 
absence of solvents and catalysts as well as the fast and easy implementation. The appropriate 
α-halogenated acetophenone to yield TPC2-A1-P (17) is not commercially available. 
Therefore, two commercially available α-bromo acetophenones (92 and 93) were used for 
model reactions. Hereby, building block 93 would provide a product very similar to TPC2-A1-
P (17), with only the trifluoromethoxy group being replaced by a methoxy group. Together with 
β-ketoester (94) and cyclohexanemethanamine (95) they were added into one microwave 
reactor each. After irradiation at 8 bar and 240 °C for 1 h, no residues of bromoacetophenones 
92 and 93 were detected. Pyrrole 96 was isolated in low yield, though no product formation 
could be observed for the pyrrole 97 closely related to TPC2-A1-P (17) (Scheme 9). Hence 
this method was not further pursued.  
 
Scheme 9: Synthetic approach for the Hantzsch pyrrole synthesis to yield the methoxy analog of TPC2-
A1-P 97 and ester 96. 
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Another method, related to the Hantzsch synthesis, is the Paal-Knorr pyrrole synthesis[100, 101]. 
Condensation of 1,4-diketone building blocks (VIII, Scheme 10) with a primary amine building 
block (III, Scheme 10) under protic or Lewis acidic conditions yields multi-substituted pyrroles 
(II, Scheme 10)[102]. The drawback of this method is, that the 1,4-diketone building blocks 
(VIII, Scheme 10) have to be synthesized in an additional step. A procedure, published by 
Kang et al.[103], exactly describes this route. With α-halogenated acetophenone (IV, Scheme 
10) and β-ketoester (V, Scheme 10) building blocks 1,4-diketones (VIII, Scheme 10) are 
synthesized using NaH as base. The authors used ammonium acetate in acetic acid to yield 
N-unsubstituted pyrroles, or primary amine building blocks (III, Scheme 10) with p-
toluenesulfonic acid in ethanol to receive N-alkyl pyrroles[103]. Most primary amine building 
blocks (III, Scheme 10) that will be used are liquids, therefore they don’t need organic solvents 
to be dissolved and acetic acid is chosen as preferred acid.  
 
Scheme 10: General reaction equation for the formation of 1,4-diketone building blocks (VIII)[103] and 
subsequent Paal-Knorr pyrrole synthesis yielding a highly substituted pyrrole derivative (II)[102]. 
 
In model reactions α-bromoacetophenones 92 and 93 together with β-ketoester 94, KI and 
NaH gave the 1,4-diketones 98 and 99. After standard work-up these diketones (98 and 99) 
were pure enough for further proceedings and following Paal-Knorr reaction using 
cyclohexanemethanamine (95) yielded pyrroles SGA-43 (96) and SGA-54 (97) in high yields 
over two steps. KI was added for an in situ Finkelstein reaction to boost the conversion of the 
first step. For the sake of time and material savings the 1,4-diketone building blocks (VIII, 
Scheme 10) were used right away after preparation, without further purification or analysis.  
 
Scheme 11: Model reactions for the synthesis of 2,3,5-trisubstituted pyrroles, yielding SGA-43 (96) and 
SGA-54 (97).  
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The final step in the synthesis of the desired carboxylic acids was the deprotection of the 
esters. Esters can be cleaved by hydrolysis in acidic or alkaline conditions. Kang et al. 
described a method using NaOH[103], which is the reason why alkaline conditions were chosen. 
For screening of deprotection conditions ester SGA-43 (96) was chosen. Using NaOH in 
dioxane/H2O at room temperature only gave starting material after 15 h (entry 1, Table 3). 
Changing to LiOH, THF/H2O[104] and reflux gave the same result (entry 2, Table 3), as well as 
refluxing with NaOH in dioxane/H2O[105] (entry 3, Table 3). A pressure tube was used to 
increase the power of the reaction, but still no deprotection was observed (entry 4, Table 3). 
To generate maximum power, a microwave reaction was applied. With dioxane/H2O rough 
conditions could be achieved and after 2 h total conversion of the ester 96 was observed (entry 
5, Table 3). For better handling LiOH was examined, also giving the carboxylic acid 100 in 
high yield (entry 6, Table 3). 
Table 3: Screening of conditions for the ester saponification using SGA-43 (96).  
 
entry base solvent temperature / conditions time product 
1 NaOH dioxane/H2O (5:1) rt 15 h only s.m. 
2 LiOH THF/H2O (4:1) 60 °C / reflux condenser 12 h only s.m. 
3 NaOH dioxane/H2O (5:1) 100 °C / reflux condenser 15 h only s.m. 
4 NaOH dioxane/H2O (5:1) 100 °C / pressure tube  18 h only s.m. 
5 NaOH dioxane/H2O (5:1) microwave reactor (pmax = 8 bar, Pmax = 80 W, Tmax = 160 °C) 2 h 93% 
6 LiOH dioxane/H2O (5:1) microwave reactor (pmax = 8 bar, Pmax = 200 W, Tmax = 180 °C) 2 h 89% 
 
With this newly developed method for the synthesis of carboxylic acid (I, Scheme 10), only 
the access to the starting materials needed to be examined. Most starting materials are 
commercially available and just two α-halogenated acetophenones (IV, Scheme 10) had to 
be synthesized to give all designed analogs for complete structure-activity relationships: 2-
Bromo-1-(2-(trifluoro-methoxy)phenyl)ethan-1-one (101) and 1-(5-bromo-2-(trifluoromethoxy)-
phenyl)-2-chloroethan-1-one (102).  
Inspired by a poorly detailed patented procedure[106] mono-bromination of 2'-(trifluoromethoxy)-
acetophenone (103) was carried out under acidic conditions. Only one equivalent of N-
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bromosuccinimide (NBS) and a catalytic amount of p-toluenesulfonic acid were used to yield 
the desired bromoketone 101 in moderate yield (Scheme 12).  
 
Scheme 12: Mono-bromination of acetophenone 103 in acidic conditions to give bromoketone 101.  
 
For the synthesis of the hit TPC2-A1-P (17), chloroketone 102 needed to be synthesized. 
Schlosser et al. published a procedure for lithiation of 1-bromo-4-(trifluoromethoxy)benzene 
(104) with LDA at C-3 (directed metalation), followed by carboxylation at -100 °C with dry 
ice[107]. The authors claimed that these conditions reduce the competing ortho- or meta-
lithiation (positions to the OCF3 group) in a ratio of 99:1 to receive a regioselective ortho-
product. As the desired ortho-lithiation is favored, the reaction was carried out at -78 °C using 
the Weinreb amide 2-chloro-N-methoxy-N-methylacetamide (105) instead of dry ice. Though 
the desired α-chloroketone 102 did not occur and only decomposition of the starting material 
was observed (a, Scheme 13). Same applied to the use of freshly prepared LDA, according 
to Schlosser et al. (b, Scheme 13)[107]. Furthermore a Friedel-Crafts acylation was performed, 
using AlCl3 and chloroacetyl chloride in 1,2-dichloroethane (EDC), but no product formation 
was observed (c, Scheme 13).  
 
Scheme 13: Attempted chloroacetylation of 104. Different reaction conditions were screened. a) 104, 
LDA, THF, -78 °C, 4 h; then 2-chloro-N-methoxy-N-methylacetamide (105) in THF, -78 °C, 5 min. b) 
104, LDA, generated out of DIPA and n-BuLi, -78 °C, 2 h; then 2-chloro-N-methoxy-N-methylacetamide 
(105) in THF, -78 °C, 5 min. c) 104, AlCl3, chloroacetyl chloride, EDC, 0 °C – 50 °C, 5 h.  
 
Lui et al. developed a method for the oxidative trifluoromethylation of phenols[108]. Among their 
examples there were ortho- and para-halogenated phenols, which seemed promising. The 
reaction was performed with commercially available phenol 106 in a custom made glove box, 
but again no product could be isolated (Scheme 14). 
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Scheme 14: Reaction conditions for the attempted trifluoromethylation of phenol 106.  
 
Another attempt to synthesize chloroketone 102 involved an iodine-lithium exchange, which 
should be favored over the bromo-lithium exchange[109]. Weinreb amide 105 was used to give 
the ketone 102 in order to avoid side reactions and over-additions. According to Nahm and 
Weinreb, a stable chelate complex is formed as intermediate, which avoids further additions to 
the ketone. Aqueous acidic work up then could yield the desired ketone (Scheme 15 A)[110]. 
The reaction was performed using commercially available iodine 108 and n-BuLi at -78 °C. 
After 20 minutes, Weinreb amide 105 was added and the reaction was monitored by TLC and 
NMR. The NMR sample was taken from the reaction mixture and after mini work-up dried 
under nitrogen flow. 1H-NMR analysis clearly showed total conversion of the starting material 
and formation of a new substance with all NMR signals required for the desired ketone 102 
after 1 h. After standard work-up of the whole reaction and NMR analysis of the material, no 
product could be observed anymore. Therefore, it was assumed that the desired ketone 102 
was highly volatile and not even stable under reduced pressure, as a rotary evaporator 
generates (40 °C, 1 mbar). The newly developed work-up avoided rotary evaporation. The 
product was dried overnight under a nitrogen flow and gave ketone 102 in moderate yield 
(Scheme 15 B).  
 
Scheme 15: Synthesis of α-chloroketone 102 using in situ generated organolithium reagents and 
Weinreb amide 105. (A) Reaction mechanism according to M. Weinreb[110]. (B) Successful reaction 
conditions for the synthesis of α-chloroketone 102. 
 
RESULTS AND D ISCUSSION 
28 
With all building blocks at hand and a well-established route, the synthesis of TPC2-A1-P (17) 
and analogs could be applied. Finally ester SGA-140 (109, entry 1, Table 4) could be 
synthesized in moderate yield using α-chloroketone 102, ethyl acetoacetate (94) and 
cyclohexanemethanamine (95). Deprotection of ester 109 gave the hit compound TPC2-A1-P 
(17) in good yield. Varying the α-halogenated ketone building block (IV, Table 4) allowed the 
synthesis of seven more esters that were all isolated in moderate to high yields (entry 2-7, 13, 
Table 4). The bioisosteric ester SGA-54 (97) was lacking the trifluoromethoxy group at C-2 
position of the aromatic ring and was instead bearing a methoxy group (entry 3, Table 4). The 
2,5-dichloro variant SGA-48 (110) also shared the substitution pattern of the hit compound 
(entry 4, Table 4). Esters SGA-59 (111) and SGA-61 (112) both had para-substituents (entry 
5, 6, Table 4) and SGA-62 (113) was the 2,4-difluoro analog (entry 7, Table 4). Ester 114 was 
lacking the bromine in C-5 position of the aromatic ring (entry 13, Table 4). All of these esters 
were further deprotected to yield the carboxylic acids SGA-50 (100), SGA-55 (115), SGA-52 
(116), SGA-66 (117), SGA-67 (118), SGA-68 (119) and SGA-162 (120) in moderate to high 
yields (entry 2-7, 13, Table 4). These compounds had in common that their α-halogenated 
ketone building blocks (IV, Table 4) were stable, which is the reason why they could be easily 
purified. Simple FCC yielded the pure esters. Purification attempts of esters synthesized with 
the volatile α-chloroketone 102 were very complicated and time consuming. A first set of 
biological experiments revealed that the ester SGA-140 (109) does in comparison to the 
carboxylic acid TPC2-A1-P (17) not show any effect in Ca2+ imaging experiments (Figure 15). 
Therefore there was no need to purify and isolate the pure esters anymore and FCC was just 
performed as a pre-cleaning process. This was of great importance, because the precipitating 
of the carboxylic acids was otherwise not successful and additional extractions had to be 
included. The absence of colorful impurities was critical as this would disturb experiments using 
fluorescent dyes.  
Table 4: Products synthesized according to the newly elaborated method for the synthesis of highly 
substituted pyrrolecarboxylic acids (I). *cy = cyclohexyl 
 
entry R1 R R2 ester (II) acid (I) 
1 R = 2-OCF3, 5-Br  R = CH3 R = CH2cy* 
 
46% 
 
54% 
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2 - R = CH3 R = CH2cy* 
 
53% 
 
89% 
3 R = 2-OCH3, 5-Br R = CH3 R = CH2cy* 
 
95% 
 
63% 
4 R = 2,5-Cl2 R = CH3 R = CH2cy* 
 
46% 
 
81% 
5 R = 4-F R = CH3 R = CH2cy* 
 
97% 
 
88% 
6 R = 4-OCH3 R = CH3 R = CH2cy* 
 
51% 
 
90% 
7 R = 2,4-F2 R = CH3 R = CH2cy* 
 
78% 
 
88% 
8 R = 2-OCF3, 5-Br  R = CH3 R = pentyl not isolated 
 
15% overall yield 
9 R = 2-OCF3, 5-Br  R = CH3 R = benzyl not isolated 
 
10% overall yield 
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10 R = 2-OCF3, 5-Br  
R = 
CH2CH3 R = CH2cy* not isolated 
 
9% overall yield 
11 R = 2-OCF3, 5-Br  R = CH3 R = iPr not isolated 
 
12% overall yield 
12 R = 2-OCF3, 5-Br  R = phenyl R = CH2cy* not isolated 
 
28% overall yield 
13 R = 2-OCF3 R = CH3 R = CH2cy* 
 
95% 
 
93% 
 
Different β-ketoester building blocks (V, Table 4) were used to generate SGA-152 (121) and 
SGA-154 (122), both with larger residues in C-2 position of the pyrrole (entry 10, 12, Table 4). 
Modifications in 1-position of the pyrrole were achieved with altering primary amine building 
blocks (III, Table 4) to give carboxylic acids SGA-149 (123) with a long and SGA-153 (124) 
with a branched side chain as well as SGA-150 (125) with a benzyl moiety (entry 8, 9, 11, 
Table 4). All yields are low to moderate but over two steps acceptable.  
Collectively, a synthesis for TPC2-A1-P (17) was developed that was also suitable for 
synthesizing analogs. In total 13 esters were synthesized and 8 of them isolated, including the 
ester SGA-140 (109). Alkaline deprotection under microwave irradiation yielded the hit 17 itself 
and 12 analogs varying all substituents of the pyrrole moiety. These 21 substances were fully 
characterized by NMR, TLC, HRMS, IR and melting points and the purity was confirmed by 
analytical HPLC.  
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3.4 Pharmacological investigation of TPC2 agonists  
The agonistic effects of the synthesized screening hits TPC2-A1-N (16) and TPC2-A1-P (17) 
and their analogs were confirmed by Fura-2 single cell calcium imaging and SAR were 
analyzed. Concentration-effect relationships using Fluo-4 calcium imaging were analyzed and 
further results from cooperation partners are briefly described for presentation of the whole 
outcome of this interdisciplinary project. Finally our novel TPC2 agonists were compared to 
activators, recently published by Zhang et al.[111]. All studies were performed in close 
cooperation with Prof. Dr. Michael Schaefer’s group (HTS, performed by myself, Fluo-4 based 
experiments, performed by Nicole Urban), Prof. Dr. Dr. Christian Grimm’s as well as Prof. Dr. 
Martin Biel’s groups (Fura-2 based calcium imaging, performed by myself and patch clamp 
experiments, performed by Dr. Yu-Kai Chao and Dr. Cheng-Chang Chen). 
 
3.4.1 Confirmation of TPC2-A1-N (16) and TPC2-A1-P (17) as TPC2 agonists 
Single cell Ca2+ imaging experiments had confirmed the two HTS hits, using HEK293 cells 
transiently expressing the plasma membrane variant of human TPC2 (hTPC2L11A/L12A)[22]. The 
membrane permeable, ratiometric dye Fura-2/AM (126) was selected as Ca2+ indicator for 
these experiments. Ca2+ imaging using Fura-2 (13) enables the detection of changes in calcium 
levels in adherent cells[112].  
 
Figure 9: The principle of Fura-2 based Ca2+-imaging. (A) Schematic overview of Fura-2/AM based 
Ca2+-imaging. Fura-2/AM (126) can enter the cell as membrane permeable AM ester. Esterases cleave 
the AM esters and the free dye 13 remains. Excitation wavelength for Fura-2 (13) changes upon 
complexation from 380 nm (no Ca2+) to 340 nm (with Ca2+). Emission can be detected at 510 nm. (B) 
Structures of Fura-2/AM (126) and the free Fura-2 (13) anion. 
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Fura-2/AM (126) can enter cells as a lipophilic AM ester and is hydrolyzed inside the cells by 
esterases. The Fura-2 (13) anion can complex Ca2+ ions and shifts its absorption maximum 
from 380 nm to 340 nm, both emitting at 510 nm (Figure 9 A and B). While Ca2+ concentrations 
rise, an increase of fluorescence for excitation at 340 nm can be observed. The level of 
transfection, as well as the loading of the cell with Fura-2 (13) have an impact on the 
fluorescence intensity. To avoid measurement inaccuracies, the ratio of chelated Fura-2 
(340 nm) divided by free Fura-2 (13, 380 nm) is determined.  
 
Figure 10: Confirmation of TPC2-A1-N (16) and TPC2-A1-P (17) as TPC2 agonists. (A) Representative 
Ca2+ signals recorded from HEK293 cells loaded with the ratiometric Ca2+ indicator, Fura-2 (13) and 
stimulated with TPC2-A1-N (16, 10 µM) and monitored for 400 s. Cells were transiently transfected with 
plasma membrane targeted human TPC2 (hTPC2L11A/L12A). Highlighted lines represent the mean 
response from a population of cells. Shaded traces represent responses of single cells (n = 10 cells for 
hTPC2; n = 3 cells for NT cells). (B) Similar to A except that cells were stimulated with TPC2-A1-P (17, 
10 µM) and monitored for 600 s. Shaded traces represent single cells responses (n = 10 cells for hTPC2; 
n = 3 cells for NT cells). (C) Similar to A except that cells were stimulated with TPC2-A1-P (17, 30 µM). 
Shaded traces represent single cells responses (n = 9 cells for hTPC2; n = 3 cells for NT cells). (D) 
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Statistical analysis of the maximal change in Fura-2 (13) ratio (mean ± SEM) with the number of 
independent transfections in parentheses. Experiments were performed over the period of 9 months 
and on the same days, each. ***p < 0.001, using one-way ANOVA followed by Tukey’s post hoc test. 
(E-F) Representative FLIPR-generated Ca2+ signals (Fluo-4 (14)) in TPC2L11A/L12A–expressing cells (red 
and blue line) or non-transfected (NT) control cells (black) after addition of TPC2-A1-N (16, E) or TPC2-
A1-P (17, F). Experiments were performed by Nicole Urban. (G-H) Concentration-effect relationships 
for Ca2+ increases (Fluo-4 (14)) in response to different concentrations of TPC2-A1-N (16, G) and TPC2-
A1-P (17, H). Experiments were performed by Nicole Urban. (I-J) Representative Ca2+ signals recorded 
from HEK293 cells loaded with the ratiometric Ca2+ indicator, Fura-2 (13) and sequentially stimulated 
with TPC2-A1-N (16, 10 µM, I, n = 6 cells) or TPC2-A1-P (17, 30 µM, J, n = 6 cells) and the TRPML 
agonist ML-SA1 (10 µM). Cells were transiently transfected with human TRPML1∆NC. Means are 
highlighted and single cell responses are shaded. (K-L) Experiment as in I-J, but HEK293 cells 
transiently transfected with human TRPML2, or TRPML3. Cells were sequentially stimulated with TPC2-
A1-N (16, 10 µM, K, n = 4 cells) or TPC2-A1-P (17, 30 µM, L, n = 4 cells) and the TRPML agonist 
ML-SA1 (10 µM) or the TRPML2 selective agonist ML2-SA1 (10 µM). Means are highlighted and single 
cell responses are shaded. Fura-2 based calcium imaging experiments were performed on a 
Polychrome IV mono-chromator (TILL photonics). 
 
Both screening hits, investigated as the independently synthesized substances, reproducibly 
evoked Ca2+ signals. Thereby the correct structures of the HTS hits were confirmed. The 
signals evoked by the compounds showed different kinetics whereby the TPC2-A1-N (16) 
response reached its plateau faster than TPC2-A1-P response (17, Figure 10 A-B and E-F). 
The slower activation could be reduced by stimulation with higher concentrations of TPC2-A1-
P (17), while control cells still remained unaffected (Figure 10 C). Hence, recommended 
experimental concentration for TPC2-A1-P (17) is 30 µM. Long term statistical analysis of 
TPC2-A1-N (16) and TPC2-A1-P (17) showed robust and significant activation of TPC2 
(Figure 10 D). Concentration-effect relationships indicated EC50 values of 7.8 μM and 10.5 μM, 
for TPC2-A1-N (16) and TPC2-A1-P (17), respectively (Figure 10 G and H). Both agonists 
failed to evoke Ca2+ signals in cells expressing human TRPML1 re-routed to the plasma 
membrane (TRPML1∆NC)[113, 114] at the recommended working concentrations (Figure 10 I and 
J). Similar negative results were obtained with the TRPML agonists ML-SA1 and ML2-SA1[115] 
as positive controls in cells expressing TRPML2 or TRPML3 (Figure 10 K and L). These 
results indicate that both hits are selective TPC2 agonists with different modes of activation.  
 
3.4.2 Structure-activity relationships for TPC2-A1-N (16) and analogs 
Fura-2 based calcium imaging experiments were performed with transiently transfected 
HEK293 cells, which allowed selection of transfected cells and non-transfected (NT) control 
cells in one experiment. False positive analogs could straight away be eliminated and 
unspecific effects on intact cells could be determined. If a compound showed no effect in Ca2+ 
imaging experiments, a control had to be added. At the beginning of the screening, TPC2-A1-
N (16) was not fully established as TPC2 activator and therefore ionomycin (4 µM) was used 
as a control for a well-functioning experiment. Ionomycin is a membrane permeable Ca2+ 
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ionophore and causes an intracellular calcium rise by transporting Ca2+ across biological 
membranes[116, 117]. This is not selective for TPC2, thus ionomycin is a control for the accuracy 
of the experiment. Stimulation of the cells with a selective activator determines whether a 
compound is inactive or an inhibitor.  
 
Figure 11: Fura-2 based Ca2+ imaging results for all TPC2-A1-N (16) analogs. (A-B) Fura-2 based Ca2+ 
imaging results showing the effect of TPC2-A1-N (16) and its analogs (10 μM, each) on HEK293 cells 
transiently transfected with hTPC2L11A/L12A-YFP (A, red) and control cells (B, grey). The red arrow 
indicates unspecific effect on control cells, the orange arrow indicates auto fluorescence and the green 
arrow indicates no effect. Mean values normalized to basal (400 s after compound application) ± SEM 
of at least three independent experiments with 3–10 cells each are shown. All experiments were 
performed on a Polychrome IV mono-chromator (TILL photonics). 
 
All synthesized analogs of TPC2-A1-N (16) were tested on their ability to activate TPC2. Out 
of 46 analogs, 23 substances have shown significant agonistic effects (Figure 11 A) and 6 
more barely any activation (SGA-1 (44), SGA-12 (52), SGA-16 (55), SGA-38 (61), SGA-72 
(66), SGA-112 (79), Figure 11 A). Ionomycin or TPC2-A1-N (16) were added for the purpose 
of verifying the accuracy of the experiments. In all experiments with inactive compounds TPC2-
A1-N (16) was added at least once. Thus there were not enough data for statistical analysis to 
verify that the inactive compounds do not inhibit the activation of TPC2. SGA-13 (53) showed 
increased levels of activation on control cells that could be identified as auto fluorescence 
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(Figure 11 B). Three substances (SGA-27 (56), SGA-85 (73), SGA-132 (84)) also had slight 
unspecific effects on control cells, that were not related to auto fluorescence. Seven 
substances (SGA-33 (60), SGA-85 (73), SGA-86 (74), SGA-90 (75), SGA-108 (77), SGA-111 
(78), SGA-132 (84)) had comparable efficacy to TPC2-A1-N (16), while all others were less 
effective.  
Analyzing the structures of the 8 most potent TPC2 activators within this series showed that 
TPC2-A1-N analogs have meta-disubstitution patterns with electron-withdrawing groups 
located on the benzoyl ring system (Figure 12). In contrast, substitution pattern at the phenyl 
ring on the anilide side of the molecule was more variable. Electron-withdrawing and -releasing 
groups (TPC2-A1-N (16), SGA-86 (74) vs. SGA-108 (77)) did not cause significant changes in 
activity. Substitution patterns could also differ from para to meta (TPC2-A1-N (16), SGA-85 
(73)) or even more strongly (SGA-33 (60), SGA-90 (75)).  
 
Figure 12: Structures of the 8 most potent TPC2 activators within the TPC2-A1-N (16) series. Structural 
differences are marked in magenta.  
 
Harsh changes on the benzoyl moiety (replacement by methyl or pyrrole residues), as 
demonstrated for the approved drugs teriflunomide (SGA-94, 76) and prinomide (SGA-31, 58) 
as well as the 4-trifluoromethyl variant of prinomide (SGA-32, 59) led to a complete loss of 
activity (Figure 13). Teriflunomide (76) and SGA-32 (59) did not show inhibitory effects after 
activation with TPC2-A1-N (16, Figure 13 B and D). Stimulation with ionomycin (Figure 13 C) 
indicates the accuracy of the experiment by strong, unspecific calcium influx as described 
above. Teriflunomide (76) is an approved drug for the treatment of multiple sclerosis and 
prinomide (58) for rheumatoid arthritis[118, 119]. Dysregulation of calcium homeostasis can be 
associated with several neurodegenerative disorders like multiple sclerosis (MS)[120], but there 
is no direct link between MS and TPC2 up to now.  
RESULTS AND D ISCUSSION 
36 
 
Figure 13: Approved drugs structurally related to TPC2-A1-N (16) show no effect on TPC2. (A) 
Structures of the approved drugs teriflunomide (SGA-94, 76) and prinomide (SGA-31, 58) and analog 
SGA-32 (59). (B-D) Representative calcium signals from HEK293 cells transiently transfected with 
hTPC2L11A/L12A-YFP. Cells were stimulated with teriflunomide (76, 10 µM, A, n = 12 cells for hTPC2; n = 
7 cells for NT cells), prinomide (58, 10 µM, B, n = 10 cells for hTPC2; n = 6 cells for NT cells) or SGA-
32 (59, 10 µM, C, n = 12 cells for hTPC2; n = 4 cells for NT cells) for 400 s each, followed by activation 
with TPC2-A1-N (16, 10 µM, B and D, 400 s) or ionomycin (C, 4 µM, 200 s). Highligted lines represent 
the mean response from a population of cells. Shaded traces represent responses of single cells. Fura-
2 based calcium imaging experiments were performed on a Polychrome IV mono-chromator (TILL 
photonics). 
 
Thio-analog SGA-167 (91) was synthesized as last compound within an Erasmus project 
(Figure 14 A). At that time, a new Ca2+-imaging setup was put into operation. Direct 
comparison from experiments using the old setup (Polychrome IV mono-chromator, TILL 
photonics) with the new setup (Leica DMi8 live cell microscope) is not possible. Intensities can 
vary due to the power of the light sources and analysis of the experiments using the 
manufacturers’ software (TILLvisION or LAS X) could also cause differences in intensities. 
Therefore, TPC2-A1-N (16) was re-evaluated and used as an established activator to analyze 
differences in agonistic effects compared to SGA-167 (91). The thio-analog 91 activates TPC2 
significantly less than TPC2-A1-N (16, Figure 14 B), clearly indicating very special SAR in this 
chemotype.  
 
Figure 14: Thio-analog SGA-167 (91) activates TPC2 less than the hit. (A) Structure of SGA-167 (91). 
Differences to TPC2-A1-N (16) are marked in red. (B) Fura-2 based Ca2+ imaging results showing the 
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effect of TPC2-A1-N (16, 10 µM) and its analog SGA-167 (91, 10 μM) on HEK293 cells stably expressing 
hTPC2L11A/L12A-RFP. Mean values normalized to basal (400 s after compound application) ± SEM of at 
least three independent experiments with 3–10 cells each are shown. ***p < 0.001 using unpaired 
student’s t-test. Fura-2 based calcium imaging experiments were performed on a Leica DMi8 live cell 
microscope. 
 
All findings were affirmed by full analysis of concentration-effect relationships, performed by 
our cooperation partner Nicole Urban, Rudolf-Boehm-Institute, Leipzig. The Fluo-4 based 
calcium imaging experiments were chosen because a large number of compounds at different 
concentrations can be analyzed in a high-throughput manner. The barely activating 
compounds show either high EC50 values (entry 3, 11, 13, 19, Table 5) or were not calculable 
because activation started at concentrations above 50 µM. With EC50 values above 100 µM 
substances were not suitable anymore because such high concentrations can cause unwanted 
side effects and solubility problems. Substances that were inactive in Fura-2 calcium imaging, 
did not show agonistic effects in Fluo-4 imaging as well. This confirmed all results from the 
Fura-2 imaging experiments. Nearly all EC50 values of the 8 most potent substances are in the 
same range, thus SGA-33 (60, 23 µM) is higher to some extent (Table 5). SGA-85 (73) and 
SGA-132 (84) have a slightly lower EC50 (3.3 µM and 5.3 µM) than TPC2-A1-N (16, 7.8 µM), 
which is relativized by the fact that control cells showed increased levels of activation in Fura-
2 imaging for SGA-85 (73) and SGA-132 (84, Figure 11 B).  
Further analysis of structural motifs shows that replacing the para-trifluoromethyl group on the 
anilide side of the molecule (R1; blue) gives more opportunities than changes on the benzoyl 
residue. Electron-withdrawing groups in para-position on the anilide side causes no significant 
changes (e.g. entry 2, 3, 5, 6, Table 5). Even the introduction of electron-releasing groups in 
para-position is tolerated to some extent (SGA-4 (47), SGA-84 (72), SGA-108 (77)). For the 
substitution pattern of the benzoyl ring system (R2, green), meta-disubstitution patterns with 
electron-withdrawing groups are most beneficial. 
Table 5: Structure variations and EC50 values of TPC2-A1-N (16) and the active analogs. No significantly 
increased efficacies or potencies were observed for the analogs. EC50 (Fluo-4 (14)) values are received 
via Fluo-4 based Ca2+ imaging experiments, performed by Nicole Urban as previously described[22]. IC50 
values (MTT) are received from in-house MTT experiments, performed by Martina Stadler. *experiment 
was performed at a later time. n.a. = not applicable.  
N
H
O
CN
OH
R1
R2
 
entry name R1 = R2 = EC50 = IC50 (MTT) = 
1 TPC2-A1-N (16) 4-CF3 3,5-Cl2 7.8 µM > 50 µM 
2 SGA-34 (19) 4-CF3 - n.a. > 50 µM 
3 SGA-1 (44) H 3,5-Cl2 35 µM > 50 µM 
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4 SGA-2 (45) 4-Cl 3,5-Cl2 24 µM > 50 µM 
5 SGA-3 (46) 4-Br 3,5-Cl2 20 µM > 50 µM 
6 SGA-4 (47) 4-CH3 3,5-Cl2 15 µM > 50 µM 
7 SGA-8 (48) 4-F 3,5-Cl2 22 µM > 50 µM 
8 SGA-9 (49) 4-I 3,5-Cl2 34 µM 48 µM 
9 SGA-10 (50) 4-CF3 H n.a. > 50 µM 
10 SGA-11 (51) 4-CF3 3,5-(NO2) 2 38 µM > 50 µM 
11 SGA-12 (52) 4-OCH3 3,5-Cl2 33 µM > 50 µM 
12 SGA-15 (54) 4-CF3 4-NO2 > 100 µM > 50 µM 
13 SGA-16 (55) 4-CF3 4-Cl 47 µM > 50 µM 
14 SGA-27 (56) 2-Br, 4-Cl 3,5-Cl2 10 µM > 50 µM 
15 SGA-28 (57) 3,4-(OCH3)2 3,5-Cl2 n.a. > 50 µM 
16 SGA-31 (58) prinomide n.a. > 50 µM 
17 SGA-32 (59) 
2-cyano-3-(1-methyl-1H-pyrrol-2-yl)-3-
hydroxy-N-(4-
(trifluoromethyl)phenyl)acrylamide 
n.a. > 50 µM 
18 SGA-33 (60) 2,4-F2, 3-Cl 3,5-Cl2 23 µM > 50 µM 
19 SGA-38 (61) 4-CN 3,5-Cl2 51 µM > 50 µM 
20 SGA-39 (62) 2-I 3,5-Cl2 > 100 µM > 50 µM 
21 SGA-40 (63) 4-CF3 2,3,4,5,6-F5 41 µM > 50 µM 
22 SGA-70 (64) 4-CF3 3,5-Br2 13 µM > 50 µM 
23 SGA-71 (65) 4-CF3 2,4,6-Cl3 40 µM > 50 µM 
24 SGA-72 (66) 4-Br 2,4,6-Cl3 > 100 µM > 50 µM 
25 SGA-73 (67) 2,4-F2, 3-Cl 2,4,6-Cl3 n.a. > 50 µM 
26 SGA-75 (68) 4-Br 3,5-Br2 22 µM > 50 µM 
27 SGA-76 (69) 4-Ac 3,5-Cl2 > 100 µM > 50 µM 
28 SGA-77 (70) 2,6-Br2 3,5-Cl2 n.a. > 50 µM 
29 SGA-78 (71) 2,3-Cl2 3,5-Cl2 n.a. > 50 µM 
30 SGA-84 (72) 4-OC3H7 3,5-Cl2 14 µM > 50 µM 
31 SGA-85 (73) 3,5-(CF3)2 3,5-Cl2 3.0 µM 29 µM 
32 SGA-86 (74) 4-OCF3 3,5-Cl2 9.5 µM 49 µM 
33 SGA-90 (75)
 
2,4-F2, 3-Cl 3,5-Br2 12 µM > 50 µM 
34 SGA-94 (76) teriflunomide n.a. > 50 µM 
35 SGA-108 (77) 4-CH3 3,5-(CF3)2 7.1 µM > 50 µM 
36 SGA-111 (78) 4-CF3 3,5-(CF3)2 6.2 µM > 50 µM 
37 SGA-112 (79) 4-CF3 3,5-(CH3)2 > 100 µM > 50 µM 
38 SGA-113 (80) 4-CF3 3,5-(OCH3)2 n.a. > 50 µM 
39 SGA-114 (81) 4-CF3 4-OCF3 > 100 µM > 50 µM 
40 SGA-115 (82) 
2-cyano-3-(3,5-dichlorophenyl)-3-hydroxy-N-
methyl-N-(4-(trifluoromethyl)phenyl)-
acrylamide 
> 100 µM 35 µM 
41 SGA-127 (83) 2-cyano-3-hydroxy-3-(pyridin-3-yl)-N-(4-(trifluoromethyl)phenyl)acrylamide n.a. > 50 µM 
42 SGA-132 (84) 4-CF3 3-Br, 5-I 5.3 µM 32 µM 
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43 SGA-133 (85) 4-COOCH3 3,5-Cl2 21 µM > 50 µM 
44 SGA-136 (86) 3-(5-chloropyridin-3-yl)-2-cyano-3-hydroxy-N-(4-(trifluoromethyl)phenyl)acrylamide n.a. > 50 µM 
45 SGA-137 (88) 4-COOH 3,5-Cl2 n.a. > 50 µM 
46 SGA-138 (87) 2-cyano-3-(3,5-dichlorophenyl)-3-hydroxy-N-(4-(trifluoromethyl)benzyl)acrylamide > 100 µM 48 µM 
47* SGA-167 (91) 
2-cyano-3-(3,5-dichlorophenyl)-3-hydroxy-N-
(4-(trifluoromethyl)phenyl)prop-2-
enethioamide 
31 µM > 50 µM 
 
The toxicity of all substances was examined by in-house MTT assays using HL-60 cells and 
was performed by Martina Stadler. The MTT assay indicates the metabolic cell activity and 
reflects cell viability[121]. IC50 represents the concentration that is required for half maximal 
inhibition and compounds with values smaller than 50 µM are acknowledged as cytotoxic. 
Nearly all analogs and the hit itself did not show toxicity and only 6 substances had slight 
cytotoxic effects (entry 8, 31, 32, 40, 42, 46, Table 5). Out of the 8 most potent substances, 
only three substances showed slight toxicity (SGA-85 (73), SGA-86 (74), SGA-132 (84), entry 
31-32, 42, Table 5) while the hit compound TPC2-A1-N (16) itself showed no toxicity (entry 1, 
Table 5).  
The HTS hit TPC2-A1-N (16) itself and some of its analogs bearing residues in para-position 
at the benzoyl residue are known as anthelmintic agents[91]. The authors performed 
mechanism of action studies using Ascaris mitochondria and have shown that these 
compounds are uncouplers of oxidative phosphorylation, comparable to salicylanilide 
anthelmintic agents[122]. There are no indications in current literature that this effect is related 
to TPC2.  
In summary, none of the 46 modified versions of TPC2-A1-N (16, auto-fluorescent SGA-13 
(53) already excluded) showed significantly increased efficacies or potencies on TPC2 (Figure 
11, Table 5) and the TPC2-A1-N chemotype showed a very flat structure-activity relationship 
on TPC2. TPC2-A1-N (16) thus remained a promising chemical tool for studies of TPC2.  
 
3.4.3 Structure-activity relationships for TPC2-A1-P (17) and analogs 
Fura-2 based calcium imaging experiments were performed as described above for TPC2-A1-
N (16) and analogs (Figure 15 A). Experiments with inactive substances were subsequently 
activated with TPC2-A1-N (16) or stimulated with ionomycin (Figure 15, E and F). Also, for 
TPC2-A1-P (17) and analogs full concentration-effect experiments were performed by Nicole 
Urban (Leipzig), using the Fluo-4 based high-throughput setup as described before (Table 6).  
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Similar to the results obtained for TPC2-A1-N (16), modified versions of TPC2-A1-P (17) 
showed no improvement of potency or efficacy. Virtually all 19 analogs were inactive, only 
compound SGA-150 (125), in which the N-cyclohexylmethyl residue is replaced by an N-benzyl 
group (of identical size) showed noteworthy, but reduced activity (Figure 15 A, Table 6). 
Analysis of SAR revealed that the free carboxylic acid is essential for the activating effect, as 
the ester SGA-140 (109) was not active (entry 2, Table 6). It may serve as a prodrug of TPC2-
A1-P (17) in living systems, but this has not been investigated further. Both, the 
trifluoromethoxy and the bromine substituent at the phenyl ring were essential for activating 
TPC2, as exemplified by the inactive methoxy (SGA-55, 115, entry 8, Table 6) and des-bromo 
(SGA-162, 120, entry 20, Table 6) analogs. Even moderate expansions of the size of the 
substituent at C-2 position of the pyrrole (methyl in TPC2-A1-P (17) vs. ethyl in SGA-152 (121) 
and phenyl analog SGA-154 (122), entry 1 vs. 17, 19, Table 6), had the same detrimental 
effect.  
 
Figure 15. Fura-2 based Ca2+ imaging results for all TPC2-A1-P (17) analogs. (A-B) Fura-2 based Ca2+ 
imaging results showing the effect of TPC2-A1-P (17) and its analogs (10 µM; each) on HEK293 cells 
transiently transfected with hTPC2L11A/L12A-YFP (A, blue) and control cells (B, grey). Mean values 
normalized to basal (400 s after compound application) ± SEM of at least three independent experiments 
with 3–10 cells each are shown. TPC2-A1-P (17) is highlighted and the analogs are shaded. (C-D) 
Representative calcium signals from HEK293 cells transiently transfected with hTPC2L11A/L12A-YFP. 
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Cells were stimulated with TPC2-A1-P (17, C, 10 µM, 600 s, n = 10 cells for hTPC2; n = 3 cells for NT 
cells) or SGA-150 (125, D, 10 µM, 800 s, n = 10 cells for hTPC2; n = 3 cells for NT cells). Highligted 
lines represent the mean response from a population of cells. Shaded traces represent responses of 
single cells. Each structure is depicted on the right of the graph and structural differences to TPC2-A1-
P (17) are marked in red. (E-F) Experiment as in C-D, but cells were sequentially stimulated with SGA-
50 (100, E, 10 µM) or SGA-149 (123, F, 10 µM) and the TPC2 activator TPC2-A1-N (16, 10 µM) for 400 
s each. All experiments were performed on a Polychrome IV mono-chromator (TILL photonics). 
 
Aforementioned, the only fairly tolerable structure modification was the replacement of the 
cyclohexylmethyl moiety in 1-positon of the pyrrole ring by a benzyl residue (SGA-150, 125, 
entry 16, Table 6). The efficacy of TPC2-A1-P (17) was significantly higher than of SGA-150 
(125) (Figure 15 A) while for both compounds control cells remained unaffected (Figure 15 
B). Linear or branched alkyl chains (SGA-149 (123), SGA-153 (124), entry 15, 18, Table 6), 
however, induced loss of activity. 
Fura-2 based single cell calcium imaging traces for the activation of TPC2 were shown in 
Figure 15 C-F. These experiments showed the slow and weak activation of TPC2 with SGA-
150 (125). This activation was even slower than the abovementioned activation using TPC2-
A1-P at 10 µM (17, Figure 15 C and D). This indicated a lower affinity of SGA-150 (125) on 
TPC2 compared to TPC2-A1-P (17). Exemplary Fura-2 traces for the inactive compounds 
SGA-50 (100) and SGA-149 (123) were shown in Figure 15 E and F. Both substances had no 
effect on TPC2 and following activation using TPC2-A1-N (16) was successful, indicating that 
SGA-50 (100) and SGA-149 (123) were neither activators, nor inhibitors.  
Table 6: Structure variations and EC50/IC50 values of TPC2-A1-P (17), its ester SGA-140 (109) and all 
other analogs. EC50 values were received via Fluo-4 based Ca2+ imaging experiments, performed by 
Nicole Urban (Leipzig) as previously described[22]. IC50 values (MTT) were received from in-house MTT 
experiments, performed by Martina Stadler. n.a. = not applicable.  
 
entry compound R = R1 = R2 = R3 = EC50 = IC50 (MTT) = 
1 TPC2-A1-P (17) H 2-OCF3, 5-Br CH2cy* CH3 10.5 µM 27 µM 
2 SGA-140 (109) CH2CH3 2-OCF3, 5-Br CH2cy* CH3 n.a. 24 µM 
3 SGA-43 (96) CH2CH3 - CH2cy* CH3 n.a. 48 µM 
4 SGA-50 (100) H -
 
CH2cy* CH3 n.a. 32 µM 
5 SGA-48 (110) CH2CH3 2,5-Cl2 CH2cy* CH3 n.a. > 50 µM 
6 SGA-52 (116) H 2,5-Cl2 CH2cy* CH3 n.a. 15 µM 
7 SGA-54 (97) CH2CH3 2-OCH3, 5-Br CH2cy* CH3 n.a. > 50 µM 
8 SGA-55 (115) H 2-OCH3, 5-Br CH2cy* CH3 n.a. > 50 µM 
9 SGA-59 (111) CH2CH3 4-F CH2cy* CH3 n.a. 40 µM 
10 SGA-66 (117) H 4-F CH2cy* CH3 n.a. > 50 µM 
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11 SGA-61 (112) CH2CH3 4-OCH3 CH2cy* CH3 n.a. 42 µM 
12 SGA-67 (118) H 4-OCH3 CH2cy* CH3 n.a. > 50 µM 
13 SGA-62 (113) CH2CH3 2,4-F2 CH2cy* CH3 n.a. > 50 µM 
14 SGA-68 (119) H 2,4-F2 CH2cy* CH3 n.a. > 50 µM 
15 SGA-149 (123) H 2-OCF3, 5-Br pentyl CH3 n.a. 14 µM 
16 SGA-150 (125) H 2-OCF3, 5-Br benzyl CH3 34 µM 36 µM 
17 SGA-152 (121) H 2-OCF3, 5-Br CH2cy* CH2CH3 n.a. 21 µM 
18 SGA-153 (124) H 2-OCF3, 5-Br iPr CH3 n.a. 31 µM 
19 SGA-154 (122) H 2-OCF3, 5-Br CH2cy* phenyl n.a. 14 µM 
20 SGA-162 (120) H 2-OCF3 CH2cy CH3 n.a. > 50 µM 
 
The toxicity of all substances was examined by in-house MTT assays as described above for 
TPC2-A1-N (16). Most substances could be classified as non-toxic (SGA-48 (110), SGA-54 
(97), SGA-55 (115), SGA-66 (117), SGA-67 (118), SGA-62 (113), SGA-68 (119), SGA-162 
(120), entry 5, 7, 8, 10, 12-14, 20, Table 6). Some IC50 values are in a moderate range between 
25 and 50 µM (entry 1, 3, 4, 9, 11, 16, 18), and 5 compounds have lower IC50 values (SGA-
140 (109), SGA-52 (116), SGA-149 (123), SGA-152 (121) SGA-154 (122), entry 2, 6, 15, 17, 
19, Table 6). TPC2-A1-P (17) itself has an IC50 of 27 µM on HL-60 cells. Recommended 
working concentration is 30 µM and control experiments are highly relevant to exclude false 
results.  
Only little information was found in the literature about biological activities of TPC2-A1-P-like 
substances. TPC2-A1-P (17) itself was namely mentioned as a precursor in the synthesis of 
cannabinoid-1 receptor (CB1R) inverse agonists, whereas the final active compounds 
contained a carboxamide group instead of the free carboxylic acid function[105]. 
Phenylpyrrolecarboxamides derived from SGA-50 (100) binding to 5-HT2A, 5-HT2C receptors 
and the 5-HT transporter were evaluated as antidepressant compounds[103]. This applies only 
to the carboxamides and there were no data published for the carboxylic acids. 
TPC2-A1-P (17) and its 19 analogs were fully analyzed in Fura-2 and Fluo-4 imaging 
experiments. Only one analog (SGA-150 (125)) was able to activate TPC2 besides the hit 17. 
No pharmacological targets were published for TPC2-A1-P (17). With its steep structure-
activity relationship TPC2-A1-P (17) developed from hit to a promising chemical tool.  
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Comparing the results of both activator classes identified by HTS of the Roche library, a 
considerable number of TPC2-A1-N analogs caused noteworthy TPC2 activation, but none of 
them showed significantly increased efficacies or potencies compared to the HTS hit TPC2-
A1-N (16). In contrast, the second hit TPC2-A1-P (17) showed an unusually steep structure-
activity relationship, and except for one modestly active analog (SGA-150, 125) none of the 
analogs showed any activity. Thus, the two high-throughput screening hits TPC2-A1-N (16) 
and TPC2-A1-P (17) can be regarded as strong chemical tools that need further 
pharmacokinetic and pharmacological characterization. 
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3.4.4 Further results of the novel TPC2 agonists 
Within our cooperation with Prof. Dr. Schaefer’s group, Leipzig, we had the opportunity to 
perform a selectivity screening of the best TPC2 activators identified in our investigations. The 
selected activators were tested on a broad panel of ion channels of the TRP superfamily. The 
screening was performed by Nicole Urban in the Schaefer lab (Leipzig).  
 
Figure 16: Selectivity screening of TPC2-A1-N (16), SGA-86 (74), SGA-108 (77), SGA-111 (78) and 
TPC2-A1-P (17). (A-E) Concentration-effect relationships for Ca2+ increases (Fluo-4 (14)) in response 
to different concentrations of TPC2-A1-N (16, A), SGA-86 (74, B), SGA-108 (77, C), SGA-111 (78, D) 
and TPC2-A1-P (17, E). Different stably expressing cell lines were used and activated with the activator 
indicated. hTPC2, control cells (HEK293), TRPML1 and TRPML3 are highlighted. (F) Legend of the 
different cell lines used. All experiments were performed by Nicole Urban. 
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At the beginning of the selectivity screening the custom-made fluorescence imaging plate 
reader was modified and cleaned, which resulted in higher intensities and slightly higher EC50 
values (for TPC2-A1-N (16) from 7.8 µM to 11 µM; for TPC2-A1-P (17) from 10.5 µM to 17 µM, 
Figure 16 A and E). TPC2-A1-P (17), TPC2-A1-N (16) and some of the most potent analogs 
were analyzed. Earlier experiments already indicated that SGA-85 (73) and SGA-132 (84) had 
nonspecific activation on control cells (Figure 11 B). The highly substituted analogs SGA-33 
(60) and SGA-90 (75) had low solubility which is problematic for experiments using high 
concentrations. Therefore, these four compounds were excluded. The selected compounds 
were tested on TPC2, non-transfected HEK-293 cells, the mucolipins TRPML1 and 3, TRPA1, 
TRPC3-7, TRPM2, 3, 8 and TRPV1-4 (Figure 16 F). Experiments were performed with test 
concentrations up to 200 µM for analysis of possible side effects.  
Comparing the maximum activation, TPC2-A1-P (17) and TPC2-A1-N (16) had the highest 
efficacy (Figure 16 A and E) and EC50 values within the TPC2-A1-N analogs were all in the 
same range (9.7 µM to 14 µM, Figure 16 A-D). All tested pre-selected compounds were able 
to activate TRPA1 at low micromolar concentrations. The activation of TRPA1 was to be 
expected because TRPA1 is a chemosensory cation channel, which reacts inter alia to 
chemical substances and generates biological signals[123, 124]. SGA-86 (74) and SGA-111 (78) 
were able to activate TRPV2 with an EC50 of 46 µM and 19 µM, respectively (Figure 16 B and 
D). TPC2-A1-P (17) activated TRPV1 at low micromolar concentrations with a very low efficacy 
(Figure 16 E). The transient receptor potential cation channel subfamily V (“vanilloid”) is 
related to thermal sensation and responsible for regulating body temperature[125, 126]. SGA-111 
(78) was also able to activate TRPM3 with an EC50 of 17 µM (Figure 16 D). Comparing the 
TPC2-A1-N series, all substances showed effects on other TRP channels in high 
concentrations (≥ 100 µM). SGA-108 (77) showed the highest selectivity and TPC2-A1-N (16) 
the highest efficacy. SGA-111 (78) was less specific than all other probes and had a 
significantly lower efficacy. As mentioned before, all of these compounds have electron-
withdrawing groups on the benzoyl moiety and are para-substituted on the anilide side (Figure 
12). SGA-108 (77) was the only one with an electron-releasing group on the anilide side, which 
was generating selectivity for TPC2 at the expense of efficacy. TPC2-A1-P (17) showed high 
selectivity for TPC2 with high efficacy. The screening further confirmed that potencies were 
not increased compared to the hits TPC2-A1-N (16) and TPC2-A1-P (17) and despite large 
efforts in chemical synthesis, these hit structures could not be improved concerning TPC2 
activation.  
In house agar diffusion test was used to analyze antimicrobial effects of the new compounds 
on bacteria (Escherichia coli, Pseudomonas marginalis, Staphylococcus equorum, 
Streptococcus entericus), yeasts (Yarrowia lipolytica, Saccharomyces cerevisiae) and 
dermatophytes (Hyphopichia burtonii). The compounds did not show any inhibition zones for 
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the investigated bacteria and yeasts, while some analogs of TPC2-A1-N and the hit compound 
itself (16) showed small (but irrelevant) inhibition zones for the dermatophyte Hyphopichia 
burtonii (Table 7).  
Table 7: Inhibition zones for the dermatophyte Hyphopichia burtonii. Agar diffusion experiments were 
performed by Martina Stadler. 
entry compound inhibition zone (Hyphopichia burtonii) 
1 TPC2-A1-N (16) 16 mm 
2 SGA-1 (44) 12 mm 
3 SGA-2 (45) 8 mm 
4 SGA-3 (46) 8 mm 
5 SGA-4 (47) 8 mm 
6 SGA-9 (49) 12 mm 
7 SGA-12 (52) 8 mm 
8 SGA-16 (55) 10 mm 
9 SGA-27 (56) 12 mm 
10 SGA-39 (62) 12 mm 
11 SGA-70 (64) 12 mm 
12 SGA-71 (65) 12 mm 
13 SGA-72 (66) 10 mm 
 
3.4.5 Malleable cation selectivity of TPC2 
TPC2-A1-N (16) and TPC2-A1-P (17) were further investigated together with different 
cooperation partners and the results are presented in a recent publication[22]. Both compounds 
did not activate TPC1 in patch clamp experiments which is stressing the selectivity of these 
compounds. Cell permeability was proven by GCamp6 experiments, which clearly 
demonstrated that both activators are able to activate TPC2. The calcium indicator GCamp6, 
located on the lysosomal membrane, is able to detect calcium efflux from the lysosome, thus 
proving the membrane permeability of the compounds.  
Furthermore, by means of the two novel small-molecules we were able to resolve the conflict 
of TPC2 being an NAADP-activated Ca2+ release channel[5, 12, 14, 127, 128] or a PI(3,5)P2 gated 
Na+ channel[15, 20, 129]. TPC2-A1-N (16) rendered the channel more calcium permeable, similar 
to NAADP-activated TPC2, whereas TPC2-A1-P (17) increased sodium permeability, similar 
to the PI(3,5)P2-activated channel. Consequently, ion permeation through TPC2 is ligand-
dependent, indicating that TPC2 is a non-selective cation channel with malleable cation 
selectivity. Appropriately, the PI(3,5)P2 (4) binding site in TPC2[8] has been identified to broadly 
overlapping with the one for TPC2-A1-P (17). It has been demonstrated that TPC2-A1-N (16) 
induces an alkalinization of single vesicles in cells expressing wild-type TPC2, as previously 
reported for NAADP (3)[130, 131]. These findings confirmed that TPC2 activation is coupled to 
RESULTS AND D ISCUSSION 
47 
lysosomal pH and vesicle motility in an agonist-dependent manner. The effect of both 
activators on lysosomal exocytosis was further evaluated. TPC2-A1-P (17), but not TPC2-A1-
N (16) promoted lysosomal exocytosis. Manipulation of lysosomal exocytosis may provide a 
therapeutic approach for LSDs[132-134].  
These findings would not have been achievable without the availability of the lipophilic small-
molecule activators TPC2-A1-N (16) and TPC2-A1-P (17) identified in this project. These tools 
have the potential to elevate studies regarding TPC2 to the next level, which will result in a 
better understanding of the various ion channel functions.  
  
RESULTS AND D ISCUSSION 
48 
3.4.6 The race to identify new TPC activators 
Small-molecule modulators of two pore channels have been a hot topic in recent literature. In 
2019, Zhang et al. identified tricyclic and phenothiazine antidepressants as TPC1 and 2 
activators by screening Sigma’s LOPAC library, containing 1280 compounds[111]. With calcium 
imaging experiments, followed by confirmation using whole-cell recordings in TPC2LL/AA-
expressing HEK293 cells, the authors identified 8 compounds as TPC2 activators. The 
dibenzazepine-type tricyclic antidepressants (TCAs) clomipramine (127), desipramine (128), 
imipramine (129), amitriptyline (130) and nortriptyline (131), as well as the phenothiazine-
based antidepressants chlorpromazine (132) and triflupromazine (133) were found to activate 
TPC2 (Figure 17 A and B). The EC50 values were between 43 and 112 µM and therefore these 
activators are presumably less potent than TPC2-A1-N (16, Figure 10 G) and TPC2-A1-P (17, 
Figure 10 H) from our project. The authors described that currents elicited with TCAs were 
strongly voltage-dependent while riluzole (134, Figure 17 C) activation was voltage-
independent. Some TCAs, clomipramine (127) and desipramine (128), also activated TPC1 in 
a voltage-dependent manner, while chlorpromazine (132) and riluzole (134) inhibited TPC1. It 
was barely possible to analyze structure-activity relationships with only seven identified 
structures. Nevertheless, the dibenzazepine carbamazepine (135) and native phenothiazine 
(136, Figure 17 D) did not activate TPC2, which highlighted the necessity of the aminoalkyl 
side chain at the central ring of the tricyclic core[135].  
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Figure 17: Structures and EC50 values, published by Zhang et al.[111]. (A-B) Structures and EC50 values 
of TCAs (A) and related phenothiazines (B) as TPC2 activators. EC50 values were obtained from whole-
cell recordings at -140 mV. (C) Structure of riluzole (134). (D) Structures of the inactive carbamazepine 
(135) and phenothiazine (136).  
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Evaluating the current literature it was noticeable that the phenothiazines triflupromazine (133) 
and fluphenazine (6), recently published by Penny et al.[31], share the same skeleton but have 
huge differences in their pharmacological activity (Figure 18). While fluphenazine (6) was 
inhibiting TPC2 signals evoked by NAADP (3) with an IC50 of 42 µM[31], triflupromazine (133) 
was identified as TPC2 activator. An inhibitor of TPC2 was most likely converted into an 
activator of TPC2 by introducing only slight changes in the side chain[135]. This example 
demonstrates how close activators and inhibitors of an ion channel can resemble each other 
and how important the analysis of structure-activity relationships is. 
 
Figure 18: Structures of the TPC2 activator triflupromazine (133) and the TPC2 inhibitor fluphenazine 
(6)[31, 111]. Differences are marked in magenta.  
 
The two independently performed HTSs by Zhang et al. and within this project created a panel 
of small-molecule TPC activators, compared in our recently published review[135]. Zhang et al. 
focused on drug repurposing and thereby identified TCAs, phenothiazines and the 
benzothiazole riluzole (134) that activate TPC2. Originally, TCAs are used to treat e.g. 
depression, bipolar disorder, panic disorder, chronic pain, and insomnia and inhibit inter alia 
monoamine (serotonin, norepinephrine, dopamine) reuptake. TCAs have a wide range of 
adverse effects and are therefore replaced as antidepressants by the selective serotonin 
reuptake inhibitors (SSRI)[136]. In addition, amitriptyline (130), imipramine (129), and 
clomipramine (127) are also potent CYP450 inhibitors, significantly inhibiting CYP450 2C19 
and 1A2[137]. Aforementioned, this bears the risk of undesired drug-drug interactions. Riluzole 
(134) blocks TTX-sensitive sodium channels, kainite receptors and NMDA receptors, has 
neuroprotective effects and it is currently approved for the treatment of amyotrophic lateral 
sclerosis (ALS)[138-142]. The activators identified in this thesis, TPC2-A1-N (16) and TPC2-A1-P 
(17), are no listed drugs. Comparing the results of both screenings, there is comprehensive 
knowledge on the pharmacological profiles of the repurposed TCA/phenothiazine-type TPC2 
activators due to their long term application in therapy, but as well a large list of undesired 
effects. Our newly identified activators still need full pharmacokinetic and pharmacological 
characterization, though have the potential to address TPCs as their main target with a high 
affinity and thus have less side effects.  
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Lately performed docking studies with the TPC2 agonists on the apo-state hTPC2 structure 
confirmed that TPC2-A1-P (17) and PI(3,5)P2 (4), as well as TPC2-A1-N (16) and riluzole (134) 
share one binding pocket, each[135]. This suggests that TPC2-A1-N (16) and riluzole (134) both 
mimic NAADP (3) actions. Furthermore the binding free energies were calculated and suggest 
that TPC2-A1-N (16) and TPC2-A1-P (17) are more efficacious than clomipramine (127) and 
chlorpromazine (132). This corresponds with the higher EC50 values for the repurposed 
activators (42 – 112 µM) compared to TPC2-A1-N (16, 7.8 µM) and TPC2-A1-P (17, 10.5 µM).  
Now there is the opportunity to choose from an impressive and highly diverse collection of new 
lipophilic small-molecule activators for either selectively activating TPC2 or activation of both 
TPC1 and TPC2 with the warning that some of the compounds are also blocking TPC1. 
Physiology and pathophysiology of TPCs can be studied in more detail with the cell permeable 
small-molecule activators. Most importantly, the novel compounds allow studies in intact cells 
and can be used as chemical tool for analyzing TPC2 inhibitors. They may also be applicable 
for in vivo studies and perhaps even for therapy[135].  
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3.5 A new generation of TPC2 inhibitors 
A high-throughput analysis of TPC2 inhibitors can be accomplished using the newly developed 
membrane permeable and small-molecule TPC2 activators. Therefore, a library of TPC2 
inhibitors was created to gain first insights into SAR for truncated variants of tetrandrine (1). 
Aforementioned, our concept was to develop TPC2 inhibitors derived from the lead structure 
tetrandrine (1). One major intention was to develop less complex analogs of this 
bisbenzylisoquinoline alkaloid. Hence, we considered both, natural products of this chemotype 
from different sources as well as monomeric benzylisoquinolines and newly synthesized 
analogs of tetrandrine (1).  
 
3.5.1 Collection of alkaloids and 1-benzylisoquinolines 
Consequently, this library included benzylisoquinoline-type intermediates of the morphine 
biosynthesis like O,O-dibenzyl coclaurine (Z3, 137), available from the substance collection of 
Prof. Dr. Meinhart Zenk (passed away in 2011), tetrandrine (1) and derivatives such as 
fangchinoline (9), kindly provided by Prof. Dr. Peter Pachaly (passed away in 2019), and 
commercially available benzylisoquinoline alkaloids like dauricine (11) and oxyacanthine (138, 
Figure 19).  
 
Figure 19: Strutures of investigated bisbenzylisoquinoline alkaloids. (A) Structures of the alkaloids 
tetrandrine (1), fanglchinoline (9) and N,N-dimethyltetrandrine dichloride (139), kindly provided by Prof. 
Dr. Peter Pachaly†. (B) Structures of the commercially available alkaloids berbamine dihydrochloride 
(10), oxyacanthine sulfate (138), cepharanthine (140) and dauricine (11). Structural differences 
compared to tetrandrine (1) are marked red.  
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The bisbenzylisoquinoline alkaloids, provided from Prof. Dr. Peter Pachaly† were analyzed by 
NMR, HRMS, specific rotation and purity was confirmed by analytical HPLC. Only tetrandrine 
(1) from natural source had to be purified by column chromatography and recrystallized from 
EtOH/water before it was subjected to biological experiments. All analytical data were in 
accordance with literature[143-145]. All substances from the collection of Prof. Dr. Meinhart Zenk† 
(Figure 20) were analyzed by NMR, HRMS and specific rotation in order to distinguish (if not 
clearly indicated) racemic from enantiomerically pure substances. Purity was confirmed by 
analytical HPLC. If a compound was not pure enough (HPLC purity < 96%), purification was 
accomplished by FCC. Analytical data for all substances were in accordance to literature or 
are stated in the experimental part of this thesis.  
 
Figure 20: Structures of substances, kindly received from Prof. Dr. Meinhart Zenk†.   
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3.5.2 Synthesis plan 
A new generation of truncated analogs of tetrandrine (1) should be synthesized to receive 
molecules that resemble tetrandrine (1, Figure 21). A short and efficient synthesis was 
developed therefore. These molecules should mimic one of the two 
benzyltetrahydroisoquinoline moieties of tetrandrine (1), therefore the racemic natural product 
N-methyl coclaurine (SG-132, 159) was chosen as basic structure. Further decoration not only 
in form of O-benzyl derivatives, but also as diaryl ethers are supposed to closely imitate 
tetrandrine (1) in shape and size. Bisbenzylisoquinolines with anti-cancer activity have already 
been described aforementioned. They have different stereochemistry at their two 
stereocenters, e.g. cepharanthine (S,R, 140)[146] or the seco-variant dauricine (R,R, 11)[80], 
compared to tetrandrine (S,S, 1), as shown in Figure 19 A and B. Within a first series of 
endolysosomal patch clamp experiments, performed by Dr. Yu-Kai Chao, antagonistic effects 
of cepharanthine (140), dauricine (11) and (±)-O,O-dibenzyl coclaurine (Z3 (137), Figure 20) 
on TPC2 were confirmed (Figure 22). Aforementioned stereochemistry was not limited to one 
isomer, a racemic synthesis for the truncated analogs of tetrandrine (1) would be most 
appropriate. Compared to the rigid, macrocyclic bisbenzylisoquinoline tetrandrine (1), the new 
truncated analogs of tetrandrine bear only one benzylisoquinoline unit. However the O-benzyl 
or O-phenyl residues mimic the two benzenoid rings of the second benzylisoquinoline moiety 
of the parent compound making these compounds similar to tetrandrine (1) in size, but are 
much more flexible. This flexibility should enable the compounds to adapt perfectly to the 
binding site in the target proteins.  
 
Figure 21: Truncation of tetrandrine (1). The racemic alkaloid (±)-N-methylcoclaurine (159) already 
represents one half of tetrandrine (1). Introduction of additional aromatic moieties (right, marked in 
magenta) enables the molecule to resemble the overall molecular geometry of tetrandrine (1).  
 
Key steps for the synthesis of truncated tetrandrine analogs are the N-acyl Pictet-Spengler 
reaction to construct the 1-benzyltetrahydroisoquinoline and the Chan-Evans-Lam coupling for 
introduction of diaryl ethers (Figure 21, right). According to Comins et al.[147], the precursors 
for the N-acyl Pictet-Spengler reaction would be different carbamate building blocks of type I 
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and enol ether building blocks of type II. These building blocks would be easily accessible 
from commercially available aldehydes bearing different residues in meta- and para-position 
(i, Scheme 16). If desired, the phenol group of these aldehydes can be protected as benzyl 
ether or alkyl carbonate (ii and v, Scheme 16). The utilization of benzyl ethers as protecting 
groups is commonly known, while the introduction of alkyl carbonates is new. Following a 
procedure published by Pouysegu et al.[148], a Henry reaction using commercially available 
benzaldehydes and nitromethane would give nitrovinyl compounds (iii, Scheme 16) and 
reduction using lithium alanate would yield desired arylethylamine (iv, Scheme 16). This 
sequence only needs to be performed for the introduction of benzyl ethers, because many 
arylethylamines (iv, Scheme 16) are already commercially available (e.g. 3-methoxytyramine 
(160) and 3,4-dimethoxyphenyl-ethylamine 161). Using ethyl chloroformate (162) and NEt3 
would give the carbamate group and further, in the case of a free phenol group, an ethyl 
carbonate (I, Scheme 16)[149]
.
 Depending on the work-up conditions, the ethyl carbonate could 
remain unaffected using neutral conditions or cleaved using alkaline conditions[73, 149]. The 
resulting free phenol group of the alkaline work-up could then be used for the introduction of 
an aryl ether via Chan-Evans-Lam coupling. Wittig olefination of 4-substituted benzaldehydes 
(i, Scheme 16) would give enol ethers of type II (Scheme 16) as masked arylacetaldehyde.  
 
Scheme 16: Synthesis plan for the preparation of the precursors for the N-acyl Pictet-Spengler reaction. 
Carbamate building blocks of type I and enol ether building blocks of type II are easily accessible from 
commercially available aldehydes or arylethylamines. 
 
The 1-benzyl-1,2,3,4-tetrahydroisoquinolines III were to be prepared by N-acyl Pictet-
Spengler reactions using precursors I and II (Scheme 17 A). Comins et al. published a 
procedure for an TFA catalyzed N-acyl Pictet-Spengler reaction, which would be pursued[147]. 
Utilization of arylethylcarbamates for N-acyl Pictet-Spengler reactions is a common method in 
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the Bracher research group. While standard Pictet-Spengler tetrahydroisoquinoline synthesis 
requires harsh reaction conditions like heating to reflux with strong acids, N-acyl Pictet-
Spengler reaction proceeds under mild conditions. This is caused by formation of an N-
acyliminium ion 163 as intermediate, which is a much stronger electrophile in comparison to 
the less powerful electrophile iminium intermediate 164 which occurs in regular Pictet-Spengler 
reactions (Scheme 17 B). Even nucleophiles that are relatively unreactive as non-activated 
benzenoids, participate effectively in cyclizations with N-acyliminum species[150, 151]. 
 
Scheme 17: The N-acyl Pictet-Spengler reaction. (A) Planed synthesis for the construction of the 
tetrahydroisoquinoline III via N-acyl Pictet-Spengler reaction. (B) N-Acyliminium ion 163 (left) and 
iminium ion 164 (right) as intermediates for Pictet-Spengler-type cyclizations. 
 
Tertiary N-methyl amines IV are available via reduction of carbamates III using lithium alanate 
(Scheme 18)[152]. Furthermore all carbonate esters can be cleaved under these conditions, 
directly yielding the free phenols and tertiary N-methyl amines in one step, while the benzyl 
protecting groups of the phenols are not affected by these conditions (not depicted).  
 
Scheme 18: Planned simultaneous deprotection of ethyl carbonates and reduction of carbamates to 
give N-methyl amines of type IV.  
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For the synthesis of truncated tetrandrine analogs, as depicted in Figure 21, diaryl ethers had 
to be introduced to the appropriate free phenols. Choosing an environmental-friendly catalyst 
led to copper-catalyzed coupling reactions. One famous example is the Ullmann coupling for 
diaryl ether synthesis[153]. Hereby, aryl halides and phenols are converted into diaryl ethers 
under copper-promotion. Requiring high temperatures and being limited on the substitution 
patterns of both coupling partners, the Ullmann coupling is not generally applicable, and a new 
version of this coupling reaction was selected. The Chan-Evans-Lam coupling was developed 
in 1998 and represents a modern copper-catalyzed oxidative coupling of boronic acids and 
heteroatom nucleophiles[154-156]. Advantages of the Chan-Evans-Lam coupling are milder 
reaction conditions (room temperature and the presence of oxygen), cheap copper catalysts, 
good to excellent yields, and a diverse substrate scope[157].  
 
Scheme 19: Proposed mechanism for the Chan-Evans-Lam diaryl ether synthesis, based on the studies 
of Stahl and coworkers[158]. 
 
A boronic acid dimethyl ester in MeOH was used as example for the studies by Stahl and 
coworkers of the mechanism of this etherification process[158, 159]. This catalytic cycle starts with 
a Cu(II) species (a, Scheme 19), in this scheme Cu(OAc)2 and e.g. pyridine as ligand (Ln). 
Transmetalation with an aryl boronic acid (marked in orange) gives aryl Cu(II) complex (b, 
Scheme 19). Oxidation of this complex (b, Scheme 19) to a Cu(III) complex (c, Scheme 19) 
occurs via disproportionation with another equivalent of the starting Cu(II) species (a, Scheme 
19). The C-O bond formation takes place within the reductive elimination to give the desired 
diaryl ether (orange, Scheme 19) and a Cu(I) species (d, Scheme 19), which is re-oxidized by 
oxygen.  
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Scheme 20: Summary of the synthesis plan for truncated tetrandrine analogs. These analogs (V) can 
be achieved in three steps, starting from precursors I and II. 
 
Following this sequence would give desired truncated tetrandrine analogs in only three steps, 
starting from building blocks I and II (Scheme 20). This short sequence was to be used to 
introduce a variety of different diaryl ethers for the generation of a set of truncated analogs to 
study SAR. 
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3.5.3 Synthesis of a new generation of TPC2 inhibitors 
First, the building blocks for the N-acyl Pictet-Spengler reaction were synthesized. Using ethyl 
chloroformate (162) and NEt3, amines can be converted into carbamates and phenols into 
ethyl carbonates. The commercially available 3-methoxytyramine hydrochloride (160) was 
protected under these conditions and depending on further proceedings yielded carbamate 
165 (bearing an ethyl carbonate protecting group) or 166 (having a free phenol group) in high 
to moderate yields (Scheme 21)[73, 149]. While neutral extraction gave the protected phenol 165, 
the addition of NaOH (1 M) in ethanol deprotected the aryl-alkyl carbonate and resulted in 
phenol 166. If the reaction mixture was extracted using 2 M aq. NaOH, the deprotection of 
carbamate 165 was not complete, because of the two-phase mixture.  
 
Scheme 21: Synthesis of carbamates 165 and 166 using ethyl chloroformate (162) under basic 
conditions. Depending on the work up, a protected phenol 165 or deprotected phenol 166 was obtained.  
 
Diaryl ether 167 was synthesized using the mild coupling conditions of the Chan-Evans-Lam 
reaction. Copper catalyzed and under alkaline conditions carbamate 166 and phenylboronic 
acid (168) were used to give diary ether 167 in high yields (Scheme 22). Full characterization 
(TLC, NMR, HRMS, IR, m.p.) confirmed the structure and analytical HPLC the purity. Initial 
experiments for this reaction were performed within the Bachelor thesis of F. Talay.  
 
Scheme 22: Copper catalyzed Chan-Evans-Lam coupling of carbamate 166 to give diaryl ether 167. 
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The aforementioned method to generate carbamates was applied for the synthesis of 
carbamate 169 as well, with commercially available 3,4-dimethoxyphenylethylamine 161 as 
starting material. The reaction time was reduced to 4 h by refluxing the mixture to give 
carbamate 169 in high yields (Scheme 23). Carbamate 169 was fully characterized (TLC, 
NMR, HRMS, IR, m.p.) and 1H and 13C NMR data were in accordance with literature[160]. 
 
Scheme 23: Protection of amine 161 with accelerated reaction time.  
 
To receive an O-benzylated carbamate (170, Scheme 25), the corresponding amine 171 had 
to be synthesized first. Following a procedure published by Pouysegu et al.[148], 4-benzyloxy-
3-methoxybenzaldehyde 172 was used as starting material for a Henry reaction, giving 
nitrovinyl compound 173 in good yield. Reduction using lithium alanate yielded the desired 
arylethylamine 171 in high yield (Scheme 24). Both products were fully characterized and 
analytical data are in accordance with literature. 
 
Scheme 24: Synthesis of benzyl-protected amine 171 in two steps, according to Pouysegu and 
colleagues[148].  
 
Using ethyl chloroformate (162) and NEt3, amine 171 was protected, giving carbamate 170 in 
moderate yield (Scheme 25). The compound was characterized by TLC, NMR, HRMS, IR and 
melting point and the analytical data were in accordance with literature[149].  
 
Scheme 25: Synthesis of carbamate 170 utilizing the above mentioned method.  
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Enol ethers were utilized as masked arylacetaldehyde equivalents, because the corresponding 
arylacetaldehydes are often instable due to their ability to easily polymerize[161]. The E/Z 
stereochemistry of the enol ethers is not relevant for the following N-acyl Pictet-Spengler 
reaction and a simple Wittig olefination of aromatic aldehydes was chosen for the synthesis. 
Enol ether 174 was to be formed starting with 4-hydroxybenzaldehyde (175), (methoxymethyl)-
triphenyl-phosphonium chloride and a strong base (Scheme 26). First, the phosphonium salt 
is deprotonated to give a colorful ylide, which then forms an oxaphosphetane via a [2+2] 
cycloaddition with the aldehyde. Elimination of triphenylphosphine oxide yields the desired E/Z-
alkene. The synthesis of enol ether 174 is known using tert-butoxide (conditions a)[162] or 
LHMDS (conditions b)[163]. Though, the first step, the ylide formation, did not show any 
conversion for potassium tert-butoxide and only slight conversion using the stronger base 
LHMDS. The even stronger base LDA (conditions c) was further tried and finally ylide formation 
was observed by formation of a deep red complex. Both known procedures described high 
yields for the Wittig olefination (81% and >95%), however, this was not reproducible. Formation 
of the enol ether 174 was observed via GC-MS but not completed even after 24 h, therefore 
another route was chosen.  
 
Scheme 26: Synthetic approach to yield enol ether 174, using different conditions.  
 
An ethyl carbonate protecting group for phenols was already used for some carbamate building 
blocks and was now introduced for protection of the free phenolic group of aldehyde 175. 
Hence 4-hydroxybenzaldehyde (175) was protected using ethyl chloroformate (162) and NEt3 
to give aldehyde 176 in high yield (Scheme 27). 
 
Scheme 27: Synthesis of protected aldehyde 176 using ethyl chloroformate (162) and NEt3.  
 
Aforementioned formation of the ylide for Wittig olefination was most successful using LDA. 
Hence LDA was used for olefination reaction of aldehyde 176. With (methoxymethyl)-
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triphenylphosphonium chloride and aldehyde 176, enol ether 177 was obtained in good yield 
(Scheme 28). The reaction was monitored by TLC and staining with DNPH as both starting 
material and product had the same Rf value. DNPH indicated the end of the reaction by 
different colors of the formed hydrazones. While the aromatic, highly conjugated aldehyde 176 
resulted in a deep orange color, the aliphatic enol ether 177 gave a lighter, yellow color. The 
generation of a side product, enol ether 174, was observed and starting material 175 was found 
as well. The ethyl carbonate protecting group is labile under alkaline conditions and therefore 
only one equivalent LDA was used. Maybe the basicity of the formed ylide is strong enough to 
cleave the ethyl carbonate protecting group and yield enol ether 174 or aldehyde 175 (if the 
starting material was deprotected). Consequentially, the reaction cannot result in a full 
conversion of aldehyde 176 into enol ether 177, as not enough ylide was present. Both side 
products were separated from the desired enol ether 177 by column chromatography. While 
being stored the enol ether 177 decomposes, as already described for enol ether 174[162]. 
Therefore it was analyzed by TLC, NMR and HRMS as fast as possible and quickly used for 
the next step without full characterization.  
 
Scheme 28: Wittig olefination of aldehyde 176. Besides the desired enol ether 177, also two side 
products were identified. 
 
This method was further applied for other para-substituted benzaldehydes. Besides para-
carbonate protecting group in enol ether 177 (entry 1, Table 8), a diaryl ether enol ether 178 
(entry 2, Table 8) and a benzyloxy enol ether 179 (entry 3, Table 8) were synthesized in 
moderate to high yields. Due to the instability of enol ether 177 and the reports in literature 
about it[162], all of them were analyzed by TLC, NMR and HRMS as fast as possible and used 
without full characterization for the next step. 
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Table 8: Wittig olefination of different aldehydes to give enol ethers using (methoxymethyl)-triphenyl-
phosphonium chloride and LDA as base.  
 
entry starting material reaction time product yield 
1 R = COOEt (176) 16 h 
 
63% 
2 R = Ph 50 h 
 
59% 
3 R = Bn 16 h 
 
85% 
 
With the four different carbamates of type I and the three enol ethers of type II (Scheme 20) 
both building blocks for N-acyl Pictet-Spengler reactions were successfully synthesized and 
ready to be combined. 
For performing the N-acyl Pictet-Spengler reaction TFA in dichloromethane was chosen as 
acidic catalyst, according to Comins et al.[147]. Molecular sieves (4 Å) were added to ensure an 
aqueous free environment and avoid side or decomposition reactions. These conditions gave 
racemic tetrahydroisoquinoline 180 in high yield (Scheme 29). NMR analysis was performed 
at 100 °C in tetrachloroethane. In NMR experiments performed at room temperature, different 
rotamers of the molecule were observed. This is the result of isomers arising from hindered 
single-bond rotation in a time frame that it is detectable by NMR. Heating up the NMR sample 
to 100 °C boosted the rotation to give a single set of resonances.  
 
Scheme 29: N-Acyl Pictet-Spengler reaction to give racemic tetrahydroisoquinoline 180. Carbamate 
165 and enol ether 177 were used as starting materials.  
 
These reaction conditions were further applied in the synthesis for racemic 
tetrahydroisoquinolines (III, Table 9) generated out of different combinations of the 
synthesized carbamates and enol ethers (I and II, Table 9). As precursor for the natural 
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product (±)-N-methylcoclaurine (159) served the ethyl carbonate protecting group (entry 1, 
Table 9). To analyze the influence of residues in C-7 position of the tetrahydroisoquinoline a 
methoxy group (entry 2 and 5, Table 9), a diaryl ether (entry 3, Table 9) and a benzyl ether 
(entry 4, Table 9) were introduced. The O-benzylated tetrahydroisoquinoline (entry 4, Table 
9) was more complex to purify because FCC mainly gave impure fractions. Hence this yield is 
lower. All other N-acyl Pictet-Spengler reactions gave the racemic tetrahydroisoquinolines in 
high yield. NMR analysis at 100 °C (to avoid rotameric NMR resonances), TLC, HRMS and IR 
confirmed the identity and analytical HPLC the purity.  
Table 9: Synthesis of various racemic 1-substituted tetrahydroisoquinolines (III) starting from different 
carbamate and enol ether building blocks (I and II) using N-acyl Pictet-Spengler reactions. *Initial 
experiments for this reaction were performed within the Bachelor thesis of F. Talay. 
 
entry carbamate I enol ether II reaction time product III yield 
1 
 
 
18 h 
 
81% 
2 
 
 
20 h 
 
77% 
3 
 
 
90 h 
 
90%* 
4 
 
 
18 h 
 
32% 
5 
 
 
20 h 
 
92% 
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Reduction of the carbamate group of tetrahydroisoquinolines III (Table 10) using LiAlH4[152] 
directly yielded the corresponding N-methyl compounds. Preparation of the corresponding 
secondary amines from the carbamate intermediates is feasible in general, but would need 
other reaction conditions, like carbamate hydrolysis using KOH and hydrazine hydrate at 120 
°C for many days[164] or refluxing in aq. 10 M HCl solution overnight[165]. Though, tertiary amines 
were preferred, as they showed more resemblance to the structure of tetrandrine (1). 
Furthermore ethyl carbonate protecting groups were cleaved one-pot within the reduction of 
the carbamate using lithium alanate, resulting in a number of N-methyl compounds (IV, Table 
10).  
A procedure published by Cava et al. was applied for the synthesis of N-methyl amines of type 
IV (Table 10) by refluxing carbamates (III, Table 10) with an excess of LiAlH4 under dry 
conditions in THF. For reaction work-up avoiding undesirable treatment with water under 
formation of aluminum hydroxide gels Glauber’s salt was chosen, which is Na2SO4 x 10 H2O. 
The crystal water of this salt causes a slow and moderate decomposition of the LiAlH4 excess 
and prevents uncontrolled heating of the mixture. The reaction was finished when no gas 
evolution could be observed anymore. After filtration the product was purified by extraction 
using the phase swap technique in which the crude organic product phase was extracted with 
2 M aq. HCl solution to transfer the protonated amine into the aqueous phase. Then, 
neutralization of the aqueous phase yielded the tertiary amine again and re-extraction with 
organic solvents resulted in the pure product. This technique avoids the more time-consuming 
FCC, especially for upscale reactions. By this means all synthesized carbamates (III) were 
reduced to the corresponding tertiary N-methyl amines (IV, Table 10) in moderate to high 
yields. Two natural products ((±)-N-methylcoclaurine (159) and (±)-armepavine (185)) were 
synthesized in their racemic form this way (entry 1, 2, Table 10), one derivative of a natural 
product (entry 4, Table 10) and two new synthetic tetrahydroisoquinolines (entry 3, 5, Table 
10). Full characterization (TLC, NMR, HRMS, IR, m.p.) confirmed the structure and analytical 
HPLC the purity of the products.  
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Table 10: Reduction of the carbamate function and deprotection of carbonic acids of 
tetrahydroisoquinolines (II) using LiAlH4 gave N-methyl amines of type IV. * Initial experiments for this 
reaction were performed within the Bachelor thesis of F. Talay. 
 
entry starting material III 
reaction 
time product IV 
name of natural 
product or derivative yield 
1 
R = COOEt 
R’ = COOEt 
180 
3 h 
 
(±)-N-methylcoclaurine 79% 
2 
R = Me 
R’ = COOEt 
SG-089 (181) 
3 h 
 
(±)-armepavine 35% 
3 
R = Ph 
R’ = COOEt 
182 
5 h 
 
- 79%* 
4 
R = Bn 
R’ = Bn 
SG-145 (183) 
18 h 
 
(±)-O,O-dibenzyl N-
methylcoclaurine 46% 
5 
R = Me 
R’ = Ph 
184 
20 h 
 
- 46% 
 
Synthesis of (±)-armepavine (185) had the lowest yield (entry 2, Table 10). A reason for this 
is, that a second tetrahydroisoquinoline (189) was isolated (Scheme 30 A and B). The N-acyl 
Pictet-Spengler reaction as well as the lithium alanate reduction were both performed in large 
scale (22.1 mmol and 16.9 mmol) and to improve time efficacy purification was reduced to a 
minimum. Therefore the enol ether 177 also had to be synthesized in large scale and 
aforementioned side products (aldehyde 175 and enol ether 174, Scheme 30 B) occurred. 
These two side products were both able to act as starting material for the N-acyl Pictet-
Spengler reaction to give 1-benzyl-carbamate 190 and 1-phenyl-carbamate 191 (Scheme 30 
B). Reduction of 1-benzyl-carbamate 190 would also result in SG-121 (185) and was therefore 
not removed. Thus, 1-phenyl-carbamate 191 was carried over as an unrevealed impurity and 
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following reduction of a mixture of three different carbamates (181, 190 and 191) yielded SG-
121 (185) and side product SG-121-NP (189). The two products were separated by FCC, 
analyzed and purity was confirmed by analytical HPLC.  
 
Scheme 30: Synthesis of tetrahydroisoquinolines 185 and 189. (A) Synthesis of (±)-armepavine (185), 
as described above. (B) Side products of the Wittig olefination 174 and 175 underwent N-acyl Pictet-
Spengler reaction to yield carbamates 190 and 191. Following lithium alanate reduction yielded (±)-
armepavine (SG-121, 185) and side product SG-121-NP (189). Shaded products were not isolated 
within this sequence.  
 
Utilizing the method developed by Chan, Evans and Lam many diaryl ethers (V, Table 11) 
were synthesized. Per phenolic group of the amine (IV, Table 11) 1 equivalent copper acetate, 
3 equivalents arylboronic acid (VI, Table 11) and a mixture of NEt3 and pyridine (1:1, 2.5 eq. 
each) were used. The resulting oily tertiary amines were characterized and then treated with 
methanolic HCl solution to give the amorphous hydrochloride salts as solids which were used 
for biological experiments. Two diaryl ethers were recrystallized as hydrochloride salts (entry 
3, 9, Table 11) and were also characterized such. The diaryl ether variant of N-
methylcoclaurine, SG-094 (192), was the first to be synthesized using the double amount of 
equivalents for the two phenolic groups of SG-132 (159, entry 1, Table 11). Two diaryl ethers 
with a methoxygroup in C-7 position of the tetrahydroisoquinoline (193 and 194, entry 2, 3, 
Table 11) and the 1-phenyl-tetrahydroisoquinoline 195 (entry 4, Table 11) were synthesized 
to study the loss of one phenyl group. Tetrandrine (1) has four methoxy moieties, which 
inspired the synthesis of compounds bearing methoxy residues (196 and 197, entry 7, 8, Table 
11) or replaced them by the metabolically stable bioisosteric trifluoromethoxy group (198, entry 
6, Table 11). Electron releasing groups were also introduced (199 and 200, entry 5, 9, Table 
11). A nitrile residue was also part of the structure of the TPC2 activator TPC2-A1-N (16). 
Hence a nitrile residue was introduced to probably have a better affinity to the ion channel 
(201, entry 11, Table 11). A 3,4-dichloro substituted aromatic ring was synthesized to study 
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the influence of halides (202, entry 12, Table 11). To analyze the influence of heterocyclic 
aromatic residues, a pyridine moiety was introduced (203, entry 10, Table 11), whereas the 
synthesis of a variant bearing a furan moiety (204) was not successful (entry 14, Table 11), 
which is in accordance with one report in literature[166]. Same applied to the 
tetrahydroisoquinoline 205, which should have been synthesized to be labeled by click 
chemistry (entry 13, Table 11). Overall 12 tetrahydroisoquinolines bearing a diaryl ether motif 
were synthesized in moderate to high yield and fully characterized by TLC, NMR, HRMS and 
IR (melting points only for the hydrochloric acid salts) and purity was affirmed by analytical 
HPLC. 
Table 11: Products of the Chan-Evans-Lam reaction. Using different arylboronic acids (VI) and a variety 
of racemic amines of type IV yielded the desired diaryl ethers of type V.  
 
entry starting material 
IV 
boronic acid 
VI 
reaction 
time 
product 
V 
yield 
1 R,R’ = H SG-132 (159) R’’ = H  18 h 
 
70% 
2 
R = Me 
R’ = H 
SG-121 (185) 
R’’ = 4-OCH3 18 h 
 
88% 
3 
R = Me 
R’ = H 
SG-121 (185) 
R’’ = 3,4,5-
(OCH3)3 18 h 
 
84% 
4 
R = Me 
R’ = H 
SG-121-NP (189) 
R’’ = 4-OCH3 18 h 
 
95% 
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5 
R = Ph 
R’ = H 
186 
R’’ = 4-CF3 18 h 
 
24% 
6 
R = Ph 
R’ = H 
186 
R’’ = 4-OCF3 13 h 
 
47% 
7 
R = Ph 
R’ = H 
186 
R’’ = 4-OCH3 20 h 
 
67% 
8 
R = Ph 
R’ = H 
186 
R’’ = 3,4,5-
(OCH3)3 20 h 
 
69% 
9 
R = Ph 
R’ = H 
186 
R’’ = 4-CH3 20 h 
 
48% 
10 
R = Ph 
R’ = H 
186 
pyridine-4-boronic 
acid 20 h 
 
25% 
11 
R = Ph 
R’ = H 
186 
R’’ = 4-CN 20 h 
 
48% 
12 
R = Ph 
R’ = H 
186 
R’’ = 3,4-Cl2 20 h 
 
78% 
13 
R = Ph 
R’ = H 
186 
R’’ = 4-C≡C 20 h 
 
- 
14 
R = Ph 
R’ = H 
186 
furan-2-ylboronic 
acid 20 h 
 
- 
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The compound collection provided by Prof. Dr. Meinhart Zenk† included racemic O,O-
dibenzylated coclaurine (Z3, 137, Scheme 31 A) and racemic O,O-dibenzylated nororientaline 
(Z6, 145, Scheme 31 B). Utilizing these secondary amines, N-methyl amines were obtained 
by Eschweiler-Clarke reaction[167]. Iminium formation with formaldehyde, followed by reduction 
with a hydride source yielded tertiary amines. Originally formic acid acted as hydride source, 
while modified versions used sodium cyanoborohydride. Using the latter yielded SG-005 (187) 
and SG-159 (206) in moderate yields, although long reaction times did not lead to complete 
consumption of the starting material (Scheme 31 A and B).  
 
Scheme 31: Eschweiler-Clarke reaction for the synthesis of the N-methyl compounds SG-005 (187, A) 
and SG-159 (206, B).   
 
Another method for the synthesis of SG-005 (187) was the Mitsunobu reaction with SG-132 
(159) as starting material (Scheme 32). Mitsunobu conditions prevented the formation of a 
quaternary ammonium salt 207, which was the result of using standard protecting conditions 
(excess of benzyl chloride and a base) for the phenolic groups (Scheme 32). Monitoring via 
TLC indicated the formation of SG-005 (187), though after 18 h only the quaternary ammonium 
salt 207 was found. Mitsunobu reaction, however, gave SG-005 (187) in moderate yield and 
analytical data were in accordance with the analytical data of the two other routes.  
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Scheme 32: Mitsunobu reaction of SG-132 (159) with benzyl alcohol yielded SG-005 (187). Protection 
of SG-132 (159) using benzyl chloride gave quaternary amine 207.  
 
Synthesis of an N-ethyl variant of bis(benzyloxy)-orientaline 208 was performed using 
bromoethane in alkaline conditions. Potassium iodide was added for an in situ Finkelstein 
reaction to boost the conversion rate. TLC monitoring did not show consumption of the starting 
material, because product and starting material had the same Rf value. ASAP showed the 
masses of starting material and product and after 6 days no changes of the conversion rate 
were observed any more. Purification needed semi-preparative HPLC, because standard FCC 
did not separate secondary amine 145 from N-ethyl amine 208. This resulted in pure SG-158 
(208, Scheme 33) in moderate yield. A Leuckart-Wallach reaction[168] could be tried to improve 
the conversion rate. This reaction is related to the Eschweiler-Clarke reaction but is not limited 
to formaldehyde. Though, the first reaction yielded enough SG-158 (208) and repetition was 
not necessary.  
 
Scheme 33: Synthesis of SG-158 (208) with Z6 (145) as starting material.  
 
A total amount of 16 N-alkyl amines was synthesized, including 3 O-benzylated compounds 
and 13 diaryl ethers. Analysis (TLC, NMR, HRMS, IR and melting points) confirmed the 
structure and analytical HPLC affirmed the purity of these molecules. All of them resemble one 
RESULTS AND D ISCUSSION 
71 
half of tetrandrine (1) plus the two benzenoid rings of the second benzylisoquinoline moiety 
and were further investigated on their biological activity. The synthetic route furthermore 
generated intermediates that therefore served as negative controls, as SG-132 (159) and SG-
145 (183). 
 
3.6 Pharmacological investigation of TPC2 antagonists 
The effect of the inhibitors of TPC2 was again analyzed by Fura-2 and Fluo-4 based calcium 
imaging as well as by endo-lysosomal patch clamp experiments. Furthermore, their ability to 
combat diseases like cancer or virus infections1 was investigated. Main focus was on 
tetrandrine (1), SG-005 (187) and SG-094 (192), because these emerged as the most 
interesting substances. All studies were performed in close cooperation with Prof. Dr. Michael 
Schaefer’s group (Fluo-4 based experiments, performed by Nicole Urban), Prof. Dr. Angelika 
Vollmar’s group (cancer investigation, performed by Martin Müller) and Prof. Dr. Dr. Christian 
Grimm’s as well as Prof. Dr. Martin Biel’s groups (Fura-2 based calcium imaging, performed 
by myself and patch clamp experiments, performed by Dr. Yu-Kai Chao). 
 
3.6.1 First identification of the truncated TPC2 inhibitors 
The whole endo-lysosomal patch clamp technique is state-of-the-art to confirm direct effects 
on the activity of endo-lysosomal ion channels[169]. In brief, endolysosomes are enlarged using 
vacuolin-1, the membrane is destroyed with a glass pipette and then the enlarged endo-
lysosomal organelle is carefully isolated. Having the isolated organelle allows the operator to 
apply hydrophilic, not membrane permeable compounds like PI(3,5)P2 (4) directly to the 
endolysosome to activate the ion channel. The addition of a potential inhibitor after activation 
then directly shows the effect of the compound. This unique technique is very accurate but 
highly complex and requires much time and effort.  
Tetrandrine (1) has been known to inhibit TPC2 since 2015[2] and was therefore analyzed as 
a reference. Thus, by applying the endo-lysosomal patch clamp technique, several other 
bisbenzylisoquinoline alkaloids were also identified as TPC2 inhibitors. Fangchinoline (9), 
cepharanthine (140) and the seco-analog dauricine (11) were virtually equipotent to tetrandrine 
(1, 54% inhibition, Figure 22 A). Fangchinoline (9) is a nor-derivative of tetrandrine (1) and is 
already known to be a TPC2 inhibitor (Figure 22 D)[30]. Cepharanthine (140) differs from 
tetrandrine (1) in the absolute stereochemistry and the connection of both benzyl residues and 
dauricine (11) is no macrocyclic compound (Figure 22 D). This gave a first hint that 
                                               
1
 Studies for virus infections are still in the early stages and not further discussed.  
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stereochemistry, the substitutions pattern of lead structure tetrandrine (1) and the fact that 
tetrandrine (1) is a macrocyclic ring is not mandatory for TPC2 inhibition. Racemic coclaurine 
(Z1, 141) had nearly no effect, whereas racemic O,O-bisbenzylcoclaurine (Z3, 137) was 
equipotent to tetrandrine (1, Figure 22 A and E). Contrary, Z6 (145) showed an (on top)-
activating effect (Figure 22 A and E). Notably, the bis-phenyl ether SG-094 (192) significantly 
increased the percentage of channel inhibition (75%) compared to tetrandrine (1, 54%), 
whereas the corresponding bis-benzyl ether SG-005 (187) showed nearly the same inhibition 
(44%) as tetrandrine (1, Figure 22 B and Figure 23 H). Both compounds are derived from the 
racemic alkaloid coclaurine (159).  
 
Figure 22: Patch clamp results to identify TPC2 inhibitors, performed by Dr. Yu-Kai Chao. (A-B) The 
inhibition percentage of several TPC2 blockers is displayed. Inhibitors (10 µM) were applied upon 
activation with PI(3,5)P2 (4, 1 µM) on isolated and vacuolin-enlarged endolysosomes from HEK293 cells 
expressing TPC2-EGFP. The bar graph indicates mean ± SEM of n independent experiments. *p < 0.05, 
ns = not significant, using unpaired students t-test. (C) Representative current density – voltage relation 
for a recording of the most potent TPC2 inhibitor of this set of compounds, SG-094 (192), is shown. (D) 
Structures of tetrandrine (1), fangchinoline (9), cepharanthine (140) and dauricine (11). Differences to 
tetrandrine (1) are marked in red. (E) Structures of Z1 (141), Z3 (137) and Z6 (145).  
 
The two lipophilic, membrane-permeable TPC2 activators TPC2-A1-N (16) and TPC2-A1-P 
(17), developed in the first part of this project, allowed to also test inhibitory activities of the 
compounds in calcium imaging experiments. Fura-2 based single cell calcium imaging 
experiments were performed first. The best option to assess inhibitory effects is to first add the 
inhibitor to the cells and incubate for a defined time, then stimulate the cells with the activator 
and monitor effects over time in the constant presence of the inhibitor. As control, a subsequent 
experiment needs to be performed in which vehicle, e.g. DMSO only is added first, followed by 
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addition of the agonist. The results of these two experiments are then directly compared. If 
activation levels do not show differences, the substance has no inhibitory activity. At least three 
independent experiments should be performed for quantification and statistical analysis. Of 
note, results strongly depend on the transfection levels and these may vary. For more 
consistent experiments HEK-293 cells stably expressing the plasma membrane variant of 
hTPC2 were therefore used.  
This method was applied for tetrandrine (1), two of the synthesized truncated variants, SG-005 
(187) and SG-094 (192), and the controls SG-132 (159) and SG-145 (183). As expected, 
tetrandrine (1), SG-005 (187) and SG-094 (192) were able to inhibit TPC2-A1-N (16) induced 
activation significantly (Figure 23 A-D). SG-132 (159) is lacking the prolonging aromatic 
groups (benzyl or diaryl ethers) while SG-145 (183) has two benzyl ethers but the 
tetrahydroisoquinoline nitrogen is not basic. Both substances were not able to inhibit TPC2-
A1-N (16) induced activation (Figure 23 E-G) and confirmed that the absent groups were 
essential for the inhibitory effect on TPC2.  
 
Figure 23: Reversed single cell calcium imaging experiments to identify TPC2 inhibitors. (A) Fura-2 
based Ca2+ imaging results showing the effect of TPC2-A1-N (16, 10 µM) after stimulation with 
tetrandrine (1, 10 µM), SG-094 (192, 10 µM), SG-005 (187, 10 µM) or a DMSO control. HEK293 cells 
stably expressing hTPC2L11A/L12A-RFP were used. Mean values normalized to basal (400 s after 
activation) ± SEM of at least three independent experiments with 3–10 cells each are shown. (B-D) 
Representative Ca2+ signals for experiments as in (A). Cells were sequentially stimulated with 
tetrandrine (1, 10 µM, B), SG-094 (192, 10 µM, C), SG-005 (187, 10 µM, D) or DMSO (0.5% DMSO in 
HBS) and the activator TPC2-A1-N (16, 10 µM, 400 s). (E) Experiments as in (A) using SG-132 (159, 
10 µM), SG-145 (183, 10 µM) or a DMSO control. (F-G) Representative Ca2+ signals for experiments as 
in (E). Cells were sequentially stimulated with SG-132 (159, 10 µM, C), SG-145 (183, 10 µM, D) or 
DMSO (0.5% DMSO in HBS) and the activator TPC2-A1-N (16, 10 µM, 400 s). **p < 0.01, *p < 0.05, ns 
= not significant, using one-way ANOVA followed by Tukey’s post hoc test. In all experiments highlighted 
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lines represent the mean response from a population of cells. Shaded traces represent responses of 
single cells. All experiments were performed on a Leica DMi8 live cell microscope. (H) Structures of SG-
005 (187) and SG-094 (192). (I) Structures of SG-132 (159) and SG-145 (183). 
 
This set of experiments proved the accuracy of the method and the previously obtained 
electrophysiology results. Of the three inhibitors again SG-094 (192) had the strongest effect 
(**) compared to tetrandrine (1, *) and SG-005 (187, *) when applied at a concentration of 10 
µM (Figure 23 A-D). In a next step the potencies of the compounds were determined by 
concentration-effect relationship measurements using the HTS system instead of using only 
single concentrations. 
 
3.6.2 Analysis of the compound library 
All compounds were analyzed by using the Fluo-4 based calcium imaging method (HTS 
system) described before. The experiments were again performed in the group of Prof. Dr. 
Michael Schaefer (Leipzig) by sequential application of inhibitors at different concentrations 
followed by the agonists TPC2-A1-P (17) and TPC2-A1-N (16).  
 
Figure 24: Fluo-4 calcium imaging experiments of the highlighted compounds tetrandrine (1), SG-005 
(187) and SG-094 (192). Concentration-effect relationships using HEK293 cells stably expressing 
hTPC2L11A/L12A-RFP are presented. Cells were sequentially stimulated with inhibitor (100 µM → 0.1 µM) 
and TPC2-A1-N (16, 10 µM) or TPC2-A1-P (17, 10 µM) as activator. IC50 values were calculated out of 
at least three independent experiments using GraphPad. All experiments were performed by Nicole 
Urban. 
 
Both activators were used at a concentration of 10 µM. All three inhibitors were found to have 
IC50 values in the range of 2.5 µM – 24 µM (Figure 24 A). Significant differences in potencies 
were not detectable. Surprisingly, SG-005 (187) showed a reduced maximum efficacy (only 
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50%) after activation with TPC2-A1-N (16), while tetrandrine (1) and SG-094 (192) 
approximated a complete inhibition (nearly 100%, Figure 24 A). All three inhibitors had nearly 
100% blocking efficacy after activation with TPC2-A1-P (17).  
 
Figure 25: Structures of the truncated tetrandrine analogs, analyzed in SAR. (A) Structures of the 1-
benzyl-tetrahydroisoquinolines synthesized within this project. (B) Structures of the 1-benzyl-tetrahydro-
isoquinolines, provided by Prof. Dr. Meinhart Zenk†. 
 
IC50 values were obtained for the other compounds as well (Table 12). For some Z compounds, 
unspecific effects were observed at concentrations above 50 µM and concentration-effect 
relationships were not applicable. Tetrandrine (1), fangchinoline (9), berbamine (10), 
cepharanthine (140), oxyacanthine (138) and dauricine (11) all showed IC50 values in the same 
range for both activators (entry 1, 4-8, Table 12, all depicted in Figure 19). These results 
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confirmed that the substitution pattern of the benzyl residue and the stereochemistry were not 
determined. SG-005 (187), SG-094 (192), SG-158 (208) and SG-159 (206) showed IC50 value 
in the same range for activation with TPC2-A1-P (17) while only SG-094 (192) had a slightly 
higher IC50 for activation with TPC2-A1-N (16, entry 2-3, 17-18, Table 12, structures in Figure 
25). Both compounds selected as controls did either show high IC50 values or fitting was not 
applicable at all (entry 12-13, Table 12, structures in Figure 25). All analogs of SG-094 (192) 
blocked TPC2 activation with both activators to some extent, while some had differences in 
potencies (entry 9-11, 14-24, Table 12, structures in Figure 25). The substances bearing a 
para-methoxy, para-methyl or their fluorinated variants (SG-153 (199), SG-154 (198), SG-155 
(196), SG-162 (200)) showed a lower IC50 value after activation with TPC2-A1-P (17) 
compared to activation with TPC2-A1-N (16) (entry 14-16, 21, Table 12, structures in Figure 
25). None of the further analogs showed significantly stronger effects on TPC2. The three Z 
substances that did not show unspecific effects, Z1 (141), Z9 (147) and Z22 (157) were not 
able to inhibit TPC2 as well, which was verified by high (>50 µM) or not applicable IC50 values 
(entry 25-27, Table 12, structures in Figure 25). All other compounds, mainly of the Z series, 
had a slight inhibitory effect on the channel (at 12.5 µM). These compounds were not of further 
interest because of their already mentioned nonspecific effects on stably transfected HEK293 
cells.  
Table 12: Screening results of the compound library using Fluo-4 based calcium imaging and toxicity 
screening using MTT assay. Concentration-effect relationships were generated using HEK293 cells 
stably expressing hTPC2L11A/L12A-RFP and were plotted using GraphPad. Experiments were performed 
as described in Figure 24 in duplicates of one replicate for each activator. Calcium imaging experiments 
were performed by Nicole Urban and MTT assay by Martina Stadler. **was activated with 30 µM TPC2-
A1-P (17). 
entry compound IC50 (Fluo-4;  TPC2-A1-P (17)) 
IC50 (Fluo-4;  
TPC2-A1-N (16)) IC50 (MTT) 
1 tetrandrine (1) 10 µM 14 µM 43 µM 
2 SG-005 (187) 7.6 µM 2.5 µM 11 µM 
3 SG-094 (192) 8.3 µM 24 µM 23 µM 
4 fangchinoline (9) 11 µM 7.0 µM 38 µM 
5 berbamine HCl (10) 10 µM 7.0 µM 21 µM 
6 cepharanthine (140) 8.1 µM 5.1 µM 25 µM 
7 oxyacanthine sulfate (138) 21 µM 4.5 µM >50 µM 
8 dauricine (11) 12 µM 8.6 µM >50 µM 
9 SG-083 (188) 11 µM 14 µM 8.2 µM 
10 SG-122 (193) 14 µM 7.3 µM 22 µM 
11 SG-127 (194) n.a. 25 µM 18 µM 
12 SG-132 (159) >50 µM** 45 µM >50 µM 
13 SG-145 (183) 43 µM n.a. >50 µM 
14 SG-153 (199) 22 µM >50 µM 15 µM 
15 SG-154 (198) 12 µM >50 µM 9.5 µM 
16 SG-155 (196) 15 µM 37 µM 14 µM 
17 SG-157 (195) 34 µM 30 µM 29 µM 
18 SG-158 (208) 9.6 µM 0.33 µM 12 µM 
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19 SG-159 (206) 9.9 µM 0.75 µM 14 µM 
20 SG-161 (197) 10 µM 24 µM 15 µM 
21 SG-162 (200) 19 µM >50 µM 16 µM 
22 SG-163 (203) 18 µM 21 µM 9.5 µM 
23 SG-164 (201) 15 µM 43 µM 21 µM 
24 SG-165 (202) 33 µM >50 µM 19 µM 
25 Z1 (141) >50 µM >50 µM >50 µM 
26 Z9 (147) >50 µM >50 µM >50 µM 
27 Z22 (157) n.a. >50 µM 29 µM 
 
For acute toxicity, MTT assays were again performed by Martina Stadler. For these 
experiments HL-60 cells were used, which are human leukemia cells. All compounds showed 
acute toxicity to HL-60 cells. That was to be expected because of the strong correlation 
between cancer and TPC2[36]. The compounds that were not able to block TPC2 also showed 
no (entry 12-13, 25-26, Table 12) or slight (entry 27, Table 12) toxicity on HL-60 cells. 
Interestingly, the TPC2 inhibitors oxyacanthine (138) and dauricine (11) were not cytotoxic as 
well (entry 7-8, Table 12). 
In house agar diffusion test (Martina Stadler) was used to exclude some side-effects on 
bacteria (Escherichia coli, Pseudomonas marginalis, Staphylococcus equorum, Streptococcus 
entericus), yeasts (Yarrowia lipolytica, Saccharomyces cerevisiae) and dermatophytes 
(Hyphopichia burtonii). All compounds of the SG-series (Figure 25) did not show an inhibition 
zone.  
A variety of TPC2 inhibitors were identified within this screening. SG-005 (187) and SG-094 
(192) emerged to be the most promising TPC2 inhibitors with low IC50 values and high 
efficacies. Decorations on the aromatic ring impaired the ability to block TPC2. The diaryl or 
benzyl ethers were necessary for the inhibitory effect as well as a basic nitrogen atom. Tertiary 
amines were preferred because secondary amines caused unspecific effects in calcium 
imaging experiments. These results further demonstrated that whole endoysosomal patch 
clamp experiments are still state-of-the-art for ultimate analysis while calcium imaging 
experiments can be used for fast ligand identification.  
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3.6.3 TPC2 and cancer 
The influence of TPC2 functions on cancer hallmarks is of high interest[34] which made TPC2 
an interesting target for the development of novel anticancer therapeutics. Hence a close 
cooperation with Martin Müller (group of Prof. Dr. Angelika Vollmar, LMU) was initiated to use 
small-molecule inhibitors of TPC2 to further study the role of TPC2 in cancer. All experiments 
discussed in this chapter were performed by Martin Müller and are to be published in a 
corporate publication.  
Thus, after the identification of the novel TPC2 inhibitors, their potential to inhibit cancer cell 
growth was investigated. More negative controls (SG-089 (181), SG-121 (185), SG-121-NP 
(189)) and substances of the Z series were also screened for their antiproliferative properties 
using RIL175 cells in a CTB assay. Numerous molecules with an increased potency in 
comparison to tetrandrine (1, IC50: 9.1 µM, entry 1, Table 13) were identified, including 
truncated variants with IC50 values in the low micromolar range. Monomeric 
benzyltetrahydroisoquinolines bearing additional aromatic residues (phenyl or benzyl ethers) 
at both benzenoid rings were found to have outstanding properties. When modifying the amino 
group, antiproliferative activity remained in a similar range. N-Alkyl residues of different lengths 
with a basic nitrogen were equipotent (NH (Z3 (137)); N-methyl (SG-005 (187), SG-159 (206)); 
N-ethyl (SG-158 (208)), IC50: 2.4-4.8 µM, entry 2, 17-18, 28, Table 13). N-Acyl variants lost 
their antiproliferative properties as well as their basicity (SG-089 (181), SG-145 (183), IC50: 
≥ 33 µM, entry 12, 25, Table 13). Variations at C-6 and C-7 of the isoquinoline unit had a slight 
effect. In most cases, the loss of the aromatic substituents (aryl- or benzyl ether) in C-7 position 
slightly decreased antiproliferative activity (SG-083 (188), SG-127 (194), SG-157 (195), IC50: 
7.6-11 µM, entry 8, 10, 16, Table 13). The same was observed if the 1-benzyl group was 
replaced by a phenyl group (SG-122 (193) vs. SG-157 (195), entry 9, 16, Table 13), whereas 
shifting a benzyloxy residue from position C-7 to C-6 had no influence (Z3 (137) vs. Z5 (144), 
entry 28-29, Table 13). Furthermore, the impact of modifications of the 1-benzyl residue was 
investigated. Substitution patterns, mostly differing in meta- or para-position, did not markedly 
affect antiproliferative activity (SG-005 (187), SG-159 (206), Z6 (145), Z11 (141), Z13 (150), 
Z15 (152), Z18 (154), Z20 (155), IC50: 1.2-4.8 µM, entry 2, 18, 30-36, Table 13). Miscellaneous 
diaryl ethers at the 1-benzyl residue were synthesized bearing both electron-donating and -
releasing substituents, mainly in meta- or para-position (SG-153 (199), SG-154 (198), SG-155 
(196), SG-161 (197), SG-162 (200), SG-164 (201), SG-165 (202)). In most cases, no changes 
in antiproliferative potencies were observed (IC50: 3.9-5.6 µM, entry 13-15, 19-23, Table 13). 
However, cyano and chlorine substituents slightly (SG-164 (201), SG-165 (202), IC50: 
8.5-9.1 µM, entry 22-23, Table 13) and the pyridine moiety strongly reduced the 
antiproliferative activity (SG-163 (203), IC50: 22 µM, entry 21, Table 13). The loss of both, 
benzyl or diaryl ether moieties resulted in significant reduction (SG-132 (159), IC50: 11 µM, 
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entry 11, Table 13) or complete loss of activity (SG-089 (181), SG-121 (185), SG-121-NP 
(189), IC50: > 50 µM, entry 25-27, Table 13).  
Table 13: Screening of the benzyltetrahydroisoquinoline compound library by cell proliferation assays. 
Antiproliferative effects of the respective compounds against RIL175 WT cells were assessed by 
CellTiter-Blue® cell viability assays. Cells were treated for 72 h with the indicated concentrations. IC50 
values were calculated by nonlinear regression. Experiments were performed by Martin Müller. 
entry compound IC50 (RIL157) entry compound IC50 (RIL157) 
1 tetrandrine (1) 9.1 µM 25 SG-089 (181) >50 µM 
2 SG-005 (187) 2.4 µM 26 SG-121 (185) >50 µM 
3 SG-094 (192) 3.7 µM 27 SG-121-NP (189) >50 µM 
4 berbamine HCl (10) 7.7 µM 28 Z3 (137) 2.9 µM 
5 cepharanthine (140) 6.8 µM 29 Z5 (144) 2.7 µM 
6 oxyacanthine sulfate (138) 11 µM 30 Z6 (145) 2.9 µM 
7 dauricine (11) 9.3 µM 31 Z11 (148) 1.2 µM 
8 SG-083 (188) 7.6 µM 32 Z13 (150) 3.5 µM 
9 SG-122 (193) 4.5 µM 33 Z15 (152) 2.7 µM 
10 SG-127 (194) 8.0 µM 34 Z16 (153) 2.6 µM 
11 SG-132 (159) 11 µM 35 Z18 (154) 4.1 µM 
12 SG-145 (183) 33 µM 36 Z20 (155) 4.2 µM 
13 SG-153 (199) 4.9 µM    
14 SG-154 (198) 3.9 µM    
15 SG-155 (196) 4.4 µM    
16 SG-157 (195) 11 µM    
17 SG-158 (208) 4.8 µM    
18 SG-159 (206) 4.2 µM    
19 SG-161 (197) 4.5 µM    
20 SG-162 (200) 5.6 µM    
21 SG-163 (203) 32 µM    
22 SG-164 (201) 9.1 µM    
23 SG-165 (202) 8.5 µM    
24 Z22 (157) 18 µM    
 
All benzyltetrahydroisoquinolines, which carry two aryl or benzyl ether groups and a basic 
amine, inhibited proliferation of RIL175 cells to a similar extent or stronger than tetrandrine (1). 
The two simplest benzyltetrahydroisoquinolines of this type, SG-005 (187) and SG-094 (192), 
were subjected to further investigations. SG-005 (187, IC50: 2.4 µM) and SG-094 (192, IC50: 
3.7 µM) both displayed markedly enhanced antiproliferative effects, compared to tetrandrine 
(1). SG-005 (187) and SG-094 (192) had similar or increased antiproliferative potencies 
against various other cancer cell lines, including human hepatocellular carcinoma (HepG2), 
human colorectal adenocarcinoma (HCT-15) and human vincristine-resistant acute 
lymphoblastic leukemia (VCR-R CEM) (entry 1-9, Table 14). While comparing IC50 values of 
the cell proliferation assay and Fluo-4 based calcium imaging, it was striking that not all 
compounds that block proliferation were TPC2 inhibitors (SG-132 (159), entry 12, Table 12, 
entry 11, Table 13) and not all TPC2 inhibitors blocked proliferation (SG-163 (203), entry 22, 
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Table 12, entry 21, Table 13). This indicated that these compounds have side effects on further 
targets in cancer cells.  
Table 14: Antiproliferative effects of tetrandrine (1), SG-005 (187) and SG-094 (192) on different cancer 
cell lines. Antiproliferative effects of the respective compounds on HCT-15, HepG2 and VCR-R CEM 
cells were assessed by CellTiter-Blue® cell viability assays. HCT-15 and HepG2 cells were treated for 
72 h, VCR-R CEM cells were treated for 48 h. IC50 values were calculated by nonlinear regression. 
Experiments were performed by Martin Müller. 
entry compound cell line IC50 (Ril-175) 
1 tetrandrine (1) HCT-15 9.7 µM 
2 tetrandrine (1) HepG2 9.4 µM 
3 tetrandrine (1) VCR-R CEM 15 µM 
4 SG-005 (187) HCT-15 7.8 µM 
5 SG-005 (187) HepG2 7.8 µM 
6 SG-005 (187) VCR-R CEM 5.5 µM 
7 SG-094 (192) HCT-15 7.6 µM 
8 SG-094 (192) HepG2 9.9 µM 
9 SG-094 (192) VCR-R CEM 10 µM 
 
Cellular uptake, toxicity and the effects on angiogenesis and glucose metabolism of SG-005 
(187) and SG-094 (192) were investigated, all in comparison to tetrandrine (1). SG-132 (159) 
and SG-145 (183) both identified as non-TPC2 blockers by Ca2+ imaging experiments were 
used as controls. The vascular endothelial growth factor (VEGF) has been demonstrated to be 
a major contributor to angiogenesis. The role of TPC2-mediated Ca2+ release in 
neoangiogenesis was already described in literature[35, 52] and VEGF inhibitors were used to 
treat cancer[38]. Western blot analysis revealed that SG-005 (187) and SG-094 (192) were 
capable of significantly reducing VEGF-induced phosphorylation levels, while tetrandrine (1) 
had no effect under the chosen treatment conditions. As expected, the analysis of the selected 
controls, SG-132 (159) and SG-145 (183), showed no reduced phosphorylation of the 
investigated VEGFR2 downstream targets.  
As the inhibitory effect on TPC2 was similar for tetrandrine (1) and SG-005 (187), the question 
arose if they differ in their pharmacokinetic properties. Therefore, together with Dr. Christoph 
Müller and Anna Niedrig, the cellular uptake was investigated by analytical HPLC. Two different 
cell lines (HUVECs and RIL175 cells) at two different compound concentrations (2 µM and 10 
µM) were tested. Incorporation of SG-005 (187) into HUVECs was slightly higher than the 
uptake of tetrandrine (1) and SG-094 (192) at 2 µM, while all other settings did not show 
significant differences. In general, cellular uptake for the cancerous liver cells (RIL175) was 
preferred compared to the primary endothelial cells (HUVECs). Initial uptake was not a major 
trigger for the improved on-target activity of SG-005 (187) and SG-094 (192) on TPC2.  
Cancer cells tend to reprogram their energy metabolism in order to boost extensive cell 
division[38] and according to the Warburg effect, many cancer cells preferentially use glycolysis 
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for ATP production[170]. Normal cells, however, favor oxidative phosphorylation and conduct 
glycolysis to generate pyruvate out of glucose for the dismantling of unnecessary biomass. 
Glucose metabolism was identified as one pathway that is altered as a result of TPC2 
deficiency. Upon loss of TPC2 function or pharmacological inhibition of this channel with 
tetrandrine (1), SG-005 (187) and SG-094 (192), a metabolic shift towards a less glycolytic, 
and therefore healthier, phenotype was observed.  
The toxicity of tetrandrine (1) is a serious drawback, especially for in vivo studies. It is 
postulated to be related to metabolic activation by cytochrome P450 (CYP) enzymes[70, 171] or 
mitochondrial pathways[172]. Both, SG-005 (187) and SG-094 (192) showed decreased toxicity 
to non-cancerous hepatic stem cells (HepaRGTM) and peripheral blood mononuclear cells 
(PBMCs), which was not related to CYP3A4 levels. This indicates that metabolic oxidation by 
CYP enzymes is not responsible for the toxicity of tetrandrine (1). Thus, truncation of 
tetrandrine (1) slightly (SG-005 (187)) or substantially (SG-094 (192)) improved the toxicity 
prolife.  
In vivo studies using tetrandrine (1) are limited due to the poor solubility as well as the high 
toxicity. The simplified, less toxic and good soluble substances SG-005 (187) and SG-094 
(192) were evaluated for their therapeutic potential in an ectopic mouse model using C57Bl/6-
Tyr mice and RIL175 HCC cells. SG-005 (187) did not show the expected in vivo efficacy, while 
SG-094 (192), successfully managed to reduce tumor growth in vivo at tolerated doses.  
In short, pharmacological inhibition of TPC2 function reduced cancer cell proliferation, altered 
cellular energy metabolism and prevented tumor growth. The two small-molecule TPC2 
inhibitors, SG-005 (187) and SG-094 (192), showed a great drug-likeness compared to the 
limited panel of currently available direct TPC2 blockers. The cellular uptake could be improved 
and the toxicity was lowered in comparison to tetrandrine (1). Using these molecules enables 
to perform in vivo experiments which increases their possible applications.  
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3.6.4 Separation of the enantiomers 
The racemic mixtures of SG-005 (187) and SG-094 (192) were separated by semipreparative 
chiral HPLC in order to identify the eutomer. The absolute stereochemistry was determined 
using ECD spectra and was confirmed by computational calculations by Aaron Gerwien (group 
of Prof. Dr. Henry Dube, LMU) (Figure 26 C and F). The separated enantiomers were analyzed 
in Fluo-4 based calcium imaging and compared with the racemic mixtures, respectively. For 
activation of the ion channel both TPC2 activators, TPC2-A1-N (16) and TPC2-A1-P (17) were 
used. (S)-SG-005 (209) showed a decreased potency (IC50: 7.8 µM) compared to its 
enantiomer (R)-SG-005 (210, IC50: 2.4 µM) after activation with TPC2-A1-N (16, Figure 26 E), 
while there was no difference after activation with TPC2-A1-P (17, Figure 26 D). The same 
applied to (S)-SG-094 (211, IC50: 31 µM) and (R)-SG-094 (212, IC50: 14 µM) to some extent 
(Figure 26 A and B). Thus, all enantiomers showed inhibition of TPC2 after activation with 
both activators.  
 
Figure 26: Fluo-4 based calcium imaging of enantiopure SG-005 (187) and SG-094 (192). (A-B) 
Concentration-effect relationships using HEK293 cells stably expressing hTPC2L11A/L12A-RFP. Cells 
were sequentially stimulated with SG-094 (rac: 192, (S): 211, (R): 212) and TPC2-A1-P (17, 10 µM, A) 
or TPC2-A1-N (16, 10 µM, B) as activator. IC50 values were calculated out of at least three independent 
experiments using GraphPad. (C) Structures of both enantiomers of SG-094 ((S): 211, (R): 212). (D-E) 
Experiment as in A-B but using SG-005 (rac: 187, (S): 209, (R): 210). (F) Structures of both enantiomers 
of SG-005 ((S): 209, (R): 210). Experiments were performed by Nicole Urban. 
 
The different enantiomers were further analyzed for toxicity and their ability to inhibit 
proliferation. All compounds were not toxic to non-cancerous HepaRG cells in a CTB assay at 
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10 µM, while tetrandrine (1) already showed toxicity at this concentration (Figure 27 A). In 
particular, SG-094 (192) and enantiomers (211, 212) showed a significantly decreased toxicity 
compared to tetrandrine (1). Antiproliferative properties of these compounds were evaluated 
using RIL175 cells in a CTB assay. Both enantiomers of both compounds did reduce cell 
proliferation, though both (R)-enantiomers (210, 212) were less potent than the corresponding 
(S)-enantiomers (209, 211) and the racemates (187, 192), as depicted in Figure 27 B and C.  
 
Figure 27: Toxicity and cell proliferation of the enantiopure compounds. (A) Toxicity of tetrandrine (1), 
SG-005 (rac: 187, (S): 209, (R): 210) and SG-094 (rac: 192, (S): 211, (R): 212) to non-cancerous cells 
was probed by treating HepaRG cells with 10 µM of the corresponding compound for 72 h. Cell viability 
was assessed by CellTiter-Blue® cell viability assay and was normalized to vehicle control. Bar graphs 
indicate mean ± SEM of three independent experiments. **p < 0.01, *p < 0.05, using one-way ANOVA 
followed by Tukey’s post hoc test. (B-C) Antiproliferative effects of the SG-005 (B, rac: 187, (S): 209, 
(R): 210) and SG-094 (C, rac: 192, (S): 211, (R): 212) were assessed by CellTiter-Blue® cell viability 
assays. RIL-175 cells were treated for 72 h. IC50 values were calculated by nonlinear regression. 
Fluorescence intensities were normalized to vehicle control and are displayed as mean ± SEM of three 
independent experiments. Experiments were performed by Martin Müller.  
 
Notably, calcium imaging revealed that both enantiomers of SG-005 (187) and SG-094 (192) 
inhibit TPC2 upon activation to a similar extent. Furthermore, the racemates showed virtually 
the same effects as the more potent compound in cell proliferation assay. Consequently, the 
racemates were preferred for all subsequent experiments.  
 
3.6.5 Expanding the TPC2 inhibitor panel 
The aforementioned panel of TPC2 inhibitors comprises indirect TPC inhibitors like trans-Ned-
19 (2)[36, 60, 173] and direct inhibitors like the flavonoid naringenin (8)[52], the listed drugs 
fluphenazine (6) and raloxifene (7)[31] and the bisbenzylisoquinoline alkaloid tetrandrine (1)[2, 
36]
. There are other reported compounds which interfere with NAADP-mediated Ca2+ signaling 
like BZ194, an N-alkylated nicotinic acid derivative[174], and pyridoxal phosphate 6-azophenyl-
2′,4′-disulfonic acid (PPADS)[175, 176]. For both compounds, however, no direct measurements 
of TPC inhibition are published, questioning the accuracy of these inhibitors.  
Naringenin (8) and trans-Ned-19 (2) require high concentrations to inhibit TPCs (500 µM and 
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125 µM, respectively)[52, 60]. Raloxifene (7) and fluphenazine (6) both exhibite a low IC50 in 
endo-lysosomal patch clamp experiments (0.63 µM and 8.2 µM) after stimulation with PI(3,5)P2 
(4)[31]. The application of raloxifene (7), however, is limited to postmenopausal women 
regarding the influence upon hormone levels and fluphenazine (6) is known for its broad 
spectrum of adverse effects. The most prominent and potent TPC inhibitor, tetrandrine (1), 
blocks TPCs at nano-molar concentrations (500 nM) in endo-lysosomal patch clamp 
experiments[2]. It is used in different studies as exemplary TPC inhibitor, but the poor solubility 
combined with the reported toxicity make tetrandrine (1) not applicable for in vivo studies. None 
of these antagonists of TPCs is selective, neither can they discriminate between the two TPC 
isoforms.  
The new developed TPC2 inhibitors, SG-005 (187) and SG-094 (192) showed improved 
efficacy in electrophysiological endo-lysosomal patch clamp experiments for SG-094 (192, 
74% inhibition) or equipotent efficacy for SG-005 (187, 44%), compared to tetrandrine (1, 54%) 
after activation with PI(3,5)P2 (4). These results were confirmed by Fura-2 calcium imaging 
experiments. Again SG-094 (192) had the strongest effect (**) compared to tetrandrine (1, *) 
and SG-005 (187, *) when applied at a concentration of 10 µM. Furthermore the cellular uptake 
could be improved and the toxicity was lowered in comparison to tetrandrine (1). The great 
solubility of SG-005 (187) and SG-094 (192) enabled in vivo studies in an ectopic mouse 
model. Both compounds were well tolerated at given doses and SG-094 (192), successfully 
managed to reduce tumor growth in vivo. These results demonstrate that the two small-
molecule TPC2 inhibitors, SG-005 (187) and SG-094 (192), showed a promising drug-likeness 
and expanded the limited panel of available TPC2 blockers. 
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3.7  Side Projects 
The developed calcium imaging methods were further used in some side projects to confirm 
inhibitory effects on TPC2 or TRPML channels. Within projects in the group of Prof. Dr. Bracher 
substances were synthesized or purchased and subsequently tested by me on TPC2 to 
evaluate their effect on endo-lysosomal ion channels.  
 
3.7.1 The isoquinoline-benzylisoquinoline alkaloid rac-muraricine (213) 
Ramona Schütz performed the first racemic total synthesis of the isoquinoline-
benzylisoquinoline alkaloid rac-muraricine (213, Figure 28 A)[177]. Pharmacological 
characterization identified rac-muraricine (213) as a moderate inhibitor of P-glycoprotein, while 
it showed only low antiproliferative effects. Structural similarities to tetrandrine (1) and 
dauricine (11) led to the presumption that rac-muraricine (213) can block TPC2. Therefore 
Fura-2 based calcium imaging was performed using TPC2-A1-N (16) for activation. The 
alkaloid rac-muraricine (213) was not able to inhibit TPC2 activation in comparison to a DMSO 
control (Figure 28 B and C).  
 
Figure 28: Fura-2 based calcium imaging results of rac‐muraricine (213) and a DMSO control using the 
TPC2 activator TPC2‐A1‐N (16). (A) Structure of rac‐muraricine (213). (B) Statistical analysis of the 
maximal change in the Fura‐2 ratio (mean ± SEM) with the number of independent experiments in 
parentheses. An unpaired t ‐test was applied. ns = not significant. (C) Representative Ca2+ signals 
recorded from HEK293 cells stably expressing TPC2L11A/L12A–RFP. After applying rac‐muraricine (213, 
10 µM; n = 19 single cells) or DMSO (0.1% in HBS; n = 16 single cells) and monitoring the signal for 
400 s, cells were stimulated with TPC2‐A1‐N (16, 10 µM) and further recorded for 400 s. Highlighted 
lines represent the mean response from a population of cells. Shaded traces represent responses of 
single cells. All experiments were performed on a Leica DMi8 live cell microscope.   
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3.7.2 The TRPML inhibitors ML-SI1 (214) and ML-SI3 (215) 
In the course of an Erasmus project the TRPML inhibitor ML-SI1 (214) was synthesized under 
the supervision of Dr. Marco Keller (Figure 29 D). This compound was one out of two published 
TRPML inhibitors with undefined stereochemistry[178]. The product was received as a racemic 
mixture of two diastereomers (4 isomers in total) and was tested on the TRPML channels for 
its postulated inhibitory effect. Experiments were performed by first activating the ion channel 
with ML-SA1 or MK6-83 (10 µM, respectively) and subsequent inhibition using ML-SI1 (214, 
10 µM) or ML-SI3 (214, 10 µM). For statistical analysis the median activation was normalized 
to 1 to compare the percentage inhibitory effect.  
 
Figure 29: Fura-2 based calcium imaging experiments for TRPML inhibitors. (A) Statistical analysis of 
the inhibitory effect of ML-SI1 (214) on TRPMLs in Fura-2 based Ca2+ imaging experiments (normalized 
activation). Experiments were carried out as previously described[115] on a Polychrome IV mono-
chromator (for hTRPML1) or a Leica DMi8 live cell microscope (for TRPML2 and 3). After stimulation 
with ML-SA1 (10 µM) for 200 s, the inhibitor ML-SI1 (214, 10 µM) was applied for another 200 s. For 
measurements HEK293 cells stably expressing hTRPML2-YFP or hTRPML3-YFP, and transiently 
transfected hTRPML1ΔNC-YFP cells were used[114]. (B) Statistical analysis as in (A), using ML-SA1 (10 
µM) or MK6-83 (10 µM) for activation of hTRPML1ΔNC-YFP transiently transfected HEK293 cells. (C) 
Representative Ca2+ signals recorded from hTRPML1ΔNC-YFP transiently transfected HEK293 cells, 
loaded with Fura-2/AM (126) and sequentially stimulated with ML-SA1 (10 µM, red, n = 5 transfected 
and 2 NT cells) or MK6-83 (10 µM, orange, n = 11 transfected and 3 NT cells) and ML-SI1 (214, 10 µM). 
Highlighted lines represent the mean response from a population of cells. Shaded traces represent 
responses of single cells. (D) Structure of rac-ML-SI1 (214), synthesized by Dr. Marco Keller. (E) 
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Statistical analysis of the inhibitory effect of ML-SI3 (215) as in (A) using ML-SA1 (10 µM) for activation 
and ML-SI3 (215, 10 µM from Enamine store) for inhibition. All experiments were performed on a Leica 
DMi8 live cell microscope. (F) Statistical analysis as in (B) but inhibition with ML-SI3 (215, 10 µM). All 
experiments were performed on a Leica DMi8 live cell microscope. (G) Representative Ca2+ signals as 
in (C) but performed on a Leica DMi8 live cell microscope. Cells were sequentially stimulated with ML-
SA1 (10 µM, blue, n = 5 transfected and 8 NT cells) or MK6-83 (10 µM, green, n = 4 transfected and 5 
NT cells) and ML-SI3 (215, 10 µM). Highlighted lines represent the mean response from a population of 
cells. Shaded traces represent responses of single cells. In all statistical analyses of Ca2+ imaging 
experiments, mean values of n independent experiments are shown as indicated. ***p < 0.001, **p < 
0.01, *p < 0.05, ns = not significant, one-way ANOVA test followed by Tukey’s post-hoc test. 
 
Single cell calcium imaging experiments confirmed that the synthesized racemic ML-SI1 (214) 
had an inhibitory effect on TRPML1 (Figure 29 A-C). Statistical analysis of the three isoforms 
of the ion channel showed strong inhibitory effect on hTRPML1, a weaker effect on hTRPML2 
and no effect on hTRPML3, all after activation with ML-SA1 (Figure 29 A). While inhibition 
after activation with ML-SA1 showed a robust signal, it was not possible to significantly block 
MK6-83 induced activation (Figure 29 B and C). This indicates an activator dependent 
inhibition.  
The second published inhibitor, ML-SI3 (215)[178], was commercially available at Enamine store 
(CAS: 891016-02-7) but with undefined stereochemistry. Within a new project, Charlotte Leser 
identified the commercially available ML-SI3 (215) as racemic mixture of trans-ML-SI3 (215, 
Figure 29 H). The commercially available ML-SI3 (215, Figure 29 H) was able to block ML-
SA1 evoked hTRPML1 and 2 activation around 50% but did not inhibit hTRPML3 activation 
(Figure 29 E). The comparison of the different activators showed that ML-SI3 (215) was able 
to block both ML-SA1 and MK6-83 induced activation in the same manner (Figure 29 F and 
G). Thus, ML-SI3 (215) seemed the more promising antagonist for further investigations.  
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4 Summary 
The first aim of this thesis was the identification of small-molecule TPC2 activators. This was 
achieved by performing a high-throughput screening of a compound library, containing 80000 
substances. Two TPC2 activators (TPC2-A1-N (16), TPC2-A1-P (17)) were identified within 
this screening process. Both compounds were confirmed by fluorescence-based Ca2+-imaging 
and electrophysiological endo-lysosomal patch clamp measurements. To verify the structures, 
both substances were synthesized and re-evaluated.  
Sjogren et al. published a two-step synthesis for α-cyano-β-hydroxypropenamides, which 
resulted in the desired TPC2-A1-N (16)[91]. Only slight changes in this procedure were 
necessary for optimization. Different aniline building blocks (IV, Figure 30 A), 2-cyanoacetic 
acid (18) and DCC as coupling reagent yielded 23 cyanoacetanilides (II, Figure 30 A), nearly 
all in high yield. Acylation of these intermediates (II, Figure 30 A) using different benzoic acid 
building blocks (III, Figure 30 A) and NaH as a strong base gave the desired 
α-cyano-β-hydroxypropenamides (I, Figure 30 A) as analogs of TPC2-A1-N (16, Figure 30 
B). Only the thio-analog SGA-167 (91) was synthesized with another method. Collectively, 47 
compounds were synthesized in moderate to high yield, including the hit TPC2-A1-N (16), and 
two drugs (prinomide (58), teriflunomide (76)).  
Fura-2 based calcium imaging experiments were performed to study SAR. Surprisingly, none 
of the 46 modified versions of TPC2-A1-N (16, Figure 30 B) did show significantly increased 
efficacies. Replacing the p-trifluoromethyl group on the anilide side of the molecule (R1; blue) 
with other electron-withdrawing groups in para-position did not lead to significant changes. The 
introduction of electron-releasing groups in para-position was tolerated to some extent (SGA-
4 (47), SGA-84 (72)). Meta-disubstitution patterns were most beneficial for the benzoyl ring 
system (R2, green), while more drastic changes in this aromatic region caused a complete loss 
of activity. This was demonstrated for the approved drugs teriflunomide (76) and prinomide 
(58) as well as the 4-trifluoromethyl variant of prinomide (SGA-32 (59)), all possessing methyl 
or pyrrole residues instead of the benzoyl ring. In total, 24 analogs were able to activate TPC2 
with similar or lower efficacy compared to TPC2-A1-N (16)[22, 135]. All results were confirmed by 
determination of concentration-effect relationships, underlining the very flat SAR of this 
chemotype on TPC2. The increased potency and efficacy of SGA-85 (73) were relativized by 
non-specific effects on control cells. Selectivity-screening revealed that SGA-108 (77) showed 
an improved selectivity spectrum, which explains the loss of efficacy. All these findings have 
proven the high efficacy of TPC2-A1-N (16) and the fact that it is the most promising candidate 
to be a great tool compound. 
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Figure 30: Synthesis and compound overview of TPC2-A1-N (16) and analogs. (A) Synthesis scheme 
for the preparation of most α-cyano-β-hydroxypropenamides. (B) Structures of TPC2-A1-N (16) and 
analogs. Differences to the hit compound are marked in magenta (TPC2 activators) or red (no TPC2 
activators).  
 
The synthesis of the second activator, TPC2-A1-P (17), was more challenging than the 
synthesis of TPC2-A1-N (16), as the required intermediate, an α-halogenated acetophenone 
(IV, Figure 31) substituted in C-2 position with a trifluoromethoxy and in C-5 position with a 
bromo group, was not commercially available. Many different synthetic approaches were not 
successful until the main problem was detected: The desired product was highly volatile. 
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Hence, a synthesis avoiding these conditions was chosen and the α-halogenated 
acetophenone (IV, Figure 31 A) was synthesized successfully.  
For the synthesis of the highly substituted TPC2-A1-P scaffold a Paal-Knorr pyrrole synthesis 
was performed. Under alkaline conditions 1,4-diketones (VIII, Figure 31 A) were synthesized, 
using the α-halogenated acetophenone (IV, Figure 31 A) and β-ketoester (V, Figure 31 A) 
building blocks. These 1,4-diketones (VIII, Figure 31 A) were not isolated and directly 
condensed with a primary amine building block (III, Figure 31 A) in acidic medium to give 
multi-substituted pyrroles (II, Figure 31 A). In total, 13 esters were synthesized and 8 of them 
isolated. Hydrolysis of the esters (II, Figure 31 A) required harsh conditions, utilizing 
microwave irradiation for several hours to give the hit TPC2-A1-P (17) and 12 analogs varying 
all substituents of the pyrrole moiety (Figure 31 B).  
 
Figure 31: Synthesis and compound overview of TPC2-A1-P (17) and analogs. (A) Synthesis scheme 
for the synthesis of TPC2-A1-P (17) and analogs. (B) Structures of TPC2-A1-P (17) and analogs. 
Differences to the hit compound are marked in magenta (TPC2 activators) or red (no TPC2 activators). 
 
Similar to TPC2-A1-N (16), calcium imaging experiments were performed to gain first insights 
into SAR. Again, all modified versions of TPC2-A1-P (17) showed no improvement of 
efficacy[22]. Every change in structure resulted in a decrease or total loss of activity. SAR 
revealed that the free carboxylic acid is essential for the activating effect, as the ester SGA-
140 (109) was not active. It could possibly serves as a prodrug of TPC-A1-P (17) in living 
systems, but this has not been investigated yet. Both substituents at the phenyl ring, the 
trifluoromethoxy and the bromine group, were essential for activating TPC2, as exemplified by 
the inactive methoxy (SGA-55, 115) and des-bromo (SGA-162, 120) analogs. Moderate 
expansion of the size of the pyrrole substituent at C-2 position (methyl in TPC2-A1-P (17) vs. 
ethyl in SGA-152 (121) and phenyl analog SGA-154 (122)), had the same effect. The only 
fairly tolerated structure modification was replacing the cyclohexylmethyl moiety in 1-positon 
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of the pyrrole ring by a benzyl residue (SGA-150, 125), whereas linear or branched alkyl chains 
(SGA-149 (123), SGA-153 (124)) caused loss of activity (Figure 31 B). All results were further 
confirmed by full concentration-effect relationships, generated by Fluo-4 calcium imaging 
experiments. These harsh limitations showed that TPC2-A1-P (17) had an unusually steep 
structure-activity relationship resulting in TPC2-A1-P (17) as great chemical tool.  
Comparing the results of both activator classes, a considerable number of TPC2-A1-N (16) 
analogs caused remarkable TPC2 activation, but none of them showed significantly increased 
efficacies. In contrast to TPC2-A1-N (16), TPC2-A1-P (17) showed an unusually steep 
structure-activity relationship, and except for one analog (SGA-150, 125) none of the analogs 
showed any activity. TPC2-A1-N (16) itself and some of its analogs bearing residues in para-
position at the benzoyl ring were known as anthelmintic agents[91], while TPC2-A1-P (17) was 
only namely mentioned as a precursor in the synthesis of cannabinoid-1 receptor (CB1R) 
inverse agonists[105]. Two analogs of TPC2-A1-N (16) were launched drugs (teriflunomide (76), 
prinomide (58)), proving the drug-likeness of the TPC2-A1-N skeleton. There were no drugs 
comprising the TPC2-A1-P skeleton and furthermore no reports for using the free carboxylic 
acids. Thus, the two HTS hits TPC2-A1-N (16) and TPC2-A1-P (17) can be regarded as novel, 
strong chemical tools. 
In a very recent publication we published initial steps for the pharmacological profile of TPC2-
A1-N (16) and TPC2-A1-P (17)[22]. The subtype selectivity to TPC1 and cell permeability were 
proven. These small-molecules finally helped to resolve the conflict, whether TPC2 is a 
NAADP-activated Ca2+ release channel[5, 12, 14, 127, 128] or a PI(3,5)P2 gated Na+ channel[15, 20, 129]: 
TPC2 is a ligand-dependent, non-selective cation channel with malleable cation selectivity. 
Depending on the agonist, TPC2 shows higher calcium permeability (activation with TPC2-A1-
N (16), similar to NAADP (3)) or increased sodium permeability (activation with TPC2-A1-P 
(17), similar to PI(3,5)P2 (4)). Additionally the PI(3,5)P2 (4) binding site in TPC2[8] has been 
identified to be the overlapping with the pore for TPC2-A1-P (17). While TPC2-A1-N (16) 
induced an alkalinization of single vesicles in cells expressing wild-type TPC2, as described 
for NAADP (3)[130, 131], TPC2-A1-P (17) promoted lysosomal exocytosis.  
In comparison with other new TPC2 activators, identified by Zhang et al.[111], our two new 
activators were more potent and selective, which made them the perfect chemical tools for the 
identification of TPC2 inhibitors.  
Because of their anti-cancer or anti-viral effects TPC2 inhibitors are currently of higher 
therapeutic significance than activators. Hence, a set of TPC2 inhibitors was synthesized, 
inspired by the known TPC2 inhibitor tetrandrine (1). These molecules mimicked one half of 
the bisbenzylisoquinoline tetrandrine (1) and further decoration, not only in form of O-benzyl 
derivatives but also as diaryl ethers, was supposed to closely imitate tetrandrine (1) in shape 
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and size (Scheme 34 A). Iturriaga-Vásquez et al. designed simplified and more accessible 
congeners of tetrandrine (1) bearing extensions as benzyl groups, which were developed as 
L-type calcium channel blockers[82]. This was a promising hint for the plan to design truncated 
analogs of tetrandrine (1). 
Starting materials for the synthesis of the desired tetrahydroisoquinolines were carbamates 
and enol ethers (I and II, Scheme 34 B). Using ethyl chloroformate (162), NEt3 and 3-
methoxytyramine (160) or its O-protected derivatives gave different carbamates (I). Enol 
ethers (II) were received via Wittig olefination of commercially available para-substituted 
benzaldehydes. These precursors underwent N-acyl Pictet-Spengler reaction using TFA and 
to yield N-acethoxycarbonyl-1-benzyltetrahydroisoquinolines (III). Tertiary N-methyl amines 
(IV) were received by reduction of the carbamate group and, if applicable, in situ deprotection 
of carbonate-protected phenols using lithium alanate. Diverse diaryl ethers (V) were introduced 
at the generated phenolic groups via gentle Chan-Evans-Lam coupling with the appropriate 
arylboronic acids. Furthermore, three routes were established to yield SG-005 (187): lithium 
alanate reduction of the carbamate SG-145 (183), Eschweiler-Clarke reaction starting with the 
secondary amine Z3 (137) and Mitsunobu reaction on N-methylcoclaurine (SG-132, 159) to 
receive benzyl protecting groups. The Eschweiler-Clarke reaction using Z6 (145) also yielded 
SG-159 (206) and an alkylation reaction using bromoethane yielded SG-158 (208).  
The racemates SG-005 (187) and SG-094 (192) were separated by semi-preparative chiral 
HPLC for the identification of the potential eutomers. The absolute configuration of the 
enantiomers was determined using ECD spectra and confirmed by computational calculations 
performed by Aaron Gerwien. Notably, Ca2+ imaging revealed that both enantiomers of SG-
005 (187) and SG-094 (192) inhibit TPC2 upon activation to a similar extent. Consequently, 
the racemates were used for all further experiments.  
A Fura-2 based single cell calcium imaging method was developed and the TPC2-blocking 
effect of SG-005 (187) and SG-094 (192) was confirmed. These two substances were 
highlighted within this project because of their outstanding effects in a variety of experiments. 
While tetrandrine (1) and SG-005 (187) were equipotent (54% and 44% inhibition or *, 
respectively), SG-094 (192) was significantly more potent (74%, **) at the tested conditions 
(10 µM of inhibitor, activated with 1 µM PI(3,5)P2 (4)) in endo-lysosomal patch-clamp 
experiments (performed by Dr. Yu-Kai Chao) and Fura-2 based calcium imaging experiments 
(10 µM TPC2-A1-N (16), followed by 10 µM of the respective inhibitor). Furthermore, two 
negative controls were identified to assure the accuracy of the experiments. SG-132 (159, N-
methylcoclaurine) is missing the decoration on the phenol groups and SG-145 (183) the 
alkaline nitrogen function of the tetrahydroisoquinoline, which represent the two most important 
structural moieties.  
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Scheme 34: Summary for the synthesis of truncated tetrandrine analogs. (A) Schematic overview for 
the truncation of tetrandrine (1). Decorations on the former phenols (R’s) make the molecule resemble 
tetrandrine (1) even more. (B) Complete synthesis branches for the synthesis of truncated analogs, 
starting with carbamate and enol ether building blocks. N-acyl Pictet-Spengler reaction resulted in 
benzyltetrahydroisoquinolines, that were deprotected and reduced using lithium alanate. The resulting 
tertiary amines received their final decoration using the Chan-Evans-Lam coupling. Shaded reactions 
are additional reactions to receive different benzylated analogs. 
 
All compounds were analyzed for their ability to inhibit TPC2-A1-N (16) and TPC2-A1-P (17) 
induced TPC2 activation in Fluo-4 calcium imaging experiments performed by Nicole Urban. 
Within this screening IC50 values were obtained not only for the synthesized substances, but 
also for more alkaloids: intermediates of the morphine biosynthesis like racemic coclaurine 
(Z1, 141), kindly provided by Prof. Dr. Meinhart Zenk†, tetrandrine (1) and derivatives as 
fangchinoline (9), kindly provided by Prof. Dr. Peter Pachaly†. Commercially available 
benzylisoquinoline alkaloids like dauricine (11) and oxyacanthine (138) completed the 
screening library. This screening pointed out that tetrandrine (1), fangchinoline (9) and the 
other alkaloids inhibit TPC2 to the same extent (around 50%). SG-005 (187), SG-094 (192) 
and the orientaline derivatives SG-158 (208) and SG-159 (206) were able to inhibit TPC2 
activation similarly or even better than tetrandrine (1). None of the further analogs showed 
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significant stronger effects on TPC2. The substances bearing a para-methoxy, para-methyl or 
their fluorinated variants (SG-153 (199), SG-154 (198), SG-155 (196), SG-162 (200)) showed 
a lower IC50 value after activation with TPC2-A1-P (17) compared to activation with TPC2-A1-
N (16). As mentioned before, SG-005 (187) and SG-094 (192), derived from the alkaloid 
coclaurine, were selected as most promising TPC2 inhibitors for further investigation.  
After the identification of the novel TPC2 inhibitors, their potential to inhibit cancer cell growth 
was investigated. All 1-benzyltetrahydroisoquinolines carrying two aryl or benzyl ether groups 
and a basic amine inhibited proliferation of RIL175 cells to a similar or stronger extent than 
tetrandrine (1). The two simplest 1-benzyltetrahydroisoquinolines, SG-005 (187, IC50: 2.4 µM) 
and SG-094 (192, IC50: 3.7 µM), both displayed markedly enhanced antiproliferative effects 
compared to tetrandrine (1) also against various other cancer cell lines including HepG2, HCT-
15 and VCR-R CEM. The comparison of IC50 values of the cell proliferation assay and Fluo-4 
based calcium imaging showed that not all compounds that block proliferation were TPC2 
inhibitors (SG-132 (159)) and not all TPC2 inhibitors block proliferation (SG-163 (203)), 
indicating additional effects of these compounds on other targets in cancer cells.  
In an effort to conclude the correlation between TPC2 inhibition and hallmarks of cancer, 
cellular uptake, toxicity and the effects on angiogenesis and glucose metabolism of SG-005 
(187) and SG-094 (192) were investigated by Martin Müller (Vollmar group), all in comparison 
to tetrandrine (1). The non TPC2-blockers SG-132 (159) and SG-145 (183) were used as 
controls. Pharmacological inhibition of TPC2 function reduced cancer cell proliferation altered 
cellular energy metabolism and prevented tumor growth in vivo. The cellular uptake could be 
improved and the toxicity was lowered in comparison to tetrandrine (1). Thus, the two small-
molecule TPC2 inhibitors SG-005 (187) and SG-094 (192) showed a great potential for drug 
development especially considering the limited panel of currently available TPC2 blockers.  
Summarizing, big steps to boost the basic research of two pore channels have been achieved 
within this project. The two novel small-molecule activators of TPC2, TPC2-A1-N (16) and 
TPC2-A1-P (17), were discovered and analyzed in extensive studies. Now they represent two 
powerful chemical tools for the analysis of TPC2 function. These activators enable the use of 
fluorescent based assays on intact cells to study TPC2 inhibitors. Therefore a new generation 
of TPC2 inhibitors was synthesized, resembling one half of the alkaloid tetrandrine (1) plus the 
two benzenoid rings of the second benzylisoquinoline moiety. The two new TPC2 inhibitors 
with improved or at least equipotent ability to inhibit TPC2 were developed, SG-005 (187) and 
SG-094 (192). Together with our cooperation partners TPC2 was proven to be an exciting 
target in tumor therapy and these two compounds were identified as promising lead structures 
for cancer therapy.  
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5 Experimental part 
Synthesis details and analytical data  
All chemicals used were of analytical grade and were obtained from abcr (Karlsruhe, 
Germany), Fischer Scientific (Schwerte, Germany), Sigma-Aldrich (now Merck, Darmstadt, 
Germany), TCI (Eschborn, Germany) or Th. Geyer (Renningen, Germany). HPLC grade and 
dry solvents were purchased from VWR (Darmstadt, Germany) or Sigma-Aldrich, all other 
solvents were purified by distillation. Hydrophobic phase separation filters (MN 617 WA, 125 
mm) were purchased from Macherey Nagel (Düren, Germany). All reactions were monitored 
by thin-layer chromatography (TLC) using pre-coated plastic sheets POLYGRAM® SIL 
G/UV254 from Macherey-Nagel and detected by irradiation with UV light (254 nm or 366 nm). 
Furthermore reactions were monitored by atmospheric pressure solids analysis probe (ASAP) 
via atmospheric-pressure chemical ionization (APCI) on an expressionL CMS device (Advion, 
Ithaca, USA). Flash column chromatography (FCC) was performed on Merck silica gel Si 60 
(0.015 – 0.040 mm). Preparative and semipreparative (chiral) HPLC was performed on a 
Shimadzu HPLC system consisting of a LC-20AP solvent delivery module, a CTO-20A column 
oven, a SPD-M20A photodiode array UV/vis detector and a CBM-20A system controller using 
a semipreparative CHIRALPAK® IC column (particle size 5 μm, Diacel) or a preparative 
NUCLEODUR® 100-5 column (particle size 5 μm, Macherey-Nagel). Microwave-assisted 
reactions were carried out in a Discover (S-Class Plus) SP microwave reactor (CEM GmbH, 
Kamp-Lintfort, Germany). NMR spectra (1H, 13C, DEPT, H-H-COSY, HMQC/HSQC, HMBC) 
were recorded at 23 °C on an Avance III 400 MHz Bruker BioSpin or Avance III 500 MHz 
Bruker BioSpin instrument, unless otherwise specified. Chemical shifts δ are stated in parts 
per million (ppm) and are calibrated using residual protic solvents as an internal reference for 
proton (CDCl3: δ = 7.26 ppm, (CD3)2SO: δ = 2.50 ppm, C2D2Cl4: δ = 5.91 ppm, CD3OD: 
δ = 3.31 ppm, C3D6O: δ = 2.05 ppm) and for carbon the central carbon resonance of the 
solvent (CDCl3: δ = 77.16 ppm, (CD3)2SO: δ = 39.52 ppm, C2D2Cl4: δ = 74.20 ppm, CD3OD: 
δ = 49.00 ppm, C3D6O: δ = 29.84 ppm). Multiplicity is defined as s = singlet, d = doublet, t = 
triplet, q = quartet, m = multiplet. NMR spectra were analyzed with NMR software MestReNova, 
version 12.0.1-20560 (Mestrelab Research S.L.). High resolution mass spectra were 
performed by the LMU Mass Spectrometry Service applying a Thermo Finnigan MAT 95 or 
Joel MStation Sektorfeld instrument at a core temperature of 250 °C and 70 eV for EI or a 
Thermo Finnigan LTQ FT Ultra Fourier Transform Ion Cyclotron Resonance device at 250 °C 
for ESI. IR spectra were recorded on a Perkin Elmer FT-IR Paragon 1000 instrument as neat 
materials. Absorption bands were reported in wave number (cm-1) with ATR PRO450-S. 
Melting points were determined by the open tube capillary method on a Büchi melting point B-
540 apparatus and are uncorrected. HPLC purities were determined using an HP Agilent 1100 
HPLC with a diode array detector and an Agilent Poroshell column (120 EC-C18; 3.0 × 100 
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mm; 2.7 micron) with acetonitrile/water as eluent. Electronic circular dichroism (ECD) spectra 
were measured on a Jasco J-810 Spectropolarimeter. Optical rotations were further measured 
at the given temperature (T in [°C]) on a Perkin Elmer 241 Polarimeter instrument using a 
sodium lamp (Na D-line, 589 nm). Measurements were carried out in a cell with path lengths 
(l) of 1.0 dm. Concentrations are given in g/100 mL.  
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5.1 Preparation of TPC2 activators 
5.1.1 General procedures 
General Procedure A – Synthesis of N-aryl cyanoacetamides 
According to Sjogren, et al.[91] the appropriate aniline (1.0 eq.) and 2-cyanoacetic acid (18, 
1.0 eq.) were dissolved in DMF and cooled to 0 °C. DCC (1.0 eq.) was added portion wise. 
The mixture was warmed up to rt over 1 h and subsequently diluted with hexanes/EtOAc (1:1). 
Precipitates were removed by filtration and the filtrate was extracted once with 1 M aq. HCl 
and thrice with EtOAc. The combined organic layers were washed with sat. aq. NaCl solution, 
dried over Na2SO4, filtered and concentrated in vacuo. Recrystallization from EtOH yielded the 
desired amides.  
 
General Procedure B – Synthesis of α-cyanoaroylacetanilides 
According to Sjogren, et al.[91] the appropriate amides received from general procedure A 
(1.0 eq.) were dissolved in dry THF, the solution was cooled to 0 °C and NaH (dispersion in 
paraffin, 60%, 2.3 eq.) was added. After stirring for 15 min, the appropriate benzoyl chloride 
(1.1 eq.) was added. The mixture was stirred at 0 °C for 1 h and then cautiously treated with 
1 M HCl. The precipitate was collected by filtration, washed with ice water and cold EtOH and 
recrystallized from toluene to give the desired cyanoaroylacetanilide. 
If the appropriate benzoyl chloride was not commercially available, it was prepared by refluxing 
the appropriate benzoic acid (1.1 eq.) in SOCl2 (55 eq.) for 1 h and concentrating in vacuo. 
The resulting acid chloride was immediately transferred to the reaction.  
 
General Procedure C – Paal Knorr Pyrrole synthesis 
Following a general procedure published by Kang, et al.[103] the appropriate β-ketoester 
(1.1 eq.) was dissolved in dry THF and cooled to 0 °C, before NaH (dispersion in paraffin, 60%, 
1.5 eq.) was added portion wise. After the suspension was stirred for 30 min, a solution of 
appropriate halogenated acetophenone (1.0 eq.) and KI (1.0 eq.) in dry THF was added 
dropwise. The reaction mixture was allowed to warm up to rt over 2 h, then poured on water 
and extracted thrice with Et2O. The combined organic phases were washed with sat. aq. 
NaHCO3 solution, dried over Na2SO4, filtered and concentrated in vacuo. The residue was 
dissolved in acetic acid and the appropriate primary amine (2.0 eq.) was added dropwise. The 
reaction mixture was stirred at 80 °C for 18 h. The solvent was removed in vacuo, the residue 
dispersed in water and extracted thrice with diethyl ether. The collected organic phases were 
washed with sat. aq. NaHCO3 solution, dried over Na2SO4 and concentrated in vacuo. 
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Purification was accomplished by FCC and recrystallization from EtOH if not otherwise 
specified.  
 
General Procedure D – Alkaline deprotection of esters 
LiOH (10 eq.) was added to a solution of the appropriate ester (1.0 eq.) in dioxane/H2O (5:1) 
and the reaction mixture was stirred in a closed vessel under microwave irradiation 
(pmax = 8 bar, Pmax = 200 W, Tmax = 180 °C) for 1-18 h. The suspension was diluted with water 
to thrice original volume and aq. 2 M HCl was added dropwise under vigorous stirring until the 
mixture was strongly acidic. The formed precipitate was collected by filtration, washed with 
water and dried. If necessary, the acids were recrystallized from EtOH to yield the pure 
products. 
 
5.1.2 Synthetic procedures 
5.1.2.1 Synthesis of TPC2-A1-N (16) and analogs 
2-Cyano-N-(4-(trifluoromethyl)phenyl)acetamide – SGA-34 (19) 
 
According to general procedure A, 4-(trifluoromethyl)aniline (20, 812 µL, 6.47 mmol, 1.1 eq.), 
2-cyanoacetic acid (18, 500 mg, 5.88 mmol, 1.0 eq.) and DCC (1.27 g, 6.17 mmol, 1.1 eq.) in 
DMF (7.0 mL) were used to yield amide SGA-34 (19) as colorless crystals (983 mg, 4.31 mmol, 
73%). Analytical data are in accordance with literature[91, 179]. 
Rf = 0.14 (4:1 hexanes/acetone).  
m.p.: 195 °C. [lit.[91]: 191 – 193 °C] 
1H NMR (400 MHz, (CD3)2SO) δ/ppm = 10.65 (s, 1H, NH), 7.75 (d, J = 8.8 Hz, 2H, 3’-H, 5’-H), 
7.70 (d, J = 8.8 Hz, 2H, 2’-H, 6’-H), 3.95 (s, 2H, 2-H). 
13C NMR (101 MHz, (CD3)2SO) δ/ppm = 161.9 (C-1), 141.9 (C-1’), 126.3 (q, JCF = 3.7 Hz, C-
3’, C-5’), 124.4 (q, JCF = 271.4 Hz, CF3), 124.0 (q, JCF = 32.0 Hz, C-4’), 119.2 (C-2’, C-6’), 115.7 
(CN), 27.0 (C-2).  
IR (ATR) ṽmax/cm-1 = 3287, 3221, 3147, 1681, 1612, 1557, 1319, 1110, 1065, 849, 835.  
HRMS (ESI): calcd. for C10H6F3N2O (M-H)- 227.04377; found 227.04371.  
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Purity (HPLC): > 96% (λ = 210 nm), > 96% (λ = 254 nm). 
 
2-Cyano-N-(p-tolyl)acetamide (21) 
 
According to general procedure A, p-toluidine (712 µL, 6.47 mmol, 1.1 eq.), 2-cyanoacetic acid 
(18, 500 mg, 5.88 mmol, 1.0 eq.) and DCC (1.27 g, 6.17 mmol, 1.1 eq.) in DMF (7.0 mL) were 
used to yield amide 21 as colorless crystals (728 mg, 4.18 mmol, 71%). Analytical data are in 
accordance with literature[180].  
Rf = 0.14 (4:1 hexanes/acetone).  
m.p.: 184 °C. [lit.[180]: 186 °C] 
1H NMR (400 MHz, (CD3)2SO) δ/ppm = 10.19 (s, 1H, NH), 7.47 – 7.36 (m, 2H, 2’-H, 6’-H), 7.13 
(d, J = 8.2 Hz, 2H, 3’-H, 5’-H), 3.86 (s, 2H, 2-H), 2.25 (s, 3H, CH3).  
13C NMR (101 MHz, (CD3)2SO) δ/ppm = 160.7 (C-1), 135.9 (C-1’), 132.9 (C-4’), 129.3 (C-3’, 
C-5’), 119.2 (C-2’, C-6’), 116.0 (CN), 26.6 (C-2), 20.4 (CH3).  
IR (ATR) ṽmax/cm-1 = 3267, 3207, 3137, 1660, 1613, 1552, 1510, 819.  
HRMS (ESI): calcd. for C10H9N2O (M-H)- 173.07204; found 173.07194.  
Purity (HPLC): > 96% (λ = 210 nm), > 96% (λ = 254 nm). 
 
2-Cyano-N-phenylacetamide (22) 
 
According to general procedure A, aniline (1.96 mL, 21.5 mmol, 1.0 eq.), 2-cyanoacetic acid 
(18, 2.01 g, 23.6 mmol, 1.1 eq.) and DCC (4.87 g, 23.6 mmol, 1.1 eq.) in DMF (20 mL) were 
used to yield amide 22 as colorless crystals (2.60 g, 16.2 mmol, 76%). Analytical data are in 
accordance with literature[180].  
Rf = 0.12 (4:1 hexanes/acetone).  
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m.p.: 202 °C. [lit.[180]: 172 °C] 
1H NMR (500 MHz, (CD3)2SO) δ/ppm = 10.28 (s, 1H, NH), 7.54 (dt, J = 8.7, 1.6 Hz, 2H, 2’-H, 
6’-H), 7.39 – 7.29 (m, 2H, 3’-H, 5’-H), 7.15 – 7.04 (m, 1H, 4’-H), 3.89 (s, 2H, 2-H).  
13C NMR (126 MHz, (CD3)2SO) δ/ppm = 161.0 (C-1), 138.4 (C-1’), 128.9 (C-3’, C-5’), 123.9 (C-
4’), 119.2 (C-2’, C-6’), 115.9 (CN), 26.7 (C-2).  
IR (ATR) ṽmax/cm-1 = 3265, 3207, 3143, 3099, 3052, 1653, 1620, 1557, 1299, 943, 761, 696.  
HRMS (ESI): calcd. for C9H7N2O (M-H)- 159.05639; found 159.05628.  
Purity (HPLC): > 96% (λ = 210 nm), > 96% (λ = 254 nm). 
 
2-Cyano-N-(4-methoxyphenyl)acetamide (23) 
 
According to general procedure A, p-anisidine (2.36 mL, 20.3 mmol, 1.0 eq.), 2-cyanoacetic 
acid (18, 19.0 g, 22.3 mmol, 1.1 eq.) and DCC (4.61 g, 22.3 mmol, 1.1 eq.) in DMF (20 mL) 
were used to yield amide 23 as pale blue crystals (1.58 g, 8.31 mmol, 41%). Analytical data 
are in accordance with literature[180].  
Rf = 0.10 (4:1 hexanes/acetone).  
m.p.: 137 °C. [lit.[180]: 176 °C] 
1H NMR (400 MHz, (CD3)2SO) δ/ppm = 10.14 (s, 1H, NH), 7.53 – 7.38 (m, 2H, 2’-H, 6’-H), 7.00 
– 6.83 (m, 2H, 3’-H, 5’-H), 3.84 (s, 2H, 2-H), 3.72 (s, 3H, OCH3).  
13C NMR (101 MHz, (CD3)2SO) δ/ppm = 160.4 (C-1), 155.6 (C-4’), 131.4 (C-1’), 120.8 (C-2’, 
C-6’), 116.0 (CN), 114.0 (C-3’, C-5’), 55.2 (OCH3), 26.5 (C-2).  
IR (ATR) ṽmax/cm-1 = 3299.3150, 1655, 1608, 1557, 1511, 1251, 1032, 828.  
HRMS (ESI): calcd. for C10H9N2O2 (M-H)- 189.06695; found 189.06688.  
Purity (HPLC): > 96% (λ = 210 nm), > 96% (λ = 254 nm). 
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N-(4-Chlorophenyl)-2-cyanoacetamide (24) 
 
According to general procedure A, 4-chloroaniline (682 µL, 23.0 mmol, 1.0 eq.), 2-cyanoacetic 
acid (18, 2.16 g, 25.4 mmol, 1.1 eq.) and DCC (5.23 g, 25.4 mmol, 1.1 eq.) in DMF (20 mL) 
were used to yield amide 24 as colorless crystals (3.46 g, 17.8 mmol, 77%). Analytical data 
are in accordance with literature[180].  
Rf = 0.14 (3:2 hexanes/acetone).  
m.p.: 207 °C. [lit.[180]: 179 °C] 
1H NMR (500 MHz, (CD3)2SO) δ/ppm = 10.42 (s, 1H, NH), 7.62 – 7.51 (m, 2H, 2’-H, 6’-H), 7.50 
– 7.27 (m, 2H, 3’-H, 5’-H), 3.91 (s, 2H, 2-H).  
13C NMR (126 MHz, (CD3)2SO) δ/ppm = 161.2 (C-1), 137.3 (C-1’), 128.8 (C-3’, C-5’), 127.5 (C-
4’), 120.8 (C-2’, C-6’), 115.8 (CN), 26.8 (C-2).  
IR (ATR) ṽmax/cm-1 = 3264, 3200, 3132, 3083, 1664, 1610, 1548, 1491, 832.  
HRMS (ESI): calcd. for C9H635ClN2O (M-H)- 193.01741; found 193.01750.  
Purity (HPLC): > 96% (λ = 210 nm), > 96% (λ = 254 nm). 
 
N-(4-Bromophenyl)-2-cyanoacetamide (25) 
 
According to general procedure A, 4-bromoaniline (2.00 mL, 17.1 mmol, 1.0 eq.), 
2-cyanoacetic acid (18, 1.60 g, 18.8 mmol, 1.1 eq.) and DCC (3.88 g, 18.8 mmol, 1.1 eq.) in 
DMF (20 mL) were used to yield amide 25 as colorless crystals (1.62 g, 6.76 mmol, 40%). 
Analytical data are in accordance with literature[180].  
Rf = 0.14 (4:1 hexanes/acetone).  
m.p.: 186 °C. [lit.[180]: 185 °C] 
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1H NMR (400 MHz, (CD3)2SO) δ/ppm = 10.42 (s, 1H, NH), 7.52 (s, 4H, 2’-H, 3’-H, 5’-H, 6’-H), 
3.90 (s, 2H, 2-H). 
13C NMR (101 MHz, (CD3)2SO) δ/ppm = 161.2 (C-1), 137.7 (C-1‘), 131.7 (C-2‘, C-6’ or C-3’, C-
5’), 121.2 (C-2‘, C-6’ or C-3’, C-5’), 115.8 (C-4’), 115.5 (CN), 26.8 (C-2).  
IR (ATR) ṽmax/cm-1 = 3322, 2927, 2849, 1608, 1547, 1245, 828.  
HRMS (ESI): calcd. for C9H679BrN2O (M-H)- 236.96690; found 236.96692.  
Purity (HPLC): > 96% (λ = 210 nm), > 96% (λ = 254 nm). 
 
2-Cyano-N-(4-fluorophenyl)acetamide (26) 
 
According to general procedure A, 4-fluoroaniline (2.16 mL, 22.5 mmol, 1.0 eq.), 2-cyanoacetic 
acid (18, 1.91 g, 22.5 mmol, 1.0 eq.) and DCC (4.64 g, 22.5 mmol, 1.0 eq.) in DMF (20 mL) 
were used to yield amide 26 as colorless crystals (3.00 g, 16.9 mmol, 75%). Analytical data 
are in accordance with literature[181].  
Rf = 0.11 (4:1 hexanes/acetone).  
m.p.: 179 °C. [lit.[181]: 158 – 160 °C] 
1H NMR (400 MHz, (CD3)2SO) δ/ppm = 10.34 (s, 1H, NH), 7.66 – 7.46 (m, 2H, 2’-H, 6’-H), 7.27 
– 7.09 (m, 2H, 3’-H, 5’-H), 3.89 (s, 2H, 2-H).  
13C NMR (101 MHz, (CD3)2SO) δ/ppm = 161.0 (C-1), 158.3 (d, JCF = 240.5 Hz, C-4’), 134.7 (d, 
JCF = 2.7 Hz, C-1’), 121.1 (d, JCF = 7.9 Hz, C-2’, C-6’), 115.9 (CN), 115.5 (d, JCF = 22.3 Hz, C-
3’, C-5’), 26.6 (C-2).  
IR (ATR) ṽmax/cm-1 = 3274, 3166, 3107, 1662, 1623, 1566, 1505, 834.  
HRMS (ESI): calcd. for C9H6FN2O (M-H)- 177.04696; found 177.04687.  
Purity (HPLC): > 96% (λ = 210 nm), > 96% (λ = 254 nm). 
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2-Cyano-N-(4-iodophenyl)acetamide (27) 
 
According to general procedure A, 4-iodoaniline (4.50 g, 20.5 mmol, 1.0 eq.), 2-cyanoacetic 
acid (18, 17.5 g, 20.5 mmol, 1.0 eq.) and DCC (4.24 g, 20.5 mmol, 1.0 eq.) in DMF (20 mL) 
were used to yield amide 27 as pale blue crystals (4.50 g, 15.7 mmol, 77%). The compound is 
literature known, but no analytical data are available[91].  
Rf = 0.11 (4:1 hexanes/acetone).  
m.p.: 218 °C.  
1H NMR (400 MHz, (CD3)2SO) δ/ppm = 10.38 (s, 1H, NH), 7.78 – 7.60 (m, 2H, 3’-H, 5’-H), 7.49 
– 7.29 (m, 2H, 2’-H, 6’-H), 3.90 (s, 2H, 2-H).  
13C NMR (101 MHz, (CD3)2SO) δ/ppm = 161.2 (C-1), 138.2 (C-1’), 137.6 (C-3’, C-5’), 121.4 (C-
2’, C-6’), 115.8 (CN), 87.6 (C-4’), 26.8 (C-2).  
IR (ATR) ṽmax/cm-1 = 3265, 3188, 3113, 3078, 1666, 1543, 1391, 1299, 823.  
HRMS (ESI): calcd. for C9H6IN2O (M-H)- 284.95303; found 284.95302.  
Purity (HPLC): > 96% (λ = 210 nm), > 96% (λ = 254 nm). 
 
2-Cyano-N-(4-nitrophenyl)acetamide (28) 
 
According to general procedure A, 4-nitroaniline (696 µL, 7.24 mmol, 1.0 eq.), 2-cyanoacetic 
acid (18, 616 mg, 7.24 mmol, 1.0 eq.) and DCC (1.49 g, 7.24 mmol, 1.0 eq.) in DMF (20 mL) 
were used to yield amide 28 as yellow solid (918 mg, 4.47 mmol, 62%). Analytical data are in 
accordance with literature[182].  
Rf = 0.11 (4:1 hexanes/acetone).  
m.p.: 218 °C. [lit.[182]: 220 °C] 
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1H NMR (400 MHz, (CD3)2SO) δ/ppm = 10.88 (s, 1H, NH), 8.35 – 8.15 (m, 2H, 3’-H, 5’-H), 7.93 
– 7.71 (m, 2H, 2’-H, 6’-H), 4.00 (s, 2H, 2-H).  
13C NMR (101 MHz, (CD3)2SO) δ/ppm = 162.2 (C-1), 144.4 (C-1’), 142.7 (C-4’), 125.1 (C-3’, 
C-5’), 119.0 (C-2’, C-6’), 115.5 (CN), 27.2 (C-2).  
IR (ATR) ṽmax/cm-1 = 3287, 1673, 1562, 1503, 1336, 1259, 860, 748.  
HRMS (ESI): calcd. for C9H6N3O3 (M-H)- 204.04146; found 204.04146.  
Purity (HPLC): > 96% (λ = 210 nm), > 96% (λ = 254 nm). 
 
2-Cyano-N-(4-cyanophenyl)acetamide (29) 
 
According to general procedure A, 4-aminobenzonitrile (1.00 g, 8.46 mmol, 1.0 eq.), 
2-cyanoacetic acid (18, 7.20 g, 8.46 mmol, 1.0 eq.) and DCC (1.75 g, 8.46 mmol, 1.0 eq.) in 
DMF (10 mL) were used to yield amide 29 as yellow solid (1.22 g, 6.57 mmol, 78%). The 
compound is literature known, but no analytical data are available[91].  
Rf = 0.08 (4:1 hexanes/acetone).  
m.p.: 201 °C.  
1H NMR (500 MHz, (CD3)2SO) δ/ppm = 10.72 (s, 1H, NH), 7.82 – 7.78 (m, 2H, 3’-H, 5’-H), 7.74 
– 7.70 (m, 2H, 2’-H, 6’-H), 3.97 (s, 2H, 2-H).  
13C NMR (126 MHz, (CD3)2SO) δ/ppm = 162.0 (C-1), 142.5 (C-1’), 133.5 (C-3’, C-5’), 119.3 (C-
2’, C-6’), 118.9 (C-4’), 115.6 (CH2CN), 105.7 (CN), 27.1 (C-2).  
IR (ATR) ṽmax/cm-1 = 3268, 3194, 3118, 2229, 1599, 1538, 1504, 845.  
HRMS (ESI): calcd. for C10H6N3O (M-H)- 184.05164; found 184.05161.  
Purity (HPLC): > 96% (λ = 210 nm), > 96% (λ = 254 nm). 
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N-(4-Acetylphenyl)-2-cyanoacetamide (30) 
 
According to general procedure A, 4-aminoacetophenone (1.30 mL, 7.40 mmol, 1.0 eq.), 
2-cyanoacetic acid (18, 629 mg, 7.40 mmol, 1.0 eq.) and DCC (1.53 g, 7.40 mmol, 1.0 eq.) in 
DMF (10 mL) were used to yield amide 30 as yellow crystals (802 mg, 3.97 mmol, 54%). 
Analytical data are in accordance with literature[183].  
Rf = 0.37 (3:2 hexanes/acetone).  
m.p.: 194 °C. [lit.[183]: 225 °C] 
1H NMR (500 MHz, (CD3)2SO) δ/ppm = 10.63 (s, 1H, NH), 7.99 – 7.91 (m, 2H, 3’-H, 5’-H), 7.74 
– 7.62 (m, 2H, 2’-H, 6’-H), 3.96 (s, 2H, 2-H), 2.53 (s, 3H, CH3).  
13C NMR (101 MHz, (CD3)2SO) δ/ppm = 196.5 (COCH3), 161.7 (C-1), 142.6 (C-1‘), 132.2 (C-
4‘), 129.6 (C-3‘, C-5‘), 118.5 (C-2‘, C-6‘), 115.7 (CN), 27.0 (C-2), 26.5 (CH3).  
IR (ATR) ṽmax/cm-1 = 3286, 2250, 1695, 1651, 1599, 1536, 1279, 1249, 833, 720.  
HRMS (ESI): calcd. for C11H9N2O2 (M-H)- 201.06695; found 201.06694.  
Purity (HPLC): > 96% (λ = 210 nm), > 96% (λ = 254 nm). 
 
2-Cyano-N-(4-propoxyphenyl)acetamide (31) 
 
According to general procedure A, 4-propoxyaniline (679 µL, 4.49 mmol, 1.0 eq.), 
2-cyanoacetic acid (18, 382 mg, 4.49 mmol, 1.0 eq.) and DCC (927 mg, 4.49 mmol, 1.0 eq.) 
in DMF (2.0 mL) were used to yield amide 31 as colorless crystals (604 mg, 2.77 mmol, 62%). 
Rf = 0.24 (95:5 CH2Cl2/EtOH).  
m.p.: 183 °C.   
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1H NMR (400 MHz, (CD3)2SO) δ/ppm = 10.13 (s, 1H, NH), 7.51 – 7.38 (m, 2H, 2’-H, 6’-H), 6.98 
– 6.83 (m, 2H, 3’-H, 5’-H), 3.88 (t, J = 7.1 Hz, 2H, CH2CH2CH3), 3.84 (s, 2H, 2-H), 1.70 (sext, 
J = 7.1 Hz, 2H, CH2CH2CH3), 0.96 (t, J = 7.1 Hz, 3H, CH2CH2CH3).  
13C NMR (101 MHz, (CD3)2SO) δ/ppm = 160.4 (C-1), 155.1 (C-4’), 131.4 (C-1’), 120.8 (C-2’, 
C-6’), 116.0 (CN), 114.5 (C-3’, C-5’), 69.0 (CH2CH2CH3), 26.5 (C-2), 22.0 (CH2CH2CH3), 10.4 
(CH2CH2CH3).  
IR (ATR) ṽmax/cm-1 = 3283, 3096, 1607, 1559, 1508, 1239, 828, 570.  
HRMS (ESI): calcd. for C12H13N2O2 (M-H)- 217.09825; found 217.09832.  
Purity (HPLC): > 96% (λ = 210 nm), > 96% (λ = 254 nm). 
 
2-Cyano-N-(4-(trifluoromethoxy)phenyl)acetamide (32) 
 
According to general procedure A, 4-(trifluoromethoxy)aniline (939 µL, 7.00 mmol, 1.0 eq.), 
2-cyanoacetic acid (18, 595 mg, 7.00 mmol, 1.0 eq.) and DCC (1.44 g, 7.00 mmol, 1.0 eq.) in 
DMF (10 mL) were used to yield amide 32 as colorless solid (1.23 g, 5.03 mmol, 72%). The 
compound is literature known, but no analytical data are available[91].  
Rf = 0.39 (95:5 CH2Cl2/EtOH).  
m.p.: 154 °C.  
1H NMR (400 MHz, (CD3)2SO) δ/ppm = 10.49 (s, 1H, NH), 7.74 – 7.55 (m, 2H, 2’-H, 6’-H), 7.47 
– 7.26 (m, 2H (3’-H, 5’-H), 3.92 (s, 2H, 2-H).  
13C NMR (101 MHz, (CD3)2SO) δ/ppm = 161.3 (C-1), 144.0 (C-4‘), 137.5 (C-1‘), 121.8 (C-3’, 
C-5’), 120.7 (C-2’, C-6’), 120.1 (q, JCF = 255.7 Hz, OCF3), 115.8 (CN), 26.8 (C-2).  
IR (ATR) ṽmax/cm-1 = 3278, 2975, 1667, 1616, 1557, 1508, 1277, 1205, 1171.  
HRMS (ESI): calcd. for C10H6F3N2O2 (M-H)- 243.03869; found 243.03869.  
Purity (HPLC): > 96% (λ = 210 nm), > 96% (λ = 254 nm). 
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Methyl 4-(2-cyanoacetamido)benzoate (33) 
 
According to general procedure A, methyl 4-aminobenzoate (3.00 g, 19.5 mmol, 1.0 eq.), 
2-cyanoacetic acid (18, 1.66 g, 19.5 mmol, 1.0 eq.) and DCC (4.01 g, 19.5 mmol, 1.0 eq.) in 
DMF (15 mL) were used to yield amide 33 as colorless solid (2.76 g, 12.6 mmol, 65%). The 
compound is literature known, but no analytical data are available[91]. 
Rf = 0.44 (3:2 hexanes/acetone).  
m.p.: 162 °C.  
1H NMR (500 MHz, (CD3)2SO) δ/ppm = 10.63 (s, 1H, NH), 8.01 – 7.87 (m, 2H, 2-H, 6-H), 7.76 
– 7.61 (m, 2H, 3-H, 5-H), 3.96 (s, 2H, 2-H), 3.82 (s, 3H, CH3).  
13C NMR (126 MHz, (CD3)2SO) δ/ppm = 165.7 (COOCH3), 161.7 (C-1’), 142.7 (C-4), 130.4 (C-
2, C-6), 124.6 (C-1), 118.6 (C-3, C-5), 115.7 (CN), 52.0 (CH3), 27.0 (C-2’).  
IR (ATR) ṽmax/cm-1 = 2809, 1722, 1608, 1558, 1507, 1431, 1274, 1110, 757.  
HRMS (ESI): calcd. for C11H9N2O3 (M-H)- 217.06187; found 217.06187.  
Purity (HPLC): > 96% (λ = 210 nm), > 96% (λ = 254 nm). 
 
N-(2-Bromo-4-chlorophenyl)-2-cyanoacetamide (34) 
 
According to general procedure A, 2-bromo-4-chloroaniline (1.00 g, 4.84 mmol, 1.0 eq.), 
2-cyanoacetic acid (18, 412 mg, 4.84 mmol, 1.0 eq.) and DCC (999 mg, 4.84 mmol, 1.0 eq.) 
in DMF (10 mL) were used to yield amide 34 as colorless crystals (919 mg, 3.36 mmol, 69%).  
Rf = 0.22 (3:2 hexanes/acetone).  
m.p.: 157 °C.  
1H NMR (400 MHz, (CD3)2SO) δ/ppm = 9.97 (s, 1H, NH), 7.83 (d, J = 2.4 Hz, 1H, 3’-H), 7.63 
(d, J = 8.7 Hz, 1H, 6’-H), 7.49 (dd, J = 8.7, 2.4 Hz, 1H, 5’-H), 3.98 (s, 2H, 2-H).  
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13C NMR (101 MHz, (CD3)2SO) δ/ppm = 161.8 (C-1), 134.7 (C-1’), 132.0 (C-3’), 130.7 (C-4’), 
128.2 (C-5’), 128.0 (C-6’), 118.5 (C-2’), 115.7 (CN), 26.1 (C-2).  
IR (ATR) ṽmax/cm-1 = 3281, 2258, 1666, 1577, 1530, 1470, 1284, 822.  
HRMS (ESI): calcd. for C9H579Br35ClN2O (M-H)- 270.92793; found 270.92809.  
Purity (HPLC): > 93% (λ = 210 nm), > 93% (λ = 254 nm). 
 
2-Cyano-N-(2-iodophenyl)acetamide (35) 
 
According to general procedure A, 2-iodoaniline (1.00 g, 4.57 mmol, 1.0 eq.), 2-cyanoacetic 
acid (18, 388 mg, 4.57 mmol, 1.0 eq.) and DCC (942 mg, 4.57 mmol, 1.0 eq.) in DMF (10 mL) 
were used to yield amide 35 as brown crystals (913 g, 3.19 mmol, 70%).  
Rf = 0.16 (4:1 hexanes/acetone).  
m.p.: 161 °C.  
1H NMR (400 MHz, (CD3)2SO) δ/ppm = 9.88 (s, 1H, NH), 7.90 (d, J = 7.6 Hz, 1H, 3’-H), 7.46 – 
7.38 (m, 2H, 5’-H, 6’-H), 7.03 (ddd, J = 8.6, 5.4, 3.6 Hz, 1H, 4’-H), 3.93 (s, 2H, 2-H).  
13C NMR (101 MHz, (CD3)2SO) δ/ppm = 161.4 (C-1), 139.1 (C-3’), 138.7 (C-1’), 128.8 (C-5’), 
128.3 (C-4’), 127.4 (C-6’), 115.8 (CN), 96.4 (C-2’), 26.0 (C-2).  
IR (ATR) ṽmax/cm-1 = 3252, 2263, 1658, 1577, 1542, 1433, 1015, 758, 768.  
HRMS (ESI): calcd. for C9H6IN2O (M-H)- 284.95303; found 284.95295.  
Purity (HPLC): > 96% (λ = 210 nm), > 96% (λ = 254 nm). 
 
N-(3-Chloro-2,4-difluorophenyl)-2-cyanoacetamide (36) 
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According to general procedure A, 3-chloro-2,4-difluoroaniline (1.06 g, 6.48 mmol, 1.0 eq.), 
2-cyanoacetic acid (18, 551 mg, 6.48 mmol, 1.0 eq.) and DCC (1.34 g, 6.48 mmol, 1.0 eq.) in 
DMF (10 mL) were used to yield amide 36 as colorless crystals (1.01 g, 4.39 mmol, 68%).  
Rf = 0.16 (4:1 hexanes/acetone).  
m.p.: 144 °C.  
1H NMR (400 MHz, (CD3)2SO) δ/ppm = 10.32 (s, 1H, NH), 7.79 (td, J = 9.0, 5.8 Hz, 1H, 6’-H), 
7.33 (td, J = 9.0, 2.1 Hz, 1H, 5’-H), 3.99 (s, 2H, 2-H).  
13C NMR (101 MHz, (CD3)2SO) δ/ppm = 162.0 (C-1), 154.8 (dd, JCF = 246.5, 2.0 Hz, C-2’ or C-
4’), 150.4 (dd, JCF = 250.4, 3.3 Hz, C-2’ or C-4’), 123.4 (dd, JCF = 8.8, 2.4 Hz, C-6’), 123.0 (dd, 
JCF = 11.8, 3.5 Hz, C-1’), 115.7 (CN), 111.9 (dd, JCF = 21.4, 3.8 Hz, C-5’), 108.7 (dd, JCF = 21.9, 
19.7 Hz, C-3’), 26.3 (C-2).  
IR (ATR) ṽmax/cm-1 = 3274.2935, 2264, 1681, 1551, 1488, 1443, 1012, 831, 628.  
HRMS (ESI): calcd. for C9H435ClF2N2O (M-H)- 228.99857; found 228.99850.  
Purity (HPLC): > 96% (λ = 210 nm), > 96% (λ = 254 nm). 
 
2-Cyano-N-(3,4-dimethoxyphenyl)acetamide (37) 
 
According to general procedure A, 3,4-dimethoxyaniline (1.00 g, 6.53 mmol, 1.0 eq.), 
2-cyanoacetic acid (18, 555 mg, 6.53 mmol, 1.0 eq.) and DCC (1.35 g, 6.53 mmol, 1.0 eq.) in 
DMF (10 mL) were used to yield amide 37 as violet crystals (1.10 g, 4.99 mmol, 76%). The 
compound is literature known, but no analytical data are available[184]. 
Rf = 0.05 (4:1 hexanes/acetone).  
m.p.: 174 °C.  
1H NMR (500 MHz, (CD3)2SO) δ/ppm = 10.15 (s, 1H, NH), 7.21 (d, J = 2.4 Hz, 1H, 2’-H), 7.04 
(dd, J = 8.7, 2.4 Hz, 1H, 6’-H), 6.90 (d, J = 8.7 Hz, 1H, 5’-H), 3.84 (s, 2H, 2-H), 3.79 – 3.66 (m, 
6H, 2x OCH3).  
13C NMR (126 MHz, (CD3)2SO) δ/ppm = 160.5 (C-1), 148.6 (C-3’), 145.3 (C-4’), 131.9 (C-1’), 
116.0 (CN), 112.0 (C-5’), 111.2 (C-6’), 104.3 (C-2’), 55.7 (OCH3), 55.4 (OCH3), 26.6 (C-2).  
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IR (ATR) ṽmax/cm-1 = 3273, 2914, 2256, 1660, 1513, 1239, 1132, 1020, 837.  
HRMS (ESI): calcd. for C11H11N2O3 (M-H)- 219.07752; found 219.07751.  
Purity (HPLC): > 96% (λ = 210 nm), > 96% (λ = 254 nm). 
 
2-Cyano-N-(2,3-dichlorophenyl)acetamide (38) 
 
According to general procedure A, 2,3-dichloroaniline (745 µL, 6.30 mmol, 1.0 eq.), 
2-cyanoacetic acid (18, 536 mg, 6.30 mmol, 1.0 eq.) and DCC (1.30 g, 6.30 mmol, 1.0 eq.) in 
DMF (10 mL) were used to yield amide 38 as colorless crystals (414 mg, 1.81 mmol, 29%).  
Rf = 0.21 (4:1 hexanes/acetone).  
m.p.: 176 °C.  
1H NMR (500 MHz, (CD3)2SO) δ/ppm = 10.11 (s, 1H, NH), 7.69 (dd, J = 8.1, 1.3 Hz, 1H, 4’-H 
or 6’-H), 7.51 (dd, J = 8.1, 1.3 Hz, 1H, 4’-H or 6’-H), 7.38 (t, J = 8.1 Hz, 1H, 5’-H), 4.02 (s, 2H, 
2-H).  
13C NMR (126 MHz, (CD3)2SO) δ/ppm = 161.9 (C-1), 136.1 (C-1’ or C-3’), 132.0 (C-1’ or C-3’), 
128.2 (C-5’), 127.3 (C-4’ or C-6’), 125.3 (C-2’), 124.8 (C-4’ or C-6’), 115.7 (CN), 26.3 (C-2).  
IR (ATR) ṽmax/cm-1 = 3287, 2253, 1666, 1580, 1527, 1415, 1338, 1182, 953, 788.  
HRMS (ESI): calcd. for C9H535Cl2N2O (M-H)- 226.97844; found 226.97859.  
Purity (HPLC): > 96% (λ = 210 nm), > 96% (λ = 254 nm). 
 
2-Cyano-N-(2,6-dibromophenyl)acetamide (39) 
 
EXPERIMENTAL PART 
111 
According to general procedure A, 2,6-dibromoaniline (1.00 g, 4.00 mmol, 1.0 eq.), 
2-cyanoacetic acid (18, 340 mg, 4.00 mmol, 1.0 eq.) and DCC (825 mg, 4.00 mmol, 1.0 eq.) 
in DMF (10 mL) were used to yield amide 39 as colorless crystals (514 mg, 1.62 mmol, 40%). 
Rf = 0.48 (3:2 hexanes/acetone).  
m.p.: 187 °C.  
1H NMR (500 MHz, (CD3)2SO) δ/ppm = 10.37 (s, 1H, NH), 7.74 (d, J = 8.1 Hz, 2H, 3’-H, 5’-H), 
7.22 (t, J = 8.1 Hz, 1H, 4’-H), 3.93 (s, 2H, 2-H).  
13C NMR (126 MHz, (CD3)2SO) δ/ppm = 161.1 (C-1), 134.7 (C-1’), 132.4 (C-3’, C-5’), 130.7 (C-
4’), 123.9 (C-2’, C-6’), 115.6 (CN), 25.4 (C-2).  
IR (ATR) ṽmax/cm-1 = 3326, 2926, 2851, 1626, 1568, 1539, 1242, 642.  
HRMS (ESI): calcd. for C9H579Br2N2O (M-H)- 314.87741; found 314.87761.  
Purity (HPLC): > 96% (λ = 210 nm), > 96% (λ = 254 nm). 
 
N-(3,5-Bis(trifluoromethyl)phenyl)-2-cyanoacetamide (40) 
 
According to general procedure A, 3,5-bis(trifluoromethyl)aniline (1.09 mL, 7.00 mmol, 1.0 
eq.), 2-cyanoacetic acid (18, 595 mg, 7.00 mmol, 1.0 eq.) and DCC (1.44 g, 7.00 mmol, 1.0 
eq.) in DMF (10 mL) were used to yield amide 40 as colorless crystals (1.68 g, 5.67 mmol, 
81%). The compound is literature known, but no analytical data are available[185]. 
Rf = 0.43 (95:5 CH2Cl2/EtOH).  
m.p.: 141 °C.  
1H NMR (500 MHz, (CD3)2SO) δ/ppm = 10.96 (s, 1H, NH), 8.28 – 8.12 (m, 2H, 2’-H, 6’-H), 7.90 
– 7.77 (m, 1H, 4’-H), 4.00 (s, 2H, 2-H).  
13C NMR (126 MHz, (CD3)2SO) δ/ppm = 162.4 (C-1), 140.2 (C-1’), 130.9 (q, JCF = 32.9 Hz, C-
3’, C-5’), 123.1 (q, JCF = 272.7 Hz, CF3), 119.2 – 118.7 (m, C-2’, C-6’), 116.9 – 116.5 (m, C-4’), 
115.4 (CN), 27.1 (C-2).  
IR (ATR) ṽmax/cm-1 = 3313, 1695, 1572, 1471, 1381, 1272, 1132, 889, 703, 681.  
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HRMS (ESI): calcd. for C11H5F6N2O (M-H)- 295.03116; found 295.03127.  
Purity (HPLC): > 96% (λ = 210 nm), > 96% (λ = 254 nm). 
 
2-Cyano-N-methyl-N-(4-(trifluoromethyl)phenyl)acetamide (41) 
 
According to general procedure A, N-methyl-4-(trifluoromethyl)aniline (403 µL, 2.85 mmol, 
1.0 eq.), 2-cyanoacetic acid (18, 243 mg, 2.85 mmol, 1.0 eq.) and DCC (589 mg, 2.85 mmol, 
1.0 eq.) in DMF (10 mL) were used to yield amide 41 as colorless solid (513 mg, 2.12 mmol, 
74%). Analytical data are in accordance with literature[186]. 
Rf = 0.58 (95:5 CH2Cl2/EtOH).  
m.p.: 70 °C. [lit.[186]: 66-68 °C] 
1H NMR (400 MHz, (CD3)2SO) δ/ppm = 7.77 (d, J = 8.6 Hz, 2H, 3’-H, 5’-H), 7.40 (d, J = 8.2 Hz, 
2H, 2’-H, 6’-H), 3.34 (s, 3H, CH3), 3.23 (s, 2H, 2-H).  
13C NMR (101 MHz, (CD3)2SO) δ/ppm = 161.4 (C-1), 145.6 (C-1’), 131.7 (C-4’), 127.9 (C-2’, 
C-6’ or C-3’, C-5’), 127.8 (C-2’, C-6’ or C-3’, C-5’), 123.5 (q, J = 271.4 Hz, CF3), 113.7 (CN), 
38.1 (CH3), 25.6 (C-2).  
IR (ATR) ṽmax/cm-1 = 3152, 2355, 1657, 1611, 1322, 1122, 1103, 1065, 848.  
HRMS (ESI): calcd. for C11H8F3N2O (M-H)- 241.05942; found 241.05939.  
Purity (HPLC): > 96% (λ = 210 nm), > 96% (λ = 254 nm). 
 
2-Cyano-N-(4-(trifluoromethyl)benzyl)acetamide (42) 
 
According to general procedure A, 4-(trifluoromethyl)benzylamine (2.50 mL, 17.5 mmol, 1.0 
eq.), 2-cyanoacetic acid (18, 1.49 g, 17.5 mmol, 1.0 eq.) and DCC (3.62 g, 17.5 mmol, 1.0 eq.) 
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in DMF (15 mL) were used to yield amide 42 as colorless solid (299 mg, 1.23 mmol, 7%). 
Analytical data are in accordance with literature[187]. 
Rf = 0.46 (3:2 hexanes/acetone). 
m.p.: 113 °C. [lit.[187]: 128 °C] 
1H NMR (500 MHz, (CD3)2SO) δ/ppm = 8.83 (t, J = 5.7 Hz, 1H, NH), 7.74 – 7.66 (m, 2H, 3’-H, 
5’-H), 7.54 – 7.44 (m, 2H, 2’-H, 6’-H), 4.38 (d, J = 5.7 Hz, 2H, CH2), 3.73 (s, 2H, 2-H).  
13C NMR (126 MHz, (CD3)2SO) δ/ppm = 162.5 (C-1), 143.6 (C-1’), 128.0 (C-2’, C-6’), 127.7 (q, 
JCF = 31.7 Hz, C-4’), 125.2 (q, JCF = 3.7 Hz, C-3’, C-5’). 124.3 (q, JCF = 272.1 Hz, CF3), 116.1 
(CN), 42.2 (CH2), 25.3 (C-2).  
IR (ATR) ṽmax/cm-1 = 3316, 2937, 2364, 1734, 1664, 1547, 1325, 1152, 1107, 1066.  
HRMS (ESI): calcd. for C11H8F3N2O (M-H)- 241.05942; found 241.05949.  
Purity (HPLC): > 96% (λ = 210 nm), > 96% (λ = 254 nm).  
 
2-Cyano-3-(3,5-dichlorophenyl)-3-hydroxy-N-(4-(trifluoromethyl)phenyl)acrylamide – 
TPC2-A1-N (16) 
 
According to general procedure B, SGA-34 (19, 228 mg, 1.00 mmol, 1.0 eq.) in dry THF 
(10 mL), NaH (92.0 mg, 2.30 mmol, 2.3 eq.) and 3,5-dichlorobenzoyl chloride (43, 230 mg, 
1.10 mmol, 1.1 eq.) were used to yield TPC2-A1-N (16) as colorless crystals (276 mg, 0.688 
mmol, 69%).  
Rf = 0.62 (4:1 hexanes/acetone).  
m.p.: 202 °C. [lit.[91]: 208 – 210 °C] 
1H NMR (500 MHz, (CD3)2SO) δ/ppm = 12.36 (s, 1H, NH), 7.79 – 7.76 (m, 2H, 2’-H, 6’-H), 7.65 
(t, J = 1.9 Hz, 1H, 4’’-H), 7.62 – 7.60 (m, 2H, 3’-H, 5’-H), 7.59 (d, J = 1.9 Hz, 2H, 2’’-H, 6’’-H).  
13C NMR (126 MHz, (CD3)2SO) δ/ppm = 182.7 (C-3), 166.5 (C-1), 144.9 (C-1’’), 143.6 (C-1’), 
133.5 (C-3’’, C-5’’), 128.6 (C-4’’), 126.2 – 125.9 (m, C-3’, C-5’ and C-2’’, C-6’’), 124.6 (q, JCF = 
286.1 Hz, CF3), 123.3 (C-2), 121.8 (q, JCF = 31.8 Hz, C-4’), 118.7 (C-2’, C-6’), 77.7 (CN).  
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IR (ATR) ṽmax/cm-1 = 3293, 2213, 1538, 1409, 1320, 1268, 1244, 1167, 1106, 1070, 837, 810, 
660, 591.  
HRMS (ESI): calcd. for C17H835Cl2F3N2O2 (M-H)- 398.99204; found 398.99202.  
Purity (HPLC): > 96% (λ = 210 nm), > 96% (λ = 254 nm). 
 
2-Cyano-3-(3,5-dichlorophenyl)-3-hydroxy-N-phenylacrylamide – SGA-1 (44) 
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According to general procedure B, amide 22 (160 mg, 1.00 mmol, 1.0 eq.) in dry THF (10 mL), 
NaH (92.0 mg, 2.30 mmol, 2.3 eq.) and 3,5-dichlorobenzoyl chloride (43, 230 mg, 1.10 mmol, 
1.1 eq.) were used to give SGA-1 (44) as yellow solid (227 mg, 0.681 mmol, 68%).  
Rf = 0.67 (3:2 hexanes/acetone).  
m.p.: 200 °C.  
1H NMR (500 MHz, (CD3)2SO) δ/ppm = 11.95 (s, 1H, NH), 7.61 (t, J = 1.9 Hz, 1H, 4’’-H), 7.56 
(d, J = 1.9 Hz, 2H, 2’’-H, 6’’-H), 7.53 (dd, J = 8.5, 1.0 Hz, 2H, 2’-H, 6’-H), 7.27 – 7.22 (m, 2H, 
3’-H, 5’-H), 6.96 – 6.90 (m, 1H, 4’-H).  
13C NMR (126 MHz, (CD3)2SO) δ/ppm = 182.2 (C-3), 166.1 (C-1), 145.3 (C-1’’), 140.1 (C-1’), 
133.4 (C-3’’, C-5’’), 128.7 (C-3’, C-5’), 128.3 (C-4’’), 126.1 (C-2’’, C-6’’), 123.6 (C-2), 121.7 (C-
4’), 118.8 (C-2’, C-6’), 77.4 (CN).  
IR (ATR) ṽmax/cm-1 = 3294, 2212, 1579, 1445, 810, 748, 683.  
HRMS (ESI): calcd. for C16H935Cl2N2O2 (M-H)- 331.00466; found 331.00465.  
Purity (HPLC): > 96% (λ = 210 nm), > 96% (λ = 254 nm). 
 
N-(4-Chlorophenyl)-2-cyano-3-(3,5-dichlorophenyl)-3-hydroxyacrylamide – SGA-2 (45) 
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According to general procedure B, amide 24 (195 mg, 1.00 mmol, 1.0 eq.) in dry THF (10 mL), 
NaH (92.0 mg, 2.30 mmol, 2.3 eq.) and 3,5-dichlorobenzoyl chloride (43, 230 mg, 1.10 mmol, 
1.1 eq.) were used to give SGA-2 (45) as yellow solid (256 mg, 0.695 mmol, 70%).  
Rf = 0.71 (3:2 hexanes/acetone).  
m.p.: 230 °C.  
1H NMR (500 MHz, (CD3)2SO) δ/ppm = 12.12 (s, 2H, NH), 7.62 (t, J = 1.9 Hz, 1H, 4’’-H), 7.60 
– 7.57 (m, 2H, 2’-H, 6’-H), 7.55 (d, J = 1.9 Hz, 2H, 2’’-H, 6’’-H), 7.30 – 7.26 (m, 2H, 3’-H, 5’-H).  
13C NMR (126 MHz, (CD3)2SO) δ/ppm = 182.5 (C-3), 166.1 (C-1), 145.4 (C-1’’), 139.1 (C-1’), 
133.4 (C-3’’, C-5’’), 128.6 (C-3’, C-5’), 128.3 (C-4’’), 126.0 (C-2’’, C-6’’), 125.0 (C-4’), 123.6 (C-
2), 120.2 (C-2’, C-6’), 77.2 (CN).  
IR (ATR) ṽmax/cm-1 = 3305, 2212, 1545, 1495, 1506, 1316, 1098, 809.  
HRMS (ESI): calcd. for C16H835Cl3N2O2 (M-H)- 364.96568; found 364.96593.  
Purity (HPLC): > 96% (λ = 210 nm), > 96% (λ = 254 nm). 
 
N-(4-Bromophenyl)-2-cyano-3-(3,5-dichlorophenyl)-3-hydroxyacrylamide – SGA-3 (46) 
 
According to general procedure B, amide 25 (239 mg, 1.00 mmol, 1.0 eq.) in dry THF (10 mL), 
NaH (92.0 mg, 2.30 mmol, 2.3 eq.) and 3,5-dichlorobenzoyl chloride (43, 230 mg, 1.10 mmol, 
1.1 eq.) were used to give SGA-3 (46) as yellow crystals (289 mg, 0.702 mmol, 70%).  
Rf = 0.73 (3:2 hexanes/acetone).  
m.p.: 237 °C.  
1H NMR (400 MHz, (CD3)2SO) δ/ppm = 12.09 (s, 1H, NH), 7.62 (t, J = 1.9 Hz, 1H, 4’’-H), 7.58 
– 7.51 (m, 4H, 2’-H, 6’-H, 2’’-H, 6’’-H), 7.44 – 7.38 (m, 2H, 3’-H, 5’-H). 
13C NMR (101 MHz, (CD3)2SO) δ/ppm = 182.4 (C-3), 166.1 (C-1), 145.2 (C-1’’), 139.4 (C-1’), 
133.4 (C-3’’, C-5’’), 131.4 (C-3’, C-5’), 128.3 (C-4’’), 126.0 (C-2’’, C-6’’), 122.6 (C-2), 120.7 (C-
2’, C-6’), 112.9 (C-4’), 77.4 (CN).  
IR (ATR) ṽmax/cm-1 = 3309, 2211, 1540, 1493, 1403, 1316, 1290, 1012, 809.  
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HRMS (ESI): calcd. for C16H879Br35Cl2N2O2 (M-H)- 408.91517; found 408.91581.  
Purity (HPLC): > 96% (λ = 210 nm), > 96% (λ = 254 nm). 
 
2-Cyano-3-(3,5-dichlorophenyl)-3-hydroxy-N-(p-tolyl)acrylamide – SGA-4 (47) 
 
According to general procedure B, amide 21 (174 mg, 1.00 mmol, 1.0 eq.) in dry THF (10 mL), 
NaH (92.0 mg, 2.30 mmol, 2.3 eq.) and 3,5-dichlorobenzoyl chloride (43, 230 mg, 1.10 mmol, 
1.1 eq.) were used to give SGA-4 (47) as yellow crystals (185 mg, 0.534 mmol, 53%).  
Rf = 0.28 (3:2 hexanes/acetone).  
m.p.: 214 °C.  
1H NMR (400 MHz, (CD3)2SO) δ/ppm = 11.82 (s, 1H, NH), 7.63 (t, J = 1.9 Hz, 1H, 4’’-H), 7.56 
(d, J = 1.9 Hz, 2H, 2’’-H, 6’’-H), 7.46 – 7.39 (m, 2H, 2’-H, 6’-H), 7.09 – 7.02 (m, 2H, 3’-H, 5’-H), 
2.24 (s, 3H, CH3).  
13C NMR (101 MHz, (CD3)2SO) δ/ppm = 182.0 (C-3), 166.0 (C-1), 145.1 (C-1’’), 137.4 (C-1’), 
133.4 (C-3’’, C-5’’), 130.6 (C-4’), 129.1 (C-3’, C-5’), 128.3 (C-4’’), 126.1 (C-2’’, C-6’’), 123.5 (C-
2), 119.0 (C-2’, C-6’), 77.5 (CN), 20.4 (CH3).  
IR (ATR) ṽmax/cm-1 = 3299, 2212, 1543, 1518.866, 806, 654.  
HRMS (ESI): calcd. for C17H1135Cl2N2O2 (M-H)- 345.02031; found 345.02052.  
Purity (HPLC): > 96% (λ = 210 nm), > 96% (λ = 254 nm). 
 
2-Cyano-3-(3,5-dichlorophenyl)-N-(4-fluorophenyl)-3-hydroxyacrylamide – SGA-8 (48) 
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According to general procedure B, amide 26 (178 mg, 1.00 mmol, 1.0 eq.) in dry THF (10 mL), 
NaH (92.0 mg, 2.30 mmol, 2.3 eq.) and 3,5-dichlorobenzoyl chloride (43, 230 mg, 1.10 mmol, 
1.1 eq.) were used to give SGA-8 (48) as white crystals (220 mg, 0.626 mmol, 63%).  
Rf = 0.69 (3:2 hexanes/acetone).  
m.p.: 225 °C.  
1H NMR (400 MHz, (CD3)2SO) δ/ppm = 11.92 (s, 1H, NH), 7.63 (t, J = 1.9 Hz, 1H, 4’’-H), 7.60 
– 7.53 (m, 4H, 2’-H, 6’-H, 2’’-H, 6’’-H), 7.12 – 7.03 (m, 2H, 3’-H, 5’-H).  
13C NMR (101 MHz, (CD3)2SO) δ/ppm = 182.2 (C-3), 166.1 (C-1), 157.3 (d, JCF = 236.9 Hz, C-
4’), 144.9 (C-1’’), 136.3 (d, JCF = 2.4 Hz, C-1’), 133.4 (C-3’’, C-5’’), 128.4 (C-4’’), 126.1 (C-2’’, 
C-6’’), 123.3 (C-2), 120.5 (d, JCF = 7.6 Hz, C-2’, C-6’), 115.2 (d, JCF = 22.0 Hz, C-3’, C-5’), 77.4 
(CN).  
IR (ATR) ṽmax/cm-1 = 3296, 2212, 1739, 1549, 1506, 1210, 823, 809, 645.  
HRMS (ESI): calcd. for C16H835Cl2FN2O2 (M-H)- 348.99523; found 348.99526.  
Purity (HPLC): > 96% (λ = 210 nm), > 96% (λ = 254 nm). 
 
2-Cyano-3-(3,5-dichlorophenyl)-N-(4-iodophenyl)-3-hydroxyacrylamide – SGA-9 (49) 
 
According to general procedure B, amide 27 (286 mg, 1.00 mmol, 1.0 eq.) in dry THF (10 mL), 
NaH (92.0 mg, 2.30 mmol, 2.3 eq.) and 3,5-dichlorobenzoyl chloride (43, 230 mg, 1.10 mmol, 
1.1 eq.) were used to give SGA-9 (49) as yellow crystals (279 mg, 0.608 mmol, 61%).  
Rf = 0.71 (3:2 hexanes/acetone).  
m.p.: 238 °C.  
1H NMR (400 MHz, (CD3)2SO) δ/ppm = 12.04 (s, 1H, NH), 7.63 (t, J = 1.9 Hz, 1H, 4’’-H), 7.59 
– 7.53 (m, 4H, 3’-H, 5’-H, 2’’-H, 6’’-H), 7.44 – 7.38 (m, 2H, 2’-H, 6’-H).  
13C NMR (101 MHz, (CD3)2SO) δ/ppm = 182.4 (C-3), 166.2 (C-1), 145.1 (C-1’’), 139.8 (C-1’), 
137.3 (C-3’, C-5’ or C-2’’, C-6’’), 133.4 (C-3’’, C-5’’), 128.4 (C-4’’), 126.1 (C-3’, C-5’ or C-2’’, C-
6’’), 123.3 (C-2), 121.1 (C-2’, C-6’), 84.5 (C-4’), 77.5 (CN).  
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IR (ATR) ṽmax/cm-1 = 3303, 2217, 1592, 1523, 1485, 1314, 817, 806, 658.  
HRMS (ESI): calcd. for C16H835Cl2IN2O2 (M-H)- 456.90130; found 456.90014.  
Purity (HPLC): > 96% (λ = 210 nm), > 96% (λ = 254 nm). 
 
2-Cyano-3-hydroxy-3-phenyl-N-(4-(trifluoromethyl)phenyl)acrylamide – SGA-10 (50) 
 
According to general procedure B, SGA-34 (19, 228 mg, 1.00 mmol, 1.0 eq.) in dry THF 
(10 mL), NaH (92.0 mg, 2.30 mmol, 2.3 eq.) and benzoyl chloride (128 µL, 1.10 mmol, 1.1 eq.) 
were used to give SGA-10 (50) as colorless crystals (185 mg, 0.557 mmol, 56%). Analytical 
data are in accordance with literature[179]. 
Rf = 0.28 (3:2 hexanes/acetone).  
m.p.: 242 °C. [lit.[179]: 245 – 247 °C] 
1H NMR (400 MHz, (CD3)2SO) δ/ppm = 12.12 (s, 1H, NH), 7.84 – 7.74 (m, 2H, 2’-H, 6’-H), 7.70 
– 7.58 (m, 4H, 3’-H, 5’-H, Ph), 7.48 – 7.39 (m, 3H, Ph).  
13C NMR (101 MHz, (CD3)2SO) δ/ppm = 185.7 (C-3), 167.3 (C-1), 143.1 (C-1’), 139.7 (qPh), 
135.0 (C-2), 130.0 (Ph), 127.8 (Ph), 127.6 (Ph), 126.0 (q, JCF = 3.8 Hz, C-3’, C-5’), 125.0 (d, 
JCF = 270.6 Hz, CF3), 122.3 (d, JCF = 35.2 Hz, C-4’), 119.4 (C-2’, C-6’), 77.8 (CN).  
IR (ATR) ṽmax/cm-1 = 3283, 2216, 1592, 1550, 1309, 1109, 1067, 840, 694.  
HRMS (ESI): calcd. for C17H10F3N2O2 (M-H)- 331.06999; found 331.06985.  
Purity (HPLC): > 96% (λ = 210 nm), > 96% (λ = 254 nm). 
 
2-Cyano-3-(3,5-dinitrophenyl)-3-hydroxy-N-(4-(trifluoromethyl)phenyl)acrylamide – 
SGA-11 (51)  
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According to general procedure B, SGA-34 (19, 228 mg, 1.00 mmol, 1.0 eq.) in dry THF 
(10 mL), NaH (92.0 mg, 2.30 mmol, 2.3 eq.) and 3,5-dinitrobenzoyl chloride (254 mg, 
1.10 mmol, 1.1 eq.) were used to give SGA-11 (51) as red crystals (124 mg, 0.294 mmol, 29%).  
Rf = 0.21 (3:2 hexanes/acetone).  
m.p.: 240 °C.  
1H NMR (500 MHz, (CD3)2SO) δ/ppm = 12.32 (s, 1H, NH), 10.00 (s, 1H, OH), 8.89 – 8.80 (m, 
3H, 2’’-H, 4’’-H, 6’’-H), 7.84 – 7.75 (m, 2H, 2’-H, 6’-H), 7.67 – 7.58 (m, 2H, 3’-H, 5’-H).  
13C NMR (126 MHz, (CD3)2SO) δ/ppm = 180.5 (C-3), 166.1 (C-1), 147.6 (C-3’’, C-5’’), 144.4 
(C-1’’), 143.5 (C-1’), 127.6 (C-2’’, C-6’’),126.1 (q, JCF = 3.5 Hz, C-3’, C-5’),124.2 (q, JCF = 271.0 
Hz, CF3), 123.3 (C-2), 121.8 (q, JCF = 31.7 Hz, C-4’), 119.0 (C-4’’), 118.6 (C-2’, C-6’), 77.7 
(CN).  
IR (ATR) ṽmax/cm-1 = 3262, 3093, 2223, 1539, 1342, 1317, 1115, 1067, 841, 730, 703, 687.  
HRMS (ESI): calcd. for C17H8F3N4O6 (M-H)- 421.04014; found 421.04021.  
Purity (HPLC): > 96% (λ = 210 nm), > 96% (λ = 254 nm). 
 
2-Cyano-3-(3,5-dichlorophenyl)-N-(4-methoxyphenyl)-3-hydroxyacrylamide – 
SGA-12 (52) 
 
According to general procedure B, amide 23 (190 mg, 1.00 mmol, 1.0 eq.) in dry THF (10 mL), 
NaH (92.0 mg, 2.30 mmol, 2.3 eq.) and 3,5-dichlorobenzoyl chloride (43, 230 mg, 1.10 mmol, 
1.1 eq.) were used to give SGA-12 (52) as yellow solid (220 mg, 0.606 mmol, 61%).  
Rf = 0.76 (3:2 hexanes/acetone).  
m.p.: 207 °C.  
1H NMR (400 MHz, (CD3)2SO) δ/ppm = 11.36 (s, 1H, NH), 9.87 (s, 1H, OH), 7.71 (t, J = 1.8 
Hz, 1H, 4’-H), 7.65 (d, J = 1.8 Hz, 2H, 2’’-H, 6’’-H), 7.49 – 7.41 (m, 2H, 2’-H, 6’-H), 6.90 – 6.85 
(m, 2H, 3’-H, 5’-H), 3.72 (s, 3H, OCH3).  
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13C NMR (101 MHz, (CD3)2SO) δ/ppm = 181.6 (C-3), 166.4 (C-1), 155.2 (C-4’), 142.6 (C-1’’), 
133.7 (C-3’’, C-5’’), 131.9 (C-1’), 129.3 (C-4’’), 126.3 (C-2’’, C-6’’), 121.7 (C-2’, C-6’), 121.4 (C-
2), 113.9 (C-3’, C-5’), 78.1 (CN), 55.2 (OCH3).  
IR (ATR) ṽmax/cm-1 = 3296, 2211, 1601, 1467, 1441, 1297, 1251, 1032, 764.  
HRMS (ESI): calcd. for C17H1135Cl2N2O3 (M-H)- 361.01522; found 361.01516.  
Purity (HPLC): > 96% (λ = 210 nm), > 96% (λ = 254 nm). 
 
2-Cyano-3-(3,5-dichlorophenyl)-N-(4-nitrophenyl)-3-hydroxyacrylamide – SGA-13 (53) 
 
According to general procedure B, amide 28 (205 mg, 1.00 mmol, 1.0 eq.) in dry THF (16 mL), 
NaH (92.0 mg, 2.30 mmol, 2.3 eq.) and 3,5-dichlorobenzoyl chloride (43, 230 mg, 1.10 mmol, 
1.1 eq.) were used to give SGA-13 (53) as yellow solid (208 mg, 0.550 mmol, 55%).  
Rf = 0.82 (3:2 hexanes/acetone).  
m.p.: 246 °C.  
1H NMR (400 MHz, (CD3)2SO) δ/ppm = 12.64 (s, 1H, NH), 8.19 – 8.13 (m, 2H, 3’-H, 5’-H), 7.82 
– 7.77 (m, 2H, 2’-H, 6’-H), 7.64 (t, J = 1.9 Hz, 1H, 4’’-H), 7.57 (d, J = 1.9 Hz, 2H, 2’’-H, 6’’-H).  
13C NMR (101 MHz, (CD3)2SO) δ/ppm = 181.6 (C-3), 166.9 (C-1), 149.4 (C-1’’), 147.0 (C-1’), 
141.3 (C-4’), 133.9 (C-3’’, C-5’’), 129.0 (C-4’’), 126.5 (C-2’’, C-6’’), 125.7 (C-3’, C-5’), 121.8 (C-
2), 118.6 (C-2’, C-6’), 77.0 (CN).  
IR (ATR) ṽmax/cm-1 = 3314, 2209, 1568, 1546, 1514, 1498, 1340, 1309, 847, 813, 656.  
HRMS (ESI): calcd. for C16H835Cl2N3O4 (M-H)- 375.98973; found 375.98970.  
Purity (HPLC): > 96% (λ = 210 nm), > 96% (λ = 254 nm). 
 
 
 
 
EXPERIMENTAL PART 
121 
2-Cyano-3-(4-nitrophenyl)-3-hydroxy-N-(4-(trifluoromethyl)phenyl)acrylamide – 
SGA-15 (54) 
 
According to general procedure B, SGA-34 (19, 228 mg, 1.00 mmol, 1.0 eq.) in dry THF 
(10 mL), NaH (92.0 mg, 2.30 mmol, 2.3 eq.) and 4-nitrobenzoyl chloride (204 mg, 1.10 mmol, 
1.1 eq.) were used to give SGA-15 (54) as yellow crystals (276 mg, 0.688 mmol, 69%).  
Rf = 0.19 (3:2 hexanes/acetone).  
m.p.: 217 °C. [lit.[91]: 211 – 214 °C] 
1H NMR (500 MHz, (CD3)2SO) δ/ppm = 12.39 (s, 1H, NH), 8.28 – 8.19 (m, 2H, 3’’-H, 5’’-H), 
7.84 – 7.80 (m, 2H, 2’’-H, 6’’-H), 7.78 (d, J = 8.6 Hz, 2H, 2’-H, 6’-H), 7.60 (d, J = 8.6 Hz, 2H, 
3’’-H, 5’’-H).  
13C NMR (126 MHz, (CD3)2SO) δ/ppm = 184.3 (C-3), 166.4 (C-1), 148.1 (C-1’’), 147.5 (C-4’’), 
143.7 (C-1’), 128.6 (C-2’’, C-6’’), 126.1 (q, JCF = 3.6 Hz, C-3’, C-5’), 124.6 (q, JCF = 270.9 Hz, 
CF3), 123.2 (C-2), 123.1 (C-3’’, C-5’’), 121.6 (q, JCF = 32.0 Hz, C-4’), 118.6 (C-2’, C-6’), 77.9 
(CN).  
IR (ATR) ṽmax/cm-1 = 3307, 2219, 1551, 1320, 1111, 1069, 844, 750, 700.  
HRMS (ESI): calcd. for C17H9F3N3O4 (M-H)- 376.05506; found 376.05509.  
Purity (HPLC): > 96% (λ = 210 nm), > 96% (λ = 254 nm). 
 
3-(4-Chlorophenyl)-2-cyano-3-hydroxy-N-(4-(trifluoromethyl)phenyl)acrylamide – 
SGA-16 (55) 
F3C
N
H
O
CN
1
21'
2'
3'
4' OH
3 1''
2''
3''
4''
5''
6''
SGA-16 (55)
5'
6'
Cl
 
According to general procedure B, SGA-34 (19, 228 mg, 1.00 mmol, 1.0 eq.) in dry THF 
(10 mL), NaH (92.0 mg, 2.30 mmol, 2.3 eq.) and 4-chlorobenzoyl chloride (141 µL, 1.10 mmol, 
1.1 eq.) were used to give SGA-16 (55) as colorless crystals (222 mg, 0.605 mmol, 61%).  
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Rf = 0.32 (3:2 hexanes/acetone).  
m.p.: 220 °C. [lit.[91]: 218 – 220 °C] 
1H NMR (500 MHz, (CD3)2SO) δ/ppm = 12.31 (s, 1H, NH), 7.81 – 7.75 (m, 2H, 2’-H, 6’-H), 7.68 
– 7.63 (m, 2H, 2’’-H, 6’’-H), 7.63 – 7.58 (m, 2H, 3’-H, 5’-H), 7.49 – 7.44 (m, 2H, 3’’-H, 5’’-H).  
13C NMR (126 MHz, (CD3)2SO) δ/ppm = 184.8 (C-3), 167.0 (C-1), 143.5 (C-1’), 139.6 (C-1’’), 
134.1 (C-4’’), 129.4 (C-2’’, C-6’’), 127.8 (C-3’’, C-5’’), 126.0 (q, JCF = 3.6 Hz, C-3’, C-5’), 124.6 
(q, JCF = 271.0 Hz, CF3), 123.0 (C-2), 121.8 (q, JCF = 31.0 Hz, C-4’), 118.9 (C-2’, C-6’), 77.5 
(CN).  
IR (ATR) ṽmax/cm-1 = 3282.2215, 1587, 1240, 1302, 1129, 1113, 1097, 839.  
HRMS (ESI): calcd. for C17H935ClF3N2O2 (M-H)- 365.03101; found 365.03108.  
Purity (HPLC): > 96% (λ = 210 nm), > 96% (λ = 254 nm). 
 
N-(2-Bromo-4-chlorophenyl)-2-cyano-3-(3,5-dichlorophenyl)-3-hydroxyacrylamide – 
SGA-27 (56) 
 
According to general procedure B, amide 34 (274 mg, 1.00 mmol, 1.0 eq.) in dry THF (10 mL), 
NaH (92.0 mg, 2.30 mmol, 2.3 eq.) and 3,5-dichlorobenzoyl chloride (43, 230 mg, 1.10 mmol, 
1.1 eq.) were used to give SGA-27 (56) as colorless solid (330 mg, 0.738 mmol, 74%).  
Rf = 0.25 (3:2 hexanes/acetone).  
m.p.: 203 °C.  
1H NMR (500 MHz, (CD3)2SO) δ/ppm = 12.29 (s, 1H, NH), 8.56 (d, J = 9.0 Hz, 1H, 6’-H), 7.68 
(d, J = 2.5 Hz, 1H, 3’-H), 7.63 (t, J = 1.9 Hz, 1H, 4’’-H), 7.58 (d, J = 1.9 Hz, 2H, 2’’-H, 6’’-H), 
7.36 (dd, J = 9.0, 2.5 Hz, 1H, 5’-H).  
13C NMR (126 MHz, (CD3)2SO) δ/ppm = 182.7 (C-3), 166.4 (C-1), 145.2 (C-1’’), 137.8 (C-1’), 
133.4 (C-3’’, C-5’’), 131.4 (C-6’), 128.4 (C-4’’), 127.8 (C-5’), 126.1 (C-2’’, C-6’’), 125.4 (C-4’), 
123.5 (C-2), 122.1 (C-3’), 112.1 (C-2’), 77.3 (CN).  
IR (ATR) ṽmax/cm-1 = 3366, 3087, 2208, 1556, 1521, 1469, 1360, 1292, 863, 815.  
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HRMS (ESI): calcd. for C16H779Br35Cl3N2O2 (M-H)- 442.87620; found 442.87736.  
Purity (HPLC): > 96% (λ = 210 nm), > 96% (λ = 254 nm). 
 
2-Cyano-3-(3,5-dichlorophenyl)-N-(3,4-dimethoxyphenyl)-3-hydroxyacrylamide – 
SGA-28 (57) 
 
According to general procedure B, amide 37 (220 mg, 1.00 mmol, 1.0 eq.) in dry THF (10 mL), 
NaH (92.0 mg, 2.30 mmol, 2.3 eq.) and 3,5-dichlorobenzoyl chloride (43, 230 mg, 1.10 mmol, 
1.1 eq.) were used to give SGA-28 (57) as yellow solid (200 mg, 0.508 mmol, 51%).  
Rf = 0.17 (3:2 hexanes/acetone).  
m.p.: 195 °C.  
1H NMR (500 MHz, (CD3)2SO) δ/ppm = 11.52 (s, 1H, NH), 7.68 (t, J = 1.8 Hz, 1H, 4’’-H), 7.62 
(d, J = 1.8 Hz, 2H, 2’’-H, 6’’-H), 7.30 (d, J = 2.2 Hz, 1H, 2’-H), 7.01 (dd, J = 8.7, 2.2 Hz, 1H, 6’-
H), 6.86 (d, J = 8.7 Hz, 1H, 5’-H), 3.73 (s, 3H, OCH3), 3.71 (s, 3H, OCH3).  
13C NMR (126 MHz, (CD3)2SO) δ/ppm = 181.7 (C-3), 166.2 (C-1), 148.6 (C-3’), 144.4 (C-4’), 
143.6 (C-1’’), 133.6 (C-3’’, C-5’’), 133.0 (C-1’), 128.9 (C-4’’), 126.2 (C-2’’, C-6’’), 122.2 (C-2), 
112.3 (C-5’), 111.5 (C-6’), 104.9 (C-2’), 77.9 (CN), 55.8 (OCH3), 55.4 (OCH3).  
IR (ATR) ṽmax/cm-1 = 3284, 2217, 1608, 1549, 1516, 1238, 1028, 810.  
HRMS (ESI): calcd. for C18H1335Cl2N2O4 (M-H)- 391.02579; found 391.02608.  
Purity (HPLC): > 96% (λ = 210 nm), > 96% (λ = 254 nm). 
 
2-Cyano-3-(1-methyl-1H-pyrrol-2-yl)-3-hydroxy-N-phenylacrylamide (prinomide) – 
SGA-31 (58) 
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According to general procedure B, amide 22 (228 mg, 1.00 mmol, 1.0 eq.) in dry THF (10 mL), 
NaH (92.0 mg, 2.30 mmol, 2.3 eq.) and 1-methylpyrrole-2-carbonyl chloride (158 mg, 
1.10 mmol, 1.1 eq.) were used to give SGA-31 (58) as colorless crystals (200 mg, 0.747 mmol, 
75%).  
Rf = 0.65 (3:2 hexanes/acetone).  
m.p.: 171 °C. [lit.[188]: 174 – 175 °C] 
1H NMR (400 MHz, CDCl3) δ/ppm = 7.74 (s, 1H, NH), 7.54 (dd, J = 4.3, 1.6 Hz, 1H, 3’’-H), 7.50 
(d, J = 8.0 Hz, 2H, 2’-H, 6’-H), 7.44 – 7.34 (m, 2H, 3’-H, 5’-H), 7.20 (t, J = 7.4 Hz, 1H, 4’-H), 
6.89 (t, J = 1.9 Hz, 1H, 5’’-H), 6.25 (dd, J = 4.3, 2.5 Hz, 1H, 4’’-H), 3.92 (s, 3H, CH3).  
13C NMR (101 MHz, CDCl3) δ/ppm = 175.6 (C-3), 170.0 (C-1), 136.2 (C-1’), 132.0 (C-5’’), 129.3 
(C-3’, C-5’), 125.7 (C-4’), 124.4 (C-2’’), 121.3 (C-2’, C-6’), 120.7 (C-3’’), 119.1 (C-2), 109.7 (C-
4’’), 72.6 (CN), 38.5 (CH3).  
IR (ATR) ṽmax/cm-1 = 3293, 2210, 1526, 1382, 1231, 751, 736, 687.  
HRMS (ESI): calcd. for C15H12N3O2 (M-H)- 266.09350; found 266.09370.  
Purity (HPLC): > 96% (λ = 210 nm), > 96% (λ = 254 nm). 
 
2-Cyano-3-(1-methyl-1H-pyrrol-2-yl)-3-hydroxy-N-(4-(trifluoromethyl)phenyl)acrylamide 
– SGA-32 (59) 
 
According to general procedure B, SGA-34 (19, 228 mg, 1.00 mmol, 1.0 eq.) in dry THF 
(10 mL), NaH (92.0 mg, 2.30 mmol, 2.3 eq.) and 1-methylpyrrole-2-carbonyl chloride (158 mg, 
1.10 mmol, 1.1 eq.) were used to give SGA-32 (59) as colorless crystals (221 mg, 0.660 mmol, 
66%).  
Rf = 0.57 (3:2 hexanes/acetone).  
m.p.: 203 °C. 
1H NMR (400 MHz, CDCl3) δ/ppm = 7.86 (s, 1H, NH), 7.69 – 7.61 (m, 4H, 2’-H, 6’-H, 3’-H, 5’-
H), 7.57 (dd, J = 4.3, 1.6 Hz, 1H, 3’’-H), 6.93 – 6.90 (m, 1H, 4’’-H), 6.27 (dd, J = 4.3, 2.5 Hz, 
1H, 5’’-H), 3.93 (s, 3H, CH3).  
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13C NMR (101 MHz, CDCl3) δ/ppm = 175.6 (C-3), 170.2 (C-1), 139.5 (C-1’), 132.6 (C-5’’), 127.4 
(q, JCF = 31.8 Hz, C-4’), 126.6 (q, J = 3.8 Hz, C-3’, C-5’), 124.1 (C-2’’), 124.0 (q, JCF = 271.4 
Hz, CF3), 121.3 (C-3’’), 120.7 (C-2’, C-6’), 119.0 (C-2), 110.0 (C-4’’), 72.6 (CN), 38.7 (CH3).  
IR (ATR) ṽmax/cm-1 = 3273, 2210, 1518, 1379, 1228, 1111, 996, 837, 745.  
HRMS (ESI): calcd. for C16H11F3N3O2 (M-H)- 334.08088; found 334.08090.  
Purity (HPLC): > 96% (λ = 210 nm), > 96% (λ = 254 nm). 
 
N-(3-Chloro-2,4-difluorophenyl)-2-cyano-3-(3,5-dichlorophenyl)-3-hydroxyacrylamide – 
SGA-33 (60) 
 
According to general procedure B, amide 36 (231 mg, 1.00 mmol, 1.0 eq.) in dry THF (10 mL), 
NaH (92.0 mg, 2.30 mmol, 2.3 eq.) and 3,5-dichlorobenzoyl chloride (43, 230 mg, 1.10 mmol, 
1.1 eq.) were used to give SGA-33 (60) as colorless crystals (290 mg, 0.719 mmol, 72%).  
Rf = 0.15 (3:2 hexanes/acetone).  
m.p.: 193 °C.  
1H NMR (400 MHz, (CD3)2SO) δ/ppm = 12.34 (s, 1H, NH), 8.43 (td, J = 9.0, 6.0 Hz, 1H, 6’-H), 
7.63 (t, J = 1.9 Hz, 1H, 4’’-H), 7.58 (d, J = 1.9 Hz, 2H, 2’’-H, 6’’-H), 7.23 (td, J = 9.2, 2.1 Hz, 
1H, 5’-H).  
13C NMR (101 MHz, (CD3)2SO) δ/ppm = 182.9 (C-3), 166.3 (C-1), 152.1 (d, JCF = 242.4 Hz, C-
4’), 147.7 (d, JCF = 245.4 Hz, C-2’), 145.0 (C-1’’), 133.4 (C-3’’, C-5’’), 128.5 (C-4’’), 126.3 (dd, 
JCF = 10.3, 2.6 Hz, C-1’), 126.1 (C-2’’, C-6’’), 123.2 (C-2), 119.1 (dd, JCF = 7.8, 3.0 Hz, C-6’), 
111.5 (dd, JCF = 20.7, 3.6 Hz, C-5’), 107.8 (dd, JCF = 22.2, 2.9 Hz, C-3’), 77.3 (CN).  
IR (ATR) ṽmax/cm-1 = 3293, 2206, 1539, 1497, 1370, 1289, 1023, 803.  
HRMS (ESI): calcd. for C16H635Cl3F2N2O2 (M-H)- 400.94684; found 400.94724.  
Purity (HPLC): > 96% (λ = 210 nm), > 96% (λ = 254 nm). 
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2-Cyano-N-(4-cyanophenyl)-3-(3,5-dichlorophenyl)-3-hydroxyacrylamide – SGA-38 (61) 
 
According to general procedure B, amide 29 (185 mg, 1.00 mmol, 1.0 eq.) in dry THF (10 mL), 
NaH (92.0 mg, 2.30 mmol, 2.3 eq.) and 3,5-dichlorobenzoyl chloride (43, 230 mg, 1.10 mmol, 
1.1 eq.) were used to give SGA-38 (61) as yellow solid (137 mg, 0.382 mmol, 38%).  
Rf = 0.12 (3:2 hexanes/acetone).  
m.p.: 236 °C.  
1H NMR (500 MHz, (CD3)2SO) δ/ppm = 12.42 (s, 1H, NH), 7.75 – 7.72 (m, 2H, 3’-H, 5’-H), 7.71 
– 7.67 (m, 2H, 2’-H, 6’-H), 7.64 (t, J = 1.9 Hz, 1H, 4’’-H), 7.57 (d, J = 1.9 Hz, 2H, 2’’-H, 6’’-H).  
13C NMR (126 MHz, (CD3)2SO) δ/ppm = 183.0 (C-3), 166.4 (C-1), 145.1 (C-1’’), 144.3 (C-1’), 
133.5 (C-3’’, C-5’’), 133.3 (C-3’, C-5’), 128.5 (C-4’’), 126.0 (C-2’’, C-6’’), 123.2 (C-4’), 119.4 (C-
2), 118.8 (C-2’, C-6’), 103.1 (4’-CN), 77.4 (2-CN).  
IR (ATR) ṽmax/cm-1 = 3321, 2360, 2340, 1533, 839, 655.  
HRMS (ESI): calcd. for C17H835Cl2N3O2 (M-H)- 355.99991; found 356.00057.  
Purity (HPLC): > 96% (λ = 210 nm), > 96% (λ = 254 nm). 
 
2-Cyano-3-(3,5-dichlorophenyl)-3-hydroxy-N-(2-iodophenyl)acrylamide – SGA-39 (62) 
 
According to general procedure B, amide 35 (286 mg, 1.00 mmol, 1.0 eq.) in dry THF (10 mL), 
NaH (92.0 mg, 2.30 mmol, 2.3 eq.) and 3,5-dichlorobenzoyl chloride (43, 230 mg, 1.10 mmol, 
1.1 eq.) were used to give SGA-39 (62) as yellow solid (237 mg, 0.515 mmol, 52%).  
Rf = 0.20 (3:2 hexanes/acetone).  
m.p.: 171 °C.  
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1H NMR (400 MHz, (CD3)2SO) δ/ppm = 11.87 (s, 1H, NH), 8.27 (dd, J = 8.3, 1.5 Hz, 1H, 6’-H), 
7.80 (dd, J = 7.9, 1.5 Hz, 1H, 3’-H), 7.63 (t, J = 1.9 Hz, 1H, 4’’-H), 7.59 (d, J = 1.9 Hz, 2H, 2’’-
H, 6’’-H), 7.29 (ddd, J = 8.4, 7.3, 1.5 Hz, 1H, 5’-H), 6.80 – 6.67 (m, 1H, 4’-H).  
13C NMR (126 MHz, (CD3)2SO) δ/ppm = 182.2 (C-3), 166.4 (C-1), 145.1 (C-1’’), 141.5 (C-1’), 
139.0 (C-3’), 133.4 (C-3’’, C-5’’), 128.4 (C-4’’), 128.3 (C-5’), 126.1 (C-2’’, C-6’’), 124.0 (C-4’), 
123.6 (C-2), 122.1 (C-6’), 89.2 (C-2’), 77.2 (CN).  
IR (ATR) ṽmax/cm-1 = 3337, 2213, 1579, 1537, 1294, 742.  
HRMS (ESI): calcd. for C16H835Cl2IN2O2 (M-H)- 456.90130; found 456.90095.  
Purity (HPLC): > 96% (λ = 210 nm), > 96% (λ = 254 nm). 
 
2-Cyano-3-hydroxy-3-(perfluorophenyl)-N-(4-(trifluoromethyl)phenyl)acrylamide – 
SGA-40 (63) 
 
According to general procedure B, SGA-34 (19, 228 mg, 1.00 mmol, 1.0 eq.) in dry THF 
(10 mL), NaH (92.0 mg, 2.30 mmol, 2.3 eq.) and 2,3,4,5,6-pentafluorobenzoyl chloride 
(158 µL, 1.10 mmol, 1.1 eq.) were used to give SGA-40 (63) as colorless crystals (236 mg, 
0.560 mmol, 56%).  
Rf = 0.28 (3:2 hexanes/acetone).  
m.p.: 161 °C.  
1H NMR (400 MHz, (CD3)2SO) δ/ppm = 11.70 (s, 1H, NH), 7.81 – 7.72 (m, 2H, 2’-H, 6’-H), 7.67 
– 7.56 (m, 2H, 3’-H, 5’-H).  
13C NMR (101 MHz, (CD3)2SO) δ/ppm = 172.6 (C-3), 164.9 (C-1), 143.9 – 140.9 (m, C-2’’, C-
6’’ or C-3’’, C-5’’), 143.3 (C-1’), 141.9 – 138.9 (m, C-4’’), 138.5 – 135.1 (m, C-2’’, C-6’’ or C-3’’, 
C-5’’), 126.1 (q, JCF = 3.6 Hz, C-3’, C-5’), 124.6 (q, JCF = 271.0 Hz, CF3), 122.0 (q, JCF = 31.9 
Hz, C-4’), 117.5 – 117.0 (m, C-1’’), 121.7 (C-2’, C-6’), 118.7 (C-2), 81.8 (CN).  
IR (ATR) ṽmax/cm-1 = 2230, 1590, 1543, 1524, 1497, 1323, 1116, 1000, 839.  
HRMS (ESI): calcd. for C17H5F8N2O2 (M-H)- 421.02288; found 421.02337.  
Purity (HPLC): > 96% (λ = 210 nm), > 96% (λ = 254 nm). 
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2-Cyano-3-(3,5-dibromophenyl)-3-hydroxy-N-(4-(trifluoromethyl)phenyl)acrylamide – 
SGA-70 (64) 
 
According to general procedure B, SGA-34 (19, 228 mg, 1.00 mmol, 1.0 eq.) in dry THF 
(10 mL), NaH (92.0 mg, 2.30 mmol, 2.3 eq.) and 3,5-dibromobenzoic acid (308 mg, 1.10 mmol, 
1.1 eq., converted into the corresponding aryl chloride) were used to give SGA-70 (64) as light 
yellow crystals (206 mg, 0.420 mmol, 42%).  
Rf = 0.32 (3:2 hexanes/acetone).  
m.p.: 211 °C.  
1H NMR (400 MHz, (CD3)2SO) δ/ppm = 12.32 (s, 1H, NH), 8.96 (s, 1H, OH), 7.91 – 7.81 (m, 
1H, 4’’-H), 7.78 – 7.72 (m, 4H, 2’-H, 6’-H, 2’’-H, 6’’-H), 7.65 – 7.55 (m, 2H, 3’-H, 5’-H).  
13C NMR (101 MHz, (CD3)2SO) δ/ppm = 182.5 (C-3), 166.4 (C-1), 145.5 (C-1’’), 143.6 (C-1’), 
133.7 (C-4’’), 129.2 (C-2’’, C-6’’), 126.0 (q, JCF = 3.5 Hz, C-3’, C-5’), 123.9 (q, JCF = 271.2 Hz, 
CF3), 123.3 (C-2), 121.8 (C-3’’, C-5’’), 121.6 (q, JCF = 31.9 Hz, C-4’), 118.5 (C-2’, C-6’), 77.4 
(CN).  
IR (ATR) ṽmax/cm-1 = 2218, 1594, 1538, 1315, 1166, 1109, 1068, 838, 750.  
HRMS (ESI): calcd. for C17H879Br2F3N2O2 (M-H)- 486.89101; found 486.89128.  
Purity (HPLC): > 96% (λ = 210 nm), > 96% (λ = 254 nm). 
 
2-Cyano-3-hydroxy-3-(2,4,6-trichlorophenyl)-N-(4-(trifluoromethyl)phenyl)acrylamide – 
SGA-71 (65) 
 
According to general procedure B, SGA-34 (19, 228 mg, 1.00 mmol, 1.0 eq.) in dry THF 
(10 mL), NaH (92.0 mg, 2.30 mmol, 2.3 eq.) and 2,4,6-trichlorobenzoyl chloride (172 µL, 
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1.10 mmol, 1.1 eq.) were used to give SGA-71 (65) as colorless crystals (158 mg, 0.363 mmol, 
36%).  
Rf = 0.14 (3:2 hexanes/acetone).  
m.p.: 220 °C.  
1H NMR (500 MHz, (CD3)2SO) δ/ppm = 11.92 (s, 1H, NH), 7.79 – 7.74 (m, 2H, 2’-H, 6’-H), 7.66 
(s, 2H, 3’’-H, 5’’-H), 7.63 – 7.58 (m, 2H, 3’-H, 5’-H).  
13C NMR (126 MHz, (CD3)2SO) δ/ppm = 180.7 (C-3), 165.7 (C-1), 143.6 (C-1’), 139.5 (C-1’’), 
133.1 (C-4’’), 132.0 (C-2’’, C-6’’), 127.8 (C-3’’, C-5’’), 126.1 (q, JCF = 3.6 Hz, C-3’, C-5’), 124.6 
(q, JCF = 271.1 Hz, CF3), 121.9 (C-2), 121.6 (q, JCF = 31.9 Hz, C-4’), 118.4 (C-2’, C-6’), 79.5 
(CN).  
IR (ATR) ṽmax/cm-1 = 2230, 1598, 1541, 1318, 1116, 841.  
HRMS (ESI): calcd. for C17H735Cl3F3N2O2 (M-H)- 432.95307; found 432.95394.  
Purity (HPLC): > 96% (λ = 210 nm), > 96% (λ = 254 nm). 
 
N-(4-Bromophenyl)-2-cyano-3-hydroxy-3-(2,4,6-trichlorophenyl)acrylamide – 
SGA-72 (66) 
 
According to general procedure B, amide 25 (239 mg, 1.00 mmol, 1.0 eq.) in dry THF (10 mL), 
NaH (92.0 mg, 2.30 mmol, 2.3 eq.) and 2,4,6-trichlorobenzoyl chloride (172 µL, 1.10 mmol, 
1.1 eq.) were used to give SGA-72 (66) as colorless solid (227 mg, 0.507 mmol, 51%).  
Rf = 0.14 (3:2 hexanes/acetone).  
m.p.: 191 °C.  
1H NMR (400 MHz, (CD3)2SO) δ/ppm = 11.69 (s, 1H, NH), 7.65 (s, 2H, 3’’-H, 5’’-H), 7.58 – 7.52 
(m, 2H, 2’-H, 6’-H), 7.44 – 7.38 (m, 2H, 3’-H, 5’-H).  
13C NMR (101 MHz, (CD3)2SO) δ/ppm = 180.3 (C-3), 165.4 (C-1), 139.6 (C-1’ or C-1’’), 139.4 
(C-1’ or C-1’’), 133.0 (C-4’’), 132.0 (C-2’’, C-6’’), 131.5 (C-3’, C-5’), 127.8 (C-3’’, C-5’’), 122.1 
(C-2), 120.5 (C-2’, C-6’), 112.9 (C-4’), 79.5 (CN).  
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IR (ATR) ṽmax/cm-1 = 2238, 1588, 1539, 1488, 1307, 856, 818.  
HRMS (ESI): calcd. for C16H779Br35Cl3N2O2 (M-H)- 442.87620; found 442.87747.  
Purity (HPLC): > 96% (λ = 210 nm), > 96% (λ = 254 nm). 
 
N-(3-Chloro-2,4-difluorophenyl)-2-cyano-3-hydroxy-3-(2,4,6-trichlorophenyl)acrylamide 
– SGA-73 (67) 
 
According to general procedure B, amide 36 (231 mg, 1.00 mmol, 1.0 eq.) in dry THF (10 mL), 
NaH (92.0 mg, 2.30 mmol, 2.3 eq.) and 2,4,6-trichlorobenzoyl chloride (172 µL, 1.10 mmol, 
1.1 eq.) were used to give SGA-73 (67) as colorless solid (217 mg, 0.496 mmol, 50%).  
Rf = 0.16 (1:1 hexanes/acetone).  
m.p.: 199 °C.  
1H NMR (500 MHz, (CD3)2SO) δ/ppm = 11.93 (s, 1H, NH), 8.45 (td, J = 9.1, 5.9 Hz, 1H, 6’-H), 
7.66 (s, 2H, 3’’-H, 5’’-H), 7.23 (td, J = 9.2, 2.0 Hz, 1H, 5’-H).  
13C NMR (126 MHz, (CD3)2SO) δ/ppm = 180.8 (C-3), 165.6 (C-1), 152.1 (d, JCF = 242.6 Hz, C-
4’), 147.5 (d, JCF = 245.6 Hz, C-2’), 139.4 (C-1’’ or C-4’’), 133.1 (C-1’’ or C-4’’), 132.0 (C-2’’, C-
6’’), 127.8 (C-3’’, C-5’’), 126.3 (dd, JCF = 10.2, 3.2 Hz, C-1’), 121.8 (C-2), 118.8 (dd, JCF = 7.9, 
2.9 Hz, C-6’), 111.5 (dd, JCF = 20.7, 3.5 Hz, C-5’), 107.9 (dd, JCF = 22.0, 19.2 Hz, C-3’), 79.4 
(CN).  
IR (ATR) ṽmax/cm-1 = 3279, 2222, 1626, 1590, 1519, 1484, 1445, 1359, 1275, 1017, 816, 631.  
HRMS (ESI): calcd. for C16H535Cl4F2N2O2 (M-H)- 434.90787; found 434.90791.  
Purity (HPLC): > 96% (λ = 210 nm), > 96% (λ = 254 nm). 
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N-(4-Bromophenyl)-2-cyano-3-(3,5-dibromophenyl)-3-hydroxyacrylamide – SGA-75 (68) 
 
According to general procedure B, amide 25 (239 mg, 1.00 mmol, 1.0 eq.) in dry THF (10 mL), 
NaH (92.0 mg, 2.30 mmol, 2.3 eq.) and 3,5-dibromobenzoic acid (308 mg, 1.10 mmol, 1.1 eq.; 
converted into the corresponding aryl chloride) were used to give SGA-75 (68) as colorless 
crystals (222 mg, 0.443 mmol, 44%). 
Rf = 0.20 (3:2 hexanes/acetone).  
m.p.: 233 °C.  
1H NMR (400 MHz, (CD3)2SO) δ/ppm = 12.05 (s, 1H, NH), 7.86 (t, J = 1.8 Hz, 1H, 4’-H), 7.73 
(d, J = 1.8 Hz, 2H, 2’’-H, 6’’-H), 7.57 – 7.50 (m, 2H, 2’-H, 6’-H), 7.46 – 7.37 (m, 2H, 3’-H, 5’-H).  
13C NMR (101 MHz, (CD3)2SO) δ/ppm = 182.2 (C-3), 166.1 (C-1), 145.5 (C-1’’), 139.4 (C-1’), 
133.7 (C-4’’), 131.5 (C-3’, C-5’), 129.2 (C-2’’, C-6’’), 122.7 (C-2), 121.8 (C-3’’, C-5’’), 120.8 (C-
2’, C-6’), 113.0 (C-4’), 77.4 (CN).  
IR (ATR) ṽmax/cm-1 = 3314, 2214, 1596, 1543, 865, 817, 748, 658.  
HRMS (ESI): calcd. for C16H879Br3N2O2 (M-H)- 496.81414; found 496.81449.  
Purity (HPLC): > 96% (λ = 210 nm), > 96% (λ = 254 nm). 
 
N-(4-Acetylphenyl)-2-cyano-3-(3,5-dichlorophenyl)-3-hydroxyacrylamide – SGA-76 (69) 
 
According to general procedure B, amide 30 (202 mg, 1.00 mmol, 1.0 eq.) in dry THF (10 mL), 
NaH (92.0 mg, 2.30 mmol, 2.3 eq.) and 3,5-dichlorobenzoyl chloride (43, 230 mg, 1.10 mmol, 
1.1 eq.) were used to give SGA-76 (69) as off white solid (296 mg, 0.789 mmol, 79%).  
Rf = 0.08 (3:2 hexanes/acetone).  
m.p.: 209 °C.  
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1H NMR (500 MHz, (CD3)2SO) δ/ppm = 12.32 (s, 1H, NH), 7.91 – 7.86 (m, 2H, 3’-H, 5’-H), 7.71 
– 7.66 (m, 2H, 2’-H, 6’-H), 7.64 (t, J = 1.9 Hz, 1H, 4’’-H), 7.58 (d, J = 1.9 Hz, 2H, 2’’-H, 6’’-H), 
2.51 (s, 3H, CH3, collapses with DMSO).  
13C NMR (101 MHz, (CD3)2SO) δ/ppm = 196.3 (CO), 182.8 (C-3), 166.3 (C-1), 145.1 (C-1’’), 
144.5 (C-1’), 133.5 (C-3’’, C-5’’), 130.4 (C-4’), 129.7 (C-3’, C-5’), 128.5 (C-4’’), 126.1 (C-2’’, C-
6’’), 123.3 (C-2), 117.9 (C-2’, C-6’), 77.6 (CN), 26.3 (CH3).  
IR (ATR) ṽmax/cm-1 = 3304, 2207, 1682, 1596, 1544, 1355, 1272, 809.  
HRMS (ESI): calcd. for C18H1135Cl2N2O3 (M-H)- 373.01522; found 373.01580.  
Purity (HPLC): > 96% (λ = 210 nm), > 96% (λ = 254 nm). 
 
2-Cyano-N-(2,6-dibromophenyl)-3-(3,5-dichlorophenyl)-3-hydroxyacrylamide – 
SGA-77 (70) 
 
According to general procedure B, amide 39 (318 mg, 1.00 mmol, 1.0 eq.) in dry THF (10 mL), 
NaH (92.0 mg, 2.30 mmol, 2.3 eq.) and 3,5-dichlorobenzoyl chloride (43, 230 mg, 1.10 mmol, 
1.1 eq.) were used to give SGA-77 (70) as colorless crystals (66.0 mg, 0.134 mmol, 13%).  
Rf = 0.78 (3:2 hexanes/acetone).  
m.p.: 226 °C.  
1H NMR (400 MHz, (CD3)2SO) δ/ppm = 10.64 (s, 1H, NH), 8.09 – 7.90 (m, 3H, 2’’-H, 6’’-H, 4’’-
H), 7.79 (d, J = 8.0 Hz, 2H, 3’-H, 5’-H), 7.26 (t, J = 8.0 Hz, 1H, 4’-H).  
13C NMR (101 MHz, (CD3)2SO) δ/ppm = 162.4 (C-1, C-3), 136.6 (C-1’’), 135.2 (C-1’), 134.6 (C-
3’’, C-5’’), 132.3 (C-3’, C-5’), 131.5 (C-4’’), 130.7 (C-4’), 126.4 (C-2’’, C-6’’), 124.4 (C-2’, C-6’), 
76.4 (CN), C-2 is missing.  
IR (ATR) ṽmax/cm-1 = 3206, 2215, 1650.1567, 1516, 1283, 779, 750, 723.  
HRMS (ESI): calcd. for C16H779Br235Cl2N2O2 (M-H)- 486.82568; found 486.82870.  
Purity (HPLC): > 96% (λ = 210 nm), > 96% (λ = 254 nm). 
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2-Cyano-N-(2,3-dichlorophenyl)-3-(3,5-dichlorophenyl)-3-hydroxyacrylamide – 
SGA-78 (71) 
 
According to general procedure B, amide 38 (229 mg, 1.00 mmol, 1.0 eq.) in dry THF (10 mL), 
NaH (92.0 mg, 2.30 mmol, 2.3 eq.) and 3,5-dichlorobenzoyl chloride (43, 230 mg, 1.10 mmol, 
1.1 eq.) were used to give SGA-78 (71) as colorless crystals (344 mg, 0.856 mmol, 86%).  
Rf = 0.17 (3:2 hexanes/acetone).  
m.p.: 211 °C.  
1H NMR (400 MHz, (CD3)2SO) δ/ppm = 12.49 (s, 1H, NH), 8.58 (dd, J = 8.3, 1.5 Hz, 1H, 6’-H), 
7.63 (t, J = 1.9 Hz, 1H, 4’’-H), 7.59 (d, J = 1.9 Hz, 2H, 2’’-H, 6’’-H), 7.27 (t, J = 8.2 Hz, 1H, 5’-
H), 7.20 (dd, J = 8.0, 1.5 Hz, 1H, 4’-H).  
13C NMR (126 MHz, (CD3)2SO) δ/ppm = 182.8 (C-3), 166.4 (C-1), 145.1 (C-1’’), 139.3 (C-1’), 
133.4 (C-3’’, C-5’’), 131.4 (C-3’), 128.5 (C-4’’), 128.0 (C-5’), 126.1 (C-2’’, C-6’’), 123.4 (C-2), 
122.6 (C-4’), 119.3 (C-2’), 119.1 (C-6’), 77.5 (CN).  
IR (ATR) ṽmax/cm-1 = 3355, 2203, 1649, 1584, 1539, 1453, 1415, 872, 812, 777.  
HRMS (ESI): calcd. for C16H735Cl4N2O2 (M-H)- 398.92671; found 398.92789.  
Purity (HPLC): > 96% (λ = 210 nm), > 96% (λ = 254 nm). 
 
2-Cyano-3-(3,5-dichlorophenyl)-3-hydroxy-N-(4-propoxyphenyl)acrylamide – 
SGA-84 (72) 
 
According to general procedure B, amide 31 (218 mg, 1.00 mmol, 1.0 eq.) in dry THF (10 mL), 
NaH (92.0 mg, 2.30 mmol, 2.3 eq.) and 3,5-dichlorobenzoyl chloride (43, 230 mg, 1.10 mmol, 
1.1 eq.) were used to give SGA-84 (72) as yellow solid (245 mg, 0.626 mmol, 63%).  
Rf = 0.15 (3:2 hexanes/acetone + 2% TEA).  
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m.p.: 184 °C.  
1H NMR (500 MHz, (CD3)2SO) δ/ppm = 11.36 (s, 1H, NH), 9.30 (s, 1H, OH), 7.71 (t, J = 1.7 
Hz, 1H, 4’’-H), 7.67 – 7.62 (m, 2H, 2’’-H, 6’’-H), 7.49 – 7.40 (m, 2H, 3’-H, 5’-H), 6.90 – 6.82 (m, 
2H, 2’-H, 6’-H), 3.88 (t, J = 6.5 Hz, 2H, CH2CH2CH3), 1.71 (sext, J = 7.2 Hz, 2H, CH2CH2CH3), 
0.97 (t, J = 7.4 Hz, 3H, CH2CH2CH3).  
13C NMR (126 MHz, (CD3)2SO) δ/ppm = 181.6 (C-3), 166.4 (C-1), 154.6 (C-4’), 142.7 (C-1’’), 
133.7 (C-3’’, C-5’’), 131.9 (C-1’), 129.3 (C-4’’), 126.3 (C-2’’, C-6’’), 121.6 (C-3’, C-5’), 121.5 (C-
2), 114.5 (C-2’, C-6’), 78.0 (CN), 69.1 (CH2CH2CH3), 22.1 (CH2CH2CH3), 10.4 (CH2CH2CH3).  
IR (ATR) ṽmax/cm-1 = 3304, 2208, 1601, 1550, 1511, 1249, 1235, 822, 811.  
HRMS (ESI): calcd. for C19H1535Cl2N2O3 (M-H)- 389.04652; found 389.04631.  
Purity (HPLC): > 96% (λ = 210 nm), > 96% (λ = 254 nm). 
 
N-(3,5-Bis(trifluoromethyl)phenyl)-2-cyano-3-(3,5-dichlorophenyl)-3-hydroxyacrylamide 
– SGA-85 (73) 
 
According to general procedure B, amide 40 (296 mg, 1.00 mmol, 1.0 eq.) in dry THF (10 mL), 
NaH (92.0 mg, 2.30 mmol, 2.3 eq.) and 3,5-dichlorobenzoyl chloride (43, 230 mg, 1.10 mmol, 
1.1 eq.) were used to give SGA-85 (73) as colorless solid (320 mg, 0.682 mmol, 68%).  
Rf = 0.15 (3:2 hexanes/acetone).  
m.p.: 210 °C.  
1H NMR (400 MHz, (CD3)2SO) δ/ppm = 12.58 (s, 1H, NH), 8.93 (s, 1H, OH), 8.25 (s, 2H, 2’-H, 
6’-H), 7.65 (t, J = 1.9 Hz, 1H, 4’’-H), 7.62 – 7.56 (m, 3H, 4’-H, 2’’-H, 6’’-H).  
13C NMR (101 MHz, (CD3)2SO) δ/ppm = 183.5 (C-3), 167.3 (C-1), 145.4 (C-1’’), 142.3 (C-1’), 
134.0 (C-3’’, C-5’’), 131.2 (q, JCF = 32.6 Hz, C-3’, C-5’), 129.1 (C-4’’), 126.5 (C-2’’, C-6’’), 123.7 
(q, JCF = 270.8 Hz, CF3), 123.4 (C-2), 119.1 – 118.8 (m, C-2’, C-6’), 114.8 – 114.5 (m, C-4’), 
77.6 (CN).  
IR (ATR) ṽmax/cm-1 = 2230, 1637, 1571, 1547, 1375, 1275, 1175, 1128, 810.  
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HRMS (ESI): calcd. for C18H735Cl2F6N2O2 (M-H)- 466.97943; found 466.97933.  
Purity (HPLC): > 96% (λ = 210 nm), > 96% (λ = 254 nm). 
 
2-Cyano-3-(3,5-dichlorophenyl)-3-hydroxy-N-(4-(trifluoromethoxy)phenyl)acrylamide – 
SGA-86 (74) 
 
According to general procedure B, amide 32 (244 mg, 1.00 mmol, 1.0 eq.) in dry THF (10 mL), 
NaH (92.0 mg, 2.30 mmol, 2.3 eq.) and 3,5-dichlorobenzoyl chloride (43, 230 mg, 1.10 mmol, 
1.1 eq.) were used to give SGA-86 (74) as colorless solid (344 mg, 0.825 mmol, 83%).  
Rf = 0.53 (3:2 hexanes/acetone).  
m.p.: 195 °C.  
1H NMR (500 MHz, (CD3)2SO) δ/ppm = 12.02 (s, 1H, NH), 9.41 (s, 1H, OH), 7.69 – 7.64 (m, 
3H, 2’-H, 6’-H, 4’’-H), 7.59 (d, J = 1.9 Hz, 2H, 2’’-H, 6’’-H), 7.28 – 7.23 (m, 2H, 3’-H, 5’-H).  
13C NMR (126 MHz, (CD3)2SO) δ/ppm = 182.3 (C-3), 166.3 (C-1), 144.6 (C-1’’), 142.7 (C-4’), 
139.1 (C-1’), 133.5 (C-3’’, C-5’’), 128.6 (C-4’’), 126.1 (C-2’’, C-6’’), 123.0 (C-2), 121.6 (C-3’, C-
5’), 120.3 (q, JCF = 255.2 Hz, OCF3), 120.2 (C-2’, C-6’), 77.6 (CN).  
IR (ATR) ṽmax/cm-1 = 3304, 2218, 1614, 1536, 1506, 1262, 1208, 1164, 661.  
HRMS (ESI): calcd. for C17H835Cl2F3N2O3 (M-H)- 414.98696; found 414.98676.  
Purity (HPLC): > 96% (λ = 210 nm), > 96% (λ = 254 nm). 
 
N-(3-Chloro-2,4-difluorophenyl)-2-cyano-3-(3,5-dibromophenyl)-3-hydroxyacrylamide – 
SGA-90 (75) 
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According to general procedure B, amide 36 (231 mg, 1.00 mmol, 1.0 eq.) in dry THF (10 mL), 
NaH (92.0 mg, 2.30 mmol, 2.3 eq.) and 3,5-dibromobenzoic acid (308 mg, 1.10 mmol, 1.1 eq.; 
converted into the corresponding aryl chloride) were used to give SGA-90 (75) as light yellow 
solid (374 mg, 0.759 mmol, 76%).  
Rf = 0.16 (1:1 hexanes/acetone).  
m.p.: 192 °C.  
1H NMR (400 MHz, (CD3)2SO) δ/ppm = 12.33 (s, 1H, NH), 8.43 (td, J = 8.9, 6.0 Hz, 1H, 6’-H), 
7.86 (t, J = 1.7 Hz, 1H, 4’’-H), 7.74 (d, J = 1.7 Hz, 2H, 2’’-H, 6’’-H), 7.23 (td, J = 9.3, 2.0 Hz, 
1H, 5’-H).  
13C NMR (101 MHz, (CD3)2SO) δ/ppm = 182.7 (C-3), 166.3 (C-1), 152.1 (d, JCF = 242.4 Hz, C-
2’), 147.7 (d, JCF = 242.4 Hz, C-4’), 145.4 (C-1’’), 133.7 (C-4’’), 129.2 (C-2’’, C-6’’), 126.3 (dd, 
JCF = 10.3, 3.2 Hz, C-1’), 123.2 (C-2), 121.8 (C-3’’, C-5’’), 119.1 (dd, JCF = 7.5, 2.9 Hz, C-6’), 
111.5 (dd, JCF = 20.7, 3.6 Hz, C-5’), 108.3 – 107.7 (m, C-3’), 77.3 (CN).  
IR (ATR) ṽmax/cm-1 = 3297, 2205, 1586, 1531, 1496, 1022, 803, 750.  
HRMS (ESI): calcd. for C16H679Br2ClF2N2O2 (M-H)- 488.84581; found 488.84607.  
Purity (HPLC): > 96% (λ = 210 nm), > 96% (λ = 254 nm). 
 
2-Cyano-3-hydroxy-N-(4-(trifluoromethyl)phenyl)but-2-enamide (teriflunomide) – 
SGA-94 (76) 
 
According to general procedure B, SGA-34 (19, 228 mg, 1.00 mmol, 1.0 eq.) in dry THF 
(10 mL), NaH (92.0 mg, 2.30 mmol, 2.3 eq.) and acetyl chloride (78.5 µL, 1.10 mmol, 1.1 eq.) 
were used to give SGA-94 (76) as colorless crystals (206 mg, 0.761 mmol, 76%). Analytical 
data are in accordance with literature.[189]  
Rf = 0.65 (3:2 hexanes/acetone).  
m.p.: 224 °C. [lit.[189]: 230 – 232 °C] 
1H NMR (400 MHz, (CD3)2SO) δ/ppm = 12.28 (s, 1H, OH), 10.91 (s, 1H, NH), 7.81 – 7.72 (m, 
2H, 2’-H, 6’-H), 7.70 – 7.61 (m, 2H, 3’-H, 5’-H), 2.25 (s, 3H, 4-H).  
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13C NMR (101 MHz, (CD3)2SO) δ/ppm = 187.1 (C-3), 166.4 (C-1), 141.9 (C-1’), 125.9 (q, JCF = 
3.7 Hz, C-3’, C-5’), 124.4 (q, JCF = 271.3 Hz, CF3), 123.5 (q, JCF = 32.1 Hz, C-4’), 120.7 (C-2’, 
C-6’), 118.9 (C-2), 80.5 (CN), 23.5 (C-4).  
IR (ATR) ṽmax/cm-1 = 2335, 2214, 1551, 1319, 1154, 1113, 840, 679.  
HRMS (ESI): calcd. for C12H8F3N2O2 (M-H)- 269.05434; found 269.05423.  
Purity (HPLC): > 96% (λ = 210 nm), > 96% (λ = 254 nm). 
 
3-(3,5-Bis(trifluoromethyl)phenyl)-2-cyano-3-hydroxy-N-(p-tolyl)acrylamide – 
SGA-108 (77) 
 
According to general procedure B, amide 21 (174 mg, 1.00 mmol, 1.0 eq.) in dry THF (10 mL), 
NaH (92.0 mg, 2.30 mmol, 2.3 eq.) and 3,5-bis(trifluoromethyl)benzoyl chloride (199 µL, 
1.10 mmol, 1.1 eq.) were used to give SGA-108 (77) as light yellow crystals (208 mg, 0.502 
mmol, 50%).  
Rf = 0.28 (3:2 hexanes/acetone).  
m.p.: 183 °C.  
1H NMR (500 MHz, CDCl3) δ/ppm = 8.45 (s, 2H, 2’’-H, 6’’-H), 8.10 (s, 1H, 4’’-H), 7.86 (s, 1H, 
NH), 7.43 – 7.37 (m, 2H, 2’-H, 6’-H), 7.25 – 7.20 (m, 2H, 3’-H, 5’-H), 2.37 (s, 3H, CH3).  
13C NMR (126 MHz, CDCl3) δ/ppm = 180.4 (C-3), 167.9 (C-1), 136.7 (C-4’), 134.7 (C-1’’), 132.7 
(C-1’), 132.6 (q, JCF = 34.2 Hz, C-3’’, C-5’’), 130.1 (C-3’, C-5’), 128.6 (q, JCF = 3.1 Hz, C-2’’, C-
6’’), 126.3 (q, JCF = 3.7 Hz, C-4’’), 122.8 (q, JCF = 272.9 Hz, CF3), 121.8 (C-2’, C-6’), 116.5 (C-
2), 79.7 (CN), 21.2 (CH3).  
IR (ATR) ṽmax/cm-1 = 3276, 2213, 1538, 1278, 1129, 811, 681.  
HRMS (ESI): calcd. for C19H11F6N2O2 (M-H)- 413.07302; found 413.07301.  
Purity (HPLC): > 96% (λ = 210 nm), > 96% (λ = 254 nm). 
 
EXPERIMENTAL PART 
138 
3-(3,5-Bis(trifluoromethyl)phenyl)-2-cyano-3-hydroxy-N-(4-(trifluoromethyl)phenyl)-
acrylamide – SGA-111 (78) 
 
According to general procedure B, SGA-34 (19, 228 mg, 1.00 mmol, 1.0 eq.) in dry THF 
(10 mL), NaH (92.0 mg, 2.30 mmol, 2.3 eq.) and 3,5-bis(trifluoromethyl)benzoyl chloride 
(199 µL, 1.10 mmol, 1.1 eq.) were used to give SGA-111 (78) as colorless crystals (357 mg, 
0.762 mmol, 76%).  
Rf = 0.43 (3:2 hexanes/acetone).  
m.p.: 230 °C.  
1H NMR (400 MHz, (CD3)2SO) δ/ppm = 12.36 (s, 1H, NH), (m, 3H, 2’’-H, 6’’-H, 4’’-H), 7.87 – 
7.71 (m, 2H, 2’-H, 6’-H), 7.69 – 7.51 (m, 2H, 3’-H, 5’-H).  
13C NMR (101 MHz, (CD3)2SO) δ/ppm = 182.4 (C-3), 166.3 (C-1), 144.0 (C-1’’), 143.6 (C-1’), 
129.8 (q, JCF = 32.8 Hz, C-3’’, C-5’’), 128.1 (q, JCF = 4.7 Hz, C-2’’, C-6’’), 126.1 (q, JCF = 3.6 
Hz, C-3’, C-5’), 126.0 (q, JCF = 257.2 Hz, m-CF3), 123.4 (C-2), 123.3 (q, JCF = 271.6 Hz, p-CF3), 
122.7 (q, JCF = 4.0 Hz, C-4’’), 121.7 (q, JCF = 31.9 Hz, C-4’), 118.5 (C-2’, C-6’), 77.7 (CN).  
IR (ATR) ṽmax/cm-1 = 3289, 2218, 1349, 1323, 1284, 1186, 1139, 1114, 836.  
HRMS (ESI): calcd. for C19H8F9N2O2 (M-H)- 467.04475; found 467.04496.  
Purity (HPLC): > 96% (λ = 210 nm), > 96% (λ = 254 nm). 
 
2-Cyano-3-(3,5-dimethylphenyl)-3-hydroxy-N-(4-(trifluoromethyl)phenyl)acrylamide – 
SGA-112 (79) 
 
According to general procedure B, SGA-34 (19, 228 mg, 1.00 mmol, 1.0 eq.) in dry THF 
(10 mL), NaH (92.0 mg, 2.30 mmol, 2.3 eq.) and 3,5-dimethylbenzoyl chloride (163 µL, 
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1.10 mmol, 1.1 eq.) were used to give SGA-112 (79) as colorless crystals (175 mg, 0.486 
mmol, 49%).  
Rf = 0.48 (3:2 hexanes/acetone).  
m.p.: 187 °C.  
1H NMR (500 MHz, (CD3)2SO) δ/ppm = 12.08 (s, 1H, NH), 7.85 – 7.74 (m, 2H, 2’-H, 6’-H), 7.66 
– 7.58 (m, 2H, 3’-H, 5’-H), 7.25 (s, 2H, 2’’-H, 6’’-H), 7.09 (s, 1H,4’’-H), 2.30 (s, 6H, CH3).  
13C NMR (126 MHz, (CD3)2SO) δ/ppm = 186.5 (C-3), 167.8 (C-1), 143.6 (C-1’), 140.1 (C-1’’), 
137.2 (C-3’’, C-5’’), 131.8 (C-4’’), 126.4 (q, JCF = 3.8 Hz, C-3’, C-5’), 125.8 (C-2’’, C-6’’), 125.3 
(q, JCF = 270.8 Hz, CF3), 122.6 (q, JCF = 31.9 Hz, C-4’), 121.8 (C-2), 119.9 (C-2’, C-6’), 78.2 
(CN), 21.4 (CH3).  
IR (ATR) ṽmax/cm-1 = 3270, 2218, 1526.1319, 1247, 1157, 1110, 1066, 839.  
HRMS (ESI): calcd. for C19H14F3N2O2 (M-H)- 359.10129; found 359.10142.  
Purity (HPLC): > 96% (λ = 210 nm), > 96% (λ = 254 nm). 
 
2-Cyano-3-(3,5-dimethoxyphenyl)-3-hydroxy-N-(4-(trifluoromethyl)phenyl)acrylamide – 
SGA-113 (80) 
 
According to general procedure B, SGA-34 (19, 228 mg, 1.00 mmol, 1.0 eq.) in dry THF 
(10 mL), NaH (92.0 mg, 2.30 mmol, 2.3 eq.) and 3,5-dimethoxybenzoyl chloride (221 mg, 
1.10 mmol, 1.1 eq.) were used to give SGA-113 (80) as colorless crystals (309 mg, 0.789 
mmol, 79%).  
Rf = 0.54 (3:2 hexanes/acetone).  
m.p.: 203 °C.  
1H NMR (400 MHz, CDCl3) δ/ppm = 7.99 (s, 1H, NH), 7.73 – 7.63 (m, 4H, 2’-H, 6’-H, 3’-H, 5’-
H), 7.12 (d, J = 2.3 Hz, 2H, 2’’-H, 6’’-H), 6.69 (t, J = 2.3 Hz, 1H, 4’’-H), 3.85 (s, 6H, OCH3). 1 
3C NMR (101 MHz, CDCl3) δ/ppm = 184.1 (C-3), 168.7 (C-1), 161.0 (C-3’’, C-5’’), 139.1 (C-1’), 
133.9 (C-1’’), 127.8 (q, JCF = 33.2 Hz, C-4’), 126.7 (q, JCF = 3.8 Hz, C-3’, C-5’), 123.9 (q, JCF = 
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270.1 Hz, CF3), 121.0 (C-2’, C-6’), 117.5 (C-2), 106.4 (C-2’’, C-6’’), 106.0 (C-4’’), 78.5 (CN), 
55.8 (OCH3).  
IR (ATR) ṽmax/cm-1 = 3297, 2215, 1550, 1324, 1208, 1156, 1095, 1067, 834.  
HRMS (ESI): calcd. for C19H14F3N2O4 (M-H)- 391.09112; found 391.09140.  
Purity (HPLC): > 96% (λ = 210 nm), > 96% (λ = 254 nm). 
 
2-Cyano-3-hydroxy-3-(4-(trifluoromethoxy)phenyl)-N-(4-(trifluoromethyl)phenyl)-
acrylamide – SGA-114 (81) 
 
According to general procedure B, SGA-34 (19, 228 mg, 1.00 mmol, 1.0 eq.) in dry THF 
(10 mL), NaH (92.0 mg, 2.30 mmol, 2.3 eq.) and 4-(trifluoromethoxy)benzoyl chloride (173 µL, 
1.10 mmol, 1.1 eq.) were used to give SGA-114 (81) as colorless crystals (200 mg, 0.481 
mmol, 48%).  
Rf = 0.58 (3:2 hexanes/acetone).  
m.p.: 198 °C. [lit.[91]: 188 – 190 °C] 
1H NMR (500 MHz, CDCl3) δ/ppm = 8.12 – 8.05 (m, 2H, 2’’-H, 6’’-H), 7.96 (s, 1H, NH), 7.78 – 
7.62 (m, 4H, 2’-H, 6’-H, 3’-H, 5’-H), 7.42 – 7.32 (m, 2H, 3’’-H, 5’’-H).  
13C NMR (126 MHz, CDCl3) δ/ppm = 182.6 (C-3), 168.5 (C-1), 152.8 (C-4’’), 139.0 (C-1’), 130.7 
(C-2’’, C-6’’), 130.5 (C-1’’), 128.0 (q, JCF = 33.0 Hz, C-4’), 126.7 (q, JCF = 3.7 Hz, C-3’, C-5’), 
123.9 (q, JCF = 271.7 Hz, CF3), 121.0 (C-2’, C-6’), 120.8 (C-3’’, C-5’’), 120.6 (q, JCF = 259.4 Hz, 
OCF3), 117.3 (C-2), 78.6 (CN).  
IR (ATR) ṽmax/cm-1 = 3285, 2215, 1597, 1551, 1505, 1268, 1168, 1128, 839.  
HRMS (ESI): calcd. for C18H9F6N2O3 (M-H)- 415.05228; found 415.05225.  
Purity (HPLC): > 96% (λ = 210 nm), > 96% (λ = 254 nm). 
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2-Cyano-3-(3,5-dichlorophenyl)-3-hydroxy-N-methyl-N-(4-(trifluoromethyl)phenyl)-
acrylamide – SGA-115 (82) 
 
According to general procedure B, amide 41 (242 mg, 1.00 mmol, 1.0 eq.) in dry THF (10 mL), 
NaH (92.0 mg, 2.30 mmol, 2.3 eq.) and 3,5-dichlorobenzoyl chloride (43, 230 mg, 1.10 mmol, 
1.1 eq.) were used to give SGA-115 (82) as colorless solid (198 mg, 0.476 mmol, 48%).  
Rf = 0.67 (3:2 hexanes/acetone).  
m.p.: 147 °C.  
1H NMR (400 MHz, CDCl3) δ/ppm = 7.80 – 7.73 (m, 2H, 3’-H, 5’-H), 7.64 (d, J = 1.9 Hz, 2H, 
2’’-H, 6’’-H), 7.49 (t, J = 1.9 Hz, 1H, 4’’-H), 7.47 – 7.41 (m, 2H, 2’-H, 6’-H), 3.48 (s, 3H, CH3).  
13C NMR (101 MHz, CDCl3) δ/ppm = 184.2 (C-3), 170.4 (C-1), 145.2 (C-1’), 135.8 (C-1’’), 135.5 
(C-3’’, C-5’’), 132.5 (C-4’’), 131.4 (q, JCF = 32.9 Hz, C-4’), 127.8 (C-2’, C-6’), 127.5 (q, J = 3.6 
Hz, C-3’, C-5’), 127.2 (C-2’’, C-6’’), 123.7 (q, JCF = 272.6 Hz, CF3), 115.3 (C-2), 78.6 (CN), 39.9 
(CH3).  
IR (ATR) ṽmax/cm-1 = 3074, 2214, 1578, 1540, 1396, 1331, 1165, 1118, 807.  
HRMS (ESI): calcd. for C18H1035Cl2F3N2O2 (M-H)- 413.00769; found 413.00806.  
Purity (HPLC): > 96% (λ = 210 nm), > 96% (λ = 254 nm). 
 
2-Cyano-3-hydroxy-3-(pyridin-3-yl)-N-(4-(trifluoromethyl)phenyl)acrylamide – 
SGA-127 (83) 
 
According to general procedure B, SGA-34 (19, 228 mg, 1.00 mmol, 1.0 eq.) in dry THF 
(10 mL), NaH (92.0 mg, 2.30 mmol, 2.3 eq.) and nicotinoyl chloride hydrochloride (196 mg, 
1.10 mmol, 1.1 eq.) were used to give SGA-127 (83) as orange solid (169 mg, 0.506 mmol, 
51%).  
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Rf = 0.00 (3:2 hexanes/EtOAc).  
m.p.: 235 °C.  
1H NMR (400 MHz, (CD3)2SO) δ/ppm = 12.22 (s, 1H, NH), 9.12 (s, 1H, 2’’-H), 8.88 (d, J = 5.6 
Hz, 1H, 6’’-H), 8.70 (d, J = 8.0 Hz, 1H, 4’’-H), 8.04 (dd, J = 8.0, 5.6 Hz, 1H, 5’’-H), 7.83 – 7.72 
(m, 2H, 2’-H, 6’-H), 7.67 – 7.56 (m, 2H, 3’-H, 5’-H).  
13C NMR (101 MHz, (CD3)2SO) δ/ppm = 180.0 (C-3), 165.9 (C-1), 143.5 (C-1’), 143.3 (C-6’’), 
143.0 (C-4’’), 141.9 (C-2’’), 139.9 (C-3’’), 126.2 (C-5’’), 126.1 (q, JCF = 3.6 Hz, C-3’, C-5’), 124.2 
(q, JCF = 270.7 Hz, CF3), 123.3 (C-2), 121.8 (q, JCF = 32.0 Hz, C-4’), 118.5 (C-2’, C-6’), 78.5 
(CN).  
IR (ATR) ṽmax/cm-1 = 2356, 2191, 1533, 1317, 1105, 1060, 849, 698.  
HRMS (ESI): calcd. for C16H9F3N3O2 (M-H)- 332.06523; found 332.06517.  
Purity (HPLC): > 96% (λ = 210 nm), > 96% (λ = 254 nm). 
 
3-(3-Bromo-5-iodophenyl)-2-cyano-3-hydroxy-N-(4-(trifluoromethyl)phenyl)acrylamide 
– SGA-132 (84) 
 
According to general procedure B, SGA-34 (19, 228 mg, 1.00 mmol, 1.0 eq.) in dry THF 
(10 mL), NaH (92.0 mg, 2.30 mmol, 2.3 eq.) and 3-bromo-5-iodobenzoic acid (360 mg, 
1.10 mmol, 1.1 eq.; converted into the corresponding aryl chloride) were used to give SGA-
132 (84) as colorless crystals (332 mg, 0.618 mmol, 62%). 
Rf = 0.38 (3:2 hexanes/EtOAc).  
m.p.: 207 °C.  
1H NMR (400 MHz, (CD3)2SO) δ/ppm = 12.31 (s, 1H, NH), 7.97 (s, 1H, 4’’-H), 7.89 (s, 1H, 2’’-
H or 6’’-H), 7.78 – 7.72 (m, 3H, 2’-H, 6’-H and 2’’-H or 6’’-H), 7.63 – 7.55 (m, 2H, 3’-H, 5’-H).  
13C NMR (101 MHz, (CD3)2SO) δ/ppm = 182.6 (C-3), 166.4 (C-1), 145.4 (C-1’’), 143.6 (C-1’), 
139.1 (C-4’’), 135.0 (C-2’’ or C-6’’), 129.5 (C-2’’ or C-6’’), 126.0 (q, JCF = 3.8 Hz, C-3’, C-5’), 
123.9 (q, JCF = 263.8 Hz, CF3), 123.3 (C-2), 121.7 (q, JCF = 31.6 Hz, C-4’), 121.6 (C-3’’ or C-
5’’), 118.6 (C-2’, C-6’), 95.0 (C-3’’ or C-5’’), 77.4 (CN).  
EXPERIMENTAL PART 
143 
IR (ATR) ṽmax/cm-1 = 3276, 2213, 1532, 1318, 1163, 1112, 731.  
HRMS (ESI): calcd. for C17H879BrIF3N2O2 (M-H)- 534.87714; found 534.87813.  
Purity (HPLC): > 96% (λ = 210 nm), > 96% (λ = 254 nm). 
 
Methyl 4-(2-cyano-3-(3,5-dichlorophenyl)-3-hydroxyacrylamido)benzoate – 
SGA-133 (85) 
 
According to general procedure B, amide 33 (218 mg, 1.00 mmol, 1.0 eq.) in dry THF (10 mL), 
NaH (92.0 mg, 2.30 mmol, 2.3 eq.) and 3,5-dichlorobenzoyl chloride (43, 230 mg, 1.10 mmol, 
1.1 eq.) were used. The resulting solid was washed with hexanes, EtOH and water to give 
SGA-133 (85) as colorless solid (331 mg, 0.846 mmol, 85%).  
Rf = 0.15 (3:2 hexanes/acetone).  
m.p.: 234 °C.  
1H NMR (400 MHz, (CD3)2SO) δ/ppm = 12.33 (s, 1H, NH), 11.41 (s, 1H, OH), 7.90 – 7.83 (m, 
2H, 2-H, 6-H), 7.71 – 7.66 (m, 2H, 3-H, 5-H), 7.64 (t, J = 1.9 Hz, 1H, 4’’-H), 7.57 (d, J = 1.9 Hz, 
2H, 2’’-H, 6’’-H), 3.81 (s, 3H, CH3).  
13C NMR (101 MHz, (CD3)2SO) δ/ppm = 182.8 (C-3’), 166.3 (C-1’), 166.0 (CO), 145.1 (C-1’’), 
144.6 (C-4), 133.4 (C-3’’, C-5’’), 130.4 (C-2, C-6), 128.5 (C-4’’), 126.1 (C-2’’, C-6’’), 123.3 (C-
2’), 122.3 (C-1), 118.1 (C-3, C-5), 77.6 (CN), 51.7 (CH3).  
IR (ATR) ṽmax/cm-1 = 3304, 3093, 2215, 1727, 1591, 1534, 1415, 1283, 1262, 1112, 810, 766.  
HRMS (ESI): calcd. for C18H1135Cl2N2O4 (M-H)- 389.01014; found 389.01077.  
Purity (NMR): > 96% (λ = 210 nm), > 96% (λ = 254 nm). 
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3-(5-Chloropyridin-3-yl)-2-cyano-3-hydroxy-N-(4-(trifluoromethyl)phenyl)acrylamide – 
SGA-136 (86) 
 
According to general procedure B, SGA-34 (19, 228 mg, 1.00 mmol, 1.0 eq.) in dry THF 
(10 mL), NaH (92.0 mg, 2.30 mmol, 2.3 eq.) and 5-chloronicotinic acid (173 mg, 1.10 mmol, 
1.1 eq.; converted into the corresponding aryl chloride) were used to give SGA-136 (86) as 
light pink crystals (225 mg, 0.611 mmol, 61%).  
Rf = 0.15 (3:2 hexanes/acetone).  
m.p.: 221 °C.  
1H NMR (500 MHz, (CD3)2SO) δ/ppm = 12.33 (s, 1H, NH), 8.74 (s, 1H, 2’’-H or 4’’-H), 8.69 – 
8.64 (m, 1H, 6’’-H), 8.11 – 8.05 (m, 1H, 2’’-H or 4’’-H), 7.81 – 7.73 (m, 2H, 2’-H, 6’-H), 7.64 – 
7.55 (m, 2H, 3’-H, 5’-H).  
13C NMR (126 MHz, (CD3)2SO) δ/ppm = 181.7 (C-3), 166.2 (C-1), 147.9 (C-6’’), 146.1 (C-2’’ or 
C-4’’), 143.6 (C-1’), 138.8 (C-3’’ or C-5’’), 134.9 (C-2’’ or C-4’’), 130.5 (C-3’’ or C-5’’), 126.1 (q, 
JCF = 3.7 Hz, C-3’, C-5’), 124.6 (q, JCF = 271.0 Hz, CF3), 123.5 (C-2), 121.6 (q, JCF = 31.5 Hz, 
C-4’), 118.5 (C-2’, C-6’), 78.2 (CN).  
IR (ATR) ṽmax/cm-1 = 3285, 2225, 1539, 1308, 1113, 951, 838.  
HRMS (ESI): calcd. for C16H835ClF3N3O2 (M-H)- 366.02626; found 366.02652.  
Purity (HPLC): > 96% (λ = 210 nm), > 96% (λ = 254 nm). 
 
4-(2-Cyano-3-(3,5-dichlorophenyl)-3-hydroxyacrylamido)benzoic acid – SGA-137 (88) 
 
Ester 85 (95.0 mg, 0.243 mmol, 1.0 eq.) was dissolved in dioxane/H2O (3:1; 4.0 mL) and LiOH 
(61.2 mg, 2.43 mmol, 10 eq.) was added. The mixture was stirred at rt for 3 h, before 1 M aq. 
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HCl (5.0 mL) was added. The precipitate was filtered off, washed with cold water and dried to 
give SGA-137 (88) as colorless solid (59.6 mg, 0.158 mmol, 65%).  
Rf = 0.00 (3:2 hexanes/acetone).  
m.p.: 244 °C. 
1H NMR (500 MHz, (CD3)2SO) δ/ppm = 12.30 (s, 1H, NH), 7.87 – 7.81 (m, 2H, 2-H, 6-H), 7.68 
– 7.64 (m, 2H, 3-H, 5-H), 7.63 (t, J = 1.9 Hz, 1H, 4’’-H), 7.57 (d, J = 1.9 Hz, 2H, 2’’-H, 6’’-H).  
13C NMR (126 MHz, (CD3)2SO) δ/ppm = 182.7 (C-3’), 167.1 (CO), 166.3 (C-1’), 145.2 (C-1’’), 
144.2 (C-4), 133.4 (C-3’’, C-5’’), 130.5 (C-2, C-6), 128.4 (C-4’’), 126.1 (C-2’’, C-6’’), 123.5 (C-
1), 123.4 (C-2’), 118.0 (C-3, C-5), 77.5 (CN).  
IR (ATR) ṽmax/cm-1 = 3311, 2215, 1696, 1595, 1550, 1415, 1294, 855, 770.  
HRMS (ESI): calcd. for C17H935Cl2N2O4 (M-H)- 374.99449; found 374.99480.  
Purity (HPLC): > 96% (λ = 210 nm), > 96% (λ = 254 nm). 
 
2-Cyano-3-(3,5-dichlorophenyl)-3-hydroxy-N-(4-(trifluoromethyl)benzyl)acrylamide – 
SGA-138 (87) 
 
According to general procedure B, amide 42 (242 mg, 1.00 mmol, 1.0 eq.) in dry THF (10 mL), 
NaH (92.0 mg, 2.30 mmol, 2.3 eq.) and 3,5-dichlorobenzoyl chloride (43, 230 mg, 1.10 mmol, 
1.1 eq.) were used to give SGA-138 (87) as colorless solid (228 mg, 0.549 mmol, 55%).  
Rf = 0.70 (3:2 hexanes/acetone).  
m.p.: 173 °C.  
1H NMR (400 MHz, CDCl3) δ/ppm = 7.80 – 7.73 (m, 2H, 3’-H, 5’-H), 7.64 (d, J = 1.9 Hz, 2H, 
2’’-H, 6’’-H), 7.49 (t, J = 1.9 Hz, 1H, 4’’-H), 7.47 – 7.41 (m, 2H, 2’-H, 6’-H), 3.48 (s, 3H, CH3).  
13C NMR (101 MHz, CDCl3) δ/ppm = 184.2 (C-3), 170.4 (C-1), 145.2 (C-1’), 135.8 (C-1’’), 135.5 
(C-3’’, C-5’’), 132.5 (C-4’’), 131.4 (q, JCF = 32.9 Hz, C-4’), 127.8 (C-2’, C-6’), 127.5 (q, J = 3.6 
Hz, C-3’, C-5’), 127.2 (C-2’’, C-6’’), 123.7 (q, JCF = 272.6 Hz, CF3), 115.3 (C-2), 78.6 (CN), 39.9 
(CH3).  
IR (ATR) ṽmax/cm-1 = 3074, 2214, 1578, 1540, 1396, 1331, 1165, 1118, 807.  
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HRMS (ESI): calcd. for C18H1035Cl2F3N2O2 (M-H)- 413.00769; found 413.00806.  
Purity (HPLC): > 96% (λ = 210 nm), > 96% (λ = 254 nm). 
 
2-Cyano-3-(3,5-dichlorophenyl)-3-hydroxy-N-(4-(trifluoromethyl)phenyl)prop-2-
enethioamide – SGA-167 (91) 
 
According to a procedure published by Sjogren, et al. [91], a stirred solution of acetonitrile 
(2.01 mL, 38.2 mmol, 4.0 eq.) in THF (70 mL) was cooled to -78 °C, n-BuLi (2.5 M in hexanes, 
11.5 mL, 28.6 mmol, 3.0 eq.) was added over 10 minutes and the mixture was stirred for further 
15 minutes. A solution of 3,5-dichlorobenzoyl chloride (43, 2.00 g, 9.55 mmol, 1.0 eq.) in THF 
(25 mL) was added over 10 minutes. The mixture was allowed to warm to rt over 40 minutes, 
followed by addition of sat. aq. NH4Cl solution (50 mL). The reaction mixture was partitioned 
between 1 M HCl and hexanes/EtOAc (two times 25 mL/25 mL). The combined organic 
phases were dried over Na2SO4, filtered and concentrated in vacuo. The oily residue was 
redissolved in aq. NH3 solution (25%, 10 mL), then acidified with 1 M HCl (10 mL) and 
extracted thrice with EtOAc (15 mL). The combined organic layers were dried over Na2SO4, 
filtered and concentrated in vacuo and then recrystallized from hexanes to yield 3-(3,5-
dichlorophenyl)-3-oxopropanenitrile (89) as orange solid (526 mg, 2.46 mmol, 26%). Analytical 
data are in accordance with literature.[190] The product was used without further purification or 
characterization for the next step.  
Rf = 0.27 (9:1 hexanes/EtOAc).  
HRMS (EI): calcd. for C9H535Cl2NO (M)˙+ 212.9743; found 212.9742.  
According to general procedure B, propanenitrile 89 (526 mg, 2.46 mmol, 1.0 eq, instead of 
an amide) in dry THF (10 mL), NaH (108 mg, 2.70 mmol, 1.1 eq.) and 4-(trifluoromethyl)phenyl 
isothiocyanate (90, 524 mg, 2.85 mmol, 1.1 eq., instead of the acid chloride) were used to give 
SGA-167 (91) as golden solid (384 mg, 0.92 mmol, 37%).  
Rf = 0.33 (9:1 hexanes/EtOAc).  
m.p.: 188 °C.  
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1H NMR (400 MHz, (CD3)2SO) δ/ppm = 14.34 (s, 1H, NH), 8.12 (d, J = 8.5 Hz, 2H, 2’-H, 6’-H), 
7.72 – 7.63 (m, 3H, 3’-H, 5’-H, 4’’-H), 7.57 (d, J = 1.9 Hz, 2H, 2’’-H, 6’’-H). 
13C NMR (101 MHz, (CD3)2SO) δ/ppm = 189.4 (C-1), 182.0 (C-3), 144.9 (C-2), 144.1 (C-1’), 
133.4 (C-3’’, C-5’’), 128.6 (C-4’’), 126.1 (C-2’’, C-6’’), 125.5 (q, JCF = 3.7 Hz, C-3’, C-5’), 124.4 
(q, JCF = 271.3 Hz, CF3), 123.8 (q, JCF = 31.9 Hz, C-4’), 123.6 (C-1’’), 122.2 (C-2’, C-6’), 90.9 
(CN). 
IR (ATR) ṽmax/cm-1 = 3267, 2362, 2202, 1550, 1521, 1323, 1106, 1067, 807, 671, 585.  
HRMS (ESI): calcd. for C17H835Cl2F3N2OS (M-H)- 414.96920; found 414.96915.  
Purity (HPLC): > 96% (λ = 210 nm). 
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5.1.2.2 Synthesis of TPC2-A1-P (17) and analogs  
1-(5-Bromo-2-(trifluoromethoxy)phenyl)-2-chloroethan-1-one (102) 
 
4-Bromo-2-iodo-1-(trifluoromethoxy)benzene (108, 610 mg, 1.66 mmol, 1.0 eq.) was dissolved 
in dry THF (8.0 mL) and cooled to -78 °C, then n-BuLi (0.670 mL, 1.66 mmol, 1.0 eq.) was 
added dropwise. The mixture was stirred for 20 min at -78 °C and a solution of 2-chloro-N-
methoxy-N-methylacetamide (105, 700 mg, 4.99 mmol, 3.0 eq.) in dry THF (8.0 mL) was added 
slowly. The mixture was stirred for 1 h at -78 °C and then poured on sat. aq. NH4Cl solution. 
The mixture was extracted with pentane, the organic layer was washed with sat. aq. NaCl 
solution, dried using hydrophobic phase separation filter papers and filtered through a short 
silica column (eluent: pentane). The product was carefully concentrated under ambient 
pressure to yield a colorless oil (102, 221 mg, 0.696 mmol, 42%).  
Rf = 0.65 (9:1 hexanes/EtOAc).  
1H NMR (500 MHz, CDCl3) δ/ppm = 7.93 (d, J = 2.5 Hz, 1H, 6’-H), 7.71 (dd, J = 8.8, 2.5 Hz, 
1H, 4’-H), 7.25 – 7.22 (m, 1H, 3’-H), 4.61 (s, 2H, 2-H).  
13C NMR (126 MHz, CDCl3) δ/ppm = 190.5 (C-1), 146.2 (C-2’), 137.1 (C-4’), 134.1 (C-6’), 130.8 
(C-5’), 122.2 (C-3’), 120.8 (C-1’), 120.3 (q, JCF = 261 Hz, OCF3), 49.0 (C-2).  
IR (ATR) ṽmax/cm-1 = 1703, 1592, 1480, 1398, 1308, 1252, 1174, 1129, 1088, 822, 664.  
HRMS (EI): calcd. for C9H579Br35ClF3O2 (M)˙+ 315.9108; found 315.9106.  
Purity (HPLC): > 96% (λ = 210 nm), > 96% (λ = 254 nm). 
 
2-Bromo-1-(2-(trifluoromethoxy)phenyl)ethan-1-one (101) 
 
2'-(Trifluoromethoxy)acetophenone (103, 779 µL, 4.90 mmol, 1.0 eq.) was dissolved in CH2Cl2 
(10 mL), then p-toluenesulfonic acid (86.1 mg, 0.490 mmol, 0.10 eq.) and N-bromosuccinimide 
(872 mg, 4.90 mmol, 1.0 eq.) were added. The mixture was stirred for 24 h at rt, then sat. aq. 
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NaCl solution (10 mL) was added. The aqueous phase was extracted with CH2Cl2 (3 x 10 mL), 
dried using a hydrophobic filter paper and concentrated in vacuo. Purification by FCC 
(pentane/EtOAc 9:1) yielded bromoketone 101 (672 mg, 2.87 mmol, 49%) as light brown 
liquid. Analytical data are in accordance with literature[106]. 
 Rf = 0.58 (9:1 hexanes/EtOAc).  
1H NMR (400 MHz, CDCl3) δ/ppm = 7.81 (dd, J = 7.8, 1.8 Hz, 1H, 6’-H), 7.60 (ddd, J = 8.3, 
7.6, 1.8 Hz, 1H, 4’-H), 7.41 (td, J = 7.6, 1.0 Hz, 1H, 5’-H), 7.37 – 7.32 (m, 1H, 3’-H), 4.47 (s, 
2H, 2-H).  
13C NMR (101 MHz, CDCl3) δ/ppm = 191.5 (C-1), 147.1 (q, J = 1.7 Hz, C-2’), 134.3 (C-4’), 
131.6 (C-6’), 129.3 (C-1’), 127.3 (C-5’), 120.6 (C-3’), 120.5 (q, J = 260.1 Hz, OCF3), 35.1 (C-
2).  
IR (ATR) ṽmax/cm-1 = 1698, 1603, 1450, 1295, 1248, 1200, 1160.  
HRMS (EI): calcd. for C9H679BrF3O2 (M)˙+ 281.9498; found 281.9494.  
Purity (HPLC): > 96% (λ = 210 nm), > 96% (λ = 254 nm). 
 
Ethyl 5-(5-bromo-2-(trifluoromethoxy)phenyl)-1-(cyclohexylmethyl)-2-methyl-1H-
pyrrole-3-carboxylate – SGA-140 (109) 
 
Following general procedure C, ethyl acetoacetate (94, 88.0 µL, 0.693 mmol, 1.1 eq.) in dry 
THF (3.0 mL), NaH (37.8 mg, 0.945 mmol, 1.5 eq.) and a solution of ketone 102 (200 mg, 
0.630 mmol, 1.0 eq.) and KI (209 mg, 1.26 mmol, 2.0 eq.) in dry THF (3.0 mL) was used. Then, 
the residue was dissolved in acetic acid (6.0 mL) and cyclohexanemethanamine (95, 160 µL, 
1.26 mmol, 2.0 eq.) was added. FCC (hexanes/EtOAc 99:1) yielded SGA-140 (109) as 
colorless oil (140 mg, 0.287 mmol, 46%).  
Rf = 0.30 (9:1 hexanes/EtOAc).  
1H NMR (400 MHz, CDCl3) δ/ppm = 7.54 – 7.50 (m, 2H, 4’-H, 6’-H), 7.20 (ddt, J = 7.6, 3.0, 1.5 
Hz, 1H, 3’-H), 6.55 (s, 1H, 4-H), 4.27 (q, J = 7.1 Hz, 2H, CH2CH3), 3.59 (d, J = 7.1 Hz, 2H, CH2-
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cy), 2.59 (s, 3H, CH3), 1.60 – 1.54 (m, 3H, cy), 1.38 – 1.32 (m, 6H, CH2CH3, cy), 1.07 – 0.99 
(m, 3H, cy), 0.68 – 0.59 (m, 2H, cy).  
13C NMR (121 MHz, CDCl3) δ/ppm = 165.6 (COOEt), 146.3 (C-2’), 137.6 (C-3), 135.7 (C-6’), 
132.4 (C-4’), 129.0 (C-5’), 126.5 (C-5), 122.1 (C-3’), 120.3 (q, JCF = 260.2 Hz, OCF3), 119.9 
(C-1’), 112.6 (C-2), 112.2 (C-4), 59.6 (CH2CH3), 50.8 (CH2-cy), 39.0 (cy), 30.6 (cy), 26.2 (cy), 
25.7 (cy), 14.7 (CH2CH3), 12.1 (CH3).  
IR (ATR) ṽmax/cm-1 = 2976, 2925, 2854, 1699, 1254, 1240, 1206, 1190, 1169, 1080, 1064, 774.  
HRMS (ESI): calcd. for C22H2679BrF3NO3 (M+H)+ 488.10427; found 488.10459.  
Purity (HPLC): > 96% (λ = 210 nm), > 96% (λ = 254 nm). 
 
5-(5-Bromo-2-(trifluoromethoxy)phenyl)-1-(cyclohexylmethyl)-2-methyl-1H-pyrrole-3-
carboxylic acid – TPC2-A1-P (17) 
 
According to general procedure D, LiOH (51.6 mg, 2.05 mmol, 10 eq.) and a solution of SGA-
140 (140, 100 mg, 0.205 mmol, 1.0 eq.) in dioxane/H2O (3.0 mL) were used. After 2 h the 
reaction was completed and recrystallization from EtOH gave TPC2-A1-P (17) as colorless 
solid (51.2 mg, 0.111 mmol, 54%).  
Rf = 0.14 (9:1 hexanes/EtOAc).  
m.p.: 202 °C.  
1H NMR (500 MHz, CDCl3) δ/ppm = 11.34 (s, 1H, COOH), 7.56 – 7.51 (m, 2H, 3’-H, 4’-H), 7.23 
– 7.19 (m, 1H, 6’-H), 6.61 (s, 1H, 4-H), 3.60 (d, J = 7.1 Hz, 2H, CH2-cy), 2.60 (s, 3H, CH3), 1.62 
– 1.56 (m, 3H, cy), 1.40 – 1.33 (m, 3H, cy), 1.09 – 1.01 (m, 3H, cy), 0.68 – 0.61 (m, 2H, cy).  
13C NMR (126 MHz, CDCl3) δ/ppm = 170.0 (COOH), 146.4 (C-2’), 138.8 (C-2), 135.7 (C-6’), 
132.6 (C-4’), 128.8 (C-5’), 126.8 (C-5), 122.2 (C-3’), 120.3 (q, JCF = 259.3 Hz, OCF3), 119.9 
(C-1’), 112.9 (C-4), 111.6 (C-3), 50.9 (CH2-cy), 39.0 (cy), 30.6 (cy), 26.2 (cy), 25.7 (cy), 12.3 
(CH3).  
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IR (ATR) ṽmax/cm-1 = 2961, 2924, 2875, 2853, 2359, 2342, 1667, 1266, 1243, 1212, 1198, 
1171, 925, 779, 658.  
HRMS (ESI): calcd. for C20H2079BrF3NO3 (M-H)- 458.05841; found 458.05889.  
Purity (HPLC): > 96% (λ = 210 nm), > 96% (λ = 254 nm). 
 
Ethyl 1-(cyclohexylmethyl)-2-methyl-5-phenyl-1H-pyrrole-3-carboxylate – SGA-43 (96) 
 
Following general procedure C, ethyl acetoacetate (94, 42.0 µL, 3.30 mmol, 1.1 eq.) in dry 
THF (12 mL), NaH (180 mg, 4.50 mmol, 1.5 eq.) and a solution of 2-bromo-1-phenylethan-1-
one (92, 0.405 mL, 3.00 mmol, 1.0 eq.) and KI (996 mg, 6.00 mmol, 2.0 eq.) in dry THF (10 mL) 
were used. Then, the residue was dissolved in acetic acid (10 mL) and 
cyclohexanemethanamine (95, 781 µL, 6.00 mmol, 2.0 eq.) was added. FCC (hexanes/EtOAc 
9:1) yielded SGA-43 (96) as colorless solid (516 mg, 1.58 mmol, 53%). The compound is 
literature known, but no analytical data are available[103]. 
Rf = 0.49 (9:1 hexanes/EtOAc).  
m.p.: 91 °C.  
1H NMR (400 MHz, CDCl3) δ/ppm = 7.42 – 7.36 (m, 2H, Ph), 7.35 – 7.29 (m, 3H, Ph), 6.53 (s, 
1H, 4-H), 4.27 (q, J = 7.1 Hz, 2H, CH2CH3), 3.78 (d, J = 7.1 Hz, 2H, CH2-cy), 2.60 (s, 3H, CH3), 
1.58 – 1.49 (m, 3H, cy), 1.41 – 1.31 (m, 6H, cy, CH2CH3), 1.06 – 0.95 (m, 3H, cy), 0.69 – 0.57 
(m, 2H, cy).  
13C NMR (121 MHz, CDCl3) δ/ppm = 165.9 (COOEt), 137.0 (C-2), 134.1 (qPh), 133.7 (C-5), 
129.6 (Ph), 128.5 (Ph), 127.4 (Ph), 112.0 (C-3), 110.0 (C-4), 59.4 (CH2CH3), 50.2 (CH2-cy), 
39.0 (cy), 30.6 (cy), 26.2 (cy), 25.8 (cy), 14.7 (CH2CH3), 12.1 (CH3).  
IR (ATR) ṽmax/cm-1 = 2975, 2926, 2850, 1738, 1698, 1420, 1242, 1224, 1191, 1062, 772, 702.  
HRMS (ESI): calcd. for C21H28NO2 (M+H)+ 326.21146; found 326.21121.  
Purity (HPLC): > 96% (λ = 210 nm), > 96% (λ = 254 nm). 
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1-(Cyclohexylmethyl)-2-methyl-5-phenyl-1H-pyrrole-3-carboxylic acid – SGA-50 (100) 
 
According to general procedure D, LiOH (38.7 mg, 1.54 mmol, 10 eq.) and a solution of SGA-
43 (96, 50.0 mg, 0.154 mmol, 1.0 eq.) in dioxane/H2O (1.3 mL) were used. After 1 h the 
reaction was completed and gave SGA-50 (100) as colorless solid (40.4 mg, 0.136 mmol, 
88%). The compound is literature known, but no analytical data are available[103]. 
Rf = 0.18 (6:1 hexanes/EtOAc).  
m.p.: 196 °C.  
1H NMR (500 MHz, CDCl3) δ/ppm = 7.42 – 7.38 (m, 2H, Ph), 7.36 – 7.32 (m, 3H, Ph), 6.59 (s, 
1H, 4-H), 3.80 (d, J = 7.2 Hz, 2H, CH2), 2.62 (s, 3H, CH3), 1.59 – 1.52 (m, 3H, cy), 1.42 – 1.33 
(m, 3H, cy), 1.06 – 0.97 (m, 3H, cy), 0.68 – 0.59 (m, 2H, cy).  
13C NMR (101 MHz, CDCl3) δ/ppm = 170.8 (COOH), 138.3 (C-2), 134.5 (C-5), 133.5 (qPh), 
129.7 (Ph), 128.5 (Ph), 127.5 (Ph), 111.2 (C-3), 110.7 (C-4), 50.3 (CH2), 39.0 (cy), 30.6 (cy), 
26.2 (cy), 25.8 (cy), 12.3 (CH3).  
IR (ATR) ṽmax/cm-1 = 3030, 2971, 2921, 2848, 1738, 1660, 1533, 1435, 1364, 1267, 1227, 
1205, 778, 768, 712, 703.  
HRMS (ESI): calcd. for C19H22NO2 (M-H)- 296.16572; found 296.16560.  
Purity (HPLC): > 96% (λ = 210 nm), > 96% (λ = 254 nm). 
 
Ethyl 1-(cyclohexylmethyl)-5-(2,5-dichlorophenyl)-2-methyl-1H-pyrrole-3-carboxylate – 
SGA-48 (110) 
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Following general procedure C, ethyl acetoacetate (94, 208 µL, 1.65 mmol, 1.1 eq.) in dry THF 
(5.0 mL), NaH (90.0 mg, 2.25 mmol, 1.5 eq.) and a solution of 2-bromo-1-(2,5-
dichlorophenyl)ethan-1-one (402 mg, 1.50 mmol, 1.0 eq.) in dry THF (1.0 mL) were used. 
Then, the residue was dissolved in acetic acid (5.0 mL) and cyclohexanemethanamine (95, 
390 µL, 3.00 mmol, 2.0 eq.) was added. FCC (hexanes/EtOAc 9:1), followed by 
recrystallization from EtOH yielded SGA-48 (100) as colorless solid (271 mg, 0.686 mmol, 
46%).  
Rf = 0.48 (9:1 hexanes/EtOAc).  
m.p.: 98 °C.  
1H NMR (400 MHz, CDCl3) δ/ppm = 7.48 (d, J = 2.0 Hz, 1H, 6’-H), 7.29 (dd, J = 8.2, 2.0 Hz, 
1H, 4’-H), 7.25 (d, J = 9.1 Hz, 1H, 3’-H, collapses with chloroform), 6.51 (s, 1H, 4-H), 4.27 (q, 
J = 7.0 Hz, 2H, CH2CH3), 3.55 (d, J = 7.0 Hz, 2H, CH2-cy), 2.59 (s, 3H, CH3), 1.61 – 1.56 (m, 
3H, cy), 1.40 – 1.31 (m, 6H, cy, CH2CH3), 1.08 – 0.99 (m, 3H, cy), 0.68 – 0.58 (m, 2H, cy).  
13C NMR (101 MHz, CDCl3) δ/ppm = 165.6 (COOEt), 137.0 (C-2), 135.9 (C-1’ or C-5’), 134.8 
(C-1’ or C-5’), 134.0 (C-3’), 131.2 (C-2’), 129.6 (C-6’), 129.2 (C-5), 127.2 (C-4’), 112.2 (C-3), 
111.1 (C-4), 59.5 (CH2CH3), 50.8 (CH2-cy), 39.1 (cy), 30.6 (cy), 26.2 (cy), 25.8 (cy), 14.7 
(CH2CH3), 12.1 (CH3).  
IR (ATR) ṽmax/cm-1 = 2981, 2923, 2845, 1739, 1723, 1695, 1565, 1454, 1262, 1238, 1201, 
1159, 1076, 1066, 800, 771.  
HRMS (ESI): calcd. for C21H2635Cl2NO2 (M+H)+ 394.13351; found 394.13343.  
Purity (HPLC): > 96% (λ = 210 nm), > 96% (λ = 254 nm). 
 
1-(Cyclohexylmethyl)-5-(2,5-dichlorophenyl)-2-methyl-1H-pyrrole-3-carboxylic acid – 
SGA-52 (116) 
 
According to general procedure D, LiOH (63.9 mg, 2.54 mmol, 10 eq.) and a solution of SGA-
48 (110, 100 mg, 0.254 mmol, 1.0 eq.) in dioxane/H2O (1.3 mL) were used. After 1 h the 
reaction was completed and gave SGA-52 (116) as colorless solid (75.7 mg, 0.207 mmol, 
81%). 
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Rf = 0.18 (6:1 hexanes/EtOAc).  
m.p.: 180 °C.  
1H NMR (500 MHz, CDCl3) δ/ppm = 7.48 (d, J = 2.0 Hz, 1H, 6’-H), 7.30 (dd, J = 8.2, 2.0 Hz, 
1H, 4’-H), 7.26 (d, J = 8.2 Hz, 1H, 3’-H, collapses with chloroform), 6.57 (s, 1H, 4-H), 3.57 (d, 
J = 6.4 Hz, 2H, CH2-cy), 2.60 (s, 3H, CH3), 1.63 – 1.57 (m, 3H, cy), 1.42 – 1.36 (m, 3H, cy), 
1.08 – 1.00 (m, 3H, cy), 0.68 – 0.59 (m, 2H, cy).  
13C NMR (126 MHz, CDCl3) δ/ppm = 170.7 (COOH), 138.3 (C-2), 136.0 (C-1’ or C-5’), 135.0 
(C-1’ or C-5’), 134.0 (C-3’), 131.0 (C-2’), 129.7 (C-6’), 129.6 (C-5), 127.2 (C-4’), 111.8 (C-4), 
111.4 (C-3), 50.9 (CH2-cy), 39.0 (cy), 30.7 (cy), 26.2 (cy), 25.8 (cy), 12.3 (CH3).  
IR (ATR) ṽmax/cm-1 = 3014, 2970, 2926, 2851, 1739, 1659, 1449, 1365, 1270, 1228, 1217, 
1204, 814, 776.  
HRMS (ESI): calcd. for C19H2035Cl2NO2 (M-H)- 364.08766; found 364.08783.  
Purity (HPLC): > 96% (λ = 210 nm), > 96% (λ = 254 nm). 
 
Ethyl 5-(5-bromo-2-methoxyphenyl)-1-(cyclohexylmethyl)-2-methyl-1H-pyrrole-3-
carboxylate – SGA-54 (97) 
 
Following general procedure C, ethyl acetoacetate (94, 143 µL, 1.10 mmol, 1.1 eq.) in dry THF 
(5.0 mL), NaH (60.0 mg, 1.50 mmol, 1.5 eq.) and a solution of 2-bromo-1-(5-bromo-2-
methoxyphenyl)ethan-1-one (93, 308 mg, 1.00 mmol, 1.0 eq.) in dry THF (1.0 mL) were used. 
Then, the residue was dissolved in acetic acid (5.0 mL) and cyclohexanemethanamine (95, 
260 µL, 2.00 mmol, 2.0 eq.) was added. FCC (hexanes/EtOAc 9:1) yielded SGA-54 (97) as 
colorless solid (411 mg, 0.947 mmol, 95%).  
Rf = 0.37 (6:1 hexanes/EtOAc).  
m.p.: 83 °C.  
1H NMR (400 MHz, CDCl3) δ/ppm = 7.45 (dd, J = 8.7, 2.5 Hz, 1H, 4’-H), 7.37 (d, J = 2.5 Hz, 
1H, 6’-H), 6.81 (d, J = 8.7 Hz, 1H, 3’-H), 6.48 (s, 1H, 4-H), 4.25 (q, J = 7.1 Hz, 2H, CH2CH3), 
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3.76 (s, 3H, OCH3), 3.56 (d, J = 7.2 Hz, 2H, CH2-cy), 2.58 (s, 3H, CH3), 1.60 – 1.54 (m, 3H, 
cy), 1.41 – 1.29 (m, 6H, cy, CH2CH3), 1.08 – 0.97 (m, 3H, cy), 0.68 – 0.57 (m, 2H, cy).  
13C NMR (101 MHz, CDCl3) δ/ppm = 165.7 (COOEt), 156.6 (C-2’), 136.9 (C-2), 135.2 (C-6’), 
132.3 (C-4’), 128.9 (C-5), 124.8 (C-1’), 112.8 (C-5’), 112.6 (C-3’), 112.1 (C-3), 110.6 (C-4), 
59.3 (CH2CH3), 55.9 (OCH3), 50.9 (CH2-cy), 39.0 (cy), 30.7 (cy), 26.3 (cy), 25.8 (cy), 14.7 
(CH2CH3), 12.1 (CH3).  
IR (ATR) ṽmax/cm-1 = 2979, 2928, 2849, 1695, 1676, 1473, 1461, 1434, 1253, 1234, 1187, 
1176, 1060, 1048, 1027, 774, 619.  
HRMS (ESI): calcd. for C22H2979BrNO3 (M+H)+ 434.13253; found 434.13229.  
Purity (HPLC): > 96% (λ = 210 nm), > 96% (λ = 254 nm). 
 
5-(5-Bromo-2-methoxyphenyl)-1-(cyclohexylmethyl)-2-methyl-1H-pyrrole-3-carboxylic 
acid – SGA-55 (115) 
 
According to general procedure D, LiOH (88.4 mg, 3.51 mmol, 10 eq.) and a solution of SGA-
54 (97, 152 mg, 0.351 mmol, 1.0 eq.) in dioxane/H2O (1.3 mL) were used. After 1 h the reaction 
was completed and gave SGA-55 (115) as colorless solid (90.0 mg, 0.222 mmol, 63%). 
Rf = 0.72 (1:1 hexanes/EtOAc).  
m.p.: 224 °C.  
1H NMR (400 MHz, CDCl3) δ/ppm = 7.46 (dd, J = 8.8, 2.5 Hz, 1H, 4’-H), 7.38 (d, J = 2.5 Hz, 
1H, 6’-H), 6.82 (d, J = 8.8 Hz, 1H, 3’-H), 6.54 (s, 1H, 4-H), 3.77 (s, 3H, OCH3), 3.57 (d, J = 7.2 
Hz, 2H, CH2-cy), 2.59 (s, 3H, CH3), 1.62 – 1.52 (m, 3H, cy), 1.43 – 1.33 (m, 3H, cy), 1.10 – 
0.98 (m, 3H, cy), 0.69 – 0.58 (m, 2H, cy).  
13C NMR (101 MHz, CDCl3) δ/ppm = 170.4 (COOH), 156.6 (C-2’), 138.2 (C-2), 135.2 (C-6’), 
132.4 (C-4’), 129.3 (C-5), 124.6 (C-1’), 112.8 (C-5’), 112.6 (C-3’), 111.4 (C-4), 111.3 (C-3), 
55.9 (OCH3), 51.0 (CH2-cy), 39.0 (cy), 30.7 (cy), 26.3 (cy), 25.8 (cy), 12.3 (CH3).  
IR (ATR) ṽmax/cm-1 = 3027, 2969, 2926, 2850, 1739, 1658, 1476, 1462, 1442, 1362, 1274, 
1244, 1205, 1018, 808, 782, 619.  
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HRMS (ESI): calcd. for C20H2379BrNO3 (M-H)- 404.08668; found 404.08697.  
Purity (HPLC): > 96% (λ = 210 nm), > 96% (λ = 254 nm). 
 
Ethyl 1-(cyclohexylmethyl)-5-(4-fluorophenyl)-2-methyl-1H-pyrrole-3-carboxylate – 
SGA-59 (111) 
 
Following general procedure C, ethyl acetoacetate (94, 208 µL, 1.65 mmol, 1.1 eq.) in dry THF 
(5.0 mL), NaH (90.0 mg, 2.25 mmol, 1.5 eq.) and a solution of 2-chloro-1-(4-
fluorophenyl)ethan-1-one (259 mg, 1.50 mmol, 1.0 eq.) and KI (249 mg, 1.50 mmol, 1.0 eq.) 
in dry THF (3.0 mL) were used. Then, the residue was dissolved in acetic acid (5.0 mL) and 
cyclohexanemethanamine (95, 390 µL, 3.00 mmol, 2.0 eq.) was added. FCC (hexanes/EtOAc 
9:1) yielded SGA-59 (111) as yellow oil (499 mg, 1.45 mmol, 97%).  
Rf = 0.43 (9:1 hexanes/EtOAc).  
1H NMR (500 MHz, CDCl3) δ/ppm = 7.28 – 7.23 (m, 2H, 2’-H, 6’-H), 7.10 – 7.01 (m, 2H, 3’-H, 
5’-H), 6.48 (s, 1H, 4-H), 4.25 (q, J = 7.1 Hz, 2H, CH2CH3), 3.71 (d, J = 7.2 Hz, 2H, CH2-cy), 
2.57 (s, 3H, CH3), 1.58 – 1.48 (m, 3H, cy), 1.38 – 1.28 (m, 6H, cy, CH2CH3), 1.06 – 0.89 (m, 
3H, cy), 0.68 – 0.53 (m, 2H, cy).  
13C NMR (121 MHz, CDCl3) δ/ppm = 165.7 (COOH), 162.2 (d, JCF = 247.0 Hz, C-4’), 136.9 (C-
2), 132.8 (C-5), 131.3 (d, JCF = 8.0 Hz, C-2’, C-6’), 129.7 (d, JCF = 3.3 Hz, C-1’), 115.4 (d, JCF 
= 21.3 Hz, C-3’, C-5’), 111.9 (C-3), 110.0 (C-4), 59.3 (CH2CH3), 50.1 (CH2-cy), 39.0 (cy), 30.5 
(cy), 26.1 (cy), 25.7 (cy), 14.6 (CH2CH3), 12.0 (CH3).  
IR (ATR) ṽmax/cm-1 = 2977, 2925, 2853, 1693, 1242, 1227, 1218, 1195, 1152, 1062, 844, 811, 
774.  
HRMS (ESI): calcd. for C21H27FNO2 (M+H)+ 344.20203; found 344.20193.  
Purity (HPLC): > 96% (λ = 210 nm), > 96% (λ = 254 nm). 
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1-(Cyclohexylmethyl)-5-(4-fluorophenyl)-2-methyl-1H-pyrrole-3-carboxylic acid – 
SGA-66 (117) 
 
According to general procedure D, LiOH (169 mg, 6.71 mmol, 10 eq.) and a solution of SGA-
59 (111, 230 mg, 0.671 mmol, 1.0 eq.) in dioxane/H2O (3.0 mL) were used. After 2 h the 
reaction was completed and gave SGA-66 (117) as colorless solid (186 mg, 0.590 mmol, 88%). 
Rf = 0.24 (6:1 hexanes/EtOAc).  
m.p.: 171 °C.  
1H NMR (400 MHz, CDCl3) δ/ppm = 7.35 – 7.27 (m, 2H, 2’-H, 6’-H), 7.14 – 7.04 (m, 2H, 3’-H, 
5’-H), 6.57 (s, 1H, 4-H), 3.75 (d, J = 7.1 Hz, 2H, CH2-cy), 2.61 (s, 3H, CH3), 1.63 – 1.51 (m, 
3H, cy), 1.41 – 1.32 (m, 3H, cy), 1.08 – 0.97 (m, 3H, cy), 0.70 – 0.57 (m, 2H, cy).  
13C NMR (121 MHz, CDCl3) δ/ppm = 171.2 (COOH), 162.37 (d, JCF = 247.1 Hz, C-4’), 138.3 
(C-2), 133.3 (C-5), 131.42 (d, JCF = 8.1 Hz, C-2’, C-6’), 129.6 (d, JCF = 3.4 Hz, C-1’), 115.57 (d, 
JCF = 21.5 Hz, C-3’, C-5’), 111.2 (C-3), 110.8 (C-4), 50.3 (CH2-cy), 39.0 (cy), 30.6 (cy), 26.2 
(cy), 25.8 (cy), 12.3 (CH3).  
IR (ATR) ṽmax/cm-1 = 2927, 2854, 1739, 1652, 1568, 1494, 1449, 1265, 1223, 1203, 1158, 840, 
776, 582.  
HRMS (ESI): calcd. for C19H21FNO2 (M-H)- 314.15618; found 314.15635.  
Purity (HPLC): > 96% (λ = 210 nm), > 96% (λ = 254 nm). 
 
Ethyl 1-(cyclohexylmethyl)-5-(4-methoxyphenyl)-2-methyl-1H-pyrrole-3-carboxylate – 
SGA-61 (112) 
 
Following general procedure C, ethyl acetoacetate (94, 208 µL, 1.65 mmol, 1.1 eq.) in dry THF 
(5.0 mL), NaH (90.0 mg, 2.25 mmol, 1.5 eq.) and a solution of 2-bromo-1-(4-
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methoxyphenyl)ethan-1-one (344 mg, 1.50 mmol, 1.0 eq.) and KI (249 mg, 1.50 mmol, 1.0 eq.) 
in dry THF (3.0 mL) were used. Then, the residue was dissolved in acetic acid (5.0 mL) and 
cyclohexanemethanamine (95, 390 µL, 3.00 mmol, 2.0 eq.) was added. FCC (hexanes/EtOAc 
9:1), followed by recrystallization from EtOH yielded SGA-61 (112) as colorless solid (274 mg, 
0.770 mmol, 51%).  
Rf = 0.37 (9:1 hexanes/EtOAc).  
m.p.: 88 °C.  
1H NMR (500 MHz, CDCl3) δ/ppm = 7.25 – 7.21 (m, 2H, 2’-H, 6’-H), 6.95 – 6.89 (m, 2H, 3’-H, 
5’-H), 6.47 (s, 1H, 4-H), 4.27 (q, J = 7.1 Hz, 2H, CH2CH3), 3.84 (s, 3H, OCH3), 3.73 (d, J = 7.3 
Hz, 2H, CH2-cy), 2.58 (s, 3H, CH3), 1.60 – 1.51 (m, 3H, cy), 1.42 – 1.31 (m, 6H, cy, CH2CH3), 
1.07 – 0.96 (m, 3H, cy), 0.70 – 0.59 (m, 2H, cy).  
13C NMR (126 MHz, CDCl3) δ/ppm = 165.9 (COOH), 159.0 (C-4’), 136.6 (C-2), 133.8 (C-5), 
130.9 (C-2’, C-6’), 126.1 (C-1’), 113.9 (C-3’, C-5’), 111.7 (C-3), 109.5 (C-4), 59.3 (CH2CH3), 
55.4 (OCH3), 50.1 (CH2-cy), 39.0 (cy), 30.6 (cy), 26.2 (cy), 25.8 (cy), 14.7 (CH2CH3), 12.1 
(CH3).  
IR (ATR) ṽmax/cm-1 = 3016, 2970, 2928, 2847, 1739, 1693, 1568, 1532, 1496, 1443, 1424, 
1373, 1243, 1226, 1195, 1175, 1064, 1031, 835, 817, 795, 774.  
HRMS (ESI): calcd. for C22H30NO3 (M+H)+ 356.22202; found 356.22192.  
Purity (HPLC): > 96% (λ = 210 nm), > 96% (λ = 254 nm). 
 
1-(Cyclohexylmethyl)-5-(4-methoxyphenyl)-2-methyl-1H-pyrrole-3-carboxylic acid – 
SGA-67 (118) 
 
According to general procedure D, LiOH (78.7 mg, 3.12 mmol, 10 eq.) and a solution of SGA-
61 (112, 111 mg, 0.312 mmol, 1.0 eq.) in dioxane/H2O (1.3 mL) were used. After 2 h the 
reaction was completed and gave SGA-67 (118) as colorless solid (95.3 mg, 0.291 mmol, 
90%). 
Rf = 0.20 (6:1 hexanes/EtOAc).  
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m.p.: 198 °C.  
1H NMR (400 MHz, CDCl3) δ/ppm = 7.27 – 7.23 (m, 2H, 2’-H, 6’-H), 6.95 – 6.91 (m, 2H, 3’-H, 
5’-H), 6.54 (s, 1H, 4-H), 3.85 (s, 3H, OCH3), 3.75 (d, J = 7.2 Hz, 2H, CH2-cy), 2.60 (s, 3H, CH3), 
1.62 – 1.53 (m, 3H, cy), 1.43 – 1.33 (m, 3H, cy), 1.09 – 0.98 (m, 3H, cy), 0.70 – 0.59 (m, 2H, 
cy).  
13C NMR (101 MHz, CDCl3) δ/ppm = 171.3 (COOH), 159.0 (C-4’), 137.8 (C-2), 134.1 (C-5), 
131.0 (C-2’, C-6’), 125.9 (C-1’), 113.9 (C-3’, C-5’), 111.0 (C-3), 110.2 (C-4), 55.3 (OCH3), 50.2 
(CH2-cy), 38.9 (cy), 30.5 (cy), 26.2 (cy), 25.8 (cy), 12.3 (CH3).  
IR (ATR) ṽmax/cm-1 = 3027, 3002, 2970, 2925, 2849, 1738, 1652, 1569, 1535, 1494, 1435, 
1364, 1266, 1247, 1228, 1203, 840, 778.  
HRMS (ESI): calcd. for C20H24NO3 (M-H)- 326.17617; found 326.17633.  
Purity (HPLC): 93% (λ = 210 nm), > 96% (λ = 254 nm). 
 
Ethyl 1-(cyclohexylmethyl)-5-(2,4-difluorophenyl)-2-methyl-1H-pyrrole-3-carboxylate – 
SGA-62 (113) 
 
Following general procedure C, ethyl acetoacetate (94, 208 µL, 1.65 mmol, 1.1 eq.) in dry THF 
(5.0 mL), NaH (90.0 mg, 2.25 mmol, 1.5 eq.) and a solution of 2-chloro-1-(2,4-
difluorophenyl)ethan-1-one (286 mg, 1.50 mmol, 1.0 eq.) and KI (249 mg, 1.50 mmol, 1.0 eq.) 
in dry THF (3.0 mL) were used. Then, the residue was dissolved in acetic acid (5.0 mL) and 
cyclohexanemethanamine (95, 390 µL, 3.00 mmol, 2.0 eq.) was added. FCC (hexanes/EtOAc 
9:1) yielded SGA-62 (113) as yellow solid (424 mg, 1.17 mmol, 78%).  
Rf = 0.43 (9:1 hexanes/EtOAc).  
m.p.: 94 °C.  
1H NMR (500 MHz, CDCl3) δ/ppm = 7.27 (td, J = 8.4, 6.5 Hz, 1H, 6’-H), 6.96 – 6.85 (m, 2H, 3’-
H, 5’-H), 6.53 (s, 1H, 4-H), 4.26 (q, J = 7.1 Hz, 2H, CH2CH3), 3.60 (d, J = 7.1 Hz, 2H, CH2-cy), 
2.58 (s, 3H, CH3), 1.59 – 1.53 (m, 3H, cy), 1.38 – 1.30 (m, 6H, cy, CH2CH3), 1.06 – 0.98 (m, 
3H, cy), 0.68 – 0.58 (m, 2H, cy).  
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13C NMR (121 MHz, CDCl3) δ/ppm = 165.5 (COOEt), 162.9 (dd, JCF = 250.1, 11.6 Hz, C-4’), 
160.2 (dd, JCF = 248.9, 12.0 Hz, C-2’), 137.2 (C-2), 133.5 (dd, JCF = 9.4, 4.1 Hz, C-6’), 126.2 
(C-5), 117.6 (dd, JCF = 15.7, 3.9 Hz, C-1’), 112.3 (C-3), 111.6 (dd, JCF = 21.1, 3.7 Hz, C-5’), 
111.3 (C-4), 104.20 (t, JCF = 25.8 Hz, C-3’), 59.4 (CH2CH3), 50.6 (d, JCF = 3.0 Hz, CH2-cy), 39.0 
(cy), 30.5 (cy), 26.1 (cy), 25.7 (cy), 14.6 (CH2CH3), 12.0 (CH3).  
IR (ATR) ṽmax/cm-1 = 2971, 2929, 2848, 1739, 1698, 1571, 1426, 1371, 1235, 1199, 1067, 834.  
HRMS (ESI): calcd. for C21H26F2NO2 (M+H)+ 362.19261; found 362.19247.  
Purity (HPLC): > 96% (λ = 210 nm), > 96% (λ = 254 nm). 
 
1-(Cyclohexylmethyl)-5-(2,4-difluorophenyl)-2-methyl-1H-pyrrole-3-carboxylic acid  - 
SGA-68 (119) 
 
According to general procedure D, LiOH (167 mg, 6.61 mmol, 10 eq.) and a solution of SGA-
62 (113, 239 mg, 0.661 mmol, 1.0 eq.) in dioxane/H2O (1.3 mL) were used. After 1 h the 
reaction was completed and gave SGA-68 (119) as colorless solid (170 mg, 0.511 mmol, 77%). 
Rf = 0.29 (6:1 hexanes/EtOAc). 
m.p.: 168 °C.  
1H NMR (400 MHz, CDCl3) δ/ppm = 7.33 – 7.25 (m, 1H, 6’-H, collapses with chloroform), 6.98 
– 6.86 (m, 2H, 3’-H, 5’-H), 6.60 (s, 1H, 4-H), 3.62 (d, J = 7.1 Hz, 2H, CH2-cy), 2.61 (s, 3H, CH3), 
1.65 – 1.51 (m, 3H, cy), 1.49 – 1.32 (m, 3H, cy), 1.14 – 0.94 (m, 3H, cy), 0.72 – 0.56 (m, 2H, 
cy).  
13C NMR (101 MHz, CDCl3) δ/ppm = 171.0 (COOH), 163.0 (dd, JCF = 250.3, 11.6 Hz, C-4’), 
160.3 (dd, JCF = 249.0, 12.0 Hz, C-2’), 138.5 (C-2), 133.6 (dd, JCF = 9.5, 4.0 Hz, C-6’), 126.7 
(C-5), 117.5 (dd, JCF = 15.8, 3.8 Hz, C-1’), 112.0 (C-3), 111.7 (dd, JCF = 21.3, 3.8 Hz, C-5’), 
111.6 (C-4), 104.3 (t, JCF = 25.9 Hz, C-3’), 50.72 (d, JCF = 3.0 Hz, CH2-cy), 39.0 (cy), 30.6 (cy), 
26.2 (cy), 25.7 (cy), 12.2 (CH3).  
IR (ATR) ṽmax/cm-1 = 2970, 2926, 2854, 1739, 1666, 1573, 1450, 1433, 1364, 1265, 1239, 
1200, 1140, 778.  
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HRMS (ESI): calcd. for C19H20F2NO2 (M-H)- 332.14676; found 332.14697.  
Purity (HPLC): > 96% (λ = 210 nm), > 96% (λ = 254 nm). 
 
5-(5-Bromo-2-(trifluoromethoxy)phenyl)-2-methyl-1-pentyl-1H-pyrrole-3-carboxylic acid 
– SGA-149 (123) 
 
Following general procedure C, ethyl acetoacetate (94, 87.6 µL, 0.693 mmol, 1.1 eq.) in dry 
THF (4.0 mL), NaH (37.8 mg, 0.945 mmol, 1.5 eq.) and a solution of ketone 102 (200 mg, 
0.630 mmol, 1.0 eq.) and KI (105 mg, 0.630 mmol, 1.0 eq.) in dry THF (2.0 mL) was used. 
Then, the residue was dissolved in acetic acid (5.0 mL) and n-pentylamine (146 µL, 1.26 mmol, 
2.0 eq.) was added. FCC (hexanes/EtOAc 99:1) yielded ethyl 5-(5-bromo-2-
(trifluoromethoxy)phenyl)-2-methyl-1-pentyl-1H-pyrrole-3-carboxylate as colorless oil (81.5 
mg, 0.176 mmol). The product was used without further purification or characterization for the 
next step. 
Rf = 0.51 (9:1 hexanes/EtOAc).  
According to general procedure D, LiOH (44.4 mg, 1.76 mmol, 10 eq.) and a solution of this 
ester (81.5 mg, 0.176 mmol, 1.0 eq.) in dioxane/H2O (3.0 mL) were used. After 18 h the 
reaction was completed and gave SGA-149 (123) as colorless solid (40.5 mg, 0.0933 mmol, 
15% over two steps). 
Rf = 0.06 (9:1 hexanes/EtOAc).  
m.p.: 121 °C.  
1H NMR (400 MHz, CDCl3) δ/ppm = 7.57 – 7.51 (m, 2H, 4’’-H, 6’’-H), 7.24 – 7.20 (m, 1H, 3’’-
H), 6.61 (s, 1H, 4-H), 3.74 – 3.68 (m, 2H, 1’-H), 2.61 (s, 3H, CH3), 1.49 – 1.43 (m, 2H, 2’-H), 
1.19 – 1.06 (m, 4H, 3’-H, 4’-H), 0.80 (t, J = 7.2 Hz, 3H, 5’-H).  
13C NMR (101 MHz, CDCl3) δ/ppm = 169.4 (COOH), 146.6 (C-2’’), 138.3 (C-2), 135.9 (C-6’’), 
132.8 (C-4’’), 128.7 (C-5’’), 126.1 (C-5), 122.5 (q, J = 279.8 Hz, OCF3), 122.4 (C-3’’), 120.0 (C-
1’’), 112.7 (C-4), 111.4 (C-3), 44.7 (C-1’), 30.2 (C-2’), 28.8 (C-3’), 22.1 (C-4’), 13.9 (C-5’), 11.9 
(CH3).  
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IR (ATR) ṽmax/cm-1 = 2929, 1663, 1471, 1436, 1247, 1212, 1194, 1160, 781.  
HRMS (ESI): calcd. for C18H2079BrF3NO3 (M+H)+ 434.05732; found 434.05765.  
Purity (HPLC): > 96% (λ = 210 nm), > 96% (λ = 254 nm). 
 
1-Benzyl-5-(5-bromo-2-(trifluoromethoxy)phenyl)-2-methyl-1H-pyrrole-3-carboxylic 
acid – SGA-150 (125) 
 
Following general procedure C, ethyl acetoacetate (94, 104 µL, 0.821 mmol, 1.1 eq.) in dry 
THF (4.0 mL), NaH (44.8 mg, 1.12 mmol, 1.5 eq.) and a solution of ketone 102 (237 mg, 0.746 
mmol, 1.0 eq.) and KI (124 mg, 0.746 mmol, 1.0 eq.) in dry THF (2.0 mL) were used. Then, 
the residue was dissolved in acetic acid (5.0 mL) and benzylamine (204 µL, 1.87 mmol, 
2.5 eq.) was added. FCC (hexanes/EtOAc 97:3) yielded ethyl 5-(5-bromo-2-
(trifluoromethoxy)phenyl)-1-isopropyl-2-methyl-1H-pyrrole-3-carboxylate as colorless oil (107 
mg, 0.222 mmol). The product was used without further purification or characterization for the 
next step. 
Rf = 0.44 (9:1 hexanes/EtOAc).  
According to general procedure D, LiOH (55.9 mg, 2.22 mmol, 10 eq.) and a solution of this 
ester (107 mg, 0.222 mmol, 1.0 eq.) in dioxane/H2O (3.0  mL) were used. After 16 h the 
reaction was completed and gave SGA-150 (125) as colorless solid (34.4 mg, 0.0757 mmol, 
10% over two steps). 
Rf = 0.27 (9:1 hexanes/EtOAc).  
m.p.: 185 °C.  
1H NMR (400 MHz, CD2Cl2) δ/ppm = 11.12 (s, 1H, COOH), 7.51 (dd, J = 8.8, 2.5 Hz, 1H, 4’-
H), 7.39 (d, J = 2.5 Hz, 1H, 6’-H), 7.30 – 7.18 (m, 4H, 3’-H, Ph), 6.83 – 6.77 (m, 2H, Ph), 6.70 
(s, 1H, 4-H), 5.00 (s, 2H, CH2), 2.49 (s, 3H, CH3).  
13C NMR (121 MHz, CD2Cl2) δ/ppm = 169.9 (COOH), 147.0 (C-2’), 139.6 (C-2), 137.4 (C-1’), 
136.3 (C-6’), 133.4 (C-4’), 129.3 (Ph), 128.5 (qPh), 128.0 (Ph), 127.3 (C-5), 126.2 (Ph), 122.8 
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(C-3’), 120.8 (q, JCF = 258.7 Hz, OCF3), 120.3 (C-5’), 113.1 (C-4), 112.3 (C-3), 48.7 (CH2), 12.2 
(CH3).  
IR (ATR) ṽmax/cm-1 = 2925, 2360, 1670, 1249, 1223, 1198, 1171, 733.  
HRMS (ESI): calcd. for C20H1479BrF3NO3 (M-H)- 452.01146; found 452.01168.  
Purity (HPLC): > 96% (λ = 210 nm), > 96% (λ = 254 nm). 
 
5-(5-Bromo-2-(trifluoromethoxy)phenyl)-1-(cyclohexylmethyl)-2-ethyl-1H-pyrrole-3-
carboxylic acid – SGA-152 (121) 
 
Following general procedure C, ethyl propionylacetate (99.9 µL, 0.693 mmol, 1.1 eq.) in dry 
THF (4.0 mL), NaH (37.8 mg, 0.945 mmol, 1.5 eq.) and a solution of ketone 102 (200 mg, 
0.630 mmol, 1.0 eq.) and KI (105 mg, 0.630 mmol, 1.0 eq.) in dry THF (2.0 mL) were used. 
Then, the residue was dissolved in acetic acid (5.0 mL) and cyclohexanemethanamine (95, 
164 µL, 1.26 mmol, 2.0 eq.) was added. FCC (hexanes/EtOAc 99:1) yielded ethyl 5-(5-bromo-
2-(trifluoromethoxy)phenyl)-1-(cyclohexylmethyl)-2-ethyl-1H-pyrrole-3-carboxylate as 
colorless oil (98.0 mg, 0.195 mmol). The product was used without further purification or 
characterization for the next step. 
Rf = 0.58 (9:1 hexanes/EtOAc).  
According to general procedure D, LiOH (49.2 mg, 1.95 mmol, 10 eq.) and a solution of this 
ester (98.0 mg, 0.195 mmol, 1.0 eq.) in dioxane/H2O (3.0 mL) were used. After 18 h the 
reaction was completed and gave SGA-152 (121) as yellow solid (30.8 mg, 0.0649 mmol, 9% 
over two steps). 
Rf = 0.24 (9:1 hexanes/EtOAc).  
m.p.: 152 °C.  
1H NMR (500 MHz, CDCl3) δ/ppm = 11.35 (s, 1H, COOH), 7.57 – 7.50 (m, 2H, 4’-H, 6’-H), 7.20 
(dd, J = 8.6, 1.4 Hz, 1H, 3’-H), 6.61 (s, 1H, 4-H), 3.61 (d, J = 7.2 Hz, 2H, CH2-cy), 3.04 (q, J = 
7.4 Hz, 2H, CH2CH3), 1.64 – 1.54 (m, 3H, cy), 1.39 – 1.31 (m, 3H, cy), 1.23 (t, J = 7.4 Hz, 3H, 
CH2CH3), 1.08 – 0.99 (m, 3H, cy), 0.70 – 0.60 (m, 2H, cy).  
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13C NMR (121 MHz, CDCl3) δ/ppm = 169.8 (COOH), 146.3 (C-2’), 145.1 (C-2), 135.5 (C-4’ or 
C-6’), 132.5 (C-4’ or C-6’), 129.1 (C-1’), 126.7 (C-5), 122.3 (C-3’), 120.3 (q, JCF = 259.2 Hz, 
OCF3), 120.0 (C-5’), 113.2 (C-4), 110.8 (C-3), 50.9 (CH2-cy), 39.6 (cy), 30.7 (cy), 26.2 (cy), 
25.8 (cy), 19.2 (CH2CH3), 14.5 (CH2CH3).  
IR (ATR) ṽmax/cm-1 = 2927, 2359, 1659, 1469, 1441, 1250, 1212, 1192, 1172.  
HRMS (ESI): calcd. for C21H2279BrF3NO3 (M-H)- 472.07406; found 472.07418.  
Purity (HPLC): > 96% (λ = 210 nm), > 96% (λ = 254 nm). 
 
5-(5-Bromo-2-(trifluoromethoxy)phenyl)-1-isopropyl-2-methyl-1H-pyrrole-3-carboxylic 
acid – SGA-153 (124) 
 
Following general procedure C, ethyl acetoacetate (94, 87.6 µL, 0.693 mmol, 1.1 eq.) in dry 
THF (4.0 mL), NaH (37.8 mg, 0.945 mmol, 1.5 eq.) and a solution of ketone 102 (200 mg, 
0.630 mmol, 1.0 eq.) and KI (105 mg, 0.630 mmol, 1.0 eq.) in dry THF (2.0 mL) were used. 
Then, the residue was dissolved in acetic acid (5.0 mL) and isopropylamine (108 µL, 
1.26 mmol, 2.0 eq.) was added. FCC (hexanes/EtOAc 99:1) yielded ethyl 5-(5-bromo-2-
(trifluoromethoxy)phenyl)-1-isopropyl-2-methyl-1H-pyrrole-3-carboxylate as colorless oil (65.9 
mg, 0.152 mmol). The product was used without further purification or characterization for the 
next step. 
Rf = 0.55 (9:1 hexanes/EtOAc).  
According to general procedure D, LiOH (38.3 mg, 1.52 mmol, 10 eq.) and a solution of this 
ester (65.9 mg, 0.152 mmol, 1.0 eq.) in dioxane/H2O (3.0 mL) were used. After 18 h the 
reaction was completed and gave SGA-153 (124) as colorless solid (32.4 mg, 0.0798 mmol, 
12% over two steps). 
Rf = 0.11 (9:1 hexanes/EtOAc).  
m.p.: 192 °C.  
1H NMR (400 MHz, C3D6O) δ/ppm = 7.75 (dd, J = 8.8, 2.6 Hz, 1H, 4’-H), 7.65 (d, J = 2.6 Hz, 
1H, 6’-H), 7.44 (dq, J = 8.8, 1.5 Hz, 1H, 3’-H), 6.47 (s, 1H, 4-H), 4.27 (p, J = 7.0 Hz, 1H, CH), 
2.72 (s, 3H, CH3), 1.45 (d, J = 7.0 Hz, 6H, CH(CH3)2).  
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13C NMR (101 MHz, C3D6O) δ/ppm = 166.4 (COOH), 147.7 (C-2’), 137.5 (C-2), 137.0 (C-6’), 
134.0 (C-4’), 130.5 (C-1’), 126.4 (C-5), 123.7 (q, J = 257.6 Hz, OCF3), 123.5 (C-3’), 120.6 (C-
5’), 113.9 (C-3), 113.0 (C-4), 50.2 (CH), 22.0 (CH(CH3)2), 13.0 (CH3).  
IR (ATR) ṽmax/cm-1 = 2936, 2358, 1672, 1248, 1214, 1200, 1166.  
HRMS (ESI): calcd. for C16H1479BrF3NO3 (M-H)- 404.01146; found 404.01164.  
Purity (HPLC): > 96% (λ = 210 nm), > 96% (λ = 254 nm). 
 
5-(5-Bromo-2-(trifluoromethoxy)phenyl)-1-(cyclohexylmethyl)-2-phenyl-1H-pyrrole-3-
carboxylic acid – SGA-154 (122) 
 
Following general procedure C, ethyl benzoylacetate (134 µL, 0.693 mmol, 1.1 eq.) in dry THF 
(4.0 mL), NaH (37.8 mg, 0.945 mmol, 1.5 eq.) and a solution of ketone 102 (200 mg, 0.630 
mmol, 1.0 eq.) and KI (105 mg, 0.630 mmol, 1.0 eq.) in dry THF (2.0 mL) were used. Then, 
the residue was dissolved in acetic acid (5.0 mL) and cyclohexanemethanamine (95, 328 µL, 
2.52 mmol, 4.0 eq.) was added. FCC (hexanes/EtOAc 99:1) yielded ethyl 5-(5-bromo-2-
(trifluoromethoxy)phenyl)-1-(cyclohexylmethyl)-2-phenyl-1H-pyrrole-3-carboxylate as yellow 
solid (151 mg, 0.274 mmol). The product was used without further purification or 
characterization for the next step. 
Rf = 0.50 (9:1 hexanes/EtOAc).  
According to general procedure D, LiOH (69.2 mg, 2.74 mmol, 10 eq.) and a solution of this 
ester (151 mg, 0.274 mmol, 1.0 eq.) in dioxane/H2O (3.0 mL) were used. After 18 h the reaction 
was completed and gave SGA-154 (122) as yellow solid (91.5 mg, 0.175 mmol, 28% over two 
steps). 
Rf = 0.12 (9:1 hexanes/EtOAc).  
m.p.: 170 °C.  
1H NMR (400 MHz, CDCl3) δ/ppm = 7.61 (d, J = 2.5 Hz, 1H, 6’-H), 7.55 (dd, J = 8.7, 2.5 Hz, 
1H, 4’-H), 7.47 – 7.41 (m, 3H, Ph), 7.39 – 7.35 (m, 2H, Ph), 7.23 (dq, J = 8.7, 1.3 Hz, 1H, 3’-
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H), 6.74 (s, 1H, 4-H), 3.56 (d, J = 7.4 Hz, 2H, CH2-cy), 1.48 – 1.42 (m, 3H, cy), 1.11 – 1.05 (m, 
2H, cy), 1.03 – 0.95 (m, 1H, cy), 0.90 – 0.82 (m, 3H, cy), 0.43 – 0.32 (m, 2H, cy).  
13C NMR (101 MHz, CDCl3) δ/ppm = 167.7 (COOH), 146.1 (C-2’), 141.7 (C-2), 135.2 (C-6’), 
132.7 (C-4’), 131.7 (C-5, C-1’, C-5’ or qPh), 131.0 (Ph), 128.8 (C-5, C-1’, C-5’ or qPh), 128.7 
(Ph), 128.3 (Ph), 122.4 (C-3’), 120.4 (q, JCF = 266.3 Hz, OCF3), 120.2 (C-5, C-1’, C-5’ or qPh), 
113.8 (C-4), 112.7 (C-3), 52.0 (CH2-cy), 38.7 (cy), 30.3 (cy), 26.1 (cy), 25.6 (cy). One 
quaternary carbon is missing.  
IR (ATR) ṽmax/cm-1 = 2915, 2335, 1667, 1487, 1248, 1208, 1169, 1127, 796, 697.  
HRMS (ESI): calcd. for C25H2279BrF3NO3 (M-H)- 520.07406; found 520.07418.  
Purity (HPLC): > 96% (λ = 210 nm), > 96% (λ = 254 nm). 
 
Ethyl 1-(cyclohexylmethyl)-2-methyl-5-(2-(trifluoromethoxy)phenyl)-1H-pyrrole-3-
carboxylate (114) 
 
Following general procedure C, ethyl acetoacetate (94, 123 µL, 0.972 mmol, 1.1 eq.) in dry 
THF (4.0 mL), NaH (53.0 mg, 1.32 mmol, 1.5 eq.) and a solution of ketone 101 (250 mg, 0.883 
mmol, 1.0 eq.) and KI (147 mg, 0.883 mmol, 1.0 eq.) in dry THF (2.0 mL) were used. Then, 
the residue was dissolved in acetic acid (5.0 mL) and cyclohexanemethanamine (95, 230 µL, 
1.77 mmol, 2.0 eq.) was added. FCC (hexanes/EtOAc 9:1) yielded ester 114 as colorless solid 
(345 mg, 0.845 mmol, 95%).  
Rf = 0.46 (9:1 hexanes/EtOAc).  
m.p.: 66 °C.  
1H NMR (100 MHz, CDCl3) δ/ppm = 7.44 – 7.29 (m, 4H, 3’-H, 4’-H, 5’-H, 6’-H), 6.53 (s, 1H, 4-
H), 4.27 (q, J = 7.1 Hz, 2H, CH2CH3), 3.59 (d, J = 7.1 Hz, 2H, CH2-cy), 2.59 (s, 3H, CH3), 1.59 
– 1.52 (m, 3H, cy), 1.40 – 1.32 (m, 6H, cy, CH2CH3), 1.06 – 0.94 (m, 3H, cy), 0.67 – 0.54 (m, 
2H, cy).  
13C NMR (101 MHz, CDCl3) δ/ppm = 165.8 (COOEt), 147.4 (C-2’), 137.1 (C-2), 133.4 (C-4’, 
C-5’ or C-6’), 129.6 (C-4’, C-5’ or C-6’), 127.9 (C-5), 126.9 (C-1’), 126.7 (C-4’, C-5’ or C-6’), 
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120.5 (q, JCF = 257.4 Hz, OCF3), 120.4 (C-3’), 112.2 (C-3), 111.4 (C-4), 59.5 (CH2CH3), 50.7 
(CH2-cy), 39.0 (cy), 30.6 (cy), 26.2 (cy), 25.8 (cy), 14.7 (CH2CH3), 12.1 (CH3).  
IR (ATR) ṽmax/cm-1 = 1934, 1692, 1447, 1422, 1242, 1192, 1155, 1059, 769.  
HRMS (ESI): calcd. for C22H27F3NO3 (M+H)+ 410.19375; found 410.19336.  
Purity (HPLC): > 96% (λ = 210 nm), > 96% (λ = 254 nm). 
 
1-(Cyclohexylmethyl)-2-methyl-5-(2-(trifluoromethoxy)phenyl)-1H-pyrrole-3-carboxylic 
acid – SGA-162 (120) 
 
According to general procedure D, LiOH (142 mg, 5.62 mmol, 10 eq.) and a solution of ester 
114 (230 mg, 0.562 mmol, 1.0 eq.) in dioxane/H2O (3.0 mL) were used. After 2 h the reaction 
was completed and gave SGA-162 (120) as colorless solid (199 mg, 0.523 mmol, 93%). 
Rf = 0.11 (9:1 hexanes/EtOAc). 
m.p.: 170 °C.  
1H NMR (400 MHz, CDCl3) δ/ppm = 11.13 (s, 1H, COOH), 7.46 – 7.30 (m, 4H, 3’-H, 4’-H, 5’-
H, 6’-H), 6.59 (s, 1H, 4-H), 3.60 (d, J = 7.1 Hz, 2H, CH2-cy), 2.61 (s, 3H, CH3), 1.61 – 1.52 (m, 
3H, cy), 1.41 – 1.31 (m, 3H, cy), 1.09 – 0.96 (m, 3H, cy), 0.67 – 0.55 (m, 2H, cy).  
13C NMR (101 MHz, CDCl3) δ/ppm = 169.9 (COOH), 147.4 (C-2’), 138.3 (C-2), 133.4 (C-4’, 
C-5’ or C-6’), 129.8 (C-4’, C-5’ or C-6’), 128.3 (C-5), 126.8 (C-4’, C-5’ or C-6’), 126.7 (C-1’), 
120.5 (q, JCF = 260.2 Hz, OCF3), 120.4 (C-4’), 112.1 (C-4), 111.2 (C-3), 50.8 (CH2-cy), 38.9 
(cy), 30.6 (cy), 26.2 (cy), 25.7 (cy), 12.3 (CH3).  
IR (ATR) ṽmax/cm-1 = 2927, 1642, 1473, 1444, 1249, 1199, 1156, 776, 759.  
HRMS (ESI): calcd. for C20H21F3NO3 (M-H)- 380.14790; found 380.14805.  
Purity (HPLC): > 96% (λ = 210 nm). 
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5.2 Preparation of TPC2 inhibitors 
5.2.1 General procedures  
General Procedure E – Protection  
Following a general procedure published by Schrittwieser et al.[149], the appropriate amines or 
phenols (1.0 eq.) were dispersed in dry CH2Cl2 and cooled to 0 °C, followed by dropwise 
addition of NEt3 (1.5-3.5 eq.) and ethyl chloroformate (162, 1.3-2.5 eq.). The reaction mixture 
was stirred at rt or was refluxed for 4-72 h, before water was added. The mixture was extracted 
thrice with CH2Cl2, the combined organic layers were dried over Na2SO4 and concentrated in 
vacuo. Purification was accomplished by flash column chromatography (FCC) to yield 
carbamates and carbonates. 
 
General Procedure F – Wittig reaction 
(Methoxymethyl)-triphenylphosphonium chloride (1.2 eq.) was suspended in dry THF and 
cooled to -4 °C, before LDA (20% in THF/ethylbenzene/heptane, 1.0-1.2 eq.) was added 
dropwise. The mixture was stirred for 20 min. at -4 °C, followed by slow, dropwise addition of 
a solution of the appropriate aldehyde (1.0 eq.) in THF. The solution was stirred for 16-50 h, 
then poured on water and the mixture was extracted thrice with CH2Cl2. The combined organic 
layers were dried over Na2SO4, filtered and concentrated in vacuo. The crude product was 
purified by FCC to give the desired cis/trans-enol ethers. The products were directly used for 
the next step without further analysis. 
 
General Procedure G – N-acyl Pictet-Spengler reaction 
Carbamate (1.0 eq.) and enol ether (1.0-1.2 eq.) were dissolved in dry CH2Cl2, 4 Å molecular 
sieves (1.00 g per 20 mL solvent) was added and the mixture was cooled to 0 °C, before TFA 
(10-11 eq.) was added dropwise. The mixture was allowed to warm to rt and stirred for 18-90 h, 
before the molecular sieves was removed by filtration and sat. aq. NaHCO3 solution was 
added. The mixture was extracted thrice with CH2Cl2, the combined organic layers were 
washed with 2 M aq. HCl solution and brine, dried over Na2SO4, filtered and concentrated in 
vacuo. Purification was accomplished by FCC to yield the desired racemic 
tetrahydroisoquinolines. 
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General Procedure H – Lithium alanate reductions of nitroolefins, carbamates and 
carbonates 
According to Cava et al.[152], LiAlH4 (7-12 eq.) was suspended in dry THF and a solution of 
carbamate (1.0 eq.) in dry THF was added dropwise and the suspension was refluxed for 3-
20 h. The mixture was allowed to cool to rt and Na2SO4 x 10 H2O was added in small portions 
under vigorous stirring over 20 minutes. Water was added and the mixture was extracted thrice 
with EtOAc. The combined organic layers were extracted with 2 M aq. HCl solution, the acidic 
phase was neutralized with sat. aq. NaHCO3 solution and extracted thrice with EtOAc again. 
This organic layer was dried over Na2SO4 and concentrated in vacuo to give tertiary amines if 
not otherwise described.  
 
General Procedure I – Chan-Evans-Lam coupling 
According to Evans et al.[155], phenols (1.0 eq), Cu(OAc)2 (1.1 eq. per phenolic group), boronic 
acid (3.0 eq. per phenolic group) and 4 Å molecular sieves (1.00 g per 40 mL solvent) were 
suspended in dry CH2Cl2 and a mixture of NEt3 and pyridine (1:1, 2.5 eq. each) was added 
dropwise. The reaction mixture was stirred for 13-22 h at rt under ambient atmosphere, 
followed by filtration through a celite pad. The organic filtrate was washed with sat. aq. NaHCO3 
solution, 10% aq. citric acid solution and brine, dried over Na2SO4, filtered and concentrated 
in vacuo. The crude products were purified by FCC or HPLC to obtain the desired diaryl ethers.  
 
General Procedure J – Formation of hydrochloride-salts 
To receive solid and stable compounds for biological experiments, the tertiary amines were 
dissolved in 1.25 M methanolic HCl solution (3.0 mL per 100 mg amine) and concentrated in 
vacuo to yield the amorphous hydrochloride salts as solids. Melting points were obtained from 
the hydrochloride salts, remaining analytical data from the free amines, unless stated 
otherwise. 
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5.2.2 Synthetic procedures  
5.2.2.1 Synthesis of arylethylamine building blocks  
 
(E)-1-(Benzyloxy)-2-methoxy-4-(2-nitrovinyl)benzene (173) 
 
Following a procedure published by Pouysegu et al.[148], 4-benzyloxy-3-methoxybenzaldehyde 
(172, 10.0 g, 41.3 mmol, 1.0 eq.) and ammonium acetate (2.80 g, 36.4 mmol, 0.90 eq.) were 
dissolved in glacial acetic acid (24 mL) and nitromethane (16.0 mL, 299 mmol, 7.4 eq.) was 
added under nitrogen atmosphere. The mixture was heated to reflux for 3 h. Water (5.0 mL) 
was added, the precipitate was collected by filtration and was washed with cold MeOH. The 
crude product was recrystallized from MeOH to yield nitroolefin 173 (7.08 g, 24.8 mmol, 62%) 
as yellow crystals. Analytical data are in accordance with literature. 
Rf = 0.46 (4:1 hexanes/acetone).  
m.p.: 123 °C. [lit.[148]: 124-125 °C] 
1H NMR (400 MHz, CDCl3) δ/ppm = 7.95 (d, J = 13.6 Hz, 1H, CHCHNO2), 7.51 (d, J = 13.6 
Hz, 1H, CHCHNO2), 7.44 – 7.32 (m, 5H, PhCH2), 7.10 (dd, J = 8.4, 2.0 Hz, 1H, 5-H), 7.02 (d, 
J = 2.0 Hz, 1H, 3-H), 6.92 (d, J = 8.4 Hz, 1H, 6-H), 5.22 (s, 2H, PhCH2), 3.93 (s, 3H, OCH3).  
13C NMR (101 MHz, CDCl3) δ/ppm = 152.1 (C-1), 150.2 (C-2), 139.4 (CHCHNO2), 136.2 (qPh), 
135.4 (CHCHNO2), 128.9 (Ph), 128.4 (Ph), 127.4 (Ph), 124.5 (C-5), 123.2 (C-4), 113.6 (C-3), 
111.0 (C-6), 71.0 (PhCH2), 56.3 (OCH3). 
IR (ATR) ṽmax/cm-1 = 3112, 3048, 2980, 2358, 1629, 1491, 1258, 1224, 1142, 976, 805, 746, 
697.  
HRMS (EI): calcd. for C16H15NO4 (M)•+ 285.0996; found 285.0994.  
Purity (HPLC): > 96% (λ = 210 nm). 
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2-(4-(Benzyloxy)-3-methoxyphenyl)ethan-1-amine (171) 
 
Similar to general procedure H, LiAlH4 (1.70 g, 44.8 mmol, 5.1 eq.) in dry THF (10 mL) and 
nitrovinyl (173, 2.53 g, 8.87 mmol, 1.0 eq.) in dry THF (20 mL) were used and the resulting 
mixture was stirred at 80 °C for 18 h. Amine 171 (1.44 g, 5.60 mmol, 63%) was isolated as 
yellow oil. Analytical data are in accordance with literature[148]. 
Rf = 0.30 (9:1 CH2Cl2/MeOH).  
1H NMR (400 MHz, CDCl3) δ/ppm = 7.46 – 7.41 (m, 2H, 2’-H, 6’-H), 7.39 – 7.34 (m, 2H, 3’-H, 
5’-H), 7.29 (ddd, J = 7.2, 4.8, 1.4 Hz, 1H, 4’-H), 6.82 (d, J = 8.1 Hz, 1H, 5-H), 6.75 (d, J = 2.0 
Hz, 1H, 2-H), 6.67 (dd, J = 8.1, 2.0 Hz, 1H, 6-H), 5.13 (s, 2H, PhCH2), 3.88 (s, 3H, OCH3), 2.94 
(t, J = 6.8 Hz, 2H, CH2CH2NH2), 2.68 (t, J = 6.8 Hz, 2H, CH2CH2NH2).  
13C NMR (101 MHz, CDCl3) δ/ppm = 149.7 (C-3), 146.7 (C-4), 137.4 (C-1’), 133.0 (C-1), 128.5 
(C-3’, C-5’), 127.8 (C-4’), 127.3 (C-2’, C-6’), 120.8 (C-6), 114.3 (C-5), 112.7 (C-2), 71.2 
(PhCH2), 56.0 (OCH3), 43.6 (CH2CH2NH2), 39.5 (CH2CH2NH2). 
IR (ATR) ṽmax/cm-1 = 3032, 2938, 2909, 2869, 2838, 1512, 1260, 1227, 1139, 1032, 738, 696.  
HRMS (ESI): calcd. for C16H20NO2 (M+H)+ 258.14886; found 258.14886.  
 
Ethyl (4-(benzyloxy)-3-methoxyphenethyl)carbamate (170) 
 
Following general procedure E, amine 171 (1.40 g, 5.44 mmol, 1.0 eq.) in CH2Cl2 (20 mL), 
NEt3 (1.10 mL, 8.16 mmol, 1.5 eq.) and ethyl chloroformate (162, 680 µL, 7.07 mmol, 1.3 eq.) 
were used. The reaction was completed after 72 h and the product was purified by FCC (4:1 
hexanes/acetone) to yield carbamate 170 (861 mg, 2.61 mmol, 48%) as light yellow solid. 
Analytical data are in accordance with literature[149]. 
Rf = 0.28 (4:1 hexanes/acetone).  
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m.p.: 76 °C. [lit.[149]: 80-81 °C] 
1H NMR (500 MHz, CDCl3) δ/ppm = 7.43 (dt, J = 8.1, 1.9 Hz, 2H, 2’-H, 6’-H), 7.36 (ddt, J = 8.1, 
6.4, 1.3 Hz, 2H, 3’-H, 5’-H), 7.32 – 7.28 (m, 1H, 4’-H), 6.82 (d, J = 8.1 Hz, 1H, 5-H), 6.76 – 6.70 
(m, 1H, 2-H), 6.66 (dd, J = 8.1, 2.0 Hz, 1H, 6-H), 5.13 (s, 2H, PhCH2), 4.65 (s, 1H, NH), 4.11 
(q, J = 7.0 Hz, 2H, CH2CH3), 3.88 (s, 3H, OCH3), 3.40 (q, J = 6.8 Hz, 2H, CH2CH2NH), 2.74 (t, 
J = 6.8 Hz, 2H, CH2CH2NH), 1.23 (t, J = 7.0 Hz, 3H, CH2CH3).  
13C NMR (126 MHz, CDCl3) δ/ppm = 156.7 (CO), 149.9 (C-3), 147.0 (C-4), 137.4 (C-1’), 132.1 
(C-1), 128.7 (C-3’, C-5’), 127.9 (C-4’), 127.4 (C-2’, C-6’), 120.8 (C-6), 114.4 (C-5), 112.6 (C-
2), 71.3 (PhCH2), 60.9 (CH2CH3), 56.1 (OCH3), 42.3 (CH2CH2NH), 35.9 (CH2CH2NH), 14.8 
(CH2CH3). 
IR (ATR) ṽmax/cm-1 = 3333, 2980, 2936, 1682, 1515, 1252, 1228, 1138.  
HRMS (ESI): calcd. for C19H24NO4 (M+H)+ 330.16998; found 330.17056.  
Purity (HPLC): > 96% (λ = 210 nm). 
 
Ethyl (4-((ethoxycarbonyl)oxy)-3-methoxyphenethyl)carbamate (165) 
 
Following general procedure E, 3-methoxytyramine hydrochloride (160, 5.00 g, 24.5 mmol, 1.0 
eq.) in CH2Cl2 (25 mL), NEt3 (12.0 mL, 58.9 mmol, 3.5 eq.) and ethyl chloroformate (162, 
5.90 mL, 61.4 mmol, 2.5 eq.) were used. The reaction was completed after 16 h and the 
product was purified by FCC (4:1 hexanes/acetone) to yield carbamate 165 (5.86 g, 
18.8 mmol, 77%) as colorless solid.  
Rf = 0.10 (CH2Cl2).  
m.p.: 68 °C.   
1H NMR (500 MHz, CDCl3) δ/ppm = 7.05 (d, J = 8.0 Hz, 1H, 5-H), 6.81 – 6.74 (m, 2H, 2-H, 6-
H), 4.68 (s, 1H, NH), 4.31 (q, J = 7.0 Hz, 2H, OCOOCH2CH3), 4.11 (q, J = 7.0 Hz, 2H, 
NCOOCH2CH3), 3.84 (s, 3H, OCH3), 3.43 (q, J = 6.5 Hz, 2H, CH2CH2NH), 2.80 (t, J = 6.5 Hz, 
2H, CH2CH2NH), 1.38 (t, J = 7.0 Hz, 3H, OCOOCH2CH3), 1.23 (t, J = 7.0 Hz, 3H, 
NCOOCH2CH3).  
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13C NMR (126 MHz, CDCl3) δ/ppm = 156.7 (N-CO), 153.5 (O-CO), 151.3 (C-3), 138.9 (C-4), 
138.1 (C-1), 122.5 (C-5), 120.9 (C-6), 113.2 (C-2), 65.1 (OCOOCH2CH3), 60.9 
(NCOOCH2CH3), 56.1 (OCH3), 42.1 (CH2CH2NH), 36.3 (CH2CH2NH), 14.8 (OCOOCH2CH3), 
14.3 (NCOOCH2CH3).  
IR (ATR) ṽmax/cm-1 = 3336, 2980, 2940, 2872, 1750, 1686, 1541, 1514, 1283, 1251, 1208, 
1059, 1032.  
HRMS (ESI): calcd. for C15H22NO6 (M+H)+ 312.14416; found 312.14425.  
Purity (HPLC): > 96% (λ = 210 nm), > 96% (λ = 254 nm). 
 
Ethyl (4-hydroxy-3-methoxyphenethyl)carbamate (166) 
 
Following general procedure E, 3-methoxytyramine hydrochloride (160, 10.2 g, 50.0 mmol, 1.0 
eq.) in CH2Cl2 (50 mL), NEt3 (24.0 mL, 175 mmol, 3.5 eq.) and ethyl chloroformate (162, 
12.0 mL, 125 mmol, 2.5 eq.) were used. After 18 h, a 1 M ethanolic NaOH solution (100 mL) 
was added and the mixture was stirred for 3.5 h. The reaction mixture was neutralized using 
2 M aq. HCl solution, followed by extraction with CH2Cl2 (4 x 80 mL). The combined organic 
layers were dried over Na2SO4 and concentrated in vacuo. Purification was accomplished by 
FCC (4:1 hexanes/acetone) to yield carbamate 166 (3.49 g, 14.6 mmol, 29%) as colorless 
solid. Analytical data are in accordance with literature[73]. 
Rf = 0.18 (4:1 hexanes/acetone).  
m.p.: 98 °C. [lit.[73]: 95.0 – 95.5 °C] 
1H NMR (400 MHz, CDCl3) δ/ppm = 6.85 (d, J = 8.4 Hz, 1H, 5-H), 6.74 – 6.63 (m, 2H, 2-H, 
6-H), 5.50 (s, 1H, OH), 4.64 (s, 1H, NH), 4.11 (q, J = 7.1 Hz, 2H, CH2CH3), 3.88 (s, 3H, OCH3), 
3.40 (q, J = 7.1 Hz, 2H, CH2CH2NH), 2.74 (t, J = 7.1 Hz, 2H, CH2CH2NH), 1.23 (t, J = 7.1 Hz, 
3H, CH2CH3).  
13C NMR (101 MHz, CDCl3) δ/ppm = 156.7 (CO), 146.7 (C-3), 144.4 (C-4), 130.8 (C-1), 121.5 
(C-2 or 6), 114.6 (C-5), 111.4 (C-2 or 6), 60.9 (CH2CH3), 56.0 (OCH3), 42.4 (CH2CH2NH), 36.0 
(CH2CH2NH), 14.8 (CH2CH3). 
IR (ATR) ṽmax/cm-1 = 3276, 2979, 1688, 1516, 1237, 1033.  
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HRMS (ESI): calcd. for C12H16NO4 (M-H)- 238.10848; found 238.10860.  
Purity (HPLC): > 96% (λ = 210 nm). 
 
Ethyl (3-methoxy-4-phenoxyphenethyl)carbamate (167) 
 
Following general procedure I, carbamate 166 (2.00 g, 8.36 mmol, 1.0 eq.), phenylboronic acid 
(168, 3.06 g, 25.1 mmol, 3.0 eq.), copper(II) acetate (1.67 g, 9.20 mmol, 1.1 eq.), NEt3 
(2.90 mL, 20.9 mmol, 2.5 eq.) and pyridine (1.70 mL, 20.9 mmol, 2.5 eq.) in CH2Cl2 (40 mL) 
were used. The reaction was completed after 22 h and the product was purified by FCC (4:1 
hexanes/acetone) to yield diaryl ether 167 (2.24 g, 8.36 mmol, 85%) as colorless solid.  
Rf = 0.35 (4:1 hexanes/acetone).  
m.p.: 40 °C.   
1H NMR (400 MHz, CDCl3) δ/ppm = 7.32 – 7.26 (m, 2H, 3’-H, 5’-H), 7.07 – 7.01 (m, 1H, 4’-H), 
6.96 – 6.92 (m, 2H, 2’-H, 6’-H), 6.90 (d, J = 8.1 Hz, 1H, 5-H), 6.83 (d, J = 1.8 Hz, 1H, 2-H), 
6.74 (dd, J = 8.1, 1.8 Hz, 1H, 6-H), 4.69 (s, 1H, NH), 4.12 (q, J = 7.2 Hz, 2H, CH2CH3), 3.83 
(s, 3H, OCH3), 3.45 (q, J = 7.0 Hz, 2H, CH2CH2NH), 2.81 (t, J = 7.0 Hz, 2H, CH2CH2NH), 1.24 
(t, J = 7.0 Hz, 3H, CH2CH3).  
13C NMR (101 MHz, CDCl3) δ/ppm = 158.1 (C-1’), 156.7 (CO), 151.6 (C-3), 143.8 (C-4), 135.7 
(C-1), 129.6 (C-3’, C-5’), 122.6 (C-4’), 121.3 (C-5 or 6), 121.3 (C-5 or 6), 117.3 (C-2’, C-6’), 
113.5 (C-2), 61.0 (CH2CH3), 56.2 (OCH3), 42.3 (CH2CH2NH), 36.2 (CH2CH2NH), 14.8 
(CH2CH3). 
IR (ATR) ṽmax/cm-1 = 3303, 2971, 1688, 1490, 1272, 1255, 1222, 1035, 754. 
HRMS (ESI): calcd. for C18H22NO4 (M+H)+ 316.15433; found 316.15425.  
Purity (HPLC): > 96% (λ = 210 nm). 
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Ethyl (3,4-dimethoxyphenethyl)carbamate (169) 
 
Following general procedure E, 3,4-dimethoxyphenylethylamine (161, 5.00 mL, 29.6 mmol, 1.0 
eq.) in CH2Cl2 (30.0 mL), NEt3 (12.0 mL, 88.9 mmol, 3.0 eq.) and ethyl chloroformate (162, 
5.70 mL, 59.3 mmol, 2.0 eq.) were used. The mixture was heated to reflux for 4 h and 
extraction yielded carbamate 169 (7.05 g, 27.8 mmol, 94%) as colorless solid. NMR data are 
in accordance with literature[160]. 
Rf = 0.25 (4:1 hexanes/acetone). 
m.p.: 63 °C.   
1H NMR (400 MHz, CDCl3) δ/ppm = 6.81 (d, J = 8.0 Hz, 1H, 5-H), 6.78 – 6.65 (m, 2H, 2-H, 6-
H), 4.65 (s, 1H, NH), 4.11 (q, J = 7.1 Hz, 2H, CH2CH3), 3.88 – 3.85 (m, 6H, 2x OCH3), 3.41 (q, 
J = 6.8 Hz, 2H, CH2CH2NH), 2.75 (t, J = 6.8 Hz, 2H, CH2CH2NH), 1.23 (t, J = 7.1 Hz, 3H, 
CH2CH3).  
13C NMR (101 MHz, CDCl3) δ/ppm = 156.7 (CO), 149.2 (C-3), 147.8 (C-4), 131.5 (C-1), 120.8 
(C-2), 112.1 (C-6), 111.5 (C-5), 60.9 (CH2CH3), 56.1 (OCH3), 56.0 (OCH3), 42.3 (CH2CH2NH), 
35.9 (CH2CH2NH), 14.8 (CH2CH3). 
IR (ATR) ṽmax/cm-1 = 3372, 2935, 1697, 1514, 1258, 1234, 1139, 1027.  
HRMS (ESI): calcd. for C13H20NO4 (M+H)+ 254.13868; found 354.13885.  
Purity (HPLC): > 96% (λ = 210 nm). 
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5.2.2.2 Synthesis of enol ethers 
 
Ethyl (4-formylphenyl) carbonate (176) 
 
Following general procedure E, 4-hydroxybenzaldehyde (175, 1.00 g, 8.19 mmol, 1.0 eq.) in 
CH2Cl2 (10 mL), NEt3 (1.70 mL, 12.3 mmol, 1.5 eq.) and ethyl chloroformate (162, 860 µL, 
9.01 mmol, 1.1 eq.) were used. The reaction was completed after 14 h and the product was 
purified by FCC (CH2Cl2) to yield aldehyde 176 (1.53 g, 7.90 mmol, 97%) as colorless solid.  
Rf = 0.63 (CH2Cl2).  
m.p.: 121 °C.   
1H NMR (500 MHz, CDCl3) δ/ppm = 9.99 (s, 1H, CHO), 7.93 – 7.91 (m, 2H, 3-H, 5-H), 7.40 – 
7.32 (m, 2H, 2-H, 6-H), 4.36 – 4.32 (m, 2H, CH2CH3), 1.41 – 1.38 (m, 3H, CH2CH3).  
13C NMR (126 MHz, CDCl3) δ/ppm = 190.9 (CHO), 155.7 (C-1), 152.9 (CO), 134.2 (C-4), 131.4 
(C-3, C-5), 121.9 (C-2, C-6), 65.4 (CH2), 14.3 (CH3). 
IR (ATR) ṽmax/cm-1 = 1757, 1668, 1602, 1254, 1210, 1159, 1055, 998, 840, 775.  
HRMS (EI): calcd. for C10H9O4 (M)•+ 194.0579; found 194.0579.  
Purity (HPLC): > 96% (λ = 210 nm), > 96% (λ = 254 nm). 
 
Ethyl (4-(2-methoxyvinyl)phenyl) carbonate (177) 
 
Following general procedure F, (methoxymethyl)-triphenylphosphonium chloride (9.53 g, 
27.8 mmol, 1.2 eq.) and LDA (20% in THF/ethylbenzene/heptane, 11.6 mL, 23.2 mmol, 1.0 
eq.) in dry THF (50 mL) and aldehyde 176 (4.50 g, 23.2 mmol, 1.0 eq.) in dry THF (50 mL) 
were used. The mixture was stirred for 16 h and the product was purified by FCC (9:1 
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hexanes/EtOAc) to yield the desired cis/trans-enol ether 177 (3.30 g, 14.8 mmol, 64%) as 
colorless oil.  
Rf = 0.28 (4:1 hexanes/EtOAc).  
1H NMR (cis/trans, 400 MHz, CDCl3) δ/ppm = 7.59 – 7.55 (m, 2H, cis 3-H, 5-H), 7.24 – 7.20 
(m, 2H, trans 3-H, 5-H), 7.10 – 7.06 (m, 4H, cis/trans 2-H, 6-H), 7.00 (d, J = 13.0 Hz, 1H, 
trans CHCH-O), 6.13 (d, J = 7.0 Hz, 1H, cis CHCH-O), 5.79 (d, J = 13.0 Hz, 1H, trans CHCH-
O), 5.21 (d, J = 7.0 Hz, 1H, cis CHCH-O), 4.31 (qd, J = 7.1, 1.6 Hz, 4H, cis/trans CH2CH3), 
3.78 (s, 3H, cis OCH3), 3.68 (s, 3H, trans OCH3), 1.38 (td, J = 7.1, 1.6 Hz, 6H, 
cis/trans CH2CH3). 
13C NMR (cis/trans, 126 MHz, CDCl3) δ/ppm = 153.9 (trans CO), 153.8 (cis CO), 149.2 
(trans CHCH-O), 149.2 (trans C-1), 148.9 (cis C-1), 148.1 (cis CHCH-O), 134.5 (trans C-4), 
134.0 (cis C-4), 129.3 (cis C-3, C-5), 126.1 (trans C-3, C-5), 121.3 (trans C-2, C-6), 120.8 
(cis C-2, C-6), 104.9 (cis CHCH-O), 104.3 (trans CHCH-O), 64.9 (trans CH2CH3), 60.8 
(cis CH2CH3), 56.7 (cis/trans CH2CH3), 14.4 (cis/trans CH2CH3).  
Cis/trans-ratio according to 1H-NMR is 0.83. 
HRMS (EI): calcd. for C12H14O4 (M)•+ 222.0887; found 222.0879.  
 
1-(2-Methoxyvinyl)-4-phenoxybenzene (178) 
 
Following general procedure F, (methoxymethyl)-triphenylphosphonium chloride (1.18 g, 
3.43 mmol, 1.2 eq.) and LDA (20% in THF/ethylbenzene/heptane, 1.90 mL, 2.86 mmol, 1.0 
eq.) in dry THF (10 mL) and 4-phenoxybenzaldehyde (500 µL, 2.86 mmol, 1.0 eq.) in dry THF 
(10 mL) were used. The mixture was stirred for 50 h and the product was purified by FCC (9:1 
hexanes/EtOAc) to yield the desired cis/trans-enol ether 178 (384 mg, 1.70 mmol, 59%) as 
colorless oil. 
Rf = 0.73 (4:1 hexanes/EtOAc).  
1H NMR (cis/trans, 400 MHz, CDCl3) δ/ppm = 7.60 – 7.53 (m, 2H, cis 3-H, 5-H), 7.36 – 7.28 
(m, 4H, cis/trans Ph), 7.22 – 7.18 (m, 2H, trans 2-H, 6-H or 3-H, 5-H), 7.12 – 7.05 (m, 2H, 
cis/trans Ph), 7.02 – 6.91 (m, 9H, 4x cis/trans Ph, trans CHCH-O, cis/trans 2-H, 6-H or/and 3-
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H, 5-H), 6.11 (d, J = 7.0 Hz, 1H, cis CHCH-O), 5.81 (d, J = 13.0 Hz, 1H, trans CHCH-O), 5.22 
(d, J = 7.0 Hz, 1H, cis CHCH-O), 3.78 (s, 3H, cis OCH3), 3.69 (s, 3H, trans OCH3). 
13C NMR (cis/trans, 101 MHz, CDCl3) δ/ppm = 157.8 (cis/trans qPh), 157.7 (cis/trans qPh), 
155.2 (cis/trans C-1), 154.9 (cis/trans C-1), 148.5 (trans CHCH-O), 147.4 (cis CHCH-O), 131.8 
(cis/trans C-4), 131.5 (cis/trans C-4), 129.9 (cis/trans Ph), 129.8 (cis/trans Ph), 129.7 (cis C-3, 
C-5), 126.5 (trans C-2, C-6 or C-3, C-5), 123.1 (cis/trans Ph), 123.0 (cis/trans Ph), 119.6 
(cis/trans Ph or C-2, C-6 or C-3, C-5), 119.1 (cis/trans Ph or C-2, C-6 or C-3, C-5), 118.7 
(cis/trans Ph or C-2, C-6 or C-3, C-5), 118.6 (cis/trans Ph or C-2, C-6 or C-3, C-5), 105.1 
(cis CHCH-O), 104.5 (trans CHCH-O), 60.8 (cis OCH3), 56.7 (trans OCH3). 
Cis/trans-ratio according to 1H-NMR is 0.75. 
IR (ATR) ṽmax/cm-1 = 3036, 2935, 2831, 1488, 1234, 1150, 1092, 750, 691.  
HRMS (EI): calcd. for C15H14O2 (M)•+ 226.0988; found 226.0987.  
 
1-(Benzyloxy)-4-(2-methoxyvinyl)benzene (179) 
 
Following general procedure F, (methoxymethyl)-triphenylphosphonium chloride (4.11 g, 
12.0 mmol, 1.2 eq.) and LDA (20% in THF/ethylbenzene/heptane, 7.90 mL, 12.0 mmol, 1.2 
eq.) in dry THF (50 mL) and 4-(benzyloxy)benzaldehyde (2.12 g, 9.99 mmol, 1.0 eq.) in dry 
THF (50 mL) were used. The mixture was stirred for 16 h and the product was purified by FCC 
(6:1 hexanes/EtOAc) to yield the desired cis/trans-enol ether 179 (2.04 g, 8.49 mmol, 85%) as 
yellow solid.  
Rf = 0.68 (4:1 hexanes/EtOAc).  
m.p.: 62 °C.   
1H NMR (cis/trans, 400 MHz, CDCl3) δ/ppm = 7.53 – 7.49 (m, 2H, cis 3-H, 5-H), 7.45 – 7.29 
(m, 10H, cis/trans PhCH2), 7.18 – 7.13 (m, 2H, trans 3-H, 5-H), 6.95 – 6.88 (m, 5H, cis/trans 2-
H, 6-H, trans CHCH-O), 6.06 (d, J = 7.0 Hz, 1H, cis CHCH-O), 5.78 (d, J = 13.0 Hz, 1H, 
trans CHCH-O), 5.18 (d, J = 7.0 Hz, 1H, cis CHCH-O), 5.09 – 5.03 (m, 4H, cis/trans PhCH2), 
3.76 (s, 3H, cis OCH3), 3.66 (s, 3H, trans OCH3). 
13C NMR (cis/trans, 101 MHz, CDCl3) δ/ppm = 157.2 (cis/trans C-1), 157.0 (cis/trans C-1), 
147.8 (trans CHCH-O), 146.6 (cis CHCH-O), 137.3 (cis/trans qPh), 137.2 (cis/trans qPh), 
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129.5 (cis C-3, C-5), 129.3 (cis/trans C-4), 129.2 (cis/trans C-4), 128.8 (cis/trans Ph), 128.7 
(cis/trans Ph), 128.1 (cis/trans Ph), 128.0 (cis/trans Ph), 127.6 (cis/trans Ph), 126.3 (trans C-
3, C-5), 115.3 (trans C-2, C-6), 114.8 (cis C-2, C-6), 105.4 (cis CHCH-O), 104.7 (trans CHCH-
O), 70.2 (cis/trans PhCH2), 70.1 (cis/trans PhCH2), 60.6 (cis OCH3), 56.6 (trans OCH3).   
Cis/trans-ratio according to 1H-NMR is 1.1. 
HRMS (EI): calcd. for C16H16O2 (M)•+ 240.1145; found 240.1146.  
 
5.2.2.3 N-Acyl Pictet-Spengler reaction 
 
(±)-Ethyl 7-((ethoxycarbonyl)oxy)-1-(4-((ethoxycarbonyl)oxy)benzyl)-6-methoxy-3,4-
dihy-droisoquinoline-2(1H)-carboxylate (180) 
 
Following general procedure G, carbamate 165 (348 mg, 1.12 mmol, 1.0 eq.), enol ether 177 
(248 mg, 1.12 mmol, 1.0 eq.) and TFA (840 µL, 11.2 mmol, 10 eq.) were dissolved in CH2Cl2 
(15 mL). The reaction was completed after 18 h and the product was purified by FCC (5:1 
hexanes/acetone) to yield compound 180 (452 mg, 0.901 mmol, 81%) as colorless oil.  
Rf = 0.20 (4:1 hexanes/acetone).  
1H NMR (400 MHz, C2D2Cl4, 100 °C) δ/ppm = 7.03 (s, 4H, 2’-H, 3’-H, 5’-H, 6’-H), 6.69 – 6.63 
(m, 2H, 5-H, 8-H), 5.19 (t, J = 6.6 Hz, 1H, 1-H), 4.28 – 4.22 (m, 4H, 2 OCOOCH2CH3), 4.05 – 
3.92 (m, 3H, NCOOCH2CH3, 3-H), 3.79 (s, 3H, OCH3), 3.23 (ddd, J = 13.6, 9.7, 4.6 Hz, 1H, 3-
H), 3.00 (h, J = 6.6 Hz, 2H, α-H), 2.81 (ddd, J = 15.8, 9.7, 5.8 Hz, 1H, 4-H), 2.61 – 2.54 (m, 
1H, 4-H), 1.35 – 1.31 (m, 6H, 2 OCOOCH2CH3), 1.12 (t, J = 7.2 Hz, 3H, NCOOCH2CH3).  
13C NMR (101 MHz, C2D2Cl4, 100 °C) δ/ppm = 155.6 (N-CO), 153.6 (O-CO), 153.3 (O-CO), 
150.4 (C-4’), 150.3 (C-6), 139.1 (C-7), 136.0 (C-1’), 133.4 (C-4a), 130.7 (C-2’, C-6’or C-3’, C-
5’), 129.3 (C-8a), 121.3 (C-5 or C-8), 120.9 (C-2’, C-6’ or C-3’, C-5’), 113.6 (C-5 or C-8), 65.1 
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(OCOOCH2CH3), 64.9 (OCOOCH2CH3), 61.5 (NCOOCH2CH3), 56.6 (OCH3), 56.0 (C-1), 42.5 
(C-α), 38.6 (C-3), 28.7 (C-4), 14.8 (NCOOCH2CH3), 14.4 (OCOOCH2CH3), 14.3 
(OCOOCH2CH3).   
IR (ATR) ṽmax/cm-1 = 2981, 2940, 1758, 1692, 1248, 1215, 1198.  
HRMS (ESI): calcd. for C26H35N2O9 (M+NH4)+ 519.23371; found 519.23373.  
Purity (HPLC): > 96% (λ = 210 nm). 
 
(±)-Ethyl 1-(4-((ethoxycarbonyl)oxy)benzyl)-6,7-dimethoxy-3,4-dihydroisoquinoline-
2(1H)-carboxylate – SG-089 (181) 
 
Following general procedure G, carbamate 169 (5.60 g, 22.1 mmol, 1.0 eq.), enol ether 177 
(4.92 g, 22.1 mmol, 1.0 eq.) and TFA (18.0 mL, 243 mmol, 11 eq.) were dissolved in CH2Cl2 
(50 mL). The reaction was completed after 20 h and the product was purified by FCC (5:1 
hexanes/acetone) to give SG-089 181 (7.50 g, 16.9 mmol, 77%) as colorless solid.  
Rf = 0.28 (4:1 hexanes/acetone).  
m.p.: 134 °C.   
1H NMR (400 MHz, C2D2Cl4, 100 °C) δ/ppm = 7.10 – 6.97 (m, 4H, 2’-H, 3’-H, 5’-H, 6’-H), 6.57 
(s, 1H, 5-H), 6.23 (s, 1H, 8-H), 5.15 (t, J = 6.6 Hz, 1H, 1-H), 4.26 (q, J = 7.1 Hz, 2H, 
OCOOCH2CH3), 4.13 – 3.98 (m, 2H, NCOOCH2CH3), 3.98 – 3.82 (m, 1H, 3-H), 3.78 (s, 3H, 6-
OCH3), 3.61 (s, 3H, 7-OCH3), 3.30 (ddd, J = 13.4, 9.4, 4.7 Hz, 1H, 3-H), 3.09 (dd, J = 13.4, 6.8 
Hz, 1H, α-H), 2.94 (dd, J = 13.4, 6.8 Hz, 1H, α-H), 2.77 (ddd, J = 15.6, 9.4, 5.9 Hz, 1H, 4-H), 
2.57 (dt, J = 15.6, 4.7 Hz, 1H, 4-H), 1.34 (t, J = 7.1 Hz, 3H, OCOOCH2CH3), 1.17 (t, J = 7.1 
Hz, 3H, NCOOCH2CH3).  
13C NMR (101 MHz, C2D2Cl4, 100 °C) δ/ppm = 155.7 (N-CO), 153.6 (O-CO), 150.3 (C-4’), 
148.8 (C-6), 148.1 (C-7), 136.4 (C-1’), 130.8 (C-2’, C-6’), 129.0 (C-8a), 127.0 (C-4a), 120.9 (C-
3’, C-5’), 113.3 (C-5), 112.3 (C-8), 64.9 (OCOOCH2CH3), 61.5 (NCOOCH2CH3), 56.7 (OCH3-
6), 56.6 (OCH3-7), 56.5 (C-1), 42.6 (C-α), 39.1 (C-3), 28.2 (C-4), 14.8 (OCOOCH2CH3), 14.4 
(NCOOCH2CH3).  
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IR (ATR) ṽmax/cm-1 = 3006, 2918, 2849, 1754, 1673, 1281, 1260, 1245, 1206, 1096, 859.  
HRMS (ESI): calcd. for C24H30NO7 (M+H)+ 444.20168; found 444.20143.  
Purity (HPLC): > 96% (λ = 210 nm), > 96% (λ = 254 nm). 
 
(±)-Ethyl 1-(4-((ethoxycarbonyl)oxy)benzyl)-6-methoxy-7-phenoxy-3,4-dihydroisoquino-
line-2(1H)-carboxylate (182) 
 
Following general procedure G, carbamate 167 (1.60 g, 5.06 mmol, 1.0 eq.), enol ether 177 
(1.35 g, 6.07 mmol, 1.2 eq.) and TFA (3.80 mL, 50.6 mmol, 10 eq.) were dissolved in CH2Cl2 
(50 mL). The reaction was completed after 90 h and the product was purified by FCC (5:1 
hexanes/acetone) to yield compound 182 (2.30 g, 4.55 mmol, 90%) as yellow oil.  
Rf = 0.31 (4:1 hexanes/acetone).  
1H NMR (400 MHz, C2D2Cl4, 100 °C) δ/ppm = 7.25 – 7.21 (m, 2H, Ar), 6.99 (s, 5H, Ph), 
6.86 – 6.82 (m, 2H, Ar), 6.69 (s, 1H, 5-H), 6.54 (s, 1H, 8-H), 5.13 (t, J = 6.6 Hz, 1H, 1-H), 4.25 
(q, J = 7.1 Hz, 2H, OCOOCH2CH3), 4.04 – 3.92 (m, 3H, NCOOCH2CH3, 3-H), 3.75 (s, 3H, 
OCH3), 3.26 (ddd, J = 13.2, 9.6, 4.6 Hz, 1H, 3-H), 3.02 (dd, J = 13.7, 7.0 Hz, 1H, α-H), 2.94 
(dd, J = 13.7, 7.0 Hz, 1H, α-H), 2.86 – 2.77 (m, 1H, 4-H), 2.60 (dt, J = 15.8, 4.6 Hz, 1H, 4-H), 
1.33 (t, J = 7.0 Hz, 3H, OCOOCH2CH3), 1.12 (t, J = 7.2 Hz, 3H, NCOOCH2CH3).  
13C NMR (101 MHz, C2D2Cl4, 100 °C) δ/ppm = 158.5 (C-4’), 155.7 (N-CO), 153.5 (O-CO), 
150.8 (C-6), 150.3 (C-7), 144.1 (C-8a), 136.0 (qPh), 131.2 (C-4a), 130.6 (Ph), 129.8 (C-1’), 
129.6 (C-2’, C-6’ or C-3’, C-5’), 122.6 (Ph), 120.8 (Ph), 120.4 (C-8), 117.5 (C-2’, C-6’ or C-3’, 
C-5’), 114.5 (C-6), 64.9 (OCOOCH2CH3), 61.5 (NCOOCH2CH3), 56.8 (OCH3), 56.0 (C-1), 42.5 
(C-α), 38.9 (C-3), 28.5 (C-4), 14.8 (NCOOCH2CH3), 14.4 (OCOOCH2CH3). 
IR (ATR) ṽmax/cm-1 = 2980, 1759, 1688, 1508, 1252, 1215, 1096, 747.  
HRMS (ESI): calcd. for C29H32NO7 (M+H)+ 506.21733; found 506.21721.  
Purity (HPLC): > 96% (λ = 210 nm), > 96% (λ = 254 nm). 
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(±)-Ethyl 7-(benzyloxy)-1-(4-(benzyloxy)benzyl)-6-methoxy-3,4-dihydroisoquinoline-
2(1H)-carboxylate - SG-145 (183) 
 
Following general procedure G, carbamate 170 (861 mg, 2.61 mmol, 1.0 eq.), enol ether 179 
(691 mg, 2.88 mmol, 1.1 eq.) and TFA (2.00 mL, 26.1 mmol, 10 eq.) were dissolved in CH2Cl2 
(25 mL). The reaction was completed after 18 h and the product was purified by FCC (5:1 
hexanes/acetone) to yield SG-145 (183, 444 mg, 0.825 mmol, 32%) as yellow solid.  
Rf = 0.26 (4:1 hexanes/acetone).  
m.p.: 96 °C. [lit.[152]: 115-118 °C] 
1H NMR (400 MHz, C2D2Cl4, 100 °C) δ/ppm = 7.36 – 7.27 (m, 10H, Ph), 6.95 – 6.92 (m, 2H, 
2’-H, 6’-H), 6.85 – 6.83 (m, 2H, 3’-H, 5’-H), 6.59 (s, 1H, 5-H), 6.37 (s, 1H, 8-H), 5.10 (t, J = 6.7 
Hz, 1H, 1-H), 4.99 (s, 2H, PhCH2), 4.86 (s, 2H, PhCH2), 4.10 – 3.90 (m, 3H, CH2CH3, 3-H), 
3.80 (s, 3H, OCH3), 3.28 – 3.20 (m, 1H, 3-H), 2.98 (dd, J = 13.6, 6.7 Hz, 1H, α-H), 2.86 (dd, J 
= 13.6, 6.7 Hz, 1H, α-H), 2.80 – 2.71 (m, 1H, 4-H), 2.56 – 2.50 (m, 1H, 4-H), 1.15 (t, J = 7.1 
Hz, 3H, CH2CH3).  
13C NMR (101 MHz, C2D2Cl4, 100 °C) δ/ppm = 158.0 (C-4’), 155.7 (CO), 149.5 (C-6), 147.2 
(C-7), 137.8 (qPh), 137.7 (qPh), 131.3 (C-1’), 131.0 (C-2’, C-6’), 129.5 (C-8a), 128.7 (Ph), 
128.6 (Ph), 128.0 (Ph), 127.9 (C-4a), 127.7 (Ph), 127.6 (Ph), 115.4 (C-8 or C-3’, C-5’), 115.3 
(C-8 or C-3’, C-5’), 113.9 (C-5), 72.2 (PhCH2), 70.7 (PhCH2), 61.4 (CH2CH3), 56.9 (OCH3), 
56.4 (C-1), 42.3 (C-α), 38.9 (C-3), 28.3 (C-2), 14.8 (CH2CH3).  
IR (ATR) ṽmax/cm-1 = 3007, 2940, 1673, 1510, 1254, 1236, 1224, 1200, 1093, 743, 697.  
HRMS (ESI): calcd. for C34H36NO5 (M+H)+ 538.25880; found 538.25880.  
Purity (HPLC): > 96% (λ = 210 nm), > 96% (λ = 254 nm). 
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(±)-Ethyl 6,7-dimethoxy-1-(4-phenoxybenzyl)-3,4-dihydroisoquinoline-2(1H)-
carboxylate (184) 
 
Following general procedure G, carbamate 169 (150 mg, 0.663 mmol, 1.0 eq.), enol ether 178 
(168 mg, 0.663 mmol, 1.0 eq.) and TFA (500 µL, 6.63 mmol, 10 eq.) were dissolved in CH2Cl2 
(5.0 mL). The reaction was completed after 6 h and the product was purified by FCC (4:1 
hexanes/acetone) to yield compound 184 (181 mg, 0.405 mmol, 92%) as colorless oil that 
solidifies upon freezing.  
Rf = 0.32 (4:1 hexanes/acetone).  
m.p.: 30 °C.   
1H NMR (400 MHz, C2D2Cl4, 100 °C) δ/ppm = 7.30 – 7.25 (m, 2H, Ar), 7.06 – 7.01 (m, 3H, Ph), 
6.95 (dd, J = 8.7, 1.1 Hz, 2H, Ar), 6.90 – 6.87 (m, 2H, Ph), 6.57 (s, 1H, 5-H), 6.30 (s, 1H, 8-H), 
5.17 (t, J = 6.9 Hz, 1H, 1-H), 4.05 (q, J = 7.1 Hz, 2H, CH2CH3), 4.00 – 3.89 (m, 1H, 3-H), 3.78 
(s, 3H, 6-OCH3), 3.66 (s, 3H, 7-OCH3), 3.30 (ddd, J = 13.5, 9.6, 4.7 Hz, 1H, 3-H), 3.07 (dd, J 
= 13.5, 6.8 Hz, 1H, α-H), 2.94 (dd, J = 13.5, 6.8 Hz, 1H, α-H), 2.78 (ddd, J = 15.8, 8.9, 6.1 Hz, 
1H, 4-H), 2.58 (dt, J = 15.0, 4.7 Hz, 1H, 4-H), 1.18 (t, J = 7.1 Hz, 3H, CH2CH3).  
13C NMR (101 MHz, C2D2Cl4, 100 °C) δ/ppm = 157.9 (C-4’), 156.2 (qPh), 155.7 (CO), 148.9 
(C-6), 148.1 (C-7), 133.7 (C-1’), 131.2 (Ph), 129.9 (Ar), 129.3 (C-8a), 127.1 (C-4a), 123.3 (Ph), 
119.1 (Ar or Ph), 119.0 (Ar or Ph), 113.3 (C-5), 112.5 (C-8), 61.4 (CH2CH3), 56.7 (6-OCH3 and 
7-OCH3), 56.5 (C-1), 42.6 (C-α), 39.0 (C-3), 28.3 (C-4), 14.9 (CH2CH3). 
IR (ATR) ṽmax/cm-1 = 2979, 1678, 1506, 1488, 1227, 1098, 694.  
HRMS (ESI): calcd. for C27H30NO5 (M+H)+ 448.21185; found 448.21224.  
Purity (HPLC): > 96% (λ = 210 nm), > 96% (λ = 254 nm). 
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5.2.2.4 Lithium alanate reductions of carbamates and deprotections of carbonates 
 
(±)-1-(4-Hydroxybenzyl)-6-methoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-7-ol 
((±)-N-methylcoclaurine) – SG-132 (159) 
 
Following general procedure H, carbamate 180 (2.58 g, 5.14 mmol, 1.0 eq.) in dry THF (40 mL) 
and LiAlH4 (1.35 g, 35.6 mmol, 7.0 eq.) in dry THF (40 mL) were used. The mixture was heated 
to reflux for 3 h to yield (±)-N-methylcoclaurine (159, 1.21 g, 4.04 mmol, 79%) as off-white 
solid.  
Rf = 0.09 (9:1 CH2Cl2/MeOH).  
m.p.: 86 °C. [lit.[191]: 110-112 °C] 
1H NMR (500 MHz, CD3OD) δ/ppm = 6.92 – 6.87 (m, 2H, Ar), 6.70 – 6.65 (m, 2H, Ar), 6.63 (s, 
1H, 5-H), 6.09 (s, 1H, 8-H), 3.80 (s, 3H, OCH3), 3.66 (dd, J = 7.5, 4.9 Hz, 1H, 1-H), 3.15 (ddd, 
J = 12.5, 9.4, 5.5 Hz, 1H, 3-H), 3.06 (dd, J = 13.8, 4.9 Hz, 1H, α-H), 2.85 (ddd, J = 15.8, 9.4, 
6.2 Hz, 1H, 4-H), 2.75 – 2.69 (m, 2H, α-H and 3-H), 2.63 (dt, J = 16.3, 4.9 Hz, 1H, 4-H), 2.45 
(s, 3H, NCH3).  
13C NMR (126 MHz, CD3OD) δ/ppm = 156.8 (C-4’), 147.8 (C-6), 145.0 (C-7), 131.7 (C-1’), 
131.6 (Ar), 130.7 (C-8a), 125.5 (C-4a), 116.0 (Ar), 115.8 (C-8), 112.6 (C-5), 66.0 (C-1), 56.3 
(OCH3), 47.5 (C-α), 42.6 (NCH3), 40.7 (C-3), 26.1 (C-4). 
IR (ATR) ṽmax/cm-1 = 2929, 1609, 1513, 1445, 1251, 1112, 1022, 830.  
HRMS (ESI): calcd. for C18H22NO3 (M+H)+ 300.15942; found 300.15932.  
Purity (HPLC): > 96% (λ = 210 nm). 
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(±)-4-((6,7-Dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)methyl)phenol 
((±)-armepavine) – SG-121 (185) and (±)-4-(6,7-dimethoxy-2-methyl-1,2,3,4-
tetrahydroisoquinolin-1-yl)phenol – SG-121-NP (189) 
 
Following general procedure H, SG-089 (181, 7.50 g, 16.9 mmol, 1.0 eq.) in dry THF (90 mL) 
and LiAlH4 (7.06 g, 186 mmol, 11 eq.) in dry THF (40 mL) were used. The mixture was heated 
to reflux for 3 h and the product was purified by FCC (9:1 CH2Cl2/MeOH) to yield 
(±)-armepavine (185, 1.83 g, 5.86 mmol, 35%) as off-white solid. NMR data are in accordance 
with literature[192]. 
Rf = 0.34 (9:1 CH2Cl2/MeOH).  
m.p.: 76 °C.  
1H NMR (400 MHz, CD3OD) δ/ppm = 6.90 – 6.86 (m, 2H, 2’-H, 6’-H), 6.72 – 6.68 (m, 2H, 3’-H, 
5’-H), 6.66 (s, 1H, 5-H or 8-H), 5.84 (s, 1H, 5-H or 8-H), 3.77 (s, 3H, OCH3), 3.72 (dd, J = 9.5, 
4.3 Hz, 1H, 1-H), 3.42 (s, 3H, OCH3), 3.24 – 3.14 (m, 2H, α-H, 3-H), 2.95 – 2.87 (m, 1H, 4-H), 
2.78 (ddd, J = 12.5, 6.3, 3.1 Hz, 1H, 3-H), 2.70 – 2.63 (m, 2H, α-H, 4-H), 2.52 (s, 3H, NCH3).  
13C NMR (101 MHz, CD3OD) δ/ppm = 157.0 (C-4’), 149.1 (C-6 or C-7), 147.5 (C-6 or C-7), 
132.0 (C-2’, C-6’), 131.3 (C-1’), 129.8 (C-4a or C-8a), 126.4 (C-4a or C-8a), 116.1 (C-3’, C-5’), 
113.0 (C-5 or C-8), 112.9 (C-5 or C-8), 66.0 (C-1), 56.3 (OCH3), 55.9 (OCH3), 47.0 (C-3), 42.4 
(NCH3), 40.0 (C-α), 26.0 (C-4). 
IR (ATR) ṽmax/cm-1 = 2979, 2901, 2834, 1509, 1251, 1226, 1100, 828.  
HRMS (ESI): calcd. for C19H24NO3 (M+H)+ 314.17507; found 314.17502.  
Purity (HPLC): > 96% (λ = 210 nm), > 96% (λ = 254 nm). 
Column chromatography furthermore yielded SG-121-NP (189, 1.03 g, 3.44 mmol, 20%) as 
light yellow solid. Due to the instability of the enol ether (177) and for the sake of time, 
purification was reduced to a minimum during up-scale reactions. This resulted in impurities in 
form of 4-hydroxybenzaldehyde (175) after the Wittig reaction. During the following N-acyl 
Pictet-Spengler reaction, a side product was formed that was carried over as impurity to the 
next step. Reduction with LiAlH4 then yielded SG-121-NP (189).  
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Rf = 0.21 (9:1 CH2Cl2/MeOH).  
m.p.: 85 °C.   
1H NMR (400 MHz, CD3OD) δ/ppm = 7.23 – 7.13 (m, 2H, 2’,6’-H), 6.98 – 6.84 (m, 3H, 5,3’.5’-
H), 6.30 (s, 1H, 8-H), 5.49 (s, 1H, 1-H), 3.85 (s, 3H, OCH3), 3.74 – 3.62 (m, 1H, 3 or 4-H), 3.59 
(s, 3H, OCH3), 3.50 – 3.43 (m, 1H, 3 or 4-H), 3.30 – 3.26 (m, 1H, 3 or 4-H), 3.23 – 3.13 (m, 
1H, 3 or 4-H), 2.83 (s, 3H, NCH3).  
13C NMR (101 MHz, CD3OD) δ/ppm = 160.6 (C-4’), 150.9 (C-6 or C-7), 149.9 (C-6 or C-7), 
133.3 (C-1’, C-2’ and/or C-6’), 133.2 (C-1’, C-2’ and/or C-6’), 133.0 (C-1’, C-2’ and/or C-6’), 
124.8 (C-4a or C-8a), 124.7 (C-4a or C-8a), 117.0 (C-3’, C-5’), 112.2 (C-5 and C-8), 69.6 (C-
1), 56.4 (OCH3), 56.3 (OCH3), 41.2 (NCH3), 25.7 (C-3 or C-4), 25.6 (C-3 or C-4). 
IR (ATR) ṽmax/cm-1 = 3132, 2980, 2725, 1615, 1516, 1270, 1229, 1105, 838.  
HRMS (ESI): calcd. for C18H22NO3 (M+H)+ 300.15942; found 300.15964.  
Purity (HPLC): > 96% (λ = 210 nm), > 96% (λ = 254 nm). 
 
(±)-4-((6-Methoxy-2-methyl-7-phenoxy-1,2,3,4-tetrahydroisoquinolin-1-yl)methyl)phenol 
(186) 
 
Following general procedure H, carbamate 182 (1.80 g, 3.56 mmol, 1.0 eq.) in dry THF (20 mL) 
and LiAlH4 (1.62 g, 42.7 mmol, 12 eq.) in dry THF (20 mL) were used. The mixture was heated 
to reflux for 5 h to yield racemic compound 186 (1.21 g, 4.04 mmol, 79%) as off-white solid.  
Rf = 0.38 (9:1 CH2Cl2/MeOH).  
m.p.: 85 °C.   
1H NMR (500 MHz, CD3OD) δ/ppm = 7.26 – 7.20 (m, 2H, Ph), 6.99 – 6.96 (m, 1H, Ph), 6.84 
– 6.80 (m, 3H, 5-H, 2’-H, 6’-H), 6.72 – 6.68 (m, 2H, Ph), 6.61 – 6.56 (m, 2H, 3’-H, 5’-H), 6.10 
(s, 1H, 8-H), 3.73 (s, 3H, OCH3), 3.67 (dd, J = 8.6, 4.3 Hz, 1H, 1-H), 3.21 (ddd, J = 13.7, 9.3, 
6.1 Hz, 1H, 3-H), 3.08 (dd, J = 13.5, 4.3 Hz, 1H, α-H), 2.98 – 2.91 (m, 1H, 4-H), 2.79 – 2.73 
(m, 2H, 3-H and 4-H), 2.69 (dd, J = 13.5, 8.6 Hz, 1H, α-H), 2.50 (s, 3H, NCH3).  
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13C NMR (126 MHz, CD3OD) δ/ppm = 158.0 (qPh), 155.3 (C-4’), 149.9 (C-6), 142.0 (C-7), 
130.3 (C-2’, C-6’), 129.9 (C-4a, C-8a or C-1’), 129.6 (C-4a, C-8a or C-1’), 129.4 (C-4a, C-8a 
or C-1’), 129.0 (Ph), 121.8 (Ph), 120.5 (C-8), 116.5 (Ph), 114.7 (C-3’, C-5’), 112.6 (C-5), 64.4 
(C-1), 54.9 (OCH3), 45.9 (C-3), 41.2 (NCH3), 38.6 (C-α), 25.1 (C-4). IR (ATR) ṽmax/cm-1 = 2980, 
2889, 1590, 1508, 1489, 1261, 1215, 749, 690.  
IR (ATR) ṽmax/cm-1 = 2980, 2889, 1590, 1508, 1489, 1261, 1215, 749, 690. 
HRMS (ESI): calcd. for C24H26NO3 (M+H)+ 376.19072; found 376.19069.  
Purity (HPLC): > 96% (λ = 210 nm). 
 
(±)-7-(Benzyloxy)-1-(4-(benzyloxy)benzyl)-6-methoxy-2-methyl-1,2,3,4-tetrahydro-
isoquinoline  – SG-005 (187) 
 
Following general procedure H, carbamate 183 (310 mg, 0.557 mmol, 1.0 eq.) in dry THF 
(10 mL) and LiAlH4 (157 mg, 4.14 mmol, 7.2 eq.) in dry THF (20 mL) were used. The mixture 
was heated to reflux for 18 h and the product was purified by FCC (9:1 CH2Cl2/MeOH) to yield 
racemic amine SG-005 (187, 126 mg, 0.263 mmol, 46%) as colorless oil. The hydrochloride 
salt was formed according to general procedure J to yield a colorless solid. Analytical data are 
in accordance with literature[82]. 
Rf = 0.39 (9:1 CH2Cl2/MeOH).  
m.p.: 68 °C (HCl salt).  
1H NMR (500 MHz, CD3OD) δ/ppm = 7.37 – 7.22 (m, 10H, PhCH2), 6.96 – 6.93 (m, 2H, 2’-H, 
6’-H), 6.93 – 6.90 (m, 2H, 3’-H, 5’-H), 6.68 (s, 1H, 5-H), 5.85 (s, 1H, 8-H), 4.99 (d, J = 2.3 Hz, 
2H, 4’-OCH2), 4.60 – 4.54 (m, 2H, 7-OCH2), 3.78 (s, 3H, OCH3), 3.72 (dd, J = 9.4, 4.2 Hz, 1H, 
1-H), 3.23 – 3.15 (m, 2H, 4-H, α-H), 2.91 (ddd, J = 16.3, 9.9, 6.3 Hz, 1H, 3-H), 2.78 (ddd, J = 
12.5, 6.3, 3.2 Hz, 1H, 4-H), 2.71 – 2.65 (m, 2H, 3-H, α-H), 2.53 (s, 3H, NCH3).  
13C NMR (126 MHz, CD3OD) δ/ppm = 158.9 (C-4’), 149.7 (C-6), 146.7 (C-7), 138.7 (qPh), 
138.6 (qPh), 132.9 (C-1’), 132.2 (C-2’, C-6’), 129.6 (C-8a), 129.5 (Ph), 129.4 (Ph), 128.9 (Ph), 
128.8 (Ph), 128.6 (Ph), 127.1 (C-4a), 115.8 (C-3’, C-5’), 115.4 (C-8), 113.2 (C-5), 71.8 
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(PhCH2), 71.0 (PhCH2), 65.9 (C-1), 56.4 (OCH3), 47.1 (C-4), 42.4 (NCH3), 39.7 (C-α), 26.2 (C-
3).  
IR (ATR) ṽmax/cm-1 = 2932, 2850, 1608, 1509, 1454, 1222, 1099, 1013, 767, 696.  
HRMS (ESI): calcd. for C32H34NO3 (M+H)+ 480.25332; found 480.25476.  
Purity (HPLC): > 96% (λ = 210 nm), > 96% (λ = 254 nm). 
 
Separation of racemic SG-005 (187) via chiral HPLC (9:1 n-heptane/isopropanol + 0.45% 
diethylamine) yielded the two enantiomers (S)-SG-005 (209, colorless oil, retention time: 
~ 10 min) and (R)-SG-005 (210, colorless oil, retention time: ~ 20 min).  
 
(S)-SG-005 (209): [] = + 54.3 (c = 0.078, CHCl3). 
(R)-SG-005 (210): [] = - 65.4 (c = 0.052, CHCl3). (lit.[193]: -37.6 (c = 0.9, CHCl3). 
 
(±)-6,7-Dimethoxy-2-methyl-1-(4-phenoxybenzyl)-1,2,3,4-tetrahydroisoquinoline – 
SG-083 (188) 
 
Following general procedure H, carbamate 184 (110 mg, 0.246 mmol, 1.0 eq.) in dry THF 
(15 mL) and LiAlH4 (37.3 mg, 0.983 mmol, 4.0 eq.) in dry THF (10 mL) were used. The mixture 
was heated to reflux for 20 h and the product was purified by FCC (9.5:0.5 CH2Cl2/MeOH) to 
yield racemic amine SG-083 (188, 44.0 mg, 0.113 mmol, 46%) as light yellow oil.  
Rf = 0.55 (9:1 CH2Cl2/MeOH).  
1H NMR (500 MHz, CD3OD) δ/ppm = 7.35 – 7.31 (m, 2H, Ph), 7.10 – 7.05 (m, 3H, Ph, 2’-H, 6’-
H), 6.96 – 6.93 (m, 2H, Ph), 6.91 – 6.87 (m, 2H, 3’-H, 5’-H), 6.67 (s, 1H, 5-H), 5.97 (s, 1H, 8-
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H), 3.81 – 3.77 (m, 4H, 1-H, OCH3), 3.50 (s, 3H, OCH3), 3.25 – 3.18 (m, 2H, 3-H, α-H), 2.94 – 
2.86 (m, 1H, 4-H), 2.81 – 2.75 (m, 2H, 3-H, α-H), 2.67 (ddd, J = 16.6, 5.4, 3.3 Hz, 1H, 4-H), 
2.53 (s, 3H, NCH3).  
13C NMR (126 MHz, CD3OD) δ/ppm = 159.0 (qPh), 157.1 (C-4’), 149.2 (C-6), 147.7 (C-7), 
135.9 (C-1’), 132.4 (C-2’, C-6’), 130.8 (Ph), 129.9 (C-8a), 126.9 (C-4a), 124.2 (Ph), 119.8 (C-
3’, C-5’), 119.6 (Ph), 113.1 (C-5 or C-8), 113.0 (C-5 or C-8), 65.9 (C-1), 56.4 (OCH3), 56.1 
(OCH3), 47.1 (C-3), 42.5 (NCH3), 40.2 (C-α), 26.1 (C-4). 
IR (ATR) ṽmax/cm-1 = 2938, 2833, 1589, 1505, 1488, 1228.  
HRMS (ESI): calcd. for C25H28NO3 (M+H)+ 390.20637; found 390.20640.  
Purity (HPLC): > 96% (λ = 210 nm), > 96% (λ = 254 nm). 
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5.2.2.5 Chan-Evans-Lam couplings 
 
(±)-6-Methoxy-2-methyl-7-phenoxy-1-(4-phenoxybenzyl)-1,2,3,4-tetrahydroisoquinoline 
– SG-094 (192) 
 
Following general procedure I, SG-132 (159, 150 mg, 0.500 mmol, 1.0 eq.), phenylboronic acid 
(168, 366 mg, 3.00 mmol, 6.0 eq.), Cu(OAc)2 (200 mg, 1.10 mmol, 2.2 eq.), NEt3 (348 µL, 
2.50 mmol, 5.0 eq.), pyridine (202 µL, 2.50 mmol, 5.0 eq.) and CH2Cl2 (50 mL) were used. The 
reaction was completed after 18 h and FCC (9.9:0.1 CH2Cl2/MeOH) yielded racemic diaryl 
ether SG-094 (192, 158 mg, 0.350 mmol, 70%) as colorless oil. The hydrochloride salt was 
formed according to general procedure J to yield a colorless solid. 
Rf = 0.61 (9:1 CH2Cl2/MeOH).  
m.p.: 75 °C (HCl salt).  
1H NMR (400 MHz, CD3OD) δ/ppm = 7.29 – 7.18 (m, 4H, Ph), 7.07 – 7.00 (m, 3H, 2’-H, 6’-H, 
Ph), 6.96 – 6.92 (m, 1H, Ph), 6.86 – 6.82 (m, 3H, 5-H, Ph), 6.79 – 6.75 (m, 2H, 3’-H, 5’-H), 
6.72 – 6.68 (m, 2H, Ph), 6.10 (s, 1H, 8-H), 3.75 (dd, J = 8.7, 4.4 Hz, 1H, 1-H), 3.72 (s, 3H, 
OCH3), 3.28 – 3.14 (m, 2H, α-H, 3-H), 2.96 (ddd, J = 15.5, 9.1, 6.6 Hz, 1H, 4-H), 2.83 – 2.74 
(m, 3H, α-H, 3-H, 4-H), 2.53 (s, 3H, NCH3).  
13C NMR (101 MHz, CD3OD) δ/ppm = 159.8 (qPh), 159.0 (qPh), 156.9 (C-4’), 151.7 (C-6), 
143.0 (C-7), 135.5 (C-1’), 132.2 (C-2’, C-6’), 131.9 (C-4a or C-8a), 130.8 (Ph), 130.6 (C-4a or 
C-8a), 130.4 (Ph), 124.0 (Ph), 123.0 (Ph), 122.6 (C-8), 119.9 (C-3’, C-5’), 119.5 (Ph), 117.3 
(Ph), 114.1 (C-5), 65.7 (C-1), 56.3 (OCH3), 47.3 (C-3), 42.6 (NCH3), 39.9 (C-α), 26.6 (C-4). 
IR (ATR) ṽmax/cm-1 = 3038, 2937, 2838, 2793, 1588, 1505, 1487, 1218, 749, 690.  
HRMS (ESI): calcd. for C30H30NO3 (M+H)+ 452.22202; found 452.22163.  
EXPERIMENTAL PART 
191 
Purity (HPLC): > 96% (λ = 210 nm). 
 
Separation of racemic SG-094 (192) via chiral HPLC (9.5:0.5 n-heptane/isopropanol + 0.45% 
diethylamine) yielded the two enantiomers (S)-SG-094 (211, colorless oil, retention time: 
~ 8 min) and (R)-SG-094 (212, colorless oil, retention time: ~ 11 min).  
 
(S)-SG-094 (211): [] = + 74.5 (c = 0.043, CHCl3). 
(R)-SG-094 (212): [] = - 52.5 (c = 0.057, CHCl3). 
 
(±)-6,7-Dimethoxy-1-(4-(4-methoxyphenoxy)benzyl)-2-methyl-1,2,3,4-tetrahydro-
isoquinoline  – SG-122 (193) 
 
Following general procedure I, SG-121 (185, 157 mg, 0.500 mmol, 1.0 eq.), 4-methoxyphenyl-
boronic acid (228 mg, 1.50 mmol, 3.0 eq.), Cu(OAc)2 (100 mg, 0.550 mmol, 1.1 eq.), NEt3 
(174 µL, 1.25 mmol, 2.5 eq.), pyridine (101 µL, 1.25 mmol, 2.5 eq.) and CH2Cl2 (50 mL) were 
used. After 18 h the reaction was completed and the product was purified by FCC (9.5:0.5 
CH2Cl2/MeOH) to yield racemic diaryl ether SG-122 (193, 185 mg, 0.441 mmol, 88%) as 
colorless oil. The hydrochloride salt was formed according to general procedure J to yield a 
colorless solid.  
Rf = 0.45 (9:1 CH2Cl2/MeOH).  
m.p.: 204 °C (HCl salt).  
1H NMR (500 MHz, CDCl3) δ/ppm = 7.04 – 7.01 (m, 2H, 2’-H, 6’-H), 6.96 – 6.92 (m, 2H, Ar), 
6.88 – 6.83 (m, 4H, 2’-H, 6’-H, Ar), 6.56 (s, 1H, 5-H), 6.05 (s, 1H, 8-H), 3.84 (s, 3H, OCH3), 
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3.80 (s, 3H, OCH3), 3.69 (dd, J = 7.5, 5.2 Hz, 1H, 1-H), 3.60 (s, 3H, OCH3), 3.23 – 3.12 (m, 
2H, α-H, 3-H), 2.86 – 2.74 (m, 3H, α-H, 3-H, 4-H), 2.58 (dt, J = 15.6, 4.5 Hz, 1H, 4-H), 2.53 (s, 
3H, NCH3).  
13C NMR (126 MHz, CDCl3) δ/ppm = 156.9 (C-4’), 155.9 (qAr), 150.6 (qAr), 147.4 (C-6), 146.4 
(C-7), 134.3 (C-1’), 131.0 (C-2’, C-6’), 129.4 (C-8a), 126.1 (C-4a), 120.7 (Ar), 117.6 (C-3’, C-
5’ or Ar), 115.0 (C-3’, C-5’ or Ar), 111.3 (C-5), 111.2 (C-8), 65.0 (C-1), 55.9 (OCH3), 55.8 
(OCH3), 55.7 (OCH3), 47.0 (C-3), 42.8 (NCH3), 40.6 (C-α), 25.6 (C-4). 
IR (ATR) ṽmax/cm-1 = 2971, 2629, 1504, 1265, 1227, 1111, 1006, 845.  
HRMS (ESI): calcd. for C26H30NO4 (M+H)+ 420.21693; found 420.21657.  
Purity (HPLC): > 96% (λ = 210 nm), > 96% (λ = 254 nm). 
 
(±)-6,7-Dimethoxy-2-methyl-1-(4-(3,4,5-trimethoxyphenoxy)benzyl)-1,2,3,4-tetrahydro-
isoquinoline hydrochloride – SG-127 (194) 
 
Following general procedure I, SG-121 (185, 157 mg, 0.500 mmol, 1.0 eq.), 3,4,5-trimethoxy-
phenylboronic acid (318 mg, 1.50 mmol, 3.0 eq.), Cu(OAc)2 (100 mg, 0.550 mmol, 1.1 eq.), 
NEt3 (174 µL, 1.25 mmol, 2.5 eq.), pyridine (101 µL, 1.25 mmol, 2.5 eq.) and CH2Cl2 (50 mL) 
were used. After 18 h the reaction was completed and the product was purified by FCC (CH2Cl2 
+ 1% NEt3), followed by recrystallization in EtOH as hydrochloride salt to yield diaryl ether SG-
127 (194, 216 mg, 0.418 mmol, 84%) as colorless solid. Analytical data are related to the 
hydrochloride salt. 
Rf = 0.47 (9:1 CH2Cl2/MeOH).  
m.p.: 183 °C (HCl salt).  
1H NMR (500 MHz, CDCl3) δ/ppm = 13.13 (s, 1H, NH), 7.11 – 7.05 (m, 2H, 2’-H, 6’-H), 6.94 
– 6.90 (m, 2H, 3’-H, 5’-H), 6.64 (s, 1H, 5-H), 6.22 (s, 2H, 2’’-H, 6’’-H), 5.71 (s, 1H, 8-H), 4.21 – 
4.11 (m, 2H, 1-H, α-H), 3.86 (s, 3H, OCH3), 3.82 (s, 3H, OCH3), 3.78 (s, 6H, 2 OCH3), 3.76 – 
3.70 (m, 1H, 3-H), 3.50 (s, 3H, OCH3), 3.40 – 3.33 (m, 1H, 3-H), 3.12 – 3.04 (m, 2H, 4-H), 2.94 
– 2.91 (m, 1H, α-H), 2.89 (s, 3H, NCH3).  
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13C NMR (126 MHz, CDCl3) δ/ppm = 157.2 (C-4’), 154.1 (C-3’’, C-5’’), 152.9 (C-1’’), 149.5 
(C-6), 147.5 (C-7), 134.6 (C-4’’), 131.8 (C-2’, C-6’), 130.2 (C-1’), 120.9 (C-4a or C-8a), 120.6 
(C-4a or C-8a), 118.5 (C-3’, C-5’), 111.3 (C-5 or C-8), 111.2 (C-5 or C-8), 97.1 (C-2’’, C-6’’), 
65.8 (C-1), 61.2 (OCH3), 56.3 (2 OCH3), 56.1 (OCH3), 55.7 (OCH3), 44.5 (C-3), 41.0 (C-α), 
40.1 (NCH3), 21.5 (C-4).  
IR (ATR) ṽmax/cm-1 = 2970, 2834, 2441, 1496, 1221, 1126, 1110, 1009, 989, 857.  
HRMS (ESI): calcd. for C28H34NO6 (M+H)+ 480.23806; found 480.23789.  
Purity (HPLC): > 96% (λ = 210 nm), > 96% (λ = 254 nm). 
 
(±)-6,7-Dimethoxy-1-(4-(4-methoxyphenoxy)phenyl)-2-methyl-1,2,3,4-tetrahydro-
isoquinoline – SG-157 (195) 
 
Following general procedure I, SG-121-NP (189, 150 mg, 0.500 mmol, 1.0 eq.), 4-methoxy-
phenylboronic acid (228 mg, 1.50 mmol, 3.0 eq.), Cu(OAc)2 (100 mg, 0.550 mmol, 1.1 eq.), 
NEt3 (174 µL, 1.25 mmol, 2.5 eq.), pyridine (101 µL, 1.25 mmol, 2.5 eq.) and CH2Cl2 (50 mL) 
were used. After 18 h the reaction was completed and the product was purified by FCC (CH2Cl2 
→ 9.8:0.2 CH2Cl2/MeOH) to yield diaryl ether SG-157 (195, 192 mg, 0.473 mmol, 95%) as 
colorless oil. The hydrochloride salt was formed according to general procedure J to yield a 
beige solid.  
Rf = 0.49 (9:1 CH2Cl2/MeOH).  
m.p.: 97 °C (HCl salt).  
1H NMR (500 MHz, (CD3)2SO) δ/ppm = 7.22 – 7.16 (m, 2H, 2’-H, 6’-H), 7.03 – 6.92 (m, 4H, 
2’’-H, 3’’-H, 5’’-H, 6’’-H), 6.90 – 6.84 (m, 2H, 3’-H, 5’-H), 6.69 (s, 1H, 5-H), 6.08 (s, 1H, 8-H), 
4.15 (s, 1H, 1-H), 3.74 (s, 3H, OCH3), 3.71 (s, 3H, OCH3), 3.46 (s, 3H, OCH3), 3.02 – 2.95 (m, 
2H, 3-H, 4-H), 2.71 – 2.63 (m, 1H, 4-H), 2.49 – 2.44 (m, 1H, 3-H), 2.12 (s, 3H, NCH3).  
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13C NMR (126 MHz, (CD3)2SO) δ/ppm = 156.9 (C-4’), 155.5 (C-4’’), 149.5 (C-1’’), 147.2 (C-6), 
146.7 (C-7), 138.2 (C-1’), 130.4 (C-2’, C-6’), 130.1 (C-8a), 126.4 (C-4a), 120.6 (C-2’’, C-6’’ or 
C-3’’, C-5’’), 116.9 (C-3’, C-5’), 115.0 (C-2’’, C-6’’ or C-3’’, C-5’’), 111.8 (C-8), 111.4 (C-5), 69.0 
(C-1), 55.5 (OCH3), 55.4 (2 OCH3), 51.2 (C-3), 43.8 (NCH3), 28.4 (C-4). 
IR (ATR) ṽmax/cm-1 = 2970, 2903, 2837, 1514, 1263, 1225, 1025, 820, 744.  
HRMS (ESI): calcd. for C25H28NO4 (M+H)+ 406.20128; found 406.20099.  
Purity (HPLC): > 96% (λ = 210 nm), > 96% (λ = 254 nm). 
 
(±)-6-Methoxy-2-methyl-7-phenoxy-1-(4-(4-(trifluoromethyl)phenoxy)benzyl)-1,2,3,4-
tetrahydroisoquinoline – SG-153 (199) 
 
Following general procedure I, phenol 186 (150 mg, 0.400 mmol, 1.0 eq.), 4-(trifluoromethyl)-
phenylboronic acid (228 mg, 1.20 mmol, 3.0 eq.), Cu(OAc)2 (79.8 mg, 0.440 mmol, 1.1 eq.), 
NEt3 (139 µL, 1.00 mmol, 2.5 eq.), pyridine (080.8 µL, 1.00 mmol, 2.5 eq.) and CH2Cl2 (50 mL) 
were used. After 18 h the reaction was completed and the product was purified by FCC (CH2Cl2 
→ 9.5:0.5 CH2Cl2/MeOH) to yield diaryl ether SG-153 (199, 50.7 mg, 0.0976 mmol, 24%) as 
brown oil. The hydrochloride salt was formed according to general procedure J to yield a yellow 
solid.  
Rf = 0.50 (9:1 CH2Cl2/MeOH).  
m.p.: 92 °C (HCl salt).  
1H NMR (400 MHz, CDCl3) δ/ppm = 7.54 – 7.48 (m, 2H, 3’’-H, 5’’-H), 7.26 – 7.22 (m, 2H, Ph), 
7.08 – 7.04 (m, 2H, 2’-H, 6’-H), 7.01 – 6.92 (m, 3H, 2’’-H, 6’’-H, Ph), 6.87 – 6.79 (m, 4H, 3’-H, 
5’-H, Ph), 6.68 (s, 1H, 5-H), 6.36 (s, 1H, 8-H), 3.77 (s, 3H, OCH3), 3.69 (t, J = 6.0 Hz, 1H, 1-
H), 3.18 (ddd, J = 13.0, 7.8, 5.2 Hz, 1H, 3-H), 3.09 (dd, J = 13.3, 5.2 Hz, 1H, α-H), 2.90 – 2.82 
(m, 2H, α-H, 4-H), 2.80 – 2.74 (m, 1H, 3-H), 2.66 (dt, J = 15.7, 5.2 Hz, 1H, 4-H), 2.53 (s, 3H, 
NCH3).  
13C NMR (101 MHz, CDCl3) δ/ppm = 160.9 (C-1’’), 158.4 (qPh), 153.8 (C-4’), 150.0 (C-6), 
142.2 (C-7), 136.0 (C-1’), 131.4 (C-2’, C-6’), 130.1 (C-8a), 129.6 (Ph), 128.7 (q, JCF = 277.9 
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Hz, CF3), 127.2 (q, JCF = 3.6 Hz, C-4’’), 124.6 (q, JCF = 32.9 Hz, C-3’’, C-5’’), 124.4 (C-4a), 
122.3 (Ph), 121.0 (C-8), 119.8 (C-3’, C-5’), 117.6 (C-2’’, C-6’’), 116.7 (Ph), 112.8 (C-5), 64.6 
(C-1), 56.1 (OCH3), 47.4 (C-3), 43.0 (NCH3), 40.0 (C-α), 26.4 (C-4). 
IR (ATR) ṽmax/cm-1 = 2980, 2907, 1602, 1506, 1325, 1243, 1221, 1103, 1064, 749.  
HRMS (ESI): calcd. for C31H29F3NO3 (M+H)+ 520.20940; found 520.20907.  
Purity (HPLC): > 96% (λ = 210 nm), > 96% (λ = 254 nm). 
 
(±)-6-Methoxy-2-methyl-7-phenoxy-1-(4-(4-(trifluoromethoxy)phenoxy)benzyl)-1,2,3,4-
tetrahydroisoquinoline – SG-154 (198) 
 
Following general procedure I, phenol 186 (150 mg, 0.400 mmol, 1.0 eq.), 4-
(trifluoromethoxy)-phenylboronic acid (247 mg, 1.20 mmol, 3.0 eq.), Cu(OAc)2 (79.8 mg, 
0.440 mmol, 1.1 eq.), NEt3 (139 µL, 1.00 mmol, 2.5 eq.), pyridine (80.8 µL, 1.00 mmol, 2.5 eq.) 
and CH2Cl2 (20 mL) were used. After 13 h the reaction was completed and purification of the 
product via preparative HPLC (7:3 n-heptane/isopropanol + 0.45% diethylamine, 15 mL flow) 
yielded diaryl ether SG-154 (198, 99.6 mg, 0.186 mmol, 47%) as light yellow oil. The 
hydrochloride salt was formed according to general procedure J to yield a light yellow solid.  
Rf = 0.51 (9:1 CH2Cl2/MeOH).  
m.p.: 90 °C (HCl salt).  
1H NMR (400 MHz, CDCl3) δ/ppm = 7.28 – 7.21 (m, 2H, Ph, collapses with chloroform), 
7.15 – 7.10 (m, 2H, 3’’-H, 5’’-H), 7.05 – 6.97 (m, 3H, 2’-H, 6’-H, Ph), 6.93 – 6.87 (m, 2H, 2’’-H, 
6’’-H), 6.85 – 6.79 (m, 4H, 3’-H, 5’-H, Ph), 6.67 (s, 1H, 5-H), 6.36 (s, 1H, 8-H), 3.77 (s, 3H, 
OCH3), 3.67 (t, J = 5.8 Hz, 1H, 1-H), 3.18 (ddd, J = 12.4, 8.0, 5.0 Hz, 1H, 3-H), 3.07 (dd, J = 
13.8, 5.8 Hz, 1H, α-H), 2.90 – 2.81 (m, 2H, 4-H, α-H), 2.76 (dt, J = 12.4, 5.2 Hz, 1H, 3-H), 2.65 
(dt, J = 15.9, 4.9 Hz, 1H, 4-H), 2.53 (s, 3H, NCH3).  
13C NMR (101 MHz, CDCl3) δ/ppm = 158.4 (qPh), 156.4 (C-1’’), 154.8 (C-4’), 150.0 (C-6), 
144.3 (q, JCF = 4.1 Hz, C-4’’), 142.2 (C-7), 135.3 (C-1’), 131.3 (C-8a), 131.2 (C-2’, C-6’), 130.2 
(C-4a), 129.5 (Ph), 122.6 (C-3’’, C-5’’), 122.2 (Ph), 121.0 (C-8), 120.7 (q, JCF = 256.5 Hz, CF3), 
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119.2 (C-3’, C-5’ or C-2’’, C-6’’), 119.1 (C-3’, C-5’ or C-2’’, C-6’’), 116.7 (Ph), 112.8 (C-5), 64.6 
(C-1), 56.1 (OCH3), 47.4 (C-3), 43.0 (NCH3), 40.0 (C-α), 26.4 (C-4). 
IR (ATR) ṽmax/cm-1 = 2980, 2889, 2440, 1510, 1497, 1239, 1218, 1187, 1163, 1106, 853, 751.  
HRMS (ESI): calcd. for C31H29F3NO4 (M+H)+ 536.20432; found 536.20393.  
Purity (HPLC): > 96% (λ = 210 nm), > 96% (λ = 254 nm). 
 
(±)-6-Methoxy-1-(4-(4-methoxyphenoxy)benzyl)-2-methyl-7-phenoxy-1,2,3,4-tetrahydro-
isoquinoline – SG-155 (196) 
 
Following general procedure I, phenol 186 (188 mg, 0.500 mmol, 1.0 eq.), 4-methoxy-
phenylboronic acid (228 mg, 1.50 mmol, 3.0 eq.), Cu(OAc)2 (100 mg, 0.550 mmol, 1.1 eq.), 
NEt3 (174 µL, 1.25 mmol, 2.5 eq.), pyridine (101 µL, 1.25 mmol, 2.5 eq.) and CH2Cl2 (20 mL) 
were used. After 20 h the reaction was completed and the product was purified by FCC (CH2Cl2 
→ 9.9:0.1 CH2Cl2/MeOH) to give diaryl ether SG-155 (196, 162 mg, 0.336 mmol, 67%) as 
colorless oil. The hydrochloride salt was formed according to general procedure J to yield a 
light yellow solid.  
Rf = 0.49 (9:1 CH2Cl2/MeOH).  
m.p.: 81 °C (HCl salt).  
1H NMR (500 MHz, CD3OD) δ/ppm = 7.23 – 7.20 (m, 2H, Ph), 6.98 – 6.94 (m, 3H, 3’-H, 5’-H, 
Ph), 6.85 – 6.79 (m, 5H, 5-H, 2’’-H, 6’’-H, 3’’-H, 5’’-H), 6.72 – 6.68 (m, 4H, 2’-H, 6’-H, 3’-H, 5’-
H), 6.07 (s, 1H, 8-H), 3.77 (s, 3H, OCH3), 3.71 (s, 4H, 1-H, OCH3), 3.23 (ddd, J = 13.7, 9.4, 6.1 
Hz, 1H, 3-H), 3.15 (dd, J = 13.3, 4.4 Hz, 1H, α-H), 2.97 (ddd, J = 15.9, 9.4, 6.8 Hz, 1H, 4-H), 
2.82 – 2.73 (m, 3H, 3-H, 4-H, α-H), 2.53 (s, 3H, NCH3).  
13C NMR (126 MHz, CD3OD) δ/ppm = 159.8 (qPh), 158.2 (C-4’), 157.2 (C-4’’), 151.9 (C-6 or 
C-1’’), 151.7 (C-6 or C-1’’), 142.9 (C-7), 134.6 (C-1’), 132.0 (C-3’, C-5’), 131.8 (C-8a), 130.6 
(C-4a), 130.4 (Ph), 123.0 (Ph), 122.6 (C-8), 121.4 (C-2’’, C-6’’ or C-3’’, C-5’’), 118.7 (C-2’, C-
6’), 117.3 (Ph), 115.9 (C-2’’, C-6’’ or C-3’’, C-5’’), 114.1 (C-5), 65.7 (C-1), 56.3 (OCH3), 56.1 
(OCH3), 47.3 (C-3), 42.6 (NCH3), 39.8 (C-α), 26.6 (C-4). 
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IR (ATR) ṽmax/cm-1 = 2940, 2907, 2523, 2360, 1496, 1264, 1218, 750, 690.  
HRMS (ESI): calcd. for C31H32NO4 (M+H)+ 482.23258; found 482.23255.  
Purity (HPLC): > 96% (λ = 210 nm), > 96% (λ = 254 nm). 
 
(±)-6-Methoxy-2-methyl-7-phenoxy-1-(4-(3,4,5-trimethoxyphenoxy)benzyl)-1,2,3,4-tetra-
hydroisoquinoline – SG-161 (197) 
 
Following general procedure I, phenol 186 (100 mg, 0.266 mmol, 1.0 eq.), 3,4,5-trimethoxy-
phenylboronic acid (169 mg, 0.799 mmol, 3.0 eq.), Cu(OAc)2 (53.2 mg, 0.293 mmol, 1.1 eq.), 
NEt3 (92.8 µL, 0.666 mmol, 2.5 eq.), pyridine (53.9 µL, 0.666 mmol, 2.5 eq.) and CH2Cl2 
(50 mL) were used. After 20 h the reaction was completed and the product was purified by 
FCC (CH2Cl2 → 9.7:0.3 CH2Cl2/MeOH) to yield diaryl ether SG-161 (197, 100 mg, 0.185 mmol, 
69%) as colorless oil. The hydrochloride salt was formed according to general procedure J to 
yield a colorless solid.  
Rf = 0.65 (9:1 CH2Cl2/MeOH).  
m.p.: 82 °C (HCl salt).  
1H NMR (500 MHz, CD3OD) δ/ppm = 7.23 – 7.18 (m, 2H, Ph), 7.04 – 7.00 (m, 2H, 2’-H, 6’-H), 
6.96 – 6.92 (m, 1H, Ph), 6.83 (s, 1H, 5-H), 6.80 – 6.76 (m, 2H, 3’-H, 5’-H), 6.71 – 6.66 (m, 2H, 
Ph), 6.20 (s, 2H, 2’’-H, 6’’-H), 6.14 (s, 1H, 8-H), 3.76 – 3.74 (m, 1H, 1-H), 3.73 (s, 3H, OCH3), 
3.71 (s, 3H, OCH3), 3.70 (s, 6H, 2 OCH3), 3.24 (ddd, J = 13.7, 9.1, 6.1 Hz, 1H, 3-H), 3.16 (dd, 
J = 13.4, 4.4 Hz, 1H, α-H), 2.99 – 2.92 (m, 1H, 4-H), 2.83 – 2.75 (m, 3H, 3-H, 4-H, α-H), 2.54 
(s, 3H, NCH3). 
13C NMR (126 MHz, CD3OD) δ/ppm = 159.8 (qPh), 157.1 (C-4’), 155.4 (C-1’’), 155.2 (C-3’’, C-
5’’), 151.7 (C-6), 143.0 (C-7), 135.4 (C-1’), 135.0 (C-4’’), 132.2 (C-2’, C-6’), 132.0 (C-8a), 130.6 
(C-4a), 130.4 (Ph), 123.0 (Ph), 122.6 (C-8), 119.6 (C-3’, C-5’), 117.3 (Ph), 114.1 (C-5), 97.6 
(C-2’’, C-6’’), 65.7 (C-1), 61.2 (OCH3), 56.5 (2 OCH3), 56.3 (OCH3), 47.5 (C-3), 42.7 (NCH3), 
39.9 (C-α), 26.7 (C-4). 
IR (ATR) ṽmax/cm-1 = 3725, 2940, 2360, 2341, 1496, 1216, 1124, 993, 690.  
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HRMS (ESI): calcd. for C33H36NO6 (M+H)+ 542.25371; found 542.25327.  
Purity (HPLC): > 96% (λ = 210 nm), > 96% (λ = 254 nm). 
 
(±)-6-Methoxy-2-methyl-7-phenoxy-1-(4-(p-tolyloxy)benzyl)-1,2,3,4-
tetrahydroisoquinoline hydrochloride – SG-162 (200) 
N
O
O
O
SG-162 (200)
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Following general procedure I, phenol 186 (100 mg, 0.266 mmol, 1.0 eq.), 4-methylbenzene-
boronic acid (109 mg, 0.799 mmol, 3.0 eq.), Cu(OAc)2 (53.2 mg, 0.293 mmol, 1.1 eq.), NEt3 
(92.8 µL, 0.666 mmol, 2.5 eq.), pyridine (53.9 µL, 0.666 mmol, 2.5 eq.) and CH2Cl2 (20 mL) 
were used. After 20 h the reaction was completed and the product was purified by FCC (CH2Cl2 
→ 9.7:0.3 CH2Cl2/MeOH) to yield diaryl ether SG-162 (200, 59.0 mg, 0.127 mmol, 48%) as 
light brown oil, which was, according to general procedure J, directly transferred into its 
hydrochloride salt to yield a beige solid. Analytical data are related to the hydrochloride salt. 
Rf = 0.61 (9:1 CH2Cl2/MeOH).  
m.p.: 79 °C (HCl salt).  
1H NMR (500 MHz, CD3OD) δ/ppm = 7.27 – 7.23 (m, 2H, Ph), 7.12 – 7.06 (m, 4H, 2’-H, 6’-H, 
2’’-H, 6’’-H), 7.03 – 6.98 (m, 2H, 5-H, Ph), 6.84 – 6.81 (m, 2H, 3’-H, 5’-H), 6.79 – 6.74 (m, 2H, 
3’’-H, 5’’-H), 6.72 – 6.68 (m, 2H, Ph), 6.07 (s, 1H, 8-H), 4.56 (dd, J = 10.0, 4.7 Hz, 1H, 1-H), 
3.90 – 3.83 (m, 1H, 3-H), 3.78 (s, 3H, OCH3), 3.54 – 3.48 (m, 1H, 3-H), 3.39 (dd, J = 13.2, 4.7 
Hz, 1H, α-H), 3.28 – 3.20 (m, 2H, 4-H), 3.11 – 2.99 (m, 4H, α-H, NCH3), 2.32 (s, 3H, CH3). 
13C NMR (126 MHz, CD3OD) δ/ppm = 159.0 (qPh), 158.8 (C-4’), 155.8 (C-4’’), 153.3 (C-6), 
144.4 (C-7), 134.4 (C-1’’), 132.3 (C-2’’, C-6’’), 131.3 (C-2’, C-6’), 130.6 (Ph), 130.4 (C-1’), 127.7 
(C-4a), 123.6 (C-8), 122.3 (C-8a), 120.2 (C-3’’, C-5’’), 119.6 (C-3’, C-5’), 117.8 (Ph), 114.2 (C-
5), 65.7 (C-1), 57.5 (C-α), 56.4 (OCH3), 46.5 (C-3), 40.7 (NCH3), 24.7 (C-4), 20.7 (CH3). 
IR (ATR) ṽmax/cm-1 = 3406, 2971, 2443, 1499, 1230, 1107, 749.  
HRMS (ESI): calcd. for C31H32NO3 (M+H)+ 466.23767; found 466.23751.  
Purity (HPLC): > 96% (λ = 210 nm), > 96% (λ = 254 nm). 
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(±)-6-Methoxy-2-methyl-7-phenoxy-1-(4-(pyridin-4-yloxy)benzyl)-1,2,3,4-tetrahydro-
isoquinoline – SG-163 (203) 
 
Following general procedure I, phenol 186 (100 mg, 0.266 mmol, 1.0 eq.), pyridine-4-boronic 
acid (98.2 mg, 0.799 mmol, 3.0 eq.), Cu(OAc)2 (53.2 mg, 0.293 mmol, 1.1 eq.), NEt3 (92.8 µL, 
0.666 mmol, 2.5 eq.), pyridine (53.9 µL, 0.666 mmol, 2.5 eq.) and CH2Cl2 (20 mL) were used. 
After 20 h the reaction was completed and the product was purified via preparative HPLC (6:4 
n-heptane/isopropanol + 0.45% diethylamine, 15 mL flow) to yield diaryl ether SG-163 (203, 
30.6 mg, 0.0676 mmol, 25%) as colorless oil. The hydrochloride salt was formed according to 
general procedure J to yield a colorless solid.  
Rf = 0.54 (9:1 CH2Cl2/MeOH).  
m.p.: 233 °C (HCl salt).  
1H NMR (400 MHz, CDCl3) δ/ppm = 8.41 (dd, J = 4.8, 1.5 Hz, 2H, 2’’-H, 6’’-H), 7.27 – 7.22 (m, 
2H, Ph, collapses with chloroform), 7.11 – 7.07 (m, 2H, 2’-H, 6’-H), 7.01 – 6.96 (m, 1H, Ph), 
6.90 – 6.86 (m, 2H, 3’-H, 5’-H), 6.85 – 6.82 (m, 2H, Ph), 6.76 – 6.72 (m, 2H, 3’’-H, 5’’-H), 6.68 
(s, 1H, 5-H), 6.37 (s, 1H, 8-H), 3.77 (s, 3H, OCH3), 3.70 (t, J = 6.2 Hz, 1H, 1-H), 3.22 – 3.15 
(m, 1H, 3-H), 3.10 (dd, J = 14.0, 5.4 Hz, 1H, α-H), 2.90 – 2.75 (m, 3H, 3-H, 4-H, α-H), 2.65 (dt, 
J = 16.6, 5.1 Hz, 1H, 4-H), 2.54 (s, 3H, NCH3). 
13C NMR (101 MHz, CDCl3) δ/ppm = 165.1 (C-1’’), 158.4 (qPh), 152.2 (C-4’), 151.5 (C-3’’, C-
5’’), 150.0 (C-6), 142.2 (C-7), 136.9 (C-1’), 131.5 (C-2’, C-6’), 131.4 (C-4a), 130.0 (C-8a), 129.6 
(Ph), 122.3 (Ph), 121.0 (C-8), 120.5 (C-3’, C-5’), 116.7 (Ph), 112.8 (C-5), 112.1 (C-2’’, C-6’’), 
64.6 (C-1), 56.1 (OCH3), 47.5 (C-3), 43.0 (NCH3), 40.0 (C-α), 26.5 (C-4). 
IR (ATR) ṽmax/cm-1 = 3406, 2979, 2451, 1636, 1509, 1490, 1273, 1219, 747.  
HRMS (ESI): calcd. for C29H29N2O3 (M+H)+ 453.21727; found 453.21781.  
Purity (HPLC): > 96% (λ = 210 nm), > 96% (λ = 254 nm). 
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(±)-4-(4-((6-Methoxy-2-methyl-7-phenoxy-1,2,3,4-tetrahydroisoquinolin-1-yl)methyl)-
phenoxy)benzonitrile – SG-164 (201) 
 
Following general procedure I, phenol 186 (100 mg, 0.266 mmol, 1.0 eq.), 4-cyanophenyl-
boronic acid (117 mg, 0.799 mmol, 3.0 eq.), Cu(OAc)2 (53.2 mg, 0.293 mmol, 1.1 eq.), NEt3 
(92.8 µL, 0.666 mmol, 2.5 eq.), pyridine (53.9 µL, 0.666 mmol, 2.5 eq.) and CH2Cl2 (50 mL) 
were used. After 20 h the reaction was completed and the product was purified by FCC (CH2Cl2 
→ 9.7:0.3 CH2Cl2/MeOH) to yield diaryl ether SG-164 (201, 61.1 mg, 0.128 mmol, 48%) as 
colorless oil. The hydrochloride salt was formed according to general procedure J to yield a 
colorless solid.  
Rf = 0.65 (9:1 CH2Cl2/MeOH).  
m.p.: 124 °C (HCl salt).  
1H NMR (400 MHz, CDCl3) δ/ppm = 7.56 – 7.51 (m, 2H, 2’’-H, 6’’-H), 7.27 – 7.22 (m, 2H, Ph, 
collapses with chloroform), 7.10 – 7.06 (m, 2H, 2’-H, 6’-H), 7.01 – 6.96 (m, 1H, Ph), 6.92 – 
6.88 (m, 2H, 3’’-H, 5’’-H), 6.88 – 6.81 (m, 4H, 3’-H, 5’-H, Ph), 6.68 (s, 1H, 5-H), 6.37 (s, 1H, 8-
H), 3.77 (s, 3H, OCH3), 3.69 (t, J = 6.1 Hz, 1H, 1-H), 3.18 (ddd, J = 12.8, 7.9, 5.1 Hz, 1H, 3-
H), 3.09 (dd, J = 13.8, 5.4 Hz, 1H, α-H), 2.90 – 2.74 (m, 3H, 3-H, 4-H, α-H), 2.65 (dt, J = 16.0, 
5.0 Hz, 1H, 4-H), 2.53 (s, 3H, NCH3). 
13C NMR (101 MHz, CDCl3) δ/ppm = 162.0 (C-1’’), 158.4 (qPh), 152.9 (C-4’), 150.0 (C-6), 
142.1 (C-7), 136.7 (C-1’), 134.2 (C-2’’, C-6’’), 131.5 (C-2’, C-6’), 131.4 (C-4a), 130.0 (C-8a), 
129.6 (Ph), 122.2 (Ph), 121.1 (C-8), 120.2 (C-3’, C-5’), 119.1 (C-4’’), 117.8 (C-3’’, C-5’’), 116.6 
(Ph), 112.8 (C-5), 105.6 (CN), 64.6 (C-1), 56.1 (OCH3), 47.4 (C-3), 43.0 (NCH3), 40.0 (C-α), 
26.4 (C-4). 
IR (ATR) ṽmax/cm-1 = 2940, 2225, 1596, 1495, 1245, 1218, 1166, 836, 750, 736, 690.  
HRMS (ESI): calcd. for C31H29N2O3 (M+H)+ 477.21727; found 477.21773.  
Purity (HPLC): > 96% (λ = 210 nm), > 96% (λ = 254 nm). 
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(±)-1-(4-(3,4-Dichlorophenoxy)benzyl)-6-methoxy-2-methyl-7-phenoxy-1,2,3,4-
tetrahydroisoquinoline – SG-165 (202) 
 
Following general procedure I, phenol 186 (100 mg, 0.266 mmol, 1.0 eq.), 3,4-dichlorophenyl-
boronic acid (152 mg, 0.799 mmol, 3.0 eq.), Cu(OAc)2 (53.2 mg, 0.293 mmol, 1.1 eq.), NEt3 
(92.8 µL, 0.666 mmol, 2.5 eq.), pyridine (53.9 µL, 0.666 mmol, 2.5 eq.) and CH2Cl2 (20 mL) 
were used. After 20 h the reaction was completed and the product was purified by FCC (CH2Cl2 
→ 9.7:0.3 CH2Cl2/MeOH) to yield diaryl ether SG-165 (202, 109 mg, 0.208 mmol, 78%) as 
brown oil. The hydrochloride salt was formed according to general procedure J to yield a beige 
solid.  
Rf = 0.58 (9:1 CH2Cl2/MeOH).  
m.p.: 92 °C (HCl salt).  
1H NMR (400 MHz, CDCl3) δ/ppm = 7.31 (d, J = 8.8 Hz, 1H, 5’’-H), 7.28 – 7.22 (m, 2H, Ph, 
collapses with chloroform), 7.06 – 6.97 (m, 4H, 2’-H, 6’-H, 2’’-H, Ph), 6.87 – 6.83 (m, 2H, Ph), 
6.82 – 6.78 (m, 2H, 3’-H, 5’-H), 6.75 (dd, J = 8.8, 2.8 Hz, 1H, 6’’-H), 6.67 (s, 1H, 5-H), 6.40 (s, 
1H, 8-H), 3.78 (s, 3H, OCH3), 3.68 (t, J = 5.6 Hz, 1H, 1-H), 3.17 (ddd, J = 12.6, 7.8, 5.1 Hz, 
1H, 3-H), 3.06 (dd, J = 13.9, 5.6 Hz, 1H, α-H), 2.89 – 2.73 (m, 3H, 3-H, 4-H, α-H), 2.64 (dt, J = 
15.6, 5.1 Hz, 1H, 4-H), 2.52 (s, 3H, NCH3). 
13C NMR (101 MHz, CDCl3) δ/ppm = 158.3 (qPh), 157.1 (C-1’’ or C-3’’), 154.2 (C-4’), 149.9 
(C-6), 142.3 (C-7), 135.8 (C-1’), 133.2 (C-1’’ or C-3’’), 131.3 (C-2’, C-6’), 131.2 (C-4a), 131.0 
(C-5’’), 130.1 (C-8a), 129.5 (Ph), 126.1 (C-4’’), 122.3 (Ph), 120.9 (C-8), 120.1 (C-2’’), 119.2 (C-
3’, C-5’), 117.7 (C-6’’), 116.8 (Ph), 112.7 (C-5), 64.6 (C-1), 56.1 (OCH3), 47.6 (C-4), 43.0 
(NCH3), 40.1 (C-α), 26.4 (C-4). 
IR (ATR) ṽmax/cm-1 = 2979, 1585, 1505, 1489, 1466, 1261, 1223, 1119, 750.  
HRMS (ESI): calcd. for C30H2835Cl2NO3 (M+H)+ 520.14408; found 520.14478.  
Purity (HPLC): > 96% (λ = 210 nm), > 96% (λ = 254 nm). 
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5.2.2.6 Further reactions 
(±)-7-(benzyloxy)-1-(4-(benzyloxy)-3-methoxybenzyl)-2-ethyl-6-methoxy-1,2,3,4-
tetrahydroisoquinoline – SG-158 (208) 
 
(±)-7-(Benzyloxy)-1-(4-(benzyloxy)-3-methoxybenzyl)-6-methoxy-1,2,3,4-
tetrahydroisoquinoline (Z6 (145), 100 mg, 0.188 mmol, 1.0 eq.), NEt3 (65.5 µL, 0.470 mmol, 
2.5 eq.) and KI (31.2 mg, 0.188 mmol, 1.0 eq.) were dispersed in CHCl3 (20 mL) and 
bromoethane (30.8 µL, 0.282 mmol, 1.5 eq.) was added. The reaction mixture was stirred at 
65 °C for 6 days and subsequently concentrated in vacuo. The residue was dissolved in CH2Cl2 
(30 mL) and washed with sat. aq. NaHCO3 solution (10 mL), 10% aq. citric acid solution 
(10 mL) and sat. aq. NaCl solution (10 mL). The organic layer was dried over Na2SO4, filtered 
and concentrated in vacuo. Purification by FCC (CH2Cl2 → 9.7:0.3 CH2Cl2/MeOH), followed by 
purification via preparative HPLC (6:4 n-heptane/isopropanol + 0.45% diethylamine, 15 mL 
flow) yielded racemic amine SG-158 (208, 23.2 mg, 0.0443 mmol, 24%) as colorless oil. The 
hydrochloride salt was formed according to general procedure J to yield a colorless solid.  
Rf = 0.54 (9:1 CH2Cl2/MeOH).  
m.p.: 211 °C (HCl salt).  
1H NMR (500 MHz, CDCl3) δ/ppm = 7.45 – 7.27 (m, 10H, PhCH2, collapses with chloroform), 
6.80 (d, J = 8.2 Hz, 1H, 5’-H), 6.62 (d, J = 1.9 Hz, 1H, 2’-H), 6.59 (s, 1H, 5-H), 6.55 (dd, J = 
8.3, 2.0 Hz, 1H, 6’-H), 6.05 (s, 1H, 8-H), 5.13 (s, 2H, PhCH2), 4.85 (d, J = 12.3 Hz, 1H, PhCH2), 
4.74 (d, J = 12.3 Hz, 1H, PhCH2), 3.86 (s, 3H, OCH3), 3.82 (s, 3H, OCH3), 3.75 (dd, J = 7.4, 
6.0 Hz, 1H, 1-H), 3.21 – 3.13 (m, 1H, 4-H), 3.04 (dd, J = 13.5, 5.2 Hz, 1H, α-H), 2.91 – 2.81 
(m, 2H, 3-H, 4-H), 2.72 – 2.66 (m, 3H, α-H, CH2CH3), 2.55 – 2.47 (m, 1H, 3-H), 1.12 (t, J = 7.1 
Hz, 3H, CH2CH3). 
13C NMR (126 MHz, CDCl3) δ/ppm = 149.4 (C-3’), 148.0 (C-6), 146.6 (C-4’), 145.6 (C-7), 137.5 
(qPhCH2), 137.5 (qPhCH2), 133.6 (C-1’), 129.8 (C-8a), 128.6 (PhCH2), 128.5 (PhCH2), 127.9 
(PhCH2), 127.8 (PhCH2), 127.4 (PhCH2), 127.3 (PhCH2), 127.1 (C-4a), 122.1 (C-6’), 114.2 (C-
2’), 113.9 (C-8 or C-5’), 113.8 (C-8 or C-5’), 111.9 (C-5), 71.3 (PhCH2), 71.0 (PhCH2), 62.6 (C-
1), 56.1 (2 OCH3), 47.8 (CH2CH3), 43.6 (C-3), 40.8 (C-α), 25.5 (C-4), 13.4 (CH2CH3). 
IR (ATR) ṽmax/cm-1 = 2998, 2359, 1589, 1514, 1264, 1226, 1021, 737, 696.  
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HRMS (ESI): calcd. for C34H38NO4 (M+H)+ 524.27954; found 524.28026.  
Purity (HPLC): > 96% (λ = 210 nm), > 96% (λ = 254 nm). 
 
(±)-7-(Benzyloxy)-1-(4-(benzyloxy)-3-methoxybenzyl)-6-methoxy-2-methyl-1,2,3,4-
tetrahydroisoquinoline – SG-159 (206) 
 
A solution of (±)-7-(benzyloxy)-1-(4-(benzyloxy)-3-methoxybenzyl)-6-methoxy-1,2,3,4-
tetrahydro-isoquinoline (Z6 (145),100 mg, 0.188 mmol, 1.0 eq.) and 37% aqueous 
formaldehyde (70.0 µL, 0.940 mmol, 5.0 eq.) in HPLC grade MeOH (5.0 mL) was acidified with 
glacial acetic acid (0.50 mL, final pH ~ 5), before NaCNBH3 (24.9 mg, 0.376 mmol, 2.0 eq.) 
was added. The reaction mixture was stirred for 2 days at rt and concentrated in vacuo to give 
a light yellow solid. The residue was dissolved in EtOAc (40 mL) and was washed with sat. aq. 
NaHCO3 solution (15 mL), 10% aq. citric acid solution (15 mL) and sat. aq. NaCl solution 
(15 mL). The organic layer was dried over Na2SO4 and concentrated in vacuo. The crude 
product was purified by FCC (CH2Cl2 → 9.7:0.3 CH2Cl2/MeOH) to yield racemic amine SG-159 
(206, 61.2 mg, 0.120 mmol, 64%) as colorless oil. The hydrochloride salt was formed 
according to general procedure J to yield a colorless solid.  
Rf = 0.57 (9:1 CH2Cl2/MeOH).  
m.p.: 87 °C (HCl salt).  
1H NMR (400 MHz, CDCl3) δ/ppm = 7.42 – 7.23 (m, 13H, PhCH2, collapses with chloroform), 
6.76 (d, J = 8.1 Hz, 1H, 5’-H), 6.61 – 6.54 (m, 2H, 5-H, 2’-H), 6.51 (dd, J = 8.1, 1.9 Hz, 1H, 6’-
H), 6.08 (s, 1H, 8-H), 5.11 (s, 2H, PhCH2), 4.84 (d, J = 12.3 Hz, 1H, PhCH2), 4.72 (d, J = 12.3 
Hz, 1H, PhCH2), 3.84 (s, 3H, OCH3), 3.78 (s, 3H, OCH3), 3.61 (dd, J = 7.2, 5.0 Hz, 1H, 1-H), 
3.17 – 3.02 (m, 2H, 3-H, α-H), 2.84 – 2.67 (m, 3H, 3-H, 4-H, α-H), 2.60 – 2.53 (m, 1H, 4-H), 
2.51 (s, 3H, NCH3). 
13C NMR (101 MHz, CDCl3) δ/ppm = 149.3 (C-3’), 147.9 (C-6), 146.6 (C-4’), 145.6 (C-7), 137.5 
(qPhCH2), 137.4 (qPhCH2), 133.2 (C-1’), 129.3 (C-8a), 128.7 (PhCH2), 128.6 (PhCH2), 127.9 
(PhCH2), 127.8 (PhCH2), 127.4 (PhCH2), 127.3 (PhCH2), 126.8 (C-4a), 122.0 (C-6’), 113.8 (C-
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8 or C-5’), 113.7 (C-8 or C-5’), 113.5 (C-2’), 111.7 (C-5), 71.2 (PhCH2), 70.9 (PhCH2), 64.8 (C-
1), 56.1 (2 OCH3), 47.2 (C-3), 42.9 (NCH3), 40.8 (C-α), 25.9 (C-4). 
IR (ATR) ṽmax/cm-1 = 2980, 2889, 2359, 1513, 1263, 1225, 1012, 696.  
HRMS (ESI): calcd. for C33H36NO4 (M+H)+ 510.26389; found 510.26339.  
Purity (HPLC): > 96% (λ = 210 nm), > 96% (λ = 254 nm). 
 
(±)-7-(Benzyloxy)-1-(4-(benzyloxy)benzyl)-6-methoxy-2-methyl-1,2,3,4-tetrahydro-
isoquinoline – SG-005 (187) 
An alternative route to receive SG-005 (187): A solution of Z3 (137, 251 mg, 0.500 mmol, 1.0 
eq.) and 37% aq. formaldehyde solution (68.9 µL, 2.50 mmol, 5.0 eq.) in HPLC grade MeOH 
(5.0 mL) was acidified with two drops of glacial acetic acid (0.50 mL, final pH ~ 5) and sodium 
cyanoborohydride (66.1 mg, 1.00 mmol, 2.0 eq.) was added. The reaction mixture was stirred 
for 4 days at rt and concentrated in vacuo to give a white solid. The residue was dissolved in 
EtOAc (40 mL) and was washed with sat. aq. NaHCO3 solution (15 mL), 10% aq. citric acid 
solution (15 mL) and sat. aq. NaCl solution (15 mL). The organic layer was dried over Na2SO4 
and concentrated in vacuo. The crude product was purified by FCC (9.5:0.5 CHCl3/MeOH) to 
yield SG-005 (187, 133 mg, 0.278 mmol, 56%) as off white solid. Analytical data are stated 
above.  
 
(±)-7-(Benzyloxy)-1-(4-(benzyloxy)benzyl)-6-methoxy-2-methyl-1,2,3,4-tetrahydro-
isoquinoline – SG-005 (187) 
An alternative route to receive SG-005 (187) via Mitsunobu reaction: SG-132 (159, 150 mg, 
0.500 mmol, 1.0 eq.) is dissolved in dry THF (5.0 mL), before PPh3 (629 mg, 2.40 mmol, 
4.8 eq.) and benzyl alcohol (145 µL, 1.40 mmol, 2.8 eq.) were added. The reaction mixture 
was cooled to 4 °C and DIAD (315 µL, 1.60 mmol, 3.2 eq.) was added dropwise. The mixture 
was allowed to warm to rt for 18 h and was then concentrated in vacuo. The residue was 
purified by FCC (9.9:0.1 → 9.7:0.3 CH2Cl2/MeOH) to yield SG-005 (187, 113 mg, 0.236 mmol, 
47%) as light yellow oil. Analytical data are stated above.  
 
5.2.2.7 Substances received from other sources 
Prof. Dr. Peter Pachaly† kindly provided tetrandrine (1) and fangchinoline (9) from natural 
sources and semi synthetic N,N-dimethyl-tetrandrine dichloride (139, Table 15). Prof. Dr. 
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Meinhart Zenk† kindly provided a compound library of 1-benzyl-1,2,3,4-tetrahydroisoquinolines 
(Z compounds, Table 15). 
Table 15: Substances received from other sources. *Analytical data are stated below.  
entry name abbreviation literature 
1 tetrandrine (1) - [143] 
2 fangchinoline (9) - [144] 
3 N,N- dimethyltetrandrine dichloride (139) - [145] 
4 (±)-coclaurine hydrochloride (141) Z1 [194, 195] 
5 R-coclaurine hydrochloride (142) Z2 [194, 195] 
6 
(±)-7-(benzyloxy)-1-(4-(benzyloxy)benzyl)-6-methoxy-1,2,3,4-
tetrahydroisoquinoline hydrochloride (137) Z3 
[82, 195]
* 
7 
(+)-O,O-dibenzyl coclaurine / (+)-7-(benzyloxy)-1-(4-
(benzyloxy)benzyl)-6-methoxy-1,2,3,4-tetrahydroisoquinoline 
(143) 
Z4 [193] 
8 
(±)-6-(benzyloxy)-1-(4-(benzyloxy)benzyl)-7-methoxy-1,2,3,4-
tetrahydroisoquinoline hydrochloride (144) Z5 
[196]
 
9 
(±)-O,O-dibenzyl nororientaline / (±)-7-(benzyloxy)-1-(4-
(benzyloxy)-3-methoxy-benzyl)-6-methoxy-1,2,3,4-
tetrahydroisoquinoline (145) 
Z6 [197] 
10 R-norreticuline (146) Z7/Z8 [198, 199] 
11 (±)-laudanosine (147) Z9 [200] 
12 
(±)-6-(benzyloxy)-1-(3-(benzyloxy)-4-methoxybenzyl)-7-
methoxy-1,2,3,4-tetrahydroisoquinoline hydrochloride (148) Z11 
[201]
 
13 
(±)-6,7-bis(benzyloxy)-1-(4-(benzyloxy)-3-methoxybenzyl)-2-
methyl-1,2,3,4-tetrahydroisoquinoline hydrochloride (149) Z12 
[202]
 
14 
(±)-5-(3,4-bis(benzyloxy)benzyl)-5,6,7,8-tetrahydro-
[1,3]dioxolo[4,5-g]isoquinoline hydrochloride (150) Z13 * 
15 
(±)-1-(benzo[d][1,3]dioxol-5-ylmethyl)-6,7-dimethoxy-1,2,3,4-
tetrahydroisoquinoline (151) Z14 
[203, 204]
 
16 
(±)-1-(benzo[d][1,3]dioxol-5-ylmethyl)-6-(benzyloxy)-7-methoxy-
1,2,3,4-tetrahydroisoquinoline (152) Z15 
[205]
 
17 
(±)-1-(benzo[d][1,3]dioxol-5-ylmethyl)-6,7-bis(benzyloxy)-
1,2,3,4-tetrahydroisoquin-oline (153) Z16/Z17 
[206]
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18 
(±)-1-(benzo[d][1,3]dioxol-5-ylmethyl)-6,7-bis(benzyloxy)-3,4-
dihydroisoquinoline (154) Z18 
[206]
 
19 
(±)-6,7-bis(benzyloxy)-1-((6-bromobenzo[d][1,3]dioxol-5-
yl)methyl)-1,2,3,4-tetrahydro-isoquinoline hydrochloride (155) Z20 * 
20 
(±)-1-((6-bromobenzo[d][1,3]dioxol-5-yl)methyl)-3,4-
dihydroisoquinoline-6,7-diol (156) Z21 
[207]
 
21 
N-(4-(benzyloxy)-3-methoxyphenethyl)-2-(4-(benzyloxy)-
phenyl)acetamide (157) Z22 
[208]
 
22 
Epiberberine chloride / 8,9-dimethoxy-11,12-dihydro-
[1,3]dioxolo-[4,5-h]isoquinolino[2,1-b]isoquinolin-13-ium chloride 
(158) 
Z23 [209] 
 
 
(±)-7-(benzyloxy)-1-(4-(benzyloxy)benzyl)-6-methoxy-1,2,3,4-tetrahydroisoquinoline 
hydrochloride – Z3 (137) 
1H NMR (500 MHz, CD3OD) δ/ppm = 7.51 – 7.25 (m, 10H), 7.21 – 7.12 (m, 2H), 7.08 – 6.99 
(m, 2H), 6.84 (s, 1H), 6.45 (s, 1H), 5.09 (s, 2H), 4.84 (d, J = 2.7 Hz, 2H), 4.64 (t, J = 7.3 Hz, 
1H), 3.85 (s, 3H), 3.61 – 3.47 (m, 1H), 3.42 – 3.34 (m, 1H), 3.31 – 3.24 (m, 1H), 3.17 – 3.00 
(m, 3H).  
13C NMR (126 MHz, CD3OD) δ/ppm = 159.8, 151.2, 148.0, 138.6, 138.3, 132.0, 129.5, 129.5, 
129.0, 128.9, 128.9, 128.7, 128.6, 125.5, 124.3, 116.5, 114.0, 113.2, 72.0, 71.0, 57.4, 56.5, 
49.5, 49.3, 49.2, 49.0, 48.8, 48.7, 48.5, 40.3, 40.1, 25.8. 
HRMS (ESI): calcd. for C31H32NO3 (M+H)+ 466.23767; found 466.23798.  
Purity (HPLC): > 96% (λ = 210 nm), > 96% (λ = 254 nm). 
 
(±)-O,O-dibenzyl nororientaline / (±)-7-(benzyloxy)-1-(4-(benzyloxy)-3-methoxy-benzyl)-
6-methoxy-1,2,3,4-tetrahydroisoquinoline – Z6 (145) 
1H NMR (500 MHz, CDCl3) δ/ppm = 9.27 (s, 1H), 7.51 – 7.23 (m, 10H), 7.04 – 6.99 (m, 2H), 
6.81 (s, 1H), 6.79 (dd, J = 8.2, 1.9 Hz, 1H), 6.63 (s, 1H), 5.05 (s, 2H), 4.90 – 4.76 (m, 2H), 4.59 
(t, J = 7.0 Hz, 1H), 3.75 (s, 6H), 3.32 – 3.29 (m, 1H), 3.27 – 3.09 (m, 3H), 3.03 – 2.87 (m, 2H). 
13C NMR (126 MHz, CDCl3) δ/ppm = 159.8, 151.2, 148.0, 138.6, 138.3, 132.0, 129.6, 129.5, 
129.0, 128.9, 128.8, 128.7, 128.6, 125.5, 124.3, 116.5, 114.0, 113.2, 72.0, 71.0, 57.4, 56.5, 
40.3, 40.1, 25.8. 
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HRMS (ESI): calcd. for C32H34NO4 (M+H)+ 496.24824; found 496.24827.  
Purity (HPLC): > 96% (λ = 210 nm), > 96% (λ = 254 nm). 
 
(±)-5-(3,4-bis(benzyloxy)benzyl)-5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g]isoquinoline 
hydrochloride – Z13 (150) 
1H NMR (500 MHz, CDCl3) δ/ppm = 10.22 (d, J = 7.6 Hz, 1H), 9.66 (d, J = 8.9 Hz, 1H), 7.42 – 
7.24 (m, 10H), 6.88 – 6.84 (m, 1H), 6.82 (s, 1H), 6.73 (dd, J = 8.2, 1.9 Hz, 1H), 6.51 (s, 1H), 
6.26 (s, 1H), 5.92 (d, J = 1.3 Hz, 1H), 5.89 (d, J = 1.2 Hz, 1H), 5.16 – 5.00 (m, 4H), 4.68 – 4.57 
(m, 1H), 3.44 – 3.34 (m, 1H), 3.27 – 3.16 (m, 2H), 3.08 – 2.95 (m, 2H), 2.83 – 2.71 (m, 1H). 
13C NMR (126 MHz, CDCl3) δ/ppm = 149.1, 148.4, 147.6, 146.8, 137.4, 128.7, 128.6, 128.4, 
127.9, 127.6, 127.5, 125.5, 124.2, 123.1, 121.5, 116.8, 115.6, 108.8, 107.0, 101.4, 77.4, 76.9, 
71.4, 55.3, 40.5, 38.9, 25.6. 
HRMS (ESI): calcd. for C31H30NO4 (M+H)+ 480.21693; found 480.21719.  
Purity (HPLC): > 96% (λ = 210 nm), > 96% (λ = 254 nm). 
 
(±)-6,7-bis(benzyloxy)-1-((6-bromobenzo[d][1,3]dioxol-5-yl)methyl)-1,2,3,4-tetrahydro-
isoquinoline hydrochloride – Z20 (155) 
1H NMR (500 MHz, (CD3)2SO) δ/ppm = 9.30 (s, 1H), 7.51 – 7.24 (m, 10H), 7.18 (s, 1H), 6.96 
(s, 1H), 6.60 (s, 1H), 6.08 (d, J = 7.7 Hz, 2H), 5.13 (s, 2H), 5.07 – 4.92 (m, 2H), 4.61 – 4.41 
(m, 1H), 3.47 – 3.37 (m, 1H), 3.37 – 3.25 (m, 3H), 3.25 – 3.14 (m, 2H), 3.12 – 3.00 (m, 1H), 
2.91 – 2.77 (m, 1H). 
13C NMR (126 MHz, (CD3)2SO) δ/ppm = 147.8, 147.7, 147.3, 146.5, 137.0, 128.4, 128.4, 128.2, 
127.8, 127.8, 127.6, 127.3, 125.0, 123.8, 115.0, 114.1, 112.7, 112.5, 111.9, 102.1, 70.2, 70.0, 
53.6, 38.8, 24.5. 
HRMS (ESI): calcd. for C31H2979BrNO4 (M+H)+ 558.12745; found 558.12829.  
Purity (HPLC): > 96% (λ = 210 nm), > 96% (λ = 254 nm). 
 
Berbamine dihydrochloride (10) was purchased from Sigma-Aldrich (now Merck, Darmstadt, 
Germany), cepharanthine (140) and dauricine (11) from Carbosynth (Compton, Berkshire, 
United Kingdom) and oxyacanthine sulfate (138) from abcr (Karlsruhe, Germany). 
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5.3 Biological methods 
5.3.1 High-throughput screening (HTS) 
The high-throughput screening was performed by Dr. Phuong Nguyen and myself in 
collaboration with the group of Prof. Dr. Michael Schaefer at the Rudolf-Böhm-Institut für 
Pharmakologie und Toxikologie, University of Leipzig. The experiments were run using a 
custom-made fluorescence imaging plate reader built into a robotic liquid handling station 
(Freedom Evo 150, Tecan, Männedorf, Switzerland) as previously described[22, 88].  
In brief, HEK-293 cells stably expressing human TPC2L11A/L12A-RFP and stably expressing 
human CLN3L253A/I254A -RFP were cultured at 37 °C with 5% of CO2 in Dulbecco’s modified 
Eagle medium (Thermo Fisher), supplemented with 10% fetal calf serum (Biochrom, Berlin, 
Germany), 2.00 mM L-glutamine, 100 U/mL penicillin, 0.100 mg/mL streptomycin, and 400-
800 µg/mL G418. Cells were incubated with Fluo-4/AM (15, 4.00 µM; Life Technologies, 
Eugene, Oregon, USA) for 30 min at 37 °C, washed and resuspended in a HEPES-buffered 
solution 1 (HBS1) comprising 132 mM NaCl, 6.00 mM KCl, 1.00 mM MgCl2, 1.00 mM CaCl2, 
10.0 mM HEPES, and 5.50 mM D-glucose (pH was adjusted to 7.4 with NaOH). Then, the cells 
were seeded on black walled, clear bottom 384-well plates (Greiner, Frickenhausen, 
Germany) and the plates were placed in the imaging reader. Experiments were performed with 
cell suspensions.  
For primary screening, individual compounds from Roche libraries (Xplore libraries X30 and 
X50, Roche, Basel, Switzerland) were diluted in HBS1 to a working concentration of 100 µM. 
After recording the baseline for 30 s, compounds were injected to a final concentration of 10 
µM. Recording continued for 180 s per quadrant (total 750 s for four quadrants). If high 
intensities were measured in both cell lines, the compounds were deemed false positives and 
excluded. From single hits with high intensities concentration effect experiments were 
performed. In case of a low IC50, hits were confirmed by single cell Ca-imaging. Concentration 
effect relationships were plotted using GraphPad Prism 5 and fitted to the Hill equation.  
Concentration-effect experiments were performed by Nicole Urban (Schäfer group) as 
described above.  
 
5.3.2 Single cell calcium imaging 
Single cell Ca2+ imaging experiments were performed as previously described[22, 115]. In more 
detail, HEK293 cells were cultured at 37 °C with 5% of CO2 in Dulbecco’s modified Eagle 
medium (Gibco), supplemented with 10% fetal bovine serum, 100 U/mL penicillin, and 0.100 
mg/mL streptomycin. Cells were plated onto poly-L-lysine (sigma)-coated glass coverslips, 
grown over two days and transiently transfected for 18-24 h with plasmids using TurboFect 
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(Thermo Fisher Scientific, Waltham, USA) according to the manufacturer’s instructions. 
Plasmids used for transfection were generated in the group of Prof. Christian Grimm and are 
literature known. Experiments for blockers were performed using HEK293 cells stably 
expressing TPC2L11A/L12A –RFP[14, 22, 28, 114, 115].  
Transfected cells were loaded for 1 h at 37 °C with 10% of CO2 with Fura-2/AM (126, 4.0 µM) 
and 0.005% (v/v) Pluronic® F-127 (both from Thermo Fisher) in HEPES-buffered solution 2 
(HBS2) comprising 138 mM NaCl, 6.00 mM KCl, 1.00 mM MgCl2, 2.00 mM CaCl2, 10.0 mM 
HEPES, and 5.50 mM D-glucose (pH was adjusted to 7.4 with NaOH). After loading, cells were 
washed in HBS2, and mounted in an imaging chamber. All recordings were performed in 
HBS2. Images were acquired every 2 s at 40X magnification using a monochromator-based 
imaging system (Polychrome IV mono-chromator, TILL photonics or a Leica DMi8 live cell 
microscope). Fura-2 (13) was excited at 340 nm/380 nm and emitted fluorescence was 
captured using 515 nm long-pass filters.  
Compound stock solutions (10 mM in DMSO) were pre diluted with HBS2 to a working 
concentration of 100 µM (1% DMSO). Chambers were filled with 450 µL HBS2 and the 
baseline was recorded for 50 s. Then, 50 µL of the compound solution to be tested were added 
to reach a final concentration of 10 µM. After 400 s the experiments were stopped. If no 
activation was observed or an inhibitor should be tested, a known activator was added to 
confirm the correctness of the experiment or if the substance is a blocker. Activation/inhibition 
was illustrated using GraphPad Prism 5.  
 
5.3.3 MTT 
The MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay was performed 
by Martina Stadler (Bracher group) and conducted with HL-60 cells. First the number of cells 
per mL was determined with a hepatocyte cell counter (Fuchs-Rosenthal). Then the cell 
suspension was diluted with medium to 9 x 105 cells mL-1.  
Compounds to be tested were dissolved in DMSO to give 10 mM stock solutions and used for 
a dilution series (10 mM, 5 mM, 2.5 mM, 1.25 mM, 0.625 mM, 0.3125 mM). For negative 
control 1% DMSO was used and for positive control Triton® X-100 solution with a final 
concentration of 1 µg/mL was added.  
Cell suspensions (99 µL each) were seeded on 96-well plates and incubated at 37 °C with 5% 
CO2 for 24 h. Then, compound solutions (1 µL) were added and again incubated at 37 °C with 
5% CO2 for 24 h. After that, 10 µL MTT solution (5.0 mg MTT in 1.0 mL PBS) was added to 
each well and further incubated for two hours, followed by addition of 190 µL DMSO. After one 
hour shaking continuously, photometric quantification was conducted at a wavelength of 570 
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nm with an MRX microplate reader (DYNEX Technologies, Chentilly, USA). Concentration-
effect relationships were plotted using GraphPad Prism 5.  
 
5.3.4 Agar diffusion test 
Agar diffusion tests were performed by Martina Stadler (Bracher group). Microorganisms were 
obtained from Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (DSMZ, 
Braunschweig) and cultivated according to recommendations in liquid culture using different 
agars. For Saccharomyces cerevisiae (DSM number: 1333), Hyphopichia burtonii (DSM 
number: 70663), Yarrowia lipolytica (DSM number: 1345), Escherichia coli (DSM number: 426) 
and Pseudomonas marginalis (DSM number: 7527) all-culture agar (AC-agar, Sigma Aldrich) 
was used. Therefore 35.2 g AC-agar and 20 g agar were suspended in 1.0 L water and treated 
by autoclave. For Staphylococcus equorum (DSM number: 20675) and Streptococcus 
entericus (DSM number: 14446) an agar is likewise prepared from 10.0 g caseinpeptone, 5.0 
g yeast extract, 5.0 g glucose and 5.0 g sodium chloride in 1.0 L water. After treatment in the 
autoclave 15 mL of the warm, liquid agar was filled into Petri dishes and cooled to 8 °C for one 
hour. 
Solutions with 1% (m/V) compound in DMSO were prepared. Then, 3.0 µL of each solution 
was plated onto small filter plates (diameter 6 mm, Macherey-Nagel), equivalent to 30 µg 
substance. As positive control clotrimazole and tetracycline were used. Blind control was 
conducted with mere DMSO. The small filter plates were then dried for 24 hours at room 
temperature.  
For final experiments the germs were brought onto the different agars using cotton swabs. The 
platelets containing the substances, the reference, and the blind control were put onto the 
agar, too. The agar plates were incubated for 36 h at 32 °C (bacteria) or 28 °C (yeasts). Then, 
the diameters of growth inhibition (inhibition zones) were measured manually. 
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6 Appendices 
6.1 Abbreviations 
5‐HT  5‐hydroxytryptamine receptors  
Å  Angstrom 
ALS amyotrophic lateral sclerosis 
AM acetoxymethyl 
APCI atmospheric-pressure chemical ionization 
aq. aqueous 
ASAP atmospheric pressure solids analysis probe 
BK large conductance calcium-activated potassium channels/big potassium 
Bn benzyl 
calcd. calculated 
Cav voltage gated calcium channel 
CB1R cannabinoid‐1 receptor 
CLN3 battenin 
CTB cell titer blue 
cy cyclohexyl 
CYP cytochrome P 
DCC N,N′-dicyclohexylcarbodiimide 
DIPA diisopropylamine 
DMF dimethylformamide 
DMSO  dimethyl sulfoxide 
ECD Electronic circular dichroism spectra 
EDC ethylene dichloride 
EGF epidermal growth factor 
EI electron ionization 
eq. equivalents 
ESI  electron spray ionization 
FCC flash column chromatography 
h  hour 
HCT-15 human colorectal adenocarcinoma cells 
HEK293 human embryonic kidney cells 
HepaRG hepatic stem cells 
HepG2 human hepatocellular carcinoma cells 
HERG human Ether-à-go-go-Related Gene 
HIV human immunodeficiency virus   
HPLC high-performance liquid chromatography 
HRMS high-resolution mass spectrometry 
HSQC heteronuclear single quantum correlation 
HTS high-throughput screening 
HUVEC human umbilical vein endothelial cells 
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Hz hertz 
IR infrared spectroscopy 
JNCL juvenile neuronal ceroid lipofuscinosis 
KATP ATP-sensitive potassium channel 
LDA lithium diisopropylamide 
LHMDS lithium bis(trimethylsilyl)amide 
LOPAC Library of Pharmacologically Active Compounds 
LRRK2 leucine‐rich repeat kinase 2 
LSD Lysosomal storage disease 
m meta 
m  multiplet (NMR) 
M molar 
m.p. melting point 
Me methyl 
MERS‐CoV Middle East respiratory syndrome coronavirus 
min  minutes 
mmol  millimole 
mol mole 
MS multiple sclerosis 
mTOR mechanistic target of rapamycin 
MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromid 
mw microwave 
n.a. not applicable 
NAADP nicotinic acid adenine dinucleotide phosphate 
Nav voltage gated sodium channel 
NBS N-bromosuccinimide 
n-BuLi n-butyllithium 
NMDA N ‐methyl‐D‐aspartate receptor 
NMR nuclear magnetic resonance 
ns not significant 
NT non-transfected 
o ortho 
p para 
PBMC peripheral blood mononuclear cells 
PG protecting group 
P-gp P-glycoprotein 
ph phenyl 
PI(3,5)P2 phosphatidylinositol 3,5‐bisphosphate 
PIKfyve FYVE finger-containing phosphoinositide kinase 
ppm  parts per million 
q  quartet (NMR) 
Rf  retardation factor 
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RFP red fluorescent protein 
rt  room temperature 
s  singlet (NMR) 
SAR structure-activity relationships 
SARS-CoV-2 severe acute respiratory syndrome coronavirus 2  
sat. saturated 
SEM standard error of the mean 
SERM selective estrogen receptor modulators 
SSRI selective serotonin reuptake inhibitors 
TCA tricyclic antidepressants 
TFA  trifluoroacetic acid 
TFEB transcription factor EB 
THF tetrahydrofuran 
TLC thin-layer chromatography 
TPC two pore channel 
TRPA transient receptor potential channel ankyrin 
TRPC transient receptor potential channel canonical 
TRPM transient receptor potential channel melastatin 
TRPML transient receptor potential cation channel 
TRPV transient receptor potential channel vanilloid 
TTX tetrodotoxin 
VCR-R CEM vincristine-resistant acute lymphoblastic leukemia cells 
VEGF vascular endothelial growth factors 
WHO world health organization 
YFP yellow fluorescent protein 
 
  
APPENDICES 
214 
6.2 References  
[1] H. Chen, J. Wu, Y. Gao, H. Chen, J. Zhou, Curr Top Med Chem 2016, 16, 2107-2114. 
[2] Y. Sakurai, A. A. Kolokoltsov, C. C. Chen, M. W. Tidwell, W. E. Bauta, N. Klugbauer, 
C. Grimm, C. Wahl-Schott, M. Biel, R. A. Davey, Science 2015, 347, 995-998. 
[3] S. Patel, Sci Signal 2015, 8, re7. 
[4] J. Castonguay, J. H. C. Orth, T. Muller, F. Sleman, C. Grimm, C. Wahl-Schott, M. Biel, 
R. T. Mallmann, W. Bildl, U. Schulte, N. Klugbauer, Sci Rep 2017, 7, 10038. 
[5] C. Grimm, L. M. Holdt, C. C. Chen, S. Hassan, C. Muller, S. Jors, H. Cuny, S. Kissing, 
B. Schroder, E. Butz, B. Northoff, J. Castonguay, C. A. Luber, M. Moser, S. Spahn, R. 
Lullmann-Rauch, C. Fendel, N. Klugbauer, O. Griesbeck, A. Haas, M. Mann, F. 
Bracher, D. Teupser, P. Saftig, M. Biel, C. Wahl-Schott, Nat Commun 2014, 5, 4699. 
[6] M. Ruas, K. T. Chuang, L. C. Davis, A. Al-Douri, P. W. Tynan, R. Tunn, L. Teboul, A. 
Galione, J. Parrington, Mol Cell Biol 2014, 34, 3981-3992. 
[7] A. F. Kintzer, R. M. Stroud, Nature 2016, 531, 258-262. 
[8] J. She, W. Zeng, J. Guo, Q. Chen, X. C. Bai, Y. Jiang, Elife 2019, 8, e45222. 
[9] C. Grimm, K. Bartel, A. M. Vollmar, M. Biel, Pharmaceuticals (Basel) 2018, 11, 4. 
[10] P. J. Calcraft, M. Ruas, Z. Pan, X. Cheng, A. Arredouani, X. Hao, J. Tang, K. Rietdorf, 
L. Teboul, K. T. Chuang, P. Lin, R. Xiao, C. Wang, Y. Zhu, Y. Lin, C. N. Wyatt, J. 
Parrington, J. Ma, A. M. Evans, A. Galione, M. X. Zhu, Nature 2009, 459, 596-600. 
[11] S. J. Pitt, T. Funnell, M. Sitsapesan, E. Venturi, K. Rietdorf, M. Ruas, A. Ganesan, R. 
Gosain, G. C. Churchill, M. X. Zhu, J. Parrington, A. Galione, R. Sitsapesan, J. Biol. 
Chem 2010, 285, 24925-24932. 
[12] M. Schieder, K. Rotzer, A. Bruggemann, M. Biel, C. A. Wahl-Schott, J Biol Chem 2010, 
285, 21219-21222. 
[13] E. Brailoiu, D. Churamani, X. Cai, M. G. Schrlau, G. C. Brailoiu, X. Gao, R. Hooper, M. 
J. Boulware, N. J. Dun, J. S. Marchant, S. Patel, J Cell Biol 2009, 186, 201-209. 
[14] E. Brailoiu, T. Rahman, D. Churamani, D. L. Prole, G. C. Brailoiu, R. Hooper, C. W. 
Taylor, S. Patel, J Biol Chem 2010, 285, 38511-38516. 
[15] X. Wang, X. Zhang, X. P. Dong, M. Samie, X. Li, X. Cheng, A. Goschka, D. Shen, Y. 
Zhou, J. Harlow, M. X. Zhu, D. E. Clapham, D. Ren, H. Xu, Cell 2012, 151, 372-383. 
[16] C. Cang, Y. Zhou, B. Navarro, Y. J. Seo, K. Aranda, L. Shi, S. Battaglia-Hsu, I. Nissim, 
D. E. Clapham, D. Ren, Cell 2013, 152, 778-790. 
[17] V. Rybalchenko, M. Ahuja, J. Coblentz, D. Churamani, S. Patel, K. Kiselyov, S. 
Muallem, J Biol Chem 2012, 287, 20407-20416. 
[18] A. Jha, M. Ahuja, S. Patel, E. Brailoiu, S. Muallem, EMBO J 2014, 33, 501-511. 
[19] M. Ruas, L. C. Davis, C. C. Chen, A. J. Morgan, K. T. Chuang, T. F. Walseth, C. Grimm, 
C. Garnham, T. Powell, N. Platt, F. M. Platt, M. Biel, C. Wahl-Schott, J. Parrington, A. 
Galione, EMBO J 2015, 34, 1743-1758. 
[20] J. Guo, W. Zeng, Y. Jiang, PNAS 2017, 114, 1009-1014. 
[21] O. A. Ogunbayo, J. Duan, J. Xiong, Q. Wang, X. Feng, J. Ma, M. X. Zhu, A. M. Evans, 
Sci Signal 2018, 11, eaao5775. 
[22] S. Gerndt, C. C. Chen, Y. K. Chao, Y. Yuan, S. Burgstaller, A. Scotto Rosato, E. 
Krogsaeter, N. Urban, K. Jacob, O. N. P. Nguyen, M. T. Miller, M. Keller, A. M. Vollmar, 
T. Gudermann, S. Zierler, J. Schredelseker, M. Schaefer, M. Biel, R. Malli, C. Wahl-
Schott, F. Bracher, S. Patel, C. Grimm, Elife 2020, 9, e54712. 
APPENDICES 
215 
[23] S. Patel, B. S. Kilpatrick, Biochim Biophys Acta Mol Cell Res 2018, 1865, 1678-1686. 
[24] A. Hamilton, Q. Zhang, A. Salehi, M. Willems, J. G. Knudsen, A. K. Ringgaard, C. E. 
Chapman, A. Gonzalez-Alvarez, N. C. Surdo, M. Zaccolo, D. Basco, P. R. V. Johnson, 
R. Ramracheya, G. A. Rutter, A. Galione, P. Rorsman, A. I. Tarasov, Diabetes 2018, 
67, 1128-1139. 
[25] R. A. Capel, E. L. Bolton, W. K. Lin, D. Aston, Y. Wang, W. Liu, X. Wang, R. A. Burton, 
D. Bloor-Young, K. T. Shade, M. Ruas, J. Parrington, G. C. Churchill, M. Lei, A. 
Galione, D. A. Terrar, J Biol Chem 2015, 290, 30087-30098. 
[26] A. L. Ambrosio, J. A. Boyle, A. E. Aradi, K. A. Christian, S. M. Di Pietro, PNAS 2016, 
113, 5622-5627. 
[27] N. W. Bellono, I. E. Escobar, E. Oancea, Sci Rep 2016, 6, 26570. 
[28] Y. K. Chao, V. Schludi, C. C. Chen, E. Butz, O. N. P. Nguyen, M. Muller, J. Kruger, C. 
Kammerbauer, M. Ben-Johny, A. M. Vollmar, C. Berking, M. Biel, C. A. Wahl-Schott, 
C. Grimm, PNAS 2017, 114, E8595-E8602. 
[29] L. N. Hockey, B. S. Kilpatrick, E. R. Eden, Y. Lin-Moshier, G. C. Brailoiu, E. Brailoiu, C. 
E. Futter, A. H. Schapira, J. S. Marchant, S. Patel, J Cell Sci 2015, 128, 232-238. 
[30] G. S. Gunaratne, Y. Yang, F. Li, T. F. Walseth, J. S. Marchant, Cell Calcium 2018, 75, 
30-41. 
[31] C. J. Penny, K. Vassileva, A. Jha, Y. Yuan, X. Chee, E. Yates, M. Mazzon, B. S. 
Kilpatrick, S. Muallem, M. Marsh, T. Rahman, S. Patel, Biochim Biophys Acta Mol Cell 
Res 2019, 1866, 1151-1161. 
[32] N. Khan, K. L. Lakpa, P. W. Halcrow, Z. Afghah, N. M. Miller, J. D. Geiger, X. Chen, 
Sci Rep 2019, 9, 12285. 
[33] X. Ou, Y. Liu, X. Lei, P. Li, D. Mi, L. Ren, L. Guo, R. Guo, T. Chen, J. Hu, Z. Xiang, Z. 
Mu, X. Chen, J. Chen, K. Hu, Q. Jin, J. Wang, Z. Qian, Nat Commun 2020, 11, 1620. 
[34] P. Faris, M. Shekha, D. Montagna, G. Guerra, F. Moccia, Cancers (Basel) 2018, 11, 
27. 
[35] A. Favia, M. Desideri, G. Gambara, A. D'Alessio, M. Ruas, B. Esposito, D. Del Bufalo, 
J. Parrington, E. Ziparo, F. Palombi, A. Galione, A. Filippini, PNAS 2014, 111, E4706-
4715. 
[36] O. N. Nguyen, C. Grimm, L. S. Schneider, Y. K. Chao, C. Atzberger, K. Bartel, A. 
Watermann, M. Ulrich, D. Mayr, C. Wahl-Schott, M. Biel, A. M. Vollmar, Cancer Res 
2017, 77, 1427-1438. 
[37] F. Li, J. P. Ji, Y. Xu, R. L. Liu, Clin Transl Oncol 2019, 411, 5555-5561. 
[38] D. Hanahan, R. A. Weinberg, Cell 2011, 144, 646-674. 
[39] K. Kupferschmidt, J. Cohen, Science 2020, 367, 1412-1413. 
[40] R. M. Mingo, J. A. Simmons, C. J. Shoemaker, E. A. Nelson, K. L. Schornberg, R. S. 
D'Souza, J. E. Casanova, J. M. White, J Virol 2015, 89, 2931-2943. 
[41] X. P. Dong, D. Shen, X. Wang, T. Dawson, X. Li, Q. Zhang, X. Cheng, Y. Zhang, L. S. 
Weisman, M. Delling, H. Xu, Nat Commun 2010, 1, 38. 
[42] R. Parkesh, A. M. Lewis, P. K. Aley, A. Arredouani, S. Rossi, R. Tavares, S. R. 
Vasudevan, D. Rosen, A. Galione, J. Dowden, G. C. Churchill, Cell Calcium 2008, 43, 
531-538. 
[43] A. Galione, K. T. Chuang, T. M. Funnell, L. C. Davis, A. J. Morgan, M. Ruas, J. 
Parrington, G. C. Churchill, Cold Spring Harb Protoc 2014, 2014, pdb prot076927. 
APPENDICES 
216 
[44] C. Dinkel, M. Moody, A. Traynor-Kaplan, C. Schultz, Angew Chem Int Ed Engl 2001, 
40, 3004-3008. 
[45] N. Provinciali, C. Suen, B. K. Dunn, A. DeCensi, Expert Rev Clin Pharmacol 2016, 9, 
1263-1272. 
[46] S. Y. Tsang, X. Yao, K. Essin, C. M. Wong, F. L. Chan, M. Gollasch, Y. Huang, Stroke 
2004, 35, 1709-1714. 
[47] Q. Wang, L. Lu, X. Gao, C. Wang, J. Wang, J. Cheng, R. Gao, H. Xiao, Pharmacology 
2011, 87, 70-80. 
[48] Y. J. Chae, D. H. Kim, H. J. Lee, K. W. Sung, O. J. Kwon, S. J. Hahn, Pflugers Arch 
2015, 467, 1663-1676. 
[49] N. Divac, M. Prostran, I. Jakovcevski, N. Cerovac, Biomed Res Int 2014, 2014, 1-6. 
[50] X. Zhou, X. W. Dong, T. Priestley, Brain Res 2006, 1106, 72-81. 
[51] M. Müller, J. R. De Weille, M. Lazdunski, Eur J Pharmacol 1991, 198, 101-104. 
[52] I. Pafumi, M. Festa, F. Papacci, L. Lagostena, C. Giunta, V. Gutla, L. Cornara, A. Favia, 
F. Palombi, F. Gambale, A. Filippini, A. Carpaneto, Sci Rep 2017, 7, 5121. 
[53] Z. Zhao, G. Jin, Y. Ge, Z. Guo, Inflammopharmacology 2019, 27, 1021-1036. 
[54] I. Straub, U. Krugel, F. Mohr, J. Teichert, O. Rizun, M. Konrad, J. Oberwinkler, M. 
Schaefer, Mol Pharmacol 2013, 84, 736-750. 
[55] H. Gumushan Aktas, T. Akgun, Biomed Pharmacother 2018, 106, 770-775. 
[56] E. P. Scholz, E. Zitron, C. Kiesecker, S. Luck, D. Thomas, S. Kathofer, V. A. Kreye, H. 
A. Katus, J. Kiehn, W. Schoels, C. A. Karle, Naunyn Schmiedebergs Arch Pharmacol 
2005, 371, 516-525. 
[57] H. T. Hsu, Y. T. Tseng, Y. C. Lo, S. N. Wu, BMC Neurosci 2014, 15, 135. 
[58] U. Fuhr, K. Klittich, A. H. Staib, Br J Clin Pharmacol 1993, 35, 431-436. 
[59] F. P. Guengerich, D. H. Kim, Carcinogenesis 1990, 11, 2275-2279. 
[60] E. Naylor, A. Arredouani, S. R. Vasudevan, A. M. Lewis, R. Parkesh, A. Mizote, D. 
Rosen, J. M. Thomas, M. Izumi, A. Ganesan, A. Galione, G. C. Churchill, Nat Chem 
Biol 2009, 5, 220-226. 
[61] G. Wang, J. R. Lemos, C. Iadecola, Trends Pharmacol Sci 2004, 25, 120-123. 
[62] N. Bhagya, K. R. Chandrashekar, Phytochemistry 2016, 125, 5-13. 
[63] Y. S. Lee, S. H. Han, S. H. Lee, Y. G. Kim, C. B. Park, O. H. Kang, J. H. Keum, S. B. 
Kim, S. H. Mun, Y. S. Seo, N. Y. Myung, D. Y. Kwon, Foodborne Pathog Dis 2012, 9, 
686-691. 
[64] L. X. Zhao, D. D. Li, D. D. Hu, G. H. Hu, L. Yan, Y. Wang, Y. Y. Jiang, PLoS One 2013, 
8, e79671. 
[65] I. Lieberman, D. P. Lentz, G. A. Trucco, W. K. Seow, Y. H. Thong, Diabetes 1992, 41, 
616-619. 
[66] P. Joshi, R. A. Vishwakarma, S. B. Bharate, Eur J Med Chem 2017, 138, 273-292. 
[67] S. Dewanjee, T. Dua, N. Bhattacharjee, A. Das, M. Gangopadhyay, R. Khanra, S. 
Joardar, M. Riaz, V. Feo, M. Zia-Ul-Haq, Molecules 2017, 22, 871. 
[68] L. W. Fu, Y. M. Zhang, Y. J. Liang, X. P. Yang, Q. C. Pan, Eur J Cancer 2002, 38, 418-
426. 
[69] L. Fu, Y. Liang, L. Deng, Y. Ding, L. Chen, Y. Ye, X. Yang, Q. Pan, Cancer Chemother 
Pharmacol 2004, 53, 349-356. 
APPENDICES 
217 
[70] H. Jin, L. Li, D. Zhong, J. Liu, X. Chen, J. Zheng, Chem Res Toxicol 2011, 24, 2142-
2152. 
[71] L. Tainlin, H. Tingyi, Z. Changqi, Y. Peipei, Z. Qiong, Ecotoxicol Environ Saf 1982, 6, 
528-534. 
[72] Y. Inubushi, Y. Masaki, S. Matsumoto, F. Takami, Tetrahedron Lett 1968, 3399-3402. 
[73] R. Schuetz, M. Meixner, I. Antes, F. Bracher, Org Biomol Chem 2020, 18, 3047-3068. 
[74] X. Wei, T. L. Qu, Y. F. Yang, J. F. Xu, X. W. Li, Z. B. Zhao, Y. W. Guo, J Asian Nat 
Prod Res 2016, 18, 966-975. 
[75] J. Tao, Y. Qian-Hao, G. Wei-Feng, X. Jin-Fang, Q. Ting-Li, J. Graham, Z. Zheng-Bao, 
ChemXpress 2018. 
[76] J. Lan, L. Huang, H. Lou, C. Chen, T. Liu, S. Hu, Y. Yao, J. Song, J. Luo, Y. Liu, B. Xia, 
L. Xia, X. Zeng, Y. Ben-David, W. Pan, Eur J Med Chem 2018, 143, 1968-1980. 
[77] J. Song, J. Lan, C. Chen, S. Hu, J. Song, W. Liu, X. Zeng, H. Lou, Y. Ben-David, W. 
Pan, Med Chem Comm 2018, 9, 1131-1141. 
[78] M. Merarchi, G. Sethi, L. Fan, S. Mishra, F. Arfuso, K. S. Ahn, Molecules 2018, 23, 
2538. 
[79] Y. Cui, M. Xu, J. Mao, J. Ouyang, R. Xu, Y. Yu, Eur J Med Chem 2012, 54, 867-872. 
[80] Z. Yang, C. Li, X. Wang, C. Zhai, Z. Yi, L. Wang, B. Liu, B. Du, H. Wu, X. Guo, M. Liu, 
D. Li, J. Luo, J Cell Physiol 2010, 225, 266-275. 
[81] G. Deng, S. Zeng, J. Ma, Y. Zhang, Y. Qu, Y. Han, L. Yin, C. Cai, C. Guo, H. Shen, Sci 
Rep 2017, 7, 41616. 
[82] P. Iturriaga-Vasquez, R. Miquel, M. D. Ivorra, M. P. D'Ocon, B. K. Cassels, J Nat Prod 
2003, 66, 954-957. 
[83] A. F. Kintzer, R. M. Stroud, FEBS J 2018, 285, 233-243. 
[84] R. E. Haskell, C. J. Carr, D. A. Pearce, M. J. Bennett, B. L. Davidson, Hum Mol Genet 
2000, 9, 735-744. 
[85] T. J. Lerner, R.-M. N. Boustany, J. W. Anderson, K. L. D'Arigo, K. Schlumpf, A. J. 
Buckler, J. F. Gusella, J. L. Haines, Cell 1995, 82, 949-957. 
[86] M. Haltia, Biochim Biophys Acta 2006, 1762, 850-856. 
[87] A. Jalanko, T. Braulke, Biochim Biophys Acta 2009, 1793, 697-709. 
[88] N. Urban, L. Wang, S. Kwiek, J. Rademann, W. M. Kuebler, M. Schaefer, Mol 
Pharmacol 2016, 89, 197-213. 
[89] K. R. Gee, K. A. Brown, W. N. Chen, J. Bishop-Stewart, D. Gray, I. Johnson, Cell 
Calcium 2000, 27, 97-106. 
[90] F. Di Virgilio, L. H. Jiang, S. Roger, S. Falzoni, A. C. Sarti, V. Vultaggio-Poma, P. 
Chiozzi, E. Adinolfi, Methods Enzymol 2019, 629, 115-150. 
[91] E. B. Sjogren, M. A. Rider, P. H. Nelson, S. Bingham, Jr., A. L. Poulton, M. A. Emanuel, 
R. Komuniecki, J Med Chem 1991, 34, 3295-3301. 
[92] M. M. Shoukry, A. El Said Mahgoub, M. H. Elnagdi, Ann. Chim. (Rome) 1980, 70, 319-
321. 
[93] M. M. Shoukry, M. H. Elnagdi, A. E.-S. Mahgoub, Ann. Chim. (Rome) 1979, 69, 211-
217. 
[94] M. Hesse, H. Meier, B. Zeeh, Spektroskopische Methoden in der organischen Chemie, 
8 ed., Georg Thieme Verlag, Stuttgart, 2012. 
APPENDICES 
218 
[95] S. L. Laurella, C. Latorre, R. Dietrich, J. J. P. Furlong, P. E. Allegretti, J Phys Org Chem 
2012, 25, 1365-1373. 
[96] A. Hantzsch, Ber Dtsch Chem Ges 1890, 23, 1474-1476. 
[97] F. Feist, Ber Dtsch Chem Ges 1902, 35, 1537-1544. 
[98] J. Menéndez, M. Leonardi, V. Estévez, M. Villacampa, Synthesis 2018, 51, 816-828. 
[99] B. Zhao, W. Kan, T. Jing, X.-h. Zhang, Y.-j. Zheng, L. Chen, Heterocycles 2015, 91, 
2367. 
[100] C. Paal, Ber Dtsch Chem Ges 1884, 17, 2756-2767. 
[101] L. Knorr, Ber Dtsch Chem Ges 1884, 17, 2863-2870. 
[102] V. Amarnath, D. C. Anthony, K. Amarnath, W. M. Valentine, L. A. Wetterau, D. G. 
Graham, J Org Chem 1991, 56, 6924-6931. 
[103] S. Y. Kang, E. J. Park, W. K. Park, H. J. Kim, D. Jeong, M. E. Jung, K. S. Song, S. H. 
Lee, H. J. Seo, M. J. Kim, M. Lee, H. K. Han, E. J. Son, A. N. Pae, J. Kim, J. Lee, 
Bioorg Med Chem Lett 2010, 20, 1705-1711. 
[104] G. Tarzia, A. Duranti, A. Tontini, G. Spadoni, M. Mor, S. Rivara, P. Vincenzo Plazzi, S. 
Kathuria, D. Piomelli, Bioorg Med Chem 2003, 11, 3965-3973. 
[105] A. Mayweg, H.P. Marty, W. Mueller, R. Narquizian, W. Neidhardt, P. Pflieger, S. 
Roever, WO 2004/060870 A1, 2003. 
[106] K. Saruta, N. Hayashi, O. Sakurai, H. Sawamoto, E. Oboki, EP 2 862 856 A1, 2015. 
[107] M. Schlosser, E. Castagnetti, Eur J Org Chem 2001, 2001, 3991-3997. 
[108] J. B. Liu, C. Chen, L. Chu, Z. H. Chen, X. H. Xu, F. L. Qing, Angew Chem Int Ed Engl 
2015, 54, 11839-11842. 
[109] W. Frick, US 2011/0059910 A1, 2011. 
[110] S. Nahm, S. M. Weinreb, Tetrahedron Lett 1981, 22, 3815-3818. 
[111] X. Zhang, W. Chen, P. Li, R. Calvo, N. Southall, X. Hu, M. Bryant-Genevier, X. Feng, 
Q. Geng, C. Gao, M. Yang, K. Tang, M. Ferrer, J. J. Marugan, H. Xu, Elife 2019, 8, 
e51423. 
[112] G. Grynkiewicz, M. Poenie, R. Y. Tsien, J Biol Chem 1985, 260, 3440-3450. 
[113] S. Yamaguchi, A. Jha, Q. Li, A. A. Soyombo, G. D. Dickinson, D. Churamani, E. 
Brailoiu, S. Patel, S. Muallem, J Biol Chem 2011, 286, 22934-22942. 
[114] C. Grimm, S. Jors, S. A. Saldanha, A. G. Obukhov, B. Pan, K. Oshima, M. P. 
Cuajungco, P. Chase, P. Hodder, S. Heller, Chem Biol 2010, 17, 135-148. 
[115] E. Plesch, C. C. Chen, E. Butz, A. Scotto Rosato, E. K. Krogsaeter, H. Yinan, K. Bartel, 
M. Keller, D. Robaa, D. Teupser, L. M. Holdt, A. M. Vollmar, W. Sippl, R. Puertollano, 
D. Medina, M. Biel, C. Wahl-Schott, F. Bracher, C. Grimm, Elife 2018, 7, e39720. 
[116] B. K. Toeplitz, A. I. Cohen, P. T. Funke, W. L. Parker, J. Z. Gougoutas, J Am Chem 
Soc 1979, 101, 3344-3353. 
[117] C.-M. Lui, T. E. Hermann, J Biol Chem 1978, 17, 5892-5894. 
[118] M. C. Claussen, T. Korn, Clin Immunol 2012, 142, 49-56. 
[119] H. A. Bird, J. Hill, J. S. Dixon, R. Bojar, A. Traficante, M. A. Catalano, S. F. Adair, L. 
Liauw, H. Sussman, H. Rotman, et al., J Rheumatol 1989, 16, 448-454. 
[120] M. Enders, T. Heider, A. Ludwig, S. Kuerten, Int J Mol Sci 2020, 21, 1663. 
[121] J. C. Stockert, R. W. Horobin, L. L. Colombo, A. Blazquez-Castro, Acta Histochem 
2018, 120, 159-167. 
APPENDICES 
219 
[122] R. L. Williamson, R. L. Metcalf, Science 1967, 158, 1694-1695. 
[123] K. Talavera, M. Gees, Y. Karashima, V. M. Meseguer, J. A. Vanoirbeek, N. Damann, 
W. Everaerts, M. Benoit, A. Janssens, R. Vennekens, F. Viana, B. Nemery, B. Nilius, 
T. Voets, Nat Neurosci 2009, 12, 1293-1299. 
[124] J. Garcia-Anoveros, K. Nagata, Handb Exp Pharmacol 2007, 347-362. 
[125] K. Shibasaki, J Physiol Sci 2016, 66, 359-365. 
[126] D. E. Clapham, D. Julius, C. Montell, G. Schultz, Pharmacol Rev 2005, 57, 427-450. 
[127] S. J. Pitt, T. M. Funnell, M. Sitsapesan, E. Venturi, K. Rietdorf, M. Ruas, A. Ganesan, 
R. Gosain, G. C. Churchill, M. X. Zhu, J. Parrington, A. Galione, R. Sitsapesan, J Biol 
Chem 2010, 285, 35039-35046. 
[128] M. Ruas, L. C. Davis, C. C. Chen, A. J. Morgan, K. T. Chuang, T. F. Walseth, C. Grimm, 
C. Garnham, T. Powell, N. Platt, F. M. Platt, M. Biel, C. Wahl-Schott, J. Parrington, A. 
Galione, EMBO J 2015, 34, 1743-1758. 
[129] A. Boccaccio, J. Scholz-Starke, S. Hamamoto, N. Larisch, M. Festa, P. V. Gutla, A. 
Costa, P. Dietrich, N. Uozumi, A. Carpaneto, Cell Mol Life Sci 2014, 71, 4275-4283. 
[130] A. J. Morgan, A. Galione, Biochem J 2007, 402, 301-310. 
[131] F. Cosker, N. Cheviron, M. Yamasaki, A. Menteyne, F. E. Lund, M. J. Moutin, A. 
Galione, J. M. Cancela, J Biol Chem 2010, 285, 38251-38259. 
[132] E. Machado, S. White-Gilbertson, D. van de Vlekkert, L. Janke, S. Moshiach, Y. 
Campos, D. Finkelstein, E. Gomero, R. Mosca, X. Qiu, C. L. Morton, I. Annunziata, A. 
d'Azzo, Sci Adv 2015, 1, e1500603. 
[133] Y. Miao, G. Li, X. Zhang, H. Xu, S. N. Abraham, Cell 2015, 161, 1306-1319. 
[134] M. A. Samie, H. Xu, J Lipid Res 2014, 55, 995-1009. 
[135] S. Gerndt, E. Krogsaeter, S. Patel, F. Bracher, C. Grimm, FEBS J 2020, ahead of print. 
[136] E. Trindade, D. Menon, L. A. Topfer, C. Coloma, CMAJ 1998, 159, 1245-1252. 
[137] P. K. Gillman, Br J Pharmacol 2007, 151, 737-748. 
[138] J. P. Hubert, J. C. Delumeau, J. Glowinski, J. Premont, A. Doble, Br J Pharmacol 1994, 
113, 261-267. 
[139] M.-W. Debono, J. Le Guern, T. Canton, A. Doble, L. Pradier, Eur J Pharmacol 1993, 
235, 283-289. 
[140] C. Malgouris, M. Daniel, A. Doble, Neurosci Lett 1994, 177, 95-99. 
[141] J. H. Song, C. S. Huang, K. Nagata, J. Z. Yeh, T. Narahashi, J Pharmacol Exp Ther 
1997, 282, 707-714. 
[142] M. Bissaro, S. Moro, Neural Regen Res 2019, 14, 2083-2085. 
[143] A. Thevand, I. Stanculescu, C. Mandravel, P. Woisel, G. Surpateanu, Spectrochim Acta 
A Mol Biomol Spectrosc 2004, 60, 1825-1830. 
[144] Z. Xie, X. Xu, C. Xie, Z. Liang, M. Yang, J. Huang, D. Yang, J Liq Chromatogr Relat 
Technol 2013, 37, 343-352. 
[145] P. L. Schiff, J Nat Prod 1997, 60, 934-953. 
[146] J. J. Lv, M. Xu, D. Wang, H. T. Zhu, C. R. Yang, Y. F. Wang, Y. Li, Y. J. Zhang, J Nat 
Prod 2013, 76, 926-932. 
[147] D. L. Comins, P. M. Thakker, M. F. Baevsky, M. M. Badawi, Tetrahedron 1997, 53, 
16327-16340. 
[148] L. Pouysegu, A. V. Avellan, S. Quideau, J Org Chem 2002, 67, 3425-3436. 
APPENDICES 
220 
[149] J. H. Schrittwieser, V. Resch, S. Wallner, W. D. Lienhart, J. H. Sattler, J. Resch, P. 
Macheroux, W. Kroutil, J Org Chem 2011, 76, 6703-6714. 
[150] W. N. Speckamp, H. Hiemstra, Tetrahedron 1985, 41, 4367-4416. 
[151] B. E. Maryanoff, H. C. Zhang, J. H. Cohen, I. J. Turchi, C. A. Maryanoff, Chem Rev 
2004, 104, 1431-1628. 
[152] M. P. Cava, K. T. Buck, Tetrahedron 1969, 25, 2795-2805. 
[153] F. Ullmann, P. Sponagel, Ber Dtsch Chem Ges 1905, 38, 2211-2212. 
[154] D. M. T. Chan, K. L. Monaco, R.-P. Wang, M. P. Winters, Tetrahedron Lett 1998, 39, 
2933-2936. 
[155] D. A. Evans, J. L. Katz, T. R. West, Tetrahedron Lett 1998, 39, 2937-2940. 
[156] P. Y. S. Lam, C. G. Clark, S. Saubern, J. Adams, M. P. Winters, D. M. T. Chan, A. 
Combs, Tetrahedron Lett 1998, 39, 2941-2944. 
[157] G. Evano, J. Wang, A. Nitelet, Org Chem Front 2017, 4, 2480-2499. 
[158] A. E. King, T. C. Brunold, S. S. Stahl, J Am Chem Soc 2009, 131, 5044-5045. 
[159] J. C. Vantourout, H. N. Miras, A. Isidro-Llobet, S. Sproules, A. J. Watson, J Am Chem 
Soc 2017, 139, 4769-4779. 
[160] E. Awuah, A. Capretta, J Org Chem 2010, 75, 5627-5634. 
[161] M. Eckert, G. Fleischmann, R. Jira, H. M. Bolt, K. Golka, in Ullmann's Encyclopedia of 
Industrial Chemistry, Wiley‐VCH Verlag, 2006. 
[162] B. J. Lidster, J. M. Behrendt, M. L. Turner, Chem Commun (Camb) 2014, 50, 11867-
11870. 
[163] C. E. Brown, J. McNulty, C. Bordon, R. Yolken, L. Jones-Brando, Org Biomol Chem 
2016, 14, 5951-5955. 
[164] G. S. Basarab, P. Hill, B. Sherer, F. Zhou, WO2010067123A1, 2009. 
[165] K. Tachibana, H. Sato, M. Ohta, M. Nakamura, T. Shiraishi, H. Yoshino, T. Emura, A. 
Honma, E. Onuma, H. Kawata, K. Taniguchi, EP1790640A1, 2004. 
[166] M. El Khatib, G. A. Molander, Org Lett 2014, 16, 4944-4947. 
[167] W. Eschweiler, Ber Dtsch Chem Ges 1905, 38, 880-882. 
[168] R. Leuckart, Ber Dtsch Chem Ges 1885, 18, 2341-2344. 
[169] C. C. Chen, C. Cang, S. Fenske, E. Butz, Y. K. Chao, M. Biel, D. Ren, C. Wahl-Schott, 
C. Grimm, Nat Protoc 2017, 12, 1639-1658. 
[170] R. A. Gatenby, R. J. Gillies, Nat Rev Cancer 2004, 4, 891-899. 
[171] Y. Tian, S. Shen, Y. Jiang, Q. Shen, S. Zeng, J. Zheng, Arch Toxicol 2016, 90, 1737-
1748. 
[172] C. Yan, Q. Xin-Ming, G. Li-Kun, L. Lin-Lin, C. Fang-Ping, X. Ying, W. Xiong-Fei, L. 
Xiang-Hong, R. Jin, Toxicology 2006, 218, 1-12. 
[173] J. J. Kelu, H. L. Chan, S. E. Webb, A. H. Cheng, M. Ruas, J. Parrington, A. Galione, A. 
L. Miller, Int J Dev Biol 2015, 59, 313-325. 
[174] W. Dammermann, B. Zhang, M. Nebel, C. Cordiglieri, F. Odoardi, T. Kirchberger, N. 
Kawakami, J. Dowden, F. Schmid, K. Dornmair, M. Hohenegger, A. Flugel, A. H. Guse, 
B. V. Potter, PNAS 2009, 106, 10678-10683. 
[175] K. Singaravelu, J. W. Deitmer, Cell Calcium 2006, 39, 143-153. 
[176] R. A. Billington, A. A. Genazzani, Cell Calcium 2007, 41, 505-511. 
APPENDICES 
221 
[177] R. Schuetz, M. Mueller, S. Gerndt, K. Bartel, F. Bracher, Arch Pharm (Weinheim) 2020, 
353, e2000106. 
[178] W. Wang, Q. Gao, M. Yang, X. Zhang, L. Yu, M. Lawas, X. Li, M. Bryant-Genevier, N. 
T. Southall, J. Marugan, M. Ferrer, H. Xu, PNAS 2015, 112, E1373-1381. 
[179] M. Davies, T. Heikkila, G. A. McConkey, C. W. Fishwick, M. R. Parsons, A. P. Johnson, 
J Med Chem 2009, 52, 2683-2693. 
[180] W. Y. Yuan, X. Chen, N. N. Liu, Y. N. Wen, B. Yang, G. Andrei, R. Snoeck, Y. H. Xiang, 
Y. W. Wu, Z. Jiang, D. Schols, Z. Y. Zhang, Q. P. Wu, Med Chem 2019, 15, 801-812. 
[181] Y. A. Ammar, M. M. Ismail, H. M. El-Sehrawi, E. Noaman, A. H. Bayomi, T. Z. Shawer, 
Arch Pharm (Weinheim) 2006, 339, 429-436. 
[182] D. H. Sohn, J. I. Park, S. J. Cho, J. Kang, Tetrahedron 2017, 73, 212-221. 
[183] N. H. Metwally, F. M. Abdelrazek, S. M. Eldaly, P. Metz, J Heterocycl Chem 2017, 54, 
289-294. 
[184] N. Edraki, A. Iraji, O. Firuzi, Y. Fattahi, M. Mahdavi, A. Foroumadi, M. 
Khoshneviszadeh, A. Shafiee, R. Miri, J Iran Chem Soc 2016, 13, 2163-2171. 
[185] N. Shah, P. N. Patel, D. C. Karia, Asian J Chem 2018, 30, 2647-2651. 
[186] Y. Kobayashi, T. Harayama, Tetrahedron Lett 2009, 50, 6665-6667. 
[187] D. Guo, T. Chen, D. Ye, J. Xu, H. Jiang, K. Chen, H. Wang, H. Liu, Org Lett 2011, 13, 
2884-2887. 
[188] G. N. Walker, US4256759, 1981. 
[189] T. X. Metro, J. Bonnamour, T. Reidon, J. Sarpoulet, J. Martinez, F. Lamaty, Chem 
Commun (Camb) 2012, 48, 11781-11783. 
[190] S. Lee, A. Pyo, A. Park, H. Jung, Synthesis 2012, 44, 2885-2888. 
[191] S.-T. Lu, Y.-C. Wu, S.-P. Leou, J Chin Chem Soc-Taip 1987, 34, 33-42. 
[192] Y. Kawabata, Y. Naito, T. Saitoh, K. Kawa, T. Fuchigami, S. Nishiyama, Eur J Org 
Chem 2014, 2014, 99-104. 
[193] B. Gawley, R. E. Gawley, G. A. Smith, ARKIVOC 2011, 2011, 167-179. 
[194] Y. Kashiwada, A. Aoshima, Y. Ikeshiro, Y. P. Chen, H. Furukawa, M. Itoigawa, T. 
Fujioka, K. Mihashi, L. M. Cosentino, S. L. Morris-Natschke, K. H. Lee, Bioorg Med 
Chem 2005, 13, 443-448. 
[195] R. Stadler, S. Loeffler, B. K. Cassels, M. H. Zenk, Phytochemistry 1988, 27, 2557-2565. 
[196] M. Tomita, H. Yamaguchi, Yakugaku Zasshi 1952, 72, 1219-1222. 
[197] T. Kametani, H. Yagi, Chem Pharm Bull (Tokyo) 1967, 15, 1283-1286. 
[198] P. Steffens, N. Nagakura, M. H. Zenk, Phytochemistry 1985, 24, 2577-2583. 
[199] R. Stadler, M. H. Zenk, Liebigs Ann 1990, 1990, 555-562. 
[200] P. Z.-T. Iturriaga-Vasquez, Gerald; Rezende, Marcos Caroli; Cassels, Bruce K., J Chil 
Chem Soc 2004, 49, 17-23. 
[201] A. Jossang, M. Lebœuf, A. Cavé, J. Pusset, J Nat Prod 1991, 54, 466-472. 
[202] A. Brossi, K. C. Rice, C. P. Mak, J. Reden, A. E. Jacobson, Y. Nimitkitpaisan, P. 
Skolnick, J. Daly, J Med Chem 1980, 23, 648-652. 
[203] M. Tomita, J. Niimi, Yakugaku Zasshi 1959, 79, 1023-1027. 
[204] N. Blank, T. Opatz, J Org Chem 2011, 76, 9777-9784. 
[205] C. H. C. Chen, Tzer Ming J Taiw Pharm Assoc 1983, 35, 1-16. 
APPENDICES 
222 
[206] C. Schoepf, W. Salzer, Liebigs Ann 1940, 544, 1. 
[207] M. Lafrance, N. Blaquiere, K. Fagnou, Eur J Org Chem 2007, 2007, 811-825. 
[208] M. Tomita, K. Nakaguchi, S. Takagi, Yakugaku Zasshi 1951, 71, 1046-1049. 
[209] Y. Tang, S. Li, S. Li, X. Yang, Y. Qin, C. Liu, Y. Zhang, Med Chem Res 2017, 26, 3384-
3394. 
 
